{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/song/miniconda3/envs/frag/lib/python3.11/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
      "  from tqdm.autonotebook import tqdm, trange\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import pickle\n",
    "import jsonlines\n",
    "from tqdm import tqdm\n",
    "from time import time\n",
    "import pandas as pd\n",
    "import csv\n",
    "from collections import defaultdict\n",
    "from rank_eval import load_rank_results, eval_rank_results\n",
    "import os\n",
    "import pickle\n",
    "from core.computation.uncertainty_measure import cluster_assignment_entropy\n",
    "\n",
    "# ALL_DATASET_NAMES = [\"nq\"]\n",
    "ALL_DATASET_NAMES = [\"trec-covid\", \"climate-fever\", \"dbpedia-entity\", \"fever\", \"fiqa\", \"hotpotqa\", \"msmarco\", \"nfcorpus\", \"scidocs\", \"scifact\", \"nq\"]\n",
    "SIZE_NAME = \"all\"\n",
    "# SIZE_NAME = \"large\"\n",
    "BEIR_DATASET_DIR = \"/home/song/dataset/beir\"\n",
    "RANK_DIR = \"dataset/rank\"\n",
    "SAMPLE_DIR = \"output/sample\"\n",
    "\n",
    "def load_pickle_file(file_path):\n",
    "    with open(file_path, 'rb') as f:\n",
    "        data = pickle.load(f)\n",
    "    return data\n",
    "\n",
    "def save_pickle_file(file_path, data):\n",
    "    with open(file_path, 'wb') as f:\n",
    "        pickle.dump(data, f)\n",
    "\n",
    "def load_samples(dataset_name, qid, doc_id):\n",
    "    file_path = f'output/rank/gen/Qwen/Qwen2.5-7B-Instruct/{dataset_name}/{dataset_name}-{qid}-{doc_id}.pkl'\n",
    "    if os.path.exists(file_path):\n",
    "        result = load_pickle_file(file_path)\n",
    "        return [x['text'] for x in result['sample']]\n",
    "    return []\n",
    "\n",
    "def load_greedy(dataset_name, qid, doc_id):\n",
    "    file_path = f'output/rank/gen/Qwen/Qwen2.5-7B-Instruct/{dataset_name}/{dataset_name}-{qid}-{doc_id}.pkl'\n",
    "    if os.path.exists(file_path):\n",
    "        result = load_pickle_file(file_path)\n",
    "        return result['greedy']\n",
    "    return None\n",
    "\n",
    "\n",
    "def load_cluster_ids(dataset_name, qid, doc_id):\n",
    "    file_path = f'output/rank/cluster/Qwen/Qwen2.5-7B-Instruct/{dataset_name}/{dataset_name}-{qid}-{doc_id}.pkl'\n",
    "    if os.path.exists(file_path):\n",
    "        result = load_pickle_file(file_path)\n",
    "        return result.get('cluster_ids', [])\n",
    "    return []\n",
    "\n",
    "\n",
    "# 计算语义熵\n",
    "def compute_entropy(cluster_ids):\n",
    "    if len(cluster_ids) == 0:\n",
    "        return None\n",
    "    return cluster_assignment_entropy(cluster_ids)\n",
    "\n",
    "\n",
    "def load_dataset(dataset_path):\n",
    "    query_path = os.path.join(dataset_path, 'queries.jsonl')\n",
    "    queries = {}\n",
    "    with jsonlines.open(query_path) as reader:\n",
    "        for query in reader:\n",
    "            queries[str(query['_id'])] = query['text']\n",
    "\n",
    "    doc_path = os.path.join(dataset_path, 'corpus.jsonl')\n",
    "    docs = {}\n",
    "    with jsonlines.open(doc_path) as reader:\n",
    "        for doc in reader:\n",
    "            docs[str(doc['_id'])] = doc['text']\n",
    "\n",
    "    rel_path = os.path.join(dataset_path, 'qrels/test.tsv')\n",
    "    df = pd.read_csv(rel_path, sep='\\t', header=0)\n",
    "    \n",
    "    qrels = defaultdict(dict)\n",
    "    for qid, docid, score in df.values:\n",
    "        qrels[str(qid)][str(docid)] = score\n",
    "    \n",
    "    return queries, docs, dict(qrels)\n",
    "\n",
    "def make_sample_data(rank_results, dataset_name):\n",
    "    sample_data = defaultdict(dict)\n",
    "    for qid, doc_ids in tqdm(rank_results.items()):\n",
    "        for doc_id in ['no']+list(doc_ids.keys()):\n",
    "            samples = load_samples(dataset_name, qid, doc_id)\n",
    "            greedy = load_greedy(dataset_name, qid, doc_id)\n",
    "            cluster_ids = load_cluster_ids(dataset_name, qid, doc_id)\n",
    "            sample_data[qid][doc_id] = {\n",
    "                'greedy': greedy,\n",
    "                'samples': samples,\n",
    "                'cluster_ids': cluster_ids,\n",
    "                'entropy': compute_entropy(cluster_ids)\n",
    "            }\n",
    "    return dict(sample_data)\n",
    "\n",
    "def make_rank_results(dataset_name):\n",
    "    rank_path = f'{RANK_DIR}/{dataset_name}/{dataset_name}-rank10-{SIZE_NAME}.tsv'\n",
    "    rank_results = load_rank_results(rank_path)\n",
    "    return rank_results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'29': {'no': {'greedy': 'Potential drug targets include interactions between SARS-CoV-2 spike protein and human ACE2, and between SARS-CoV-2 nucleocapsid protein and host RNA. Drugs like remdesivir (targeting viral RNA-dependent RNA polymer',\n",
       "   'samples': ['',\n",
       "    'Potential drug targets include interactions between SARS-CoV-2 spike protein and human ACE2, as well as viral protease and host cellular factors. Remdesivir and lopinavir/ritonavir have been repurposed',\n",
       "    'Potential drug targets include interactions involving the Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N) proteins. Repurposed drugs like remdesivir (targeting RNA-dependent RNA polymerase)',\n",
       "    'Potential drug targets include interactions between SARS-CoV-2 spike protein and human ACE2, and between Nsp1 and human nuclear proteins. Drugs like camostat (for ACE2 interaction) and Lopinavir/ritonav',\n",
       "    'SARS-CoV-2 spike protein, protease, and RNA-dependent RNA polymerase interact with human proteins. Drugs like lopinavir (HIV protease inhibitor), ritonavir (HIV protease and inhibitor), and',\n",
       "    '',\n",
       "    'Potential drug targets include interactions between SARS-CoV-2 spike protein and human ACE2, and between viral RNA-dependent RNA polymerase and host factors. Drugs like remdesivir, which targets the viral RNA polymerase, are being considered for',\n",
       "    'Proteins like spike (S), envelope (E), membrane (M), and nucleocapsid (N) show potential. Drugs like remdesivir (S), lopinavir/ritonavir (S), and cam',\n",
       "    '',\n",
       "    ''],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 5, 6, 0, 0],\n",
       "   'entropy': 1.7480673485460891},\n",
       "  '38d6gb7o': {'greedy': 'The study identified 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and/or preclinical compounds. These interactions indicate potential for drug targets against SARS-CoV-2.',\n",
       "   'samples': ['The study identified 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and/or preclinical compounds that could potentially be repurposed as antiviral therapies against SARS-Co',\n",
       "    'Sixty-six druggable human proteins or host factors were identified, and they are targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and/or preclinical compounds. These can be repurposed as potential treatments for SARS',\n",
       "    'The study identified 66 druggable human proteins or host factors that interact with SARS-CoV-2 proteins. These interactions suggest potential drug targets, and among them, 69 existing FDA-approved drugs, drugs in clinical trials, and',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and/or preclinical compounds. These interactions suggest potential drug targets for treating SARS-CoV-2 infection',\n",
       "    'The study identified 66 druggable human proteins or host factors that interact with SARS-CoV-2 proteins, and these interactions indicate potential drug targets. Additionally, 69 existing FDA-approved drugs, drugs in clinical trials, and pre',\n",
       "    'The study identified 66 druggable human proteins or host factors that interact with SARS-CoV-2 proteins and are targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and preclinical compounds. These interactions suggest potential',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and preclinical compounds. These interactions indicate potential for drug targets against SARS-CoV-2. Yes',\n",
       "    'Yes, 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and/or preclinical compounds were identified through the study. These indicate potential drug targets for developing antiviral ther',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and/or preclinical compounds. These indicate potential drug targets for developing antiviral therapeutics against SARS',\n",
       "    'The study identified 66 druggable human proteins or host factors that interact with SARS-CoV-2 proteins, and these interactions suggest potential drug targets. Additionally, 69 existing FDA-approved drugs, drugs in clinical trials, and pre'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  'eje3i558': {'greedy': 'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. These interactions suggest potential for',\n",
       "   'samples': ['Interactions between SARS-CoV-2 proteins and 66 druggable human proteins were identified. Yes, among the interacting proteins are targets for 29 FDA-approved drugs, suggesting potential repurposing opportunities. Answering briefly: Yes',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. These compounds interact with',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. Two sets of pharmacological',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. This indicates potential repur',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. These interactions suggest potential for',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. These interactions suggest potential rep',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. These compounds could potentially be',\n",
       "    'Sixty-six druggable human proteins or host factors were targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. Two sets of pharmacological agents that',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. Two sets of pharmacological',\n",
       "    'Sixty-six druggable human proteins or host factors targeted by 69 compounds were identified, including 29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds. Yes, some approved drugs that'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 2, 1, 1, 2, 2, 2],\n",
       "   'entropy': 0.9433483923290393},\n",
       "  '7qd8z5e7': {'greedy': 'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, with 29 of those being FDA-approved drugs, 12 in clinical trials, and 28 preclinical compounds. Potential drug targets',\n",
       "   'samples': ['The study identified 66 druggable human proteins or host factors targeted by 69 compounds, with 29 being FDA-approved drugs, 12 in clinical trials, and 28 preclinical compounds. These interactions indicate potential drug',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, with 29 of those drugs being approved by the US Food and Drug Administration. These interactions suggest potential for drug targets. Yes, there are',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, with 29 of those drugs being approved by the US Food and Drug Administration, 12 in clinical trials, and 28 pre',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, with 29 of those being FDA-approved drugs, 12 in clinical trials, and 28 preclinical compounds. This indicates potential',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 in clinical trials, and 28 preclinical compounds. Interactions involving mRNA translation inhibitors',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, of which 29 are approved by the US FDA, 12 are in clinical trials, and 28 are preclinical compounds.',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, of which 29 are approved by the US Food and Drug Administration, indicating potential for drug targets and repurposing existing drugs. Yes,',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, including 29 FDA-approved drugs, 12 in clinical trials, and 28 preclinical compounds. These interactions suggest potential drug targets',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, of which 29 are approved by the US Food and Drug Administration, indicating potential for drug targets. Yes, some approved drugs can be rep',\n",
       "    'The study identified 66 druggable human proteins or host factors targeted by 69 compounds, of which 29 are FDA-approved drugs, 12 are in clinical trials, and 28 are preclinical compounds. These interactions'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '74xvvwrw': {'greedy': \"The S-protein's receptor-binding domain (RBD) interacts with human proteins, indicating potential drug targets. Approved drugs like ivermectin show promise for repurposing based on these interactions.\",\n",
       "   'samples': [\"The S-protein's receptor-binding domain (RBD) shows potential as a drug target. Ivermectin, among other FDA-approved drugs identified, could potentially repurpose for targeting SARS-CoV-2.\",\n",
       "    'The receptor-binding domain (RBD) of the S-protein is a potential target. Approved drugs like ivermectin show promise as potential repurposed treatments.',\n",
       "    'The receptor-binding domain (RBD) of the S-protein interacts with human proteins, indicating potential for drug targets. Approved drugs like ivermectin show promise based on this information.',\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacting with human cells indicates potential for drug targets. Approved drugs like ivermectin show promise for repurposing. Question asks about protein interactions and approved drugs, answer focuses on S\",\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacts with human cells, indicating potential for drug targets. Approved drugs like ivermectin show promise in inhibiting SARS-CoV-2 S-protein function.\",\n",
       "    'The receptor-binding domain (RBD) of the S-protein interacts with human proteins, indicating potential drug targets. Approved drugs like ivermectin show promise as repurposed treatments. Briefly, 24 best-scored ligands',\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacts with human proteins, indicating potential for drug targets. Approved drugs like ivermectin show promise for repurposing based on these interactions.\",\n",
       "    \"The S-protein's receptor-binding domain (RBD) showed potential as a drug target. Specifically, the docking calculations identified 24 best-scored ligands, including both traditional herbal isolates and approved drugs, with binding energies below -8\",\n",
       "    \"The S-protein's receptor-binding domain (RBD) showed potential as a drug target. Ivermectin, an approved drug, was identified as a promising candidate to inhibit the SARS-CoV-2 S-protein.\",\n",
       "    \"The receptor-binding domain (RBD) of SARS-CoV-2's S-protein interacts with human proteins, indicating potential drug targets. Approved drugs like ivermectin show promise in inhibiting S-protein function.\"],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 1, 2, 3, 3],\n",
       "   'entropy': 1.2206072645530175},\n",
       "  '5vgfliv0': {'greedy': \"The S-protein's receptor-binding domain (RBD) interacts with human proteins, indicating potential drug targets. Approved drugs like ivermectin show promise for repurposing based on these interactions.\",\n",
       "   'samples': [\"The S-protein's receptor-binding domain (RBD) interacts with human proteins, indicating potential drug targets. Approved drugs like ivermectin show promise in inhibiting SARS-CoV-2 S-protein function.\",\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacts with human cells, indicating potential for drug targets. Approved drugs like ivermectin show promise for inhibiting SARS-CoV-2 S-protein interaction and preventing infection.\",\n",
       "    'The receptor-binding domain (RBD) of the S-protein interacts with human cells. Based on molecular docking, several FDA-approved drugs, including ivermectin, show potential as repurposed treatments to inhibit SARS-CoV-2',\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacts with human proteins, indicating potential drug targets. Yes, approved drugs like ivermectin show promise based on this information.\",\n",
       "    'The receptor-binding domain (RBD) of the S-protein is a key target. Yes, approved drugs like ivermectin show potential as repurposed treatments. Briefly, 24 best-scored ligands from FDA-approved',\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacts with human proteins, indicating potential drug targets. Yes, approved drugs like ivermectin show promise based on this information. Briefly.\",\n",
       "    'The receptor-binding domain (RBD) of the S-protein is a potential target, as it undergoes conformational changes and is more exposed to the solvent. Yes, there are approved drugs like ivermectin that show potential as',\n",
       "    'The receptor-binding domain (RBD) of the S-protein interacts with human cells. Ivermectin and other drugs with binding energy below -8.1 kcal/mol are potential repurposed drug candidates.',\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacts with human cells, indicating potential for drug targets. Approved drugs like ivermectin show promise for repurposing based on these interactions.\",\n",
       "    \"The S-protein's receptor-binding domain (RBD) interacts with human proteins, indicating potential drug targets. Approved drugs like ivermectin show promise for repurposing based on this information.\"],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 1, 2, 3, 1, 2],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'yv2gjjzg': {'greedy': 'The study identified 20 drugs that may be repurposable for COVID-19 by targeting host proteins interacting with SARS-CoV-2 proteins. Yes, some of these drugs are already being tested for SARS-CoV-2,',\n",
       "   'samples': ['The study analyzed interactions between 332 host proteins that interact with 27 SARS-CoV-2 viral proteins to identify potential drug targets. Yes, the analysis identified 20 drugs that may be repurposable for COVID-1',\n",
       "    'The study identified 20 drugs that may be repurposable for COVID-19 by analyzing their effect on gene expression profiles relative to SARS-associated expression. Yes, some of these drugs are already being tested for clinical activity against SARS-Co',\n",
       "    'The study analyzed interactions between 332 host proteins that interact with 27 SARS-CoV-2 viral proteins. From this interactome, they identified 20 drugs that may be repurposed against SARS-CoV-2',\n",
       "    'The host protein interactome (HoP) of 332 host proteins interacting with 27 SARS-CoV-2 viral proteins was analyzed. From this, 20 drugs showing negative correlation with SARS-associated gene expression profiles were',\n",
       "    'The study identified 332 host proteins that interact with 27 SARS-CoV-2 viral proteins. From analyzing drugs that target these host proteins, 20 drugs showed potential for repurposing against SARS-CoV-2',\n",
       "    'The study identified 20 drugs that showed potential for repurposing against SARS-CoV-2 based on their correlation with gene expression profiles negatively associated with SARS expression. These drugs target proteins in the host protein interactome (HoP)',\n",
       "    'The study identified potential drug targets by analyzing protein-protein interactions between 332 host proteins and 27 SARS-CoV-2 viral proteins. From this interactome, 20 drugs were identified as potential repurposable candidates against',\n",
       "    'The protein-protein interactions between 332 host proteins interacting with 27 SARS-CoV-2 viral proteins indicate potential drug targets. An integrated computational analysis of the host interactome and drug-induced transcriptomic data revealed 20 drugs',\n",
       "    'The study found that out of 332 host proteins interacting with 27 SARS-CoV-2 viral proteins, certain drug interactions showed potential for repurposing. Twenty drugs were identified whose differential gene expression patterns showed negative correlation with S',\n",
       "    'The protein-protein interactions between 332 host proteins interacting with 27 SARS-CoV-2 viral proteins indicate potential drug targets. Yes, the analysis identified 20 drugs that may be repurposable for COVID-19'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 0, 3, 0, 4, 2, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'uuy94dwa': {'greedy': 'SARS-CoV-2 proteins that interact with human oncogenic pathways may present potential drug targets. Approved drugs targeting these pathways could be repurposed for treating COVID-19. However, specific drugs are not mentioned in the given context. Answer',\n",
       "   'samples': [\"Gordon and colleagues' research mapped SARS-CoV-2 human protein–protein interactions, identifying druggable targets that the virus hijacks. Oncogenic pathways at the host-virus interface were highlighted, suggesting potential for drug repurposing from cancer\",\n",
       "    'SARS-CoV-2 proteins that interact with human oncogenic pathways may present potential drug targets. Approved drugs targeting these pathways could be repurposed based on this information. (Note: Specific proteins and drugs not included due to brevity.)',\n",
       "    'SARS-CoV-2 proteins that interact with human oncogenic pathways include those interacting with host factors like ACE2, TMPRSS2, and others. Some approved drugs that could potentially be repurposed based on these interactions include antivirals',\n",
       "    'SARS-CoV-2 interacts with several human oncogenic pathways, identifying potential drug targets. Some approved drugs that may be repurposed include those targeting these pathways. (Specific drugs not mentioned due to brevity.)',\n",
       "    'SARS-CoV-2 interacts with several human oncogenic pathways, identifying potential drug targets. Approved drugs targeting these pathways may be repurposed for treating COVID-19.',\n",
       "    'SARS-CoV-2 interacts with multiple human oncogenic pathways, suggesting potential drug targets. Yes, some approved drugs targeting these pathways may be repurposed for treating COVID-19.',\n",
       "    'SARS-CoV-2 proteins that interact with human oncogenic pathways show potential as drug targets. Yes, some approved drugs targeting these pathways may be repurposed for treating COVID-19.',\n",
       "    'Several oncogenic pathways were identified where SARS-CoV-2 proteins interact with human proteins. These interactions suggest potential drug targets. Approved drugs that target these pathways might be repurposed to treat COVID-19. However, specific drugs are not',\n",
       "    'SARS-CoV-2 interacts with human oncogenic pathways, identifying potential druggable targets. Yes, cancer-targeting drugs may be repurposed based on these interactions. However, specific drugs are not listed in the given context.',\n",
       "    'Gordon and colleagues mapped SARS-CoV-2 human protein–protein interactions, identifying druggable targets. Some oncogenic pathways disrupted by SARS-CoV-2 could allow for drug repurposing from oncology, though specific approved drugs are'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 3, 3, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'qrfx165d': {'greedy': 'The study identifies human proteins involved in host-virus interactions that could be potential drug targets. For instance, HSPA5 (heat shock protein family A member 5) shows promise in viral entry regulation. Additionally, tubulin proteins related to ciliary',\n",
       "   'samples': ['The approach identifies human proteins that interact with SARS-CoV-2 proteins, focusing on those involved in host biological processes potentially co-opted by the virus. For instance, HSPA5 (Heat Shock Protein Family A Member 5) may play',\n",
       "    'The study identifies human proteins potentially co-opted by SARS-CoV-2 and ranks them based on their importance in host-virus interactions. Top-ranked proteins like HSPA5 (heat shock protein family A member 5) show promise as drug',\n",
       "    'The study identified human proteins involved in host-virus interactions, such as HSPA5, which could have potential as drug targets. Anti-clotting agents and anti-mitotic drugs targeting tubulin proteins are also suggested. Some of these drugs are',\n",
       "    'The study identifies human proteins like HSPA5 (heat shock protein family A member 5) and tubulin proteins as potential targets. These interactions suggest that drugs targeting HSPA5, such as certain anti-clotting agents, and anti-mit',\n",
       "    'The study identifies human proteins like HSPA5 (heat shock protein A5) and tubulin proteins that could be potential drug targets due to their interactions with SARS-CoV-2 proteins. HSPA5 is linked to viral entry, and tub',\n",
       "    'The study identified potential human-SARS-CoV-2 protein interactors, including HSPA5, which could be targeted for therapy. Approved drugs like anti-clotting agents (potentially connected to HSPA5) and anti-mitotic drugs',\n",
       "    'The study identifies human proteins that interact with SARS-CoV-2 proteins, some of which are enriched in host biological processes co-opted by the virus. For instance, HSPA5 (Heat shock 70 kDa protein 5)',\n",
       "    'The method predicts human-SARS-CoV-2 protein interactors with high accuracy. HSPA5 is highlighted as a potential target for viral entry regulation. Tubulin proteins involved in ciliary assembly could also be targets. Some drugs that target these proteins',\n",
       "    'The study identifies human proteins involved in host-virus interactions, such as HSPA5, which may play a role in viral entry. There are approved drugs, like anti-clotting agents and anti-mitotic drugs, that could be repur',\n",
       "    'The study identifies human proteins involved in host-virus interactions, such as HSPA5, which may have potential as drug targets. Anti-clotting agents and anti-mitotic drugs, targeting tubulin proteins involved in ciliary assembly, could also'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '2cvvkrx9': {'greedy': 'SARS-CoV-2 proteins that interact with human oncogenic pathways, such as those involving host cell entry factors (e.g., ACE2), signaling molecules, and transcription factors, may indicate potential drug targets. Approved drugs targeting these pathways could be',\n",
       "   'samples': ['SARS-CoV-2 proteins interacting with oncogenic pathways may present potential drug targets. Approved drugs targeting these pathways could potentially be repurposed for treating COVID-19.',\n",
       "    'SARS-CoV-2 proteins interacting with oncogenic pathways have potential as drug targets. Some approved drugs targeting these pathways might be repurposed for COVID-19 treatment. However, specific drugs are not listed in the given context.',\n",
       "    'Several oncogenic pathways targeted by SARS-CoV-2 protein-human protein interactions suggest potential drug targets. Approved drugs targeting these pathways might be repurposed for treating COVID-19. Examples include inhibitors of tyrosine kinase receptors like EGFR',\n",
       "    'SARS-CoV-2 proteins interacting with oncogenic pathways, such as those involving host cell entry factors (e.g., ACE2) and signaling molecules (e.g., TMPRSS2), indicate potential drug targets. Yes, some approved drugs targeting',\n",
       "    'SARS-CoV-2 proteins interacting with oncogenic pathways, such as those involving host cell signaling and immune responses, may indicate potential drug targets. Approved drugs targeting these pathways might be repurposed for treating COVID-19. Examples include prote',\n",
       "    'SARS-CoV-2 interacts with human proteins in oncogenic pathways, revealing potential druggable targets. Approved drugs targeting these pathways could be repurposed for COVID-19 treatment.',\n",
       "    'SARS-CoV-2 interacts with several oncogenic host pathways, suggesting potential drug targets. Repurposed drugs like remdesivir, an antiviral, have shown promise. Other drugs targeting hijacked pathways could also be considered for rep',\n",
       "    'SARS-CoV-2 proteins interacting with oncogenic pathways show potential as drug targets. Approved drugs targeting these pathways might be repurposed for treating COVID-19.',\n",
       "    'SARS-CoV-2 interacts with several human oncogenic pathways, indicating potential drug targets. Approved drugs targeting these pathways could be repurposed for treating COVID-19.',\n",
       "    'SARS-CoV-2 proteins interacting with host oncogenic pathways show potential as drug targets. Approved drugs targeting these pathways could be repurposed for treating COVID-19. Examples include inhibitors of tyrosine kinases and other signaling molecules exploited'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 0, 0, 3, 0, 0, 0],\n",
       "   'entropy': 0.9404479886553263},\n",
       "  'eja8fkwv': {'greedy': 'The three essential SARS-CoV-2 proteins analyzed are RdRp, 3CL-protease, and helicase. Approved drugs that show binding to the 3CL-protease, either at the catalytic pocket or an allo',\n",
       "   'samples': ['Three FDA-approved drugs potentially interact with 3CL-protease, and one drug-like molecule interacts with RdRp, indicating these proteins as potential drug targets. Yes, some approved drugs can be repurposed based on these interactions.',\n",
       "    'The three essential SARS-CoV-2 proteins targeted are RdRp, 3CL-protease, and helicase. Approved drugs showing binding to the 3CL-protease include three FDA-approved drugs that interact either at the catal',\n",
       "    'The study identifies three FDA-approved drugs that show binding to the 3CL-protease either at the catalytic pocket or an allosteric site involved in dimer formation. Additionally, a drug-like molecule binds to the RdRp in its catal',\n",
       "    'Three FDA-approved drugs show potential to interact with SARS-CoV-2 3CL-protease, and one drug-like molecule binds to SARS-CoV-2 RdRp. Additionally, two drug-like molecules interact with SARS-CoV',\n",
       "    'Three essential SARS-CoV-2 proteins—RdRp, 3CL-protease, and helicase—showed interactions with specific binding sites. Approved drugs, including three FDA-approved drugs, demonstrated binding to the 3CL',\n",
       "    'The study identifies potential drug targets by focusing on three essential SARS-CoV-2 proteins: RdRp, 3CL-protease, and helicase. Approved drugs like those targeting 3CL-protease show promise, binding either',\n",
       "    'Essential SARS-CoV-2 proteins like RdRp, 3CL-protease, and helicase interact with human proteins. Approved drugs such as those interacting with 3CL-protease show promise for repurposing. Yes,',\n",
       "    'The study identifies interactions with the SARS-CoV-2 3CL protease, RdRp, and helicase proteins. Three FDA-approved drugs show binding to the 3CL protease, and two drug-like molecules interact with the Rd',\n",
       "    'Three FDA-approved drugs bind to the 3CL-protease either at the catalytic pocket or an allosteric site related to dimer formation, indicating potential for drug targets. Additionally, a drug-like molecule binds to the RdRp catalytic',\n",
       "    'Three FDA-approved drugs show potential to interact with 3CL-protease, one drug-like molecule with RdRp, and two other drug-like molecules with helicase. These interactions suggest these proteins could be potential drug targets, and some approved drugs'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 1, 2, 2, 3, 0, 3],\n",
       "   'entropy': 1.3321790402101223}},\n",
       " '49': {'no': {'greedy': 'Yes, many individuals develop a robust immune response, including antibodies and T-cells, which may help prevent re-infection. However, the duration and effectiveness of this protection are still being studied.',\n",
       "   'samples': ['Studies suggest that recovered individuals develop both antibody and T-cell immunity, offering some protection against re-infection, but the duration and level of protection are still being researched.',\n",
       "    'Yes, some studies suggest that individuals who recover from COVID-19 develop a protective immune response, including antibodies and T-cell immunity, which may help prevent re-infection. However, the duration and extent of this protection are still being researched. Vari',\n",
       "    'Yes, individuals who recover from COVID-19 often develop a protective immune response, including antibodies and T-cell immunity, which can potentially prevent re-infection. However, the duration and strength of this protection are still being studied.',\n",
       "    'Evidence suggests that recovered individuals develop both antibody and T-cell immunity, which may provide some protection against re-infection. However, the duration and extent of this protection are still being studied. Answer is moderate confidence. [Ref: Nature Medicine, Cell,',\n",
       "    'Yes, many recoveries demonstrate protective immune responses, including antibodies and T-cells, which may reduce the risk of reinfection. However, individual variability exists. Additional research is ongoing. Answer modified for brevity.',\n",
       "    'Yes, many individuals develop protective immune responses, including antibodies and T-cell mediated immunity, after recovering from COVID-19, which may help prevent re-infection. However, the duration and effectiveness of this protection are still being studied. Answering more',\n",
       "    'Yes, many recoverees develop a protective immune response, including antibodies and T-cells, which may reduce the risk of reinfection. However, the long-term efficacy is still being studied. Answer.',\n",
       "    'Yes, many individuals develop a robust immune response including antibodies and T-cell mediated immunity after recovering from COVID-19, which may provide protection against reinfection. However, the duration and effectiveness of this immunity are still being studied. Answering briefly:',\n",
       "    'Evidence suggests recovered individuals develop both antibodies and T-cell immunity, which may offer protection against re-infection. However, the duration and strength of this immunity are still being studied. Answering briefly: Yes, but duration uncertain.',\n",
       "    'Studies suggest that individuals who recover from COVID-19 develop an immune response, including antibodies and T-cells, which may provide some protection against re-infection. However, the duration and effectiveness of this immunity are still being researched. Answering briefly'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 2, 2, 3, 0, 0],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'kqanoog7': {'greedy': 'Yes, based on the reported findings, individuals who recover from mild-to-moderate COVID-19 show significant immune responses, including increased antibody-secreting cells, follicular T-helper cells, and activated T-cells, along with detectable',\n",
       "   'samples': ['The study indicates that individuals who recover from mild-to-moderate COVID-19 show significant immune responses, including increased antibody-secreting cells, follicular T-helper cells, and activated CD4+ and CD8+ T-cells, as',\n",
       "    'The provided context indicates that individuals with mild-to-moderate COVID-19 show significant immune responses, including increased antibody-secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T-cells, and detectable',\n",
       "    'Based on the context provided, individuals who recover from mild-to-moderate COVID-19 appear to develop significant immune responses, including increased antibody-secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T-c',\n",
       "    'Based on the described case, individuals who recover from mild-to-moderate COVID-19 can develop significant immune responses, including antibody levels and T-cell mediated immunity, which may help prevent re-infection. However, this specific case alone is not',\n",
       "    'Yes, based on the observed immune response, including increased antibody-secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T-cells, and detectable SARS-CoV-2-binding antibodies, there is evidence',\n",
       "    'Yes, based on the described case, individuals who recover from mild-to-moderate COVID-19 can develop significant immune responses, including increased antibody-secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T',\n",
       "    'The study indicates that individuals recover from mild-to-moderate COVID-19 showing a robust immune response with increased antibody-secreting cells, follicular T-helper cells, and activated CD4+ and CD8+ T-cells, along with',\n",
       "    'Based on the described case, individuals who recover from mild-to-moderate COVID-19 likely develop substantial anti-viral immunity, including increased antibody-secreting cells, follicular T-helper cells, and activated T-cells. However, the',\n",
       "    'The study suggests that individuals who recover from mild-to-moderate COVID-19 show evidence of substantial anti-viral immunity, including increased antibody-secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T-c',\n",
       "    'Yes, based on the observed immune response, including increased antibody-secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T-cells, and detectable IgM/IgG SARS-CoV-2-binding'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 0, 6, 0, 4],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'qg01p4bq': {'greedy': 'Based on current evidence, it is not clear if individuals develop sufficient immunity to prevent re-infection. More research is needed to fully understand the immune response and its duration.',\n",
       "   'samples': ['Based on current knowledge, there is uncertainty about whether individuals who recover from COVID-19 have sufficient immune protection to prevent re-infection. Further studies are needed to understand immune responses and their duration.',\n",
       "    'Based on current evidence, it is not yet clear if individuals who recover from COVID-19 show sufficient immune response to fully prevent re-infection. More research is needed to better understand the duration and effectiveness of immunity. (Note: This answer is',\n",
       "    'Based on current knowledge, larger studies are needed to conclusively determine if individuals develop sufficient immunity to prevent re-infection. The reported cases suggest variability in immune responses. Antibody levels and T-cell mediated immunity likely play roles, but more data is required',\n",
       "    'The provided information does not conclusively answer this question. Further studies are required to determine if recovered individuals have adequate immune responses, such as antibodies and T-cell immunity, to prevent re-infections. Some cases suggest possible re-infections or reactivations',\n",
       "    'Based on current evidence, larger studies are needed to fully understand immune responses and prevention of re-infection after recovery from COVID-19. Early data suggest variable immune responses among individuals.',\n",
       "    'Based on current evidence, it is unclear if individuals develop sufficient immune protection to prevent re-infection. This case series suggests reinfections can occur despite prior infection. More research is needed to fully understand immune responses and duration of protection.',\n",
       "    'Based on current evidence, it is unclear if individuals who recover from COVID-19 show sufficient immune response to fully prevent re-infection. More research is needed to understand immune responses and their duration.',\n",
       "    'The evidence suggests that while some degree of immune protection may occur, it is not yet clear if current immune responses fully prevent re-infection. More research is needed to better understand the duration and strength of protective immunity against SARS-CoV-2.',\n",
       "    'The evidence suggests that some individuals may experience re-infection, indicating incomplete or waning immunity. More research is needed to fully understand the duration and effectiveness of the immune response to SARS-CoV-2. Antibody levels and T-cell mediated immunity',\n",
       "    'Based on the given context, larger studies with comprehensive virological, immunological, and epidemiologic data are needed to determine if individuals who recover from COVID-19 exhibit sufficient immune responses, such as antibodies and T-cell immunity, to prevent re'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 0, 0, 0, 3, 4],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  '8aezcyf9': {'greedy': 'The study suggests that individuals who recover from COVID-19 may have some immune response, including increased plasma cells and T-cell expansion, but it is not clear if this is sufficient to prevent re-infection. Further research is needed to fully understand the',\n",
       "   'samples': ['Based on the study described, individuals recovering from COVID-19 exhibit changes in immune cell subsets and states, including increased inflammatory monocytes, decreased T cells, and expanded T cell clones. Additionally, there are significant B cell responses, including increased plasma',\n",
       "    'The study indicates that while individuals who recover from COVID-19 have some immune response, including increased plasma cells and T-cell clones, they may still be vulnerable to reinfection due to the observed immune dysregulation and lack of clear long-term immunity',\n",
       "    'Based on the provided context, individuals recovering from COVID-19 exhibit some immune responses, such as increased plasma cells and specific BCR changes, which could contribute to antibody production. However, T cells are decreased and show a monoclonal state,',\n",
       "    'The study suggests that while some key immune cell subsets and responses are altered in early recovery from COVID-19, there is evidence of both antibody production and T-cell mediated immunity. However, the vulnerability observed in the early recovery stage indicates ongoing immune dys',\n",
       "    'The study does not provide conclusive evidence regarding long-term immunity or prevention of re-infection. It characterizes the immune changes in early recovery, showing altered immune cell subsets and states, but does not assess long-term immunity or protection against re-infection.',\n",
       "    'Based on current knowledge, individuals who recover from COVID-19 may have some protection against re-infection, but the extent and duration of this protection are not fully understood. This study indicates changes in immune cell subsets and states post-recovery, suggesting',\n",
       "    'Based on the provided information, the study suggests that recovered COVID-19 patients may have some level of immune response, including increased B cells and plasma cells, and expanded T-cell clones, particularly memory T-cells. However, the study does not',\n",
       "    'The study does not provide direct evidence regarding whether individuals who recover from COVID-19 have sufficient immune response to prevent re-infection. However, it highlights the presence of increased plasma cells and specific B-cell receptor changes, suggesting an adaptive immune response.',\n",
       "    'The study indicates that individuals who recover from COVID-19 exhibit certain immune responses, such as increased plasma cells and specific BCR changes, which might provide some protection. However, the study does not definitively answer whether these responses are sufficient to prevent',\n",
       "    'The study indicates that individuals who recover from COVID-19 have a unique immune cell signature with both decreased T-cells and increased inflammation, and an expansion of specific T-cell clones and B cells producing antibodies. However, whether this immune response is sufficient'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  '5lhvix51': {'greedy': 'The study suggests that individuals who recover from mild COVID-19 may develop sufficient T-cell mediated immunity to contribute to convalescence, but it does not provide information on antibody levels or long-term protection against re-infection. Further research is needed to',\n",
       "   'samples': ['The study suggests that individuals who recover from COVID-19 may develop T-cell mediated immunity that contributes to convalescence, but does not definitively address antibody levels or long-term protection against re-infection. Further research is needed to fully understand the',\n",
       "    'The study suggests that individuals who recover from mild COVID-19 show an increase in effector and memory T cells, which may contribute to convalescence. However, the study does not provide information on antibody levels or long-term protection against re-in',\n",
       "    'The provided context does not directly address antibody levels, but it suggests that recovery is associated with the formation of T cell memory, which could contribute to preventing re-infection. However, the effectiveness of this T cell-mediated immunity in preventing re-infection is',\n",
       "    'The study suggests that individuals who recover from mild cases of COVID-19 may develop sufficient T-cell mediated immunity to contribute to convalescence. However, it does not provide information on antibody levels or the prevention of re-infection. Further research is',\n",
       "    'The study suggests that recovery from mild COVID-19 is associated with the formation of T cell memory, which may contribute to protection against re-infection. However, it does not provide information on antibody levels or complete prevention of re-infection. Further',\n",
       "    'Based on the provided context, the data suggests that individuals who recover from mild COVID-19 (MD) show a formation of T cell memory, which could contribute to preventing re-infection. However, the data does not explicitly mention antibody levels or',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which could contribute to preventing re-infection. However, the study did not specifically measure antibody levels or provide definitive evidence regarding protection against re-infection.',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which may contribute to protection against re-infection. However, antibody levels and other aspects of immunity were not specifically addressed in this research. Further studies are',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which may contribute to preventing re-infection. However, antibody levels and their role in long-term protection are not discussed in this specific context. Answering',\n",
       "    'The study suggests that recovery from mild cases of COVID-19 is associated with the formation of T cell memory, which could contribute to preventing re-infection. However, for severely affected patients, there is no evidence of the formation of effector and'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 1, 3, 1, 0, 1, 4],\n",
       "   'entropy': 1.4184836619456562},\n",
       "  'eg84q35t': {'greedy': 'The study suggests that individuals recovering from COVID-19 may still have an inflammatory immune signature and could be vulnerable post-discharge, indicating potential ongoing risk of reinfection. However, it does not provide definitive evidence on long-term immunity or protection against re',\n",
       "   'samples': ['Based on the provided context, it is suggested that individuals who recover from COVID-19 exhibit changes in immune cell subsets and states, but there is insufficient information to determine if they have a sufficient immune response to prevent re-infection. The study indicates',\n",
       "    \"Based on the given context, it's not clear if individuals fully recover from COVID-19 with sufficient immune response to prevent re-infection. The study indicates changes in immune cell subsets and states but does not directly address long-term immunity or reinfection\",\n",
       "    'Based on the provided information, individuals who recover from COVID-19 exhibit changes in immune cell subsets and states, but whether they have sufficient immune response to prevent re-infection is not conclusively determined. The study highlights alterations in T cells and B',\n",
       "    'The study suggests that while individuals may show certain immune responses, they might still be vulnerable post-recovery, indicating potential risk of re-infection. Further research is needed to fully understand the durability and effectiveness of the immune response to SARS-CoV-',\n",
       "    'Based on the given information, this study does not provide conclusive evidence regarding whether individuals who recover from COVID-19 have sufficient immune responses to prevent re-infection. The findings suggest ongoing vulnerability post-hospital discharge and highlight specific immune changes, but they',\n",
       "    'The study does not provide clear evidence regarding whether recovered individuals have sufficient immunity to prevent re-infection. While it characterizes immune changes during recovery, it does not directly address long-term immunity or reinfection risk. Further research is needed to determine the durability',\n",
       "    'Based on the given information, the study suggests that individuals recovering from COVID-19 exhibit changes in immune cell subsets and states, indicating potential vulnerability post-hospital discharge. However, the specific levels of antibodies and T-cell mediated immunity to prevent re-in',\n",
       "    'Based on the provided context, the study suggests individuals in the early recovery stage of COVID-19 exhibit an inflammatory immune signature and changes in B-cell receptor signals. While the study does not definitively address whether recovered individuals have sufficient immunity to prevent re',\n",
       "    'The study suggests that while there is an increase in plasma cells, indicating some antibody production, and decreases in T cells, showing potential immune cell impairment, the full extent of long-term immunity and protection against reinfection is not clear based on this data alone',\n",
       "    'Based on current research, individuals who recover from COVID-19 may have some immune protection, but the duration and full effectiveness of this protection are still uncertain. Antibody levels and T-cell mediated immunity have been observed, but reinfections have been reported'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 3, 2, 4, 1, 5],\n",
       "   'entropy': 1.6957425341696344},\n",
       "  '9iuesnxo': {'greedy': 'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which may offer some protection against re-infection. However, it does not provide definitive information on antibody levels or long-term immunity. Further research is needed',\n",
       "   'samples': ['The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which may offer protection against re-infection. However, individual immune responses can vary. Answering your specific points:',\n",
       "    'The study suggests that recovery is associated with the formation of T cell memory, indicated by an increase in effector and memory subsets in convalescing patients. However, the information provided does not directly address antibody levels or complete prevention of re-infection.',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which could offer protection against re-infection. However, the study does not provide definitive information on antibody levels or complete prevention of re-infection. Further',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, indicating potential protection against re-infection. However, it does not provide information on antibody levels or their duration. Further research is needed to fully understand the',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which could offer some protection against re-infection. However, the data does not definitively confirm whether the immune response, including antibodies and T-cell mediated',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which may offer protection against re-infection. However, more research is needed to fully understand the duration and effectiveness of this immunity. Note: This answer',\n",
       "    'The study suggests recovery is associated with formation of T cell memory, but it does not provide definitive information on preventing re-infection. Further research is needed to fully understand the protective immune response to COVID-19.',\n",
       "    'The study suggests recovery is associated with the formation of T cell memory, which may offer some protection against re-infection, though antibody levels are not discussed. Further research is needed to fully understand protective immunity against SARS-CoV-2.',\n",
       "    'The provided context suggests that recovery from COVID-19 is associated with the formation of T-cell memory, which may contribute to preventing re-infection. However, it does not explicitly mention antibody levels or provide a definitive answer on preventing re-infection.',\n",
       "    'The provided context does not directly address antibody levels or re-infection prevention but suggests that recovery is associated with the formation of T cell memory, implying potential for future immunity. For a definitive answer, more specific studies on antibody levels and long-term immunity would'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 3, 3, 4, 5, 2],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'qyo9x78w': {'greedy': 'The provided context does not address antibody levels or T-cell mediated immunity in recovered individuals, so it is not possible to determine from this information alone whether recovered individuals have sufficient immunity to prevent re-infection. Answering this question would require additional studies focusing on',\n",
       "   'samples': ['The provided context does not address antibody levels or T-cell mediated immunity in individuals who recover from COVID-19, so it cannot be used to determine if these responses prevent re-infection. To answer your question, further studies on long-term immune responses',\n",
       "    'The provided context does not address whether recovered individuals have sufficient immune response to prevent re-infection. It focuses on the severity of symptoms and immune markers in hospitalized individuals with HIV and COVID-19. To answer your question, further research on long-term',\n",
       "    'The provided context does not address antibody levels or T-cell mediated immunity in recovered individuals to determine their risk of re-infection. Therefore, based on this information, we cannot answer the question.',\n",
       "    'The provided context does not address antibody levels or T-cell mediated immunity in individuals who recover from COVID-19. Therefore, no information can be drawn regarding prevention of re-infection based on this study.',\n",
       "    'The provided context does not address whether individuals who recover from COVID-19 have sufficient immune response, including antibody levels and T-cell mediated immunity, to prevent re-infection. It only discusses the severity of symptoms and immune marker levels in people with HIV',\n",
       "    'The provided context does not address antibody levels or T-cell mediated immunity in recovered individuals, so it is not possible to determine based on this information alone whether recovered individuals have sufficient immunity to prevent re-infection. Answering this question would require specific data on',\n",
       "    'The provided context does not address antibody levels or T-cell mediated immunity in individuals who recover from COVID-19. It only discusses lymphopenia, levels of inflammatory markers, and outcomes in people with HIV infected with COVID-19. Therefore,',\n",
       "    'The provided context does not address antibody levels or T-cell mediated immunity in recovered individuals, so it cannot be determined from this information alone whether recovered individuals have sufficient immune response to prevent re-infection. Further research is needed to answer this specific question. Answer',\n",
       "    'The provided context does not address antibody levels or T-cell mediated immunity in recovered individuals, so it cannot be determined from this information alone whether recovered individuals have sufficient immunity to prevent re-infection. Answering this specific question would require additional data on immune responses',\n",
       "    'The provided context does not address whether individuals who recover from COVID-19 have sufficient immune response to prevent re-infection. To answer this question, specific information on antibody levels and T-cell mediated immunity post-recovery would be needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 2, 4, 2, 2, 5],\n",
       "   'entropy': 1.4978661367769952},\n",
       "  '871812f7': {'greedy': 'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which may offer some protection against re-infection. However, it does not provide definitive information on antibody levels or complete prevention of re-infection. Further',\n",
       "   'samples': ['The provided information does not directly address antibody levels, but it suggests that recovery is associated with the formation of T cell memory, which could contribute to preventing re-infection. However, more research is needed to fully understand the long-term immune response to S',\n",
       "    'The provided context does not directly address antibody levels or re-infection prevention. It indicates an increase in effector T cells and memory subsets in convalescing patients, suggesting some level of adaptive immunity. However, specific information about preventing re-infection is',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, but it does not provide conclusive evidence on long-term protection or prevention of re-infection. Further research is needed to determine the duration and effectiveness of the',\n",
       "    'The study suggests that recovery is associated with the formation of T cell memory, which may indicate a sufficient immune response. However, it does not provide information on antibody levels or complete protection against re-infection. More research is needed to fully understand the immune',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, indicating potential long-term immunity. However, antibody levels and other aspects of immunity were not specifically addressed in this research. Answering your question directly: There',\n",
       "    'The study suggests that recovery from COVID-19 is associated with the formation of T cell memory, which may offer protection against re-infection. However, the specific levels of antibodies and their efficacy are not detailed in the provided context. Further research is',\n",
       "    'The provided context does not directly address antibody levels, but it suggests that recovery is associated with the formation of T cell memory, which could contribute to preventing re-infection. However, for a complete answer, further research on antibody levels and long-term immunity',\n",
       "    'The study suggests that recovery is associated with the formation of T cell memory, which may contribute to preventing re-infection. However, it does not provide specific information on antibody levels or complete prevention of re-infection. More research is needed to fully understand',\n",
       "    'The provided context does not specifically address antibody levels or prevention of re-infection, focusing instead on differential changes in lymphocyte subsets and T-cell activation between mild and severe cases of COVID-19. For a direct answer to your question about preventing re',\n",
       "    'The study suggests recovery from COVID-19 is associated with formation of T cell memory, indicating potential protection against re-infection, though long-term immunity remains uncertain. Antibody levels are not discussed in this specific context. Further research is needed to fully'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 4, 4, 5, 4],\n",
       "   'entropy': 1.6094379124341},\n",
       "  'q5i8lpan': {'greedy': 'The study suggests that some individuals may have a lower level of protective antibodies upon discharge, indicating potential vulnerability to re-infection. However, the relationship between antibody levels and T-cell mediated immunity and their effectiveness in preventing re-infection is not fully addressed in',\n",
       "   'samples': ['Based on the study, individuals who recover from severe/critical cases have higher antibody levels but they decrease during recovery, suggesting poorer outcomes. For virus-free patients, RBD and S-specific IgG levels were higher, indicating potentially better immunity. However,',\n",
       "    'The study suggests that individuals who recover from COVID-19 may have sufficient IgG levels, particularly targeting RBD and S proteins, which are 2-fold higher in virus-free patients. However, the evidence on long-term protection, including T-cell',\n",
       "    'The study suggests that RBD- and S-specific IgG levels are higher in virus-free patients, indicating a stronger immune response. However, individuals who got re-infected had low levels of protective antibodies, suggesting incomplete or waning immunity. Thus,',\n",
       "    'The study suggests that individuals who recover from severe/critical COVID-19 have higher antibody levels but also a slower antibody response. While some individuals may develop a robust immune response, others, especially those re-infected, show lower protective antibody levels,',\n",
       "    \"Based on the study, individuals who recover from COVID-19 may have some protection, indicated by higher RBD- and S-specific IgG levels, but there's still a risk of re-infection, as some re-infected patients showed low\",\n",
       "    'The study suggests that some individuals may have a strong antibody response (particularly RBD- and S-specific IgG) post-recovery, which could indicate potential protection. However, re-infected patients showed lower levels of protective antibodies upon discharge, suggesting incomplete',\n",
       "    'Based on the study, some re-infected patients showed lower levels of protective antibodies, suggesting insufficient immunity. However, the study primarily focused on antibody levels and did not directly address T-cell mediated immunity. More comprehensive research is needed to fully understand the role',\n",
       "    'Based on the provided context, re-infected patients had low levels of protective antibodies upon discharge, suggesting insufficient immunity. However, the study did not directly address T-cell mediated immunity or comprehensive overall immune responses post-recovery. More research is needed to fully',\n",
       "    'Based on the study, severe/critical patients have higher IgG levels but they decrease indicating poor outcomes. Virus-free patients show higher RBD- and S-specific IgG levels. Re-infected patients had low protective antibody levels on discharge. This suggests',\n",
       "    'The study suggests that individuals who recover from severe/critical cases have higher antibody levels, but those who get re-infected may have lower protective antibody levels. This indicates varying degrees of protection, highlighting the need for further research on long-term immunity and potential'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 2, 5, 6, 0, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '58sc6xgq': {'greedy': 'Based on the provided context, the study did not directly assess T-cell mediated immunity or long-term antibody levels post-recovery. It found that RP patients had similar plasma antibody levels compared to NRP patients during hospitalization, but this does not necessarily indicate',\n",
       "   'samples': ['Based on the given context, the study found that RP patients had similar plasma antibody levels compared to NRP patients, but it did not specifically mention T-cell mediated immunity. Therefore, the answer is not fully clear, but there is some indication of sufficient',\n",
       "    'Based on the provided context, the study did not directly assess T-cell mediated immunity, but it found that RP patients had similar plasma antibody levels compared to NRP patients. Therefore, it suggests that these individuals likely showed sufficient immune responses including antibodies, though',\n",
       "    'Based on the provided context, the study did not directly address T-cell mediated immunity, but it found that RP patients had similar plasma antibody levels compared to NRP patients. Therefore, it can be inferred that some individuals recovering from COVID-19 may',\n",
       "    'The study did not specifically evaluate T-cell mediated immunity or long-term antibody levels to determine prevention of re-infection. However, it did find that RP patients had similar plasma antibody levels to NRP patients during their hospitalization period. Therefore, based on',\n",
       "    'The provided context does not give specific information about T-cell mediated immunity or whether recovered individuals have sufficient immune responses to prevent re-infection. It mentions that RP patients had similar plasma antibody levels compared to NRP patients, but it does not discuss T-c',\n",
       "    'The study found that RP patients had similar plasma antibody levels compared to NRP patients, but more research is needed to determine if this is sufficient to prevent re-infection. The role of T-cell mediated immunity was not assessed in this study. Answering',\n",
       "    'Based on the given context, it is not explicitly stated whether recovered individuals have sufficient immune responses to prevent re-infection. The study found that RP patients had similar plasma antibody levels compared to NRP patients, but this alone does not indicate overall immune protection',\n",
       "    'Based on the provided context, the study did not directly assess T-cell mediated immunity, but it found that antibody levels were similar between re-detected positive (RP) and non-re-detected positive (NRP) patients during hospitalization, suggesting a',\n",
       "    'Based on the given context, the study found that RP patients had similar plasma antibody levels to NRP patients, but it does not provide clear information on T-cell mediated immunity. Therefore, the answer is not fully determined from the provided context alone. The',\n",
       "    'The study did not specifically address T-cell mediated immunity, but it found that re-detected positive (RP) patients had similar plasma antibody levels compared to non-re-detected positive (NRP) patients. This suggests that they may have developed sufficient immune'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 2, 3, 4, 5, 4, 1],\n",
       "   'entropy': 1.6094379124341003}},\n",
       " '41': {'no': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['Higher infection and death rates, disparate access to healthcare.',\n",
       "    'Higher infection and mortality rates, disproportionate economic impacts, and underlying health disparities.',\n",
       "    'Higher infection and death rates, disproportionate economic impact.',\n",
       "    'Higher infection and mortality rates, economic disparities, and unequal access to healthcare.',\n",
       "    'Higher infection and mortality rates, disparate access to healthcare.',\n",
       "    'Higher infection and mortality rates, disproportionate economic impact, and existing health disparities exacerbated.',\n",
       "    'Higher infection and death rates, economic hardships, and systemic racism exacerbating disparities.',\n",
       "    'Higher infection rates, mortality, and economic impact.',\n",
       "    'African-Americans face higher infection and mortality rates, disparate economic impacts, and structural racism exacerbating vulnerabilities.',\n",
       "    'African-Americans have higher infection rates, hospitalization rates, and mortality rates due to systemic health disparities and socioeconomic factors. They face more comorbidities and have less access to quality healthcare.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 5, 5, 5, 3],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  '97mg41jl': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['African-Americans face higher infection and death rates, economic hardships, and healthcare disparities due to systemic racism.',\n",
       "    'African-Americans face higher infection rates, mortality, and economic impacts due to systemic inequalities, underlying health conditions, and disproportionate frontline work.',\n",
       "    'African-Americans have higher infection, hospitalization, and mortality rates compared to other racial groups in the U.S., partly due to socioeconomic factors. They are also overrepresented among essential workers at higher risk of exposure.',\n",
       "    'African-Americans have higher infection and mortality rates, face greater economic hardships, and encounter more racial discrimination due to COVID-19.',\n",
       "    'Higher infection rates, worse health outcomes, and greater economic impact.',\n",
       "    'Higher infection and death rates, disproportionate economic impact, existing health disparities exacerbated.',\n",
       "    'African-Americans face higher infection, hospitalization, and mortality rates; face more economic hardships; and experience disproportionate police violence and racism.',\n",
       "    'African-Americans face higher infection and death rates, disparate access to healthcare, and economic challenges due to job losses.',\n",
       "    'Higher infection rates, worse health outcomes, economic hardships, and disproportionate representation in essential worker roles.',\n",
       "    'Higher infection and death rates, disproportionate economic impact.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 5, 6, 1, 3],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'ujlsdpzf': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['Higher infection rates, higher hospitalization, and higher death rates. African-Americans face systemic health disparities, socioeconomic challenges, and residential segregation, which contribute to these differences.',\n",
       "    'Higher infection and death rates, comorbidities, and systemic racism contribute to unique challenges.',\n",
       "    'Higher infection rates, disproportionately severe health outcomes, and economic hardships.',\n",
       "    'Higher infection and death rates, economic hardships, and pre-existing health conditions exacerbate disparities.',\n",
       "    'African-Americans have higher infection and mortality rates, face greater economic impacts, and experience disparities in healthcare access.',\n",
       "    'African-Americans face higher infection and death rates, economic impacts, and disproportionate representation in essential worker roles during the pandemic.',\n",
       "    'Higher infection and mortality rates, socioeconomic disparities, and unequal access to healthcare.',\n",
       "    'African-Americans face higher infection rates, mortality, and economic impacts due to systemic disparities.',\n",
       "    'Higher infection and death rates, disproportionately affected economically, pre-existing health disparities exacerbated.',\n",
       "    'African-Americans face higher infection rates, hospitalization, and mortality rates due to COVID-19, partly due to socioeconomic factors. They also experience greater economic impact and disparities in healthcare access.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.639031859650177},\n",
       "  'ey1sqch4': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['Higher infection and death rates, socioeconomic disparities, and underlying health conditions.',\n",
       "    'African-Americans face higher infection and death rates, economic strain, and healthcare disparities compared to the general U.S. population.',\n",
       "    'Higher infection rates, worse outcomes, and economic impacts.',\n",
       "    'Higher infection and death rates, underlying health conditions, and economic disparities contribute to distinct impacts among African-Americans during the pandemic.',\n",
       "    'Higher infection and mortality rates, underlying health conditions.',\n",
       "    'Higher infection and death rates, disproportionate economic impacts, and underlying health conditions.',\n",
       "    'Higher infection and mortality rates, economic disparities, and pre-existing health conditions contribute to unique challenges for African-Americans during the pandemic.',\n",
       "    'African-Americans face higher infection and mortality rates, disparate access to healthcare, and economic impacts.',\n",
       "    'Higher infection and mortality rates, disproportionate economic impact, and existing health disparities exacerbated.',\n",
       "    'African-Americans face higher infection rates, hospitalization rates, and mortality rates due to underlying health conditions exacerbated by systemic inequalities. They also experience economic hardships at disproportionate levels.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 1, 2, 3, 3, 2],\n",
       "   'entropy': 1.3661588475692017},\n",
       "  'crqvdk4k': {'greedy': 'Areas with large proportions of Black/African American residents are at markedly higher risk of positive COVID-19 tests, which is not fully explained by environmental and pre-existing health condition factors.',\n",
       "   'samples': ['The study found that areas with large proportions of Black/African American residents are at a significantly higher risk of positive COVID-19 tests, which is not fully explained by environmental factors or pre-existing conditions. Specifically, the risk was nearly five-fold higher',\n",
       "    'Areas with large proportions of Black/African American residents are at markedly higher risk of positive COVID-19 tests, which is not fully explained by environmental factors and pre-existing conditions.',\n",
       "    'African-Americans are at a higher risk of contracting COVID-19, with a nearly five-fold increase in the risk compared to other communities. This increased risk is not fully explained by environmental or pre-existing health condition factors alone. Additionally, the proportion of',\n",
       "    'The study found that areas with large proportions of Black/African American residents had a nearly five-fold increased risk of positive COVID-19 tests compared to other communities, even after accounting for environmental and health factors. This suggests that African-Americans are disproportionately affected',\n",
       "    'The study found that areas with large proportions of Black/African American residents had a nearly five-fold increased risk of positive COVID-19 tests, not fully explained by environmental and health factors. This indicates a significant disparity in the impact of COVID-1',\n",
       "    'The study found that areas with large proportions of Black/African American residents are at a markedly higher risk of positive COVID-19 tests compared to other populations, even when accounting for environmental factors and pre-existing conditions. This indicates disparities in COVID-1',\n",
       "    'Areas with large proportions of Black/African American residents are at markedly higher risk of positive COVID-19 tests, not fully explained by environmental and health factors. This highlights disparities impacting African-American communities.',\n",
       "    'Areas with large proportions of Black/African American residents are at markedly higher risk of COVID-19 infections that is not fully explained by environmental and health factors. The study found a nearly five-fold increase in the risk of a positive COVID-19',\n",
       "    'African-American communities have a markedly higher risk of positive COVID-19 tests, which is not fully explained by environmental or pre-existing health condition factors. The proportion of Black/African American residents remains significantly associated with increased risk in a multivariable model',\n",
       "    'African-American communities have a significantly higher risk of positive COVID-19 tests compared to other populations, even when controlling for environmental and health factors. This increased risk is notably associated with race and age.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 2, 3, 0, 4, 5],\n",
       "   'entropy': 1.4978661367769952},\n",
       "  'i6a26q3j': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['African-Americans have higher infection and mortality rates, face more discrimination, and have greater economic hardships due to job losses.',\n",
       "    'Higher infection rates, worse outcomes, and disproportionate economic impacts.',\n",
       "    'Higher infection rates, higher hospitalization rates, and higher mortality rates. African-Americans also face economic challenges and discrimination.',\n",
       "    'Higher infection and mortality rates, economic disparities, and pre-existing health conditions contribute to distinct impacts on African-Americans.',\n",
       "    'Higher infection rates, worse outcomes, economic hardships, and disparities in healthcare access.',\n",
       "    'Higher infection and mortality rates, socioeconomic disparities, and healthcare access issues.',\n",
       "    'Higher infection rates, higher hospitalization rates, and higher death rates.',\n",
       "    'African-Americans have higher infection rates, hospitalization rates, and death rates from COVID-19 compared to the general U.S. population. They also face greater socioeconomic challenges that exacerbate these disparities.',\n",
       "    'African-Americans face higher infection and death rates, economic impacts, and racial discrimination related to COVID-19.',\n",
       "    'Higher infection rates, worse outcomes, and occupational disparities.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 3, 4, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'fs983x5g': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['African-Americans face higher infection and mortality rates, economic hardships, and systemic racism exacerbating health disparities.',\n",
       "    'Higher infection and mortality rates, underlying health conditions, and job losses disproportionately affect African-Americans.',\n",
       "    'African-Americans have higher infection and mortality rates, face more economic hardships, and encounter racial biases in healthcare.',\n",
       "    'Higher infection and mortality rates, underlying health conditions, and disproportionate job losses.',\n",
       "    'African-Americans face higher infection, hospitalization, and mortality rates due to systemic health disparities and socioeconomic factors.',\n",
       "    'Higher infection and death rates, underlying health conditions, economic disparities, and healthcare access issues.',\n",
       "    'Higher infection rates, worse outcomes, economic strain, and disproportionate impact on pre-existing conditions.',\n",
       "    'Higher infection and death rates, underlying health conditions, and socioeconomic factors contribute to distinct impacts among African-Americans.',\n",
       "    'Higher infection rates, worse outcomes, economic hardship, and disparities in healthcare access.',\n",
       "    'Higher infection and death rates, economic hardship, and disproportionate healthcare access issues.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 4, 4, 4, 4],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  '9zjtwp19': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['Higher infection and mortality rates, economic hardships, and unequal access to healthcare.',\n",
       "    'Higher infection and mortality rates, disparate economic impacts, and existing health disparities exacerbated.',\n",
       "    'Higher infection and death rates, economic disparities, and pre-existing health conditions contribute to distinct impacts on African-Americans.',\n",
       "    'Higher infection and mortality rates, disproportionate economic impact.',\n",
       "    'Higher infection rates, worse outcomes, and occupational risks.',\n",
       "    'African-Americans have higher infection and mortality rates, face greater economic hardships, and encounter more systemic racism, affecting their health outcomes differently than the general U.S. population.',\n",
       "    'Higher infection and mortality rates, underlying health conditions, and socioeconomic factors contribute to unique challenges for African-Americans.',\n",
       "    'Higher infection and death rates, underlying health conditions, and economic disparities.',\n",
       "    'Higher infection and death rates, disproportionate economic impact, and pre-existing health disparities.',\n",
       "    'Higher infection and death rates, economic disparities, and pre-existing health conditions.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 4, 1, 1, 1, 1],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'cv3op3bb': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['Higher infection and mortality rates, economic hardships, and distrust in healthcare.',\n",
       "    'African-Americans have higher infection and mortality rates, face more workplace risks, and encounter healthcare disparities.',\n",
       "    'Higher infection and mortality rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "    'African-Americans have higher infection, hospitalization, and death rates from COVID-19 compared to the overall U.S. population, partly due to pre-existing health disparities. They also face greater economic impacts and social determinants of health.',\n",
       "    'African-Americans face higher infection, hospitalization, and death rates due to systemic inequalities and underlying health conditions. They also experience economic impacts more severely.',\n",
       "    'Higher infection and death rates, disproportionate economic impact, and existing health disparities exacerbated.',\n",
       "    'Higher infection rates, mortality, and economic impacts.',\n",
       "    'Higher infection and death rates, disparate access to healthcare.',\n",
       "    'Higher infection and death rates, underlying health conditions, and economic impacts.',\n",
       "    'African-Americans face higher infection and mortality rates, disparate economic impacts, and systemic health disparities exacerbated by the pandemic.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 2, 5, 4, 3],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'vgtc0k3a': {'greedy': 'Higher infection and death rates, economic hardships, and disproportionate representation in frontline jobs.',\n",
       "   'samples': ['Higher infection and death rates, socioeconomic disparities, and distrust in healthcare.',\n",
       "    'Higher infection and mortality rates, disproportionate economic impact, existing health disparities exacerbated.',\n",
       "    'Higher infection rates, severe health outcomes, and economic hardships disproportionately affect African-Americans.',\n",
       "    'African-Americans have higher infection and mortality rates, face more workplace risks, and encounter greater healthcare disparities compared to the general U.S. population.',\n",
       "    'Higher infection and mortality rates, economic disparities, and pre-existing health conditions contribute to unique challenges for African-Americans during the pandemic.',\n",
       "    'Higher infection and death rates, underlying health conditions.',\n",
       "    'Higher infection rates, severe illness, and mortality among African-Americans due to systemic health disparities, underlying conditions, and socioeconomic factors.',\n",
       "    'Higher infection and death rates, economic hardship, and disproportionate representation in frontline jobs.',\n",
       "    'Higher infection and death rates, underlying health conditions, and economic hardships.',\n",
       "    'Higher infection rates, severe illness, and death rates among African-Americans compared to other racial groups. Structural inequalities contribute to these disparities.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 4, 3, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '92o3dujh': {'greedy': 'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.',\n",
       "   'samples': ['African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population. These findings highlight',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to other groups. These behaviors can increase their risk of contracting and',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often. This suggests disparities in knowledge and adherence to safety measures.',\n",
       "    'African-Americans are less likely to know how the disease is spread, less likely to know symptoms of COVID-19, wash their hands less frequently, and leave the home more often compared to the rest of the U.S. population.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0],\n",
       "   'entropy': 0.3250829733914482}},\n",
       " '20': {'no': {'greedy': 'No direct evidence of increased risk, but some studies suggest ACE inhibitors may slightly increase viral entry. More research needed.',\n",
       "   'samples': ['No direct evidence supports increased risk for COVID-19 from ACE inhibitors.',\n",
       "    'No direct evidence of increased risk, but some studies suggest ACE inhibitors may slightly increase viral entry. Further research needed.',\n",
       "    'No direct increased risk, but may experience more severe symptoms.',\n",
       "    'No, ACE inhibitors do not increase the risk of COVID-19. Answer: No.',\n",
       "    'No direct evidence shows increased risk for COVID-19 due to ACE inhibitors. However, those with underlying conditions treated by these drugs may have other risks. Consult healthcare provider for personalized advice.',\n",
       "    'No direct evidence of increased risk, but some studies suggest ACE inhibitors may slightly increase viral entry. Further research needed.',\n",
       "    'No direct evidence of increased risk, but some reports suggest potential for more severe outcomes. Always consult healthcare provider. Answering briefly: No direct increased risk, but may face more severe outcomes. Consult healthcare provider.',\n",
       "    'No direct increased risk, but may have comorbidities that increase COVID-19 risk.',\n",
       "    'No, but they may be at higher risk for severe outcomes if infected. ACE inhibitors do not increase susceptibility to COVID-19 infection.',\n",
       "    'No, but they may have more severe outcomes if infected. ACE inhibitors do not increase the risk of contracting COVID-19; however, if a patient does contract the virus, they may experience more severe symptoms. It is important for patients to continue'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 1, 3, 0, 4, 4],\n",
       "   'entropy': 1.6094379124341005},\n",
       "  'nxrg9fi6': {'greedy': 'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19.',\n",
       "   'samples': ['No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19.',\n",
       "    'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19.',\n",
       "    'No, according to the studies, there is no increased risk of infection, severe disease, or in-hospital death associated with ACE inhibitors for patients with COVID-19.',\n",
       "    'No, according to recent studies, patients taking ACE inhibitors are not at an increased risk for COVID-19.',\n",
       "    'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19, severe disease, or in-hospital death.',\n",
       "    'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19.',\n",
       "    'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19, severe disease, or in-hospital death.',\n",
       "    'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19, severe disease, or in-hospital death.',\n",
       "    'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19 or its severity.',\n",
       "    'No, according to the studies, patients taking ACE inhibitors are not at an increased risk for COVID-19 or its severity.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 0, 2, 2, 3, 3],\n",
       "   'entropy': 1.2798542258336676},\n",
       "  '3ljfeizg': {'greedy': 'No direct evidence of increased risk, but some studies suggest ACE inhibitors may slightly increase viral entry. More research needed.',\n",
       "   'samples': ['No, ACE inhibitor use is not associated with an increased risk of COVID-19. However, individuals with hypertension and related conditions treated with ACE inhibitors may have underlying health conditions that increase their risk of severe illness from COVID-19. Always follow',\n",
       "    \"No, ACE inhibitor use is not associated with an increased risk of contracting or having severe COVID-19. However, it's crucial to consult healthcare providers regarding any medication adjustments during the pandemic.\",\n",
       "    'No, but they may have more severe outcomes if infected.',\n",
       "    'No direct increased risk, but may have more severe symptoms if infected.',\n",
       "    'No direct increased risk, but may have comorbidities that raise risk. ACE inhibitors do not increase COVID-19 risk but management should follow guidelines.',\n",
       "    'No, ACE inhibitor use is not associated with an increased risk of COVID-19. However, individuals with hypertension and cardiovascular disease, which may be managed with ACE inhibitors, are at higher risk for severe COVID-19 complications. Consult healthcare provider',\n",
       "    'No, ACE inhibitors do not increase the risk of COVID-19 but may increase the risk of developing more severe symptoms if infected.',\n",
       "    'No direct evidence of increased risk, but ACE inhibitors may affect viral entry. Consult healthcare provider for personalized advice.',\n",
       "    'No direct increased risk, but some may experience more severe symptoms.',\n",
       "    'No direct increased risk, but may have worse outcomes if infected.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 3, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'z3l6eden': {'greedy': 'No, there is no evidence that patients taking ACE inhibitors are at increased risk for adverse outcomes from COVID-19. They should continue taking these medications unless clinically indicated otherwise.',\n",
       "   'samples': ['No, based on the review, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. Continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, patients taking ACE inhibitors are not at an increased risk for adverse COVID-19 outcomes. They should continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, based on the review of available evidence, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. They should continue their medication unless clinically indicated otherwise.',\n",
       "    'No, based on the available evidence, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. They should continue taking their medication unless clinically indicated otherwise.',\n",
       "    'No, patients taking ACE inhibitors are not at an increased risk for COVID-19. They should continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, patients taking ACE inhibitors are not at an increased risk for COVID-19. They should continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. They should continue taking these medications unless clinically indicated otherwise.',\n",
       "    'No, based on the review of available evidence, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. Continue medication unless clinically indicated otherwise.',\n",
       "    'No, there is no evidence that patients taking ACE inhibitors are at an increased risk for adverse outcomes from COVID-19. They should continue taking the medication unless there is a clinical indication to discontinue it.',\n",
       "    'No, based on the review of available evidence, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. Continue medication unless clinically indicated otherwise.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 0, 0, 0, 1, 1, 1],\n",
       "   'entropy': 0.6931471805599453},\n",
       "  '53107z56': {'greedy': 'No, based on the review of available evidence, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. They should continue using these medications unless clinically indicated otherwise.',\n",
       "   'samples': ['No, based on the available evidence, patients taking ACE inhibitors are not at increased risk for adverse outcomes from COVID-19. Continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, based on the available evidence, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. They should continue their medication unless clinically indicated otherwise.',\n",
       "    'No, based on the review, patients taking ACE inhibitors are not at increased risk for adverse outcomes from COVID-19. They should continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, based on the review, patients on ACE inhibitors do not appear to be at increased risk for adverse outcomes from COVID-19. Continue medication unless clinically indicated otherwise.',\n",
       "    'No, patients taking ACE inhibitors are not at an increased risk for COVID-19. They should continue taking these medications unless clinically indicated otherwise.',\n",
       "    'No, based on the review of available evidence, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. Continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, there is no evidence that patients taking ACE inhibitors are at increased risk for adverse outcomes from COVID-19. They should continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, based on the review, patients taking ACE inhibitors are not at an increased risk for adverse outcomes from COVID-19. Continue using these medications unless clinically indicated otherwise.',\n",
       "    'No, there is no evidence that patients taking ACE inhibitors are at increased risk for adverse outcomes from COVID-19. They should continue taking the medication unless clinically indicated otherwise.',\n",
       "    'No, there is no evidence suggesting that patients taking ACE inhibitors are at increased risk for adverse outcomes from COVID-19. They should continue their medication unless clinically indicated.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 0, 1, 2, 2, 2, 2],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'paxcmex6': {'greedy': 'No, there is currently no evidence suggesting that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. However, decisions regarding continued use should consider individual patient factors such as hemodynamic status',\n",
       "   'samples': ['No, there is currently no evidence suggesting that patients taking ACE inhibitors are at an increased risk for COVID-19.',\n",
       "    'No, there is currently no evidence suggesting that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. However, decisions about continuing these medications should consider individual patient factors.',\n",
       "    \"No, there is currently no evidence suggesting that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. However, healthcare providers should assess each patient's individual clinical condition before making any changes\",\n",
       "    'No, there is currently no clinical evidence to suggest that patients taking ACE inhibitors are at increased risk for COVID-19. However, decisions about continuing these medications should consider individual patient conditions.',\n",
       "    'No, there is currently no evidence that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19.',\n",
       "    'No, there is currently no evidence that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. However, decisions regarding these medications in hospitalized patients should consider their overall clinical condition.',\n",
       "    'No, there is currently no evidence that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. However, decisions about continued use should consider individual patient factors such as hemodynamic status and',\n",
       "    'No, there is currently no clinical evidence suggesting that patients taking ACE inhibitors are at an increased risk for COVID-19.',\n",
       "    'No, there is currently no evidence that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19.',\n",
       "    'No, there is currently no clinical evidence to suggest that patients taking ACE inhibitors are at increased risk for COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 2, 2, 1, 2, 1],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'aqh90wmk': {'greedy': 'No, there is currently no evidence suggesting that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. However, decisions regarding continued use should consider individual patient factors such as hemodynamic status',\n",
       "   'samples': [\"No, there is currently no evidence suggesting that ACE inhibitors increase the risk of COVID-19. However, decisions about continuing these medications should consider the patient's overall clinical condition.\",\n",
       "    \"No, there is currently no clinical evidence suggesting that patients taking ACE inhibitors are at an increased risk for COVID-19. However, decisions regarding continued use of these medications should be made on a case-by-case basis, considering the patient's clinical condition\",\n",
       "    'No, there is currently no clinical evidence to suggest that patients taking ACE inhibitors are at an increased risk for COVID-19. Answer briefly. No, patients taking ACE inhibitors are not at an increased risk for COVID-19. Answer: No',\n",
       "    'No, there is currently no evidence suggesting that patients taking ACE inhibitors are at increased risk for COVID-19. However, decisions regarding their continued use should consider individual patient factors such as hemodynamic status and renal function.',\n",
       "    'No, there is currently no evidence suggesting that patients taking ACE inhibitors are at increased risk for COVID-19. However, healthcare providers should consider individual patient conditions when making medication decisions.',\n",
       "    'No, there is currently no clinical evidence to suggest that ACE inhibitor use increases the risk of SARS-CoV-2 infection or worsens outcomes in patients with COVID-19. However, decisions about continuing these medications should consider individual patient factors such',\n",
       "    'No, there is currently no evidence suggesting that ACE inhibitors increase the risk of SARS-CoV-2 infection or worsen outcomes in patients with COVID-19. However, decisions regarding continued use should consider individual patient conditions.',\n",
       "    'No, there is currently no evidence suggesting that patients taking ACE inhibitors are at an increased risk for COVID-19.',\n",
       "    'No, there is currently no clinical evidence to suggest that patients taking ACE inhibitors are at an increased risk for COVID-19.',\n",
       "    'No, there is currently no evidence suggesting that ACE inhibitors increase the risk of COVID-19 or worsen outcomes.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 1, 0, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '3l1nru0l': {'greedy': 'No, there is no compelling clinical evidence showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, they should continue to be used as recommended.',\n",
       "   'samples': ['No, there is currently no compelling clinical data showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV-2 infections. Unless contraindicated, patients should continue taking ACE inhibitors as recommended',\n",
       "    'No, there is currently no compelling clinical evidence indicating that ACE inhibitors increase the risk of contracting COVID-19 or worsen its outcomes. However, further research is needed. Unless contraindicated, patients should continue their medication as recommended by medical',\n",
       "    'No, there is no conclusive evidence that ACE inhibitors increase the risk of contracting COVID-19 or worsen its outcome. Continue using them unless contraindicated.',\n",
       "    'There is no conclusive evidence that ACE inhibitors increase the risk of contracting COVID-19 or worsening its outcome. Patients should continue using them as recommended unless contraindicated. Further research is needed.',\n",
       "    'No, there are no compelling clinical data showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV-2 infections. Unless contraindicated, their use should continue.',\n",
       "    'No, there is no compelling clinical evidence suggesting that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, patients should continue using ACE inhibitors as recommended by medical societies.',\n",
       "    'No, there is no compelling clinical evidence showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV-2 infections. Unless contraindicated, use of ACE inhibitors should continue. Answer briefly',\n",
       "    'No, there is currently no compelling clinical data showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, they should continue to be used as recommended by medical societies.',\n",
       "    'No, there is currently no compelling evidence that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, patients should continue taking ACE inhibitors as prescribed.',\n",
       "    'No, there are presently no compelling clinical data showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV-2 infections. Unless contraindicated, use of ACE inhibitors should continue.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 0, 2, 0, 2, 1, 0],\n",
       "   'entropy': 1.0549201679861442},\n",
       "  'd9wfmvp8': {'greedy': 'No, there is no compelling clinical evidence showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, they should continue to be used as recommended.',\n",
       "   'samples': ['No, there is no compelling clinical evidence to show that patients taking ACE inhibitors are at an increased risk for COVID-19. However, more research is needed. Unless contraindicated, patients should continue their ACE inhibitor therapy as recommended by medical',\n",
       "    'There is currently no compelling evidence to show that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. However, more research is needed. Unless contraindicated, patients should continue their ACE inhibitor therapy as recommended by medical',\n",
       "    'No, there is no compelling clinical evidence suggesting that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, they should continue to be used as recommended.',\n",
       "    'There is currently no compelling clinical evidence suggesting that ACE inhibitors increase the risk of contracting COVID-19 or worsen its outcome. Therefore, unless contraindicated, patients should continue using ACE inhibitors as recommended by medical societies. However, further research',\n",
       "    'No, there is currently no compelling clinical evidence showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, they should continue to be used as recommended by medical societies. Answer briefly. No',\n",
       "    'No, there is currently no compelling evidence suggesting that ACE inhibitors increase the risk of contracting COVID-19 or worsen its outcome. Unless contraindicated, patients should continue their medication as recommended by medical societies.',\n",
       "    'No, there is currently no compelling clinical data showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, patients should continue their ACE inhibitor therapy.',\n",
       "    'No, there is currently no compelling evidence to suggest that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. However, further research is warranted. Unless contraindicated, these medications should continue to be used as recommended',\n",
       "    'No, there is no compelling clinical evidence showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen its outcome. Unless contraindicated, patients should continue taking them. Answer briefly. No, there is no evidence showing an',\n",
       "    'No, there are presently no compelling clinical data showing that ACE inhibitors increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV-2 infections. Unless contraindicated, use of ACE inhibitors/ARBs in'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 3, 3, 1, 3, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  '4ti8l2ea': {'greedy': 'No, there is no clear evidence that patients taking ACE inhibitors are at an increased risk for COVID-19. The role of ACE inhibitors and angiotensin receptor blockers (ARBs) in these patients remains contentious due to conflicting results. Further',\n",
       "   'samples': ['No, there is no clear evidence indicating that patients taking ACE inhibitors are at increased risk for COVID-19. The relationship between ACE inhibitors and SARS CoV-2 remains complex and conflicting results exist. Further research is needed to clarify this issue',\n",
       "    'No, the context does not definitively state that patients taking ACE inhibitors are at an increased risk for COVID-19. The text mentions conflicting results regarding the use of ACE inhibitors and ACE2 receptors but does not provide a clear conclusion. Answering',\n",
       "    'No, the context mentions conflicting results regarding the use of ACE inhibitors in patients with diabetes and COVID-19, but does not indicate an increased risk. The role of these medications is a contentious issue with limited evidence. Answer as briefly as possible:',\n",
       "    'The context mentions conflicting results regarding the use of ACE inhibitors in patients with diabetes during COVID-19, but does not provide a clear answer. The evidence is limited. Answer: No clear evidence.',\n",
       "    'No, the context does not definitively support that patients taking ACE inhibitors are at an increased risk for COVID-19. The text mentions conflicting results regarding the use of ACE inhibitors in diabetic patients with COVID-19.',\n",
       "    'The context suggests conflicting results regarding the use of ACE inhibitors in patients with diabetes during COVID-19, but it does not definitively state an increased risk. More research is needed. Answer briefly: There is no clear evidence that ACE inhibitors increase COVID',\n",
       "    'No, the context does not provide clear evidence that patients taking ACE inhibitors are at increased risk for COVID-19. The text mentions conflicting results regarding the use of ACE inhibitors and ARBs in patients with diabetes who have contracted SARS CoV-',\n",
       "    'No, there is no conclusive evidence that patients taking ACE inhibitors are at an increased risk for COVID-19. The relationship between ACE inhibitors and COVID-19 remains controversial and more research is needed. Answer briefly. No, there is no conclusive',\n",
       "    'The context mentions conflicting results regarding the use of ACE inhibitors in patients with diabetes during COVID-19, but it does not definitively state an increased risk. Answering your specific question: No, there is no clear evidence that patients taking ACE inhibitors',\n",
       "    'No, there is conflicting evidence regarding the increased risk of COVID-19 in patients taking ACE inhibitors. The role of ACE2 in lung injury and its relation to SARS CoV-2 has raised theoretical concerns but studies have produced mixed results.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 3, 4, 3, 3, 5],\n",
       "   'entropy': 1.4978661367769954},\n",
       "  'gwnb6ofi': {'greedy': 'No direct evidence of increased risk, but some studies suggest ACE inhibitors may slightly increase viral entry. More research needed.',\n",
       "   'samples': ['No direct increased risk, but may have more severe outcomes. ACE inhibitors do not increase COVID-19 risk but may exacerbate symptoms if infected.',\n",
       "    'No direct evidence supports increased risk of COVID-19 from ACE inhibitors. However, monitor for possible side effects like cough.',\n",
       "    'No direct evidence supports increased risk of COVID-19 from ACE inhibitors. However, patients with underlying conditions treated with these drugs may have higher overall risk due to their health status. Consult healthcare provider for personalized advice.',\n",
       "    'No direct increased risk, but may have comorbidities that increase COVID-19 risk.',\n",
       "    'No direct evidence shows ACE inhibitors increase COVID-19 risk.',\n",
       "    'No, ACE inhibitor use is not associated with an increased risk of COVID-19. However, individuals with hypertension, a common condition managed with ACE inhibitors, may be at higher risk for severe illness if infected.',\n",
       "    'No direct evidence supports an increased risk for COVID-19 from ACE inhibitors. However, individuals with underlying conditions treated by these medications may have other risk factors. Consult healthcare provider for personalized advice.',\n",
       "    'No direct evidence supports an increased risk of COVID-19 from ACE inhibitors.',\n",
       "    'No direct increased risk, but may have more severe symptoms.',\n",
       "    'No, but they may be at higher risk for severe illness if infected. ACE inhibitors do not increase the likelihood of contracting COVID-19; however, individuals on these medications might experience more severe symptoms if they contract the virus. Consult healthcare provider for'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 4, 2, 3, 0, 2],\n",
       "   'entropy': 1.5047882836811908}},\n",
       " '40': {'no': {'greedy': 'SARS-CoV-2 has been observed to accumulate mutations at a rate of about 2-4 mutations per month. Common mutations include D614G, N501Y, and others. Variants like B.1.',\n",
       "   'samples': ['SARS-CoV-2 has accumulated over 1,000 mutations. On average, one mutation occurs approximately every 16 days. However, not all mutations are significant. Some variants, like Delta and Omicron, have several',\n",
       "    'SARS-CoV-2 has shown various mutations, with an estimated mutation rate of about 2-4 mutations per month. Mutations observed include changes in the spike protein, affecting virus entry into host cells.',\n",
       "    'SARS-CoV-2 mutations are common, occurring approximately once in every 10,000 nucleotides. Observed mutations include changes in the spike protein, affecting virus binding and immune evasion.',\n",
       "    'SARS-CoV-2 mutations are common, occurring approximately once every 10-20 replicative cycles. Numerous mutations have been observed, with some strains, like B.1.1.7 (Alpha), showing higher mutation rates.',\n",
       "    \"SARS-CoV-2 has shown various mutations, with around 1-2 new mutations arising every month. Mutations have been observed in multiple regions of the virus's genome. However, not all mutations lead to significant changes in the virus's\",\n",
       "    'SARS-CoV-2 has shown various mutations, with about 1-2 new mutations arising every month on average. Mutations occur due to errors during viral replication.',\n",
       "    'SARS-CoV-2 has over 40,000 nucleotides. Mutations occur frequently, with over 18,000 unique mutations identified. Most mutations have minimal impact on virus function. New variants arise regularly',\n",
       "    'Mutations in SARS-CoV-2 occur frequently, with hundreds identified. Many are in the spike protein. Mutation frequency varies but can be around one mutation per 30,000 nucleotides per generation.',\n",
       "    \"SARS-CoV-2 has numerous mutations, with around 1-3 new mutations appearing every month. Mutations have been observed in various regions of the virus's genome. However, not all mutations lead to changes in the virus's behavior or\",\n",
       "    'SARS-CoV-2 has been observed to accumulate mutations at a rate of about 2-4 mutations per month. Mutations have been found in various regions of the genome, with some appearing more frequently than others. However, most mutations do'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'miujzgtd': {'greedy': 'The observed mutations in the SARS-CoV-2 genome include 37 single-nucleotide substitutions occurring in >1% of the genomes, with majority being C to T or G to A. Two of these substitutions occur within highly conserved',\n",
       "   'samples': ['The SARS-CoV-2 genome showed 37 single-nucleotide substitutions occurring in >1% of the genomes, with majority being C to T or G to A. Two of these substitutions occurred within highly conserved secondary structures in the',\n",
       "    'The observed mutations in the SARS-CoV-2 genome are 37 single-nucleotide substitutions, with C to T or G to A being the majority. These mutations occur in >1% of the genomes analyzed.',\n",
       "    \"The study identified 37 single-nucleotide substitutions occurring in >1% of the genomes, mostly C to T or G to A. Two substitutions occurred within highly conserved secondary structures in the 5' and 3' untranslated regions.\",\n",
       "    'The observed mutations in the SARS-CoV-2 genome are 37 single-nucleotide substitutions occurring in >1% of the genomes, with majority being C to T or G to A.',\n",
       "    'Thirty-seven single-nucleotide substitutions were identified in over 1% of the SARS-CoV-2 genomes, with the majority being C to T or G to A changes. Two of these substitutions occur within critical, highly conserved secondary structures',\n",
       "    \"Thirty-seven single-nucleotide substitutions occurring in >1% of the genomes were identified, with majority being C to T or G to A. Two substitutions were found within highly conserved secondary structures in the 5' and 3' untranslated regions\",\n",
       "    'In the SARS-CoV-2 genome, 37 single-nucleotide substitutions were identified, occurring in >1% of the genomes. The majority of these substitutions were C to T or G to A. Two of these substitutions were found',\n",
       "    'The observed mutations in the SARS-CoV-2 genome are 37 single-nucleotide substitutions occurring in >1% of the genomes, with majority being C to T or G to A.',\n",
       "    \"The study identified 37 single-nucleotide substitutions occurring in >1% of the genomes, predominantly C to T or G to A. Two of these substitutions are found within highly conserved secondary structures in the 5' and 3'\",\n",
       "    \"37 single-nucleotide substitutions were identified, occurring in >1% of the genomes. The majority were C to T or G to A. Two mutations occurred within highly conserved secondary structures in the 5' and 3' untranslated\"],\n",
       "   'cluster_ids': [0, 1, 1, 1, 0, 0, 0, 1, 1, 0],\n",
       "   'entropy': 0.6931471805599453},\n",
       "  'a51vkiei': {'greedy': 'The study identified recurrent mutations in the SARS-CoV-2 genome, which occurred multiple times independently (homoplasies) within a dataset of over 23,000 genomes. However, none of these mutations were found to be',\n",
       "   'samples': ['The study identified recurrent mutations in the SARS-CoV-2 genome, meaning these mutations occur frequently across different samples. However, none of these recurrent mutations were found to be significantly associated with increased viral transmission. The mutations seemed to be mostly induced by',\n",
       "    'Recurrent mutations in the SARS-CoV-2 genome have been observed, occurring multiple times independently (homoplasies). Over 23,000 SARS-CoV-2 genomes were analyzed to identify these recurrent mutations.',\n",
       "    'Recurrent mutations in the SARS-CoV-2 genome have been observed and occur multiple times independently. These mutations are currently in circulation and appear to be evolutionary neutral, suggesting they are primarily induced by the human immune system via host RNA editing rather than',\n",
       "    'The observed mutations in the SARS-CoV-2 genome are recurrent, meaning they emerge repeatedly and independently across different lineages. There are over 23,000 SARS-CoV-2 genomes analyzed in the study, and these',\n",
       "    'The study identifies recurrent mutations in the SARS-CoV-2 genome, meaning these mutations have appeared multiple times independently. These mutations are primarily induced by the human immune system through host RNA editing rather than indicating adaptation to the human host. The study did',\n",
       "    'The observed mutations in the SARS-CoV-2 genome include recurrent mutations that have emerged repeatedly and independently (homoplasies). These mutations are found in a dataset of over 23,000 SARS-CoV-2 genomes',\n",
       "    'The study identified recurrent mutations in the SARS-CoV-2 genome, but did not find any single mutation convincingly associated with increased viral transmission. These recurrent mutations appear to be evolutionary neutral and are primarily induced by the human immune system through host RNA',\n",
       "    'The document does not provide specific information on what mutations have been observed in the SARS-CoV-2 genome or how often they occur. It only mentions that there are recurrent mutations observed in the virus. However, it states that none of these recurrent',\n",
       "    'The study identified recurrent mutations within a dataset of over 23,000 SARS-CoV-2 genomes isolated from patients worldwide. However, the study did not find a single recurrent mutation convincingly associated with increased viral transmission. These recurrent',\n",
       "    'The study identified recurrent mutations in the SARS-CoV-2 genome, meaning mutations that have appeared multiple times independently. These mutations are currently circulating and appear to be evolutionary neutral, with no clear evidence of increased transmissibility. They are likely induced'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '1vhxcbx7': {'greedy': 'The study identified 14 frequent mutations in the SARS-CoV-2 genome, which characterize six main clusters of strains. These mutations occur in the viral genome and have been spreading globally, contributing to the evolution and adaptation of the virus. The',\n",
       "   'samples': ['Six phylogenetic clusters of SARS-CoV-2 strains were identified based on the distribution of 14 frequent mutations. These mutations occur relatively frequently, as they are present in over 1,932 sequenced genomes. The study',\n",
       "    'The study identified 14 frequent mutations in the SARS-CoV-2 genome. The mutations occur in the form of single nucleotide variations (SNVs) and have spread globally. Six phylogenetic clusters were identified based on these mutations.',\n",
       "    'The study identified 14 frequent mutations in the SARS-CoV-2 genome among 1,932 sequenced genomes. These mutations contribute to the formation of six phylogenetic clusters with geographic preferences. The mutations occur at varying frequencies',\n",
       "    'Fourteen frequent mutations were identified in the SARS-CoV-2 genome that characterize the six main clusters of strains. The mutations occur in the form of single nucleotide variations (SNVs). The study did not provide specific frequencies of occurrence for each',\n",
       "    'Six phylogenetic clusters of SARS-CoV-2 strains were identified based on mutations in the form of single nucleotide variations (SNVs). Fourteen frequent mutations characterized these six main clusters. The study suggests that these mutations are spreading globally and',\n",
       "    'The study identified 14 frequent mutations in the SARS-CoV-2 genome, which can characterize the six main clusters of SARS-CoV-2 strains. These mutations occur at varying frequencies globally.',\n",
       "    'The study identified 14 frequent mutations in the SARS-CoV-2 genome, occurring in over 5% of the genomes analyzed. These mutations contribute to the identification of six main clusters of SARS-CoV-2 strains.',\n",
       "    'Six phylogenetic clusters of SARS-CoV-2 strains were identified, characterized by 14 frequent mutations. These mutations occur frequently across the globe and are associated with increased fatality rates in COVID-19 patients.',\n",
       "    'The study identified 14 frequent mutations in the SARS-CoV-2 genome from 1,932 sequenced genomes. These mutations contribute to the formation of six main clusters of SARS-CoV-2 strains. The frequency of',\n",
       "    'Six phylogenetic clusters of SARS-CoV-2 strains were identified, characterized by fourteen frequent mutations. These mutations occur in the form of single nucleotide variations (SNVs) and have spread globally. The study found a positive correlation between the'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '5mh3ds6y': {'greedy': 'The study identified 782 variant sites in the SARS-CoV-2 genome, with 512 (65.47%) having a non-synonymous effect. Among these, 38 recurrent non-synonymous',\n",
       "   'samples': ['782 variant sites were observed, with 512 (65.47%) having a non-synonymous effect. Among these, 38 recurrent non-synonymous mutations were identified, including 10 hotspot mutations',\n",
       "    'The study identified 782 variant sites, with 512 (65.47%) having a non-synonymous effect. It also found 38 recurrent non-synonymous mutations, including ten hotspot mutations with a prevalence',\n",
       "    'The study observed 782 variant sites in the SARS-CoV-2 genome, with 512 (65.47%) having a non-synonymous effect. Recurrent non-synonymous mutations included 38',\n",
       "    '782 variant sites were observed, of which 512 (65.47%) had a non-synonymous effect. There were 38 recurrent non-synonymous mutations, including ten hotspot mutations with a prevalence higher',\n",
       "    'The study identified 782 variant sites in the SARS-CoV-2 genome, with 512 (65.47%) having a non-synonymous effect. Among these, 38 recurrent non-synonymous',\n",
       "    'The study identified 782 variant sites in the SARS-CoV-2 genome, with 512 (65.47%) being non-synonymous mutations. Among these, 38 recurrent non-synonymous mutations',\n",
       "    'The study observed 782 variant sites in the SARS-CoV-2 genome, with 512 (65.47%) having a non-synonymous effect. Among these, there were 38 recurrent non-s',\n",
       "    'The study identified 782 variant sites in the SARS-CoV-2 genome, with 512 (65.47%) having a non-synonymous effect. Among these, 38 recurrent non-synonymous',\n",
       "    'In the study, 782 variant sites were observed in the SARS-CoV-2 genome, with 512 (65.47%) having a non-synonymous effect. Among these, 38 recurrent non',\n",
       "    '782 variant sites were observed in the SARS-CoV-2 genome, with 512 (65.47%) having a non-synonymous effect. Out of these, 38 recurrent non-synonymous'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 1, 2, 1, 1, 2],\n",
       "   'entropy': 1.0549201679861442},\n",
       "  'r0gr0bhl': {'greedy': 'The SARS-CoV-2 genome has 39,900 unique positions with 39,920 mutations. These mutations include 11,829 synonymous mutations and 21,701 nonsyn',\n",
       "   'samples': ['The SARS-CoV-2 genome has 39920 mutations across 3990 unique positions, with 11829 being synonymous and 21701 being nonsynonymous. Mutation frequencies are not',\n",
       "    'The SARS-CoV-2 genome has 39,900 unique positions with 39,920 mutations observed. Mutations include 11,829 synonymous (681 synonymous frameshifts) and',\n",
       "    'The SARS-CoV-2 genome has 39,900 unique mutation positions, with 11,829 synonymous and 21,701 nonsynonymous mutations. Mutation frequency varies across positions. To get',\n",
       "    'The SARS-CoV-2 genome has 3990 unique positions with 39920 mutations. There are 11829 synonymous mutations and 21701 nonsynonymous mutations. Mutations occur',\n",
       "    'The SARS-CoV-2 genome has 39,900 unique mutation positions, with 11,829 synonymous and 21,701 nonsynonymous mutations. The mutations occur at various frequencies across different',\n",
       "    'The SARS-CoV-2 genome incorporates 39,920 mutations over 3,990 unique positions. These mutations include 11,829 synonymous mutations (including 681 synonymous frameshifts)',\n",
       "    'The SARS-CoV-2 genome contains 21701 nonsynonymous mutations and 11829 synonymous mutations, totaling 39920 mutations across 3990 unique positions. The mutations occur at',\n",
       "    'There are 39,920 mutations observed in 3,990 unique positions in the SARS-CoV-2 genome. Among them, 11,829 are synonymous mutations (including 681 synonymous',\n",
       "    'The SARS-CoV-2 genome has 39920 mutations across 3990 unique positions. There are 11829 synonymous mutations and 21701 nonsynonymous mutations. Mutation frequencies are',\n",
       "    'The SARS-CoV-2 genome has 39,900 unique mutation positions, with 11,829 synonymous and 21,701 nonsynonymous mutations. Mutation occurrence varies across these positions. To'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 1, 0, 0, 2, 2, 1],\n",
       "   'entropy': 1.0549201679861442},\n",
       "  'fglghjy6': {'greedy': 'The observed mutations in the SARS-CoV-2 genome include 14408 C>T and 23403 A>G in the RdRp and S genes, respectively. These mutations become more frequent over time, particularly in',\n",
       "   'samples': ['The observed mutations in the SARS-CoV-2 genome include 14408 C>T and 23403 A>G in the RdRp and S genes, respectively. Mutations occur more frequently in the S and Or',\n",
       "    'The SARS-CoV-2 genome contains 14408 C>T and 23403 A>G mutations in RdRp and S, respectively, which become widespread. Mutation densities vary over time, with significant increases observed in',\n",
       "    'The observed mutations in the SARS-CoV-2 genome include 14408 C>T and 23403 A>G in the RdRp and S genes, respectively. These mutations become more frequent, especially in European and',\n",
       "    'The observed mutations in the SARS-CoV-2 genome include 14408 C>T and 23403 A>G in RdRp and S genes, respectively. Mutations occur at varying frequencies, with some becoming widespread',\n",
       "    'Two mutations, 14408 C>T in RdRp and 23403 A>G in S, occurred frequently in the SARS-CoV-2 genome in Europe and the US. The mutation densities (MDe)',\n",
       "    \"Two mutations, 14408 C>T and 23403 A>G, in the RdRp and S genes, respectively, became dominant in Europe and the US. The mutations' occurrence varies over time, with noticeable increases\",\n",
       "    'The observed mutations in the SARS-CoV-2 genome include 14408 C>T and 23403 A>G, which are more frequent in Europe and the US. These mutations are located in the RdRp and',\n",
       "    'The observed mutations in the SARS-CoV-2 genome include 14408 C>T and 23403 A>G in RdRp and S genes, respectively. These mutations became dominant in Europe and the US. Mutation',\n",
       "    'The SARS-CoV-2 genome has mutations such as 14408 C>T and 23403 A>G, which occur frequently in Europe and the US. These mutations are found in the RdRp and S genes',\n",
       "    'Two mutations, 14408 C>T and 23403 A>G, became dominant in Europe and the US. Mutation densities increased over time, particularly in critical genes S and Orf1ab. However, the mutant'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 5, 5, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'bsypo08l': {'greedy': 'The SARS-CoV-2 genome has 198 recurrent mutations, with nearly 80% producing non-synonymous changes. Some regions, such as Orf1ab (encoding Nsp6, Nsp11, N',\n",
       "   'samples': ['The SARS-CoV-2 genome shows recurrent mutations at 198 sites, with nearly 80% producing non-synonymous changes. Some regions, like Orf1ab (encoding Nsp6, Nsp11,',\n",
       "    'The SARS-CoV-2 genome shows nearly 80% of recurrent mutations producing non-synonymous changes at the protein level, indicating possible ongoing adaptation. Three specific sites, including Orf1ab encoding Nsp6, Nsp1',\n",
       "    '198 recurrent mutations were identified in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Three sites in Orf1ab (encoding Nsp6, Nsp11, N',\n",
       "    'Three sites in Orf1ab and one in the Spike protein show a particularly large number of recurrent mutations (>15 events), indicating possible adaptation to the human host. A total of 198 filtered recurrent mutations were identified, with nearly',\n",
       "    '198 recurrent mutations were identified in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Three sites in Orf1ab and one in the Spike protein had more than 15',\n",
       "    'The SARS-CoV-2 genome has 198 recurrent mutations, with nearly 80% producing non-synonymous changes at the protein level. Some regions, including Orf1ab encoding Nsp6, Nsp11',\n",
       "    'The study identified 198 filtered recurrent mutations in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Three specific sites—encoding Nsp6, Nsp11, Nsp1',\n",
       "    'Three sites in Orf1ab and one in the Spike protein exhibit a large number of recurrent mutations (>15 events), indicating possible adaptation to the human host. These mutations may signify convergent evolution. Nearly 80% of the recurrent mutations',\n",
       "    '198 recurrent mutations were identified in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes at the protein level. Three sites in Orf1ab (encoding Nsp6, Nsp',\n",
       "    '198 recurrent mutations were identified in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Three sites in Orf1ab (encoding Nsp6, Nsp11, N'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 2],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'msggi1p2': {'greedy': '198 recurrent mutations were identified in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Some regions, such as Orf1ab and the Spike protein, had more recurrent mutations (>',\n",
       "   'samples': ['198 recurrent mutations were observed in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Some sites, particularly in Orf1ab and the Spike protein, showed a high frequency of',\n",
       "    'The SARS-CoV-2 genome has 198 recurrent mutations that have emerged independently multiple times. Nearly 80% of these recurrent mutations produce non-synonymous changes at the protein level, suggesting possible ongoing adaptation. Some sites,',\n",
       "    '198 recurrent mutations were observed in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes at the protein level. Some sites, particularly in Orf1ab and the Spike protein, had',\n",
       "    '198 recurrent mutations were observed in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Some regions, like Orf1ab encoding Nsp6, Nsp11, N',\n",
       "    'Three sites in Orf1ab (encoding Nsp6, Nsp11, Nsp13) and one in the Spike protein show a high frequency of recurrent mutations (>15 events), indicating potential adaptation to the human host. The',\n",
       "    '198 recurrent mutations were observed in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes at the protein level. Certain sites in Orf1ab and the Spike protein had a particularly large',\n",
       "    'The study identified 198 recurrent mutations in the SARS-CoV-2 genome, with nearly 80% producing non-synonymous changes. Three regions—Orf1ab encoding Nsp6, Nsp11, N',\n",
       "    'Three sites in Orf1ab (encoding Nsp6, Nsp11, Nsp13) and one in the Spike protein show a large number of recurrent mutations (over 15 events), suggesting possible ongoing adaptation to the human',\n",
       "    'The SARS-CoV-2 genome has 198 filtered recurrent mutations, nearly 80% of which produce non-synonymous changes. Some sites, such as those in Orf1ab encoding Nsp6, Nsp1',\n",
       "    'Three sites in Orf1ab and one in the Spike protein have a particularly large number of recurrent mutations, occurring more than 15 times each. These mutations may indicate convergent evolution and adaptation to the human host. Nearly 80%'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 0, 2, 3, 2, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  '5od0tegt': {'greedy': 'The study identified 11 high-frequency substitutions in the SARS-CoV-2 genome, with four of them showing potential positive selection. These mutations are found in various proteins including non-structural proteins (nsp2, nsp5, n',\n",
       "   'samples': ['The study identified 11 high-frequency substitutions in the SARS-CoV-2 genome, occurring in non-structural proteins (nsp2, nsp5, nsp6, nsp12, nsp13), accessory proteins',\n",
       "    'The study identified 11 high-frequency substitutions in the SARS-CoV-2 genome across non-structural proteins (nsp2, nsp5, nsp6, nsp12, nsp13), accessory proteins (OR',\n",
       "    'The study identified 11 high-frequency substitutions across various proteins including non-structural proteins (nsp2, nsp5, nsp6, nsp12, nsp13), accessory proteins (ORF3a, ORF',\n",
       "    'Eleven high-frequency substitution residues were identified, with four currently showing potential positive selection. These mutations are found in various proteins, including non-structural proteins (nsp2, nsp5, nsp6, nsp12, nsp1',\n",
       "    'The study identified 11 high-frequency substitution residues in the SARS-CoV-2 genome, including mutations in non-structural proteins (nsp2, nsp5, nsp6, nsp12, nsp13),',\n",
       "    'The study identified 11 high-frequency substitution residues in the SARS-CoV-2 genome. Four of these sites currently show potential signals for positive selection. These mutations are found in non-structural proteins, accessory proteins, and structural proteins, and',\n",
       "    'The study identified 11 high-frequency substitutions in the SARS-CoV-2 genome, occurring in non-structural proteins (nsp2, nsp5, nsp6, nsp12, nsp13), accessory proteins',\n",
       "    'Eleven high-frequency substitutions were identified in the SARS-CoV-2 genome, with four currently showing signals for potential positive selection. These mutations are distributed across various proteins including non-structural proteins, accessory proteins, and structural proteins. Temporal and spatial',\n",
       "    'The study identified 11 high-frequency substitutions in the SARS-CoV-2 genome across various proteins including non-structural proteins (nsp2, nsp5, nsp6, nsp12, nsp13), accessory',\n",
       "    'Eleven high-frequency substitution residues were identified in the SARS-CoV-2 genome, with four currently showing potential positive selection. These mutations are distributed across various proteins including non-structural proteins (nsp2, nsp5, nsp6,'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 3, 0, 3, 0, 1],\n",
       "   'entropy': 1.2206072645530175},\n",
       "  'sd0ah7k5': {'greedy': 'SARS-CoV-2 has numerous mutations, particularly in the ACE2 binding region of the spike glycoprotein, ORF1ab, ORF8, and spike glycoprotein regions. These mutations occur frequently, indicating rapid evolution of the',\n",
       "   'samples': ['SARS-CoV-2 has numerous mutations, particularly in the ACE2 binding region of the spike glycoprotein, as well as in the ORF1ab and ORF8 regions. These mutations occur frequently, indicating rapid evolution of the virus',\n",
       "    'SARS-CoV-2 has numerous mutations, particularly in the ACE2 binding region of the spike glycoprotein, ORF1ab, ORF8, and spike glycoprotein regions. These mutations occur frequently, leading to rapid evolution of',\n",
       "    'Mutations have been observed in the ACE2 binding region of the SARS-CoV-2 spike glycoprotein, as well as in the ORF1ab, ORF8, and spike glycoprotein regions. The virus is evolving rapidly',\n",
       "    'SARS-CoV-2 has numerous mutations, particularly in the ACE2 binding region of the spike glycoprotein, ORF1ab, ORF8, and spike glycoprotein regions. The mutations occur frequently, indicating rapid evolution.',\n",
       "    'Mutations have been observed in the ACE2 binding region of the SARS-CoV-2 spike glycoprotein, as well as in the ORF1ab, ORF8, and spike glycoprotein regions. These mutations occur frequently,',\n",
       "    'Mutations have been observed in the ORF1ab, ORF8, and spike glycoprotein regions of SARS-CoV-2, and they occur frequently, with the virus evolving rapidly. Specific mutations have also been found in the ACE',\n",
       "    'SARS-CoV-2 has numerous mutations, particularly in the ACE2 binding region of the spike glycoprotein, ORF1ab, ORF8, and spike glycoprotein regions. The mutations occur frequently, indicating rapid evolution of the',\n",
       "    'SARS-CoV-2 has numerous mutations and single nucleotide polymorphisms (SNPs), especially in the ACE2 binding region of the spike glycoprotein, ORF1ab, ORF8, and spike glycoprotein regions.',\n",
       "    'Mutations have been found in the ACE2 binding region of the spike glycoprotein, ORF1ab, ORF8, and spike glycoprotein regions. The mutations occur frequently, with the virus evolving rapidly and accumulating numerous mutations and SN',\n",
       "    'Mutations have been observed in the ACE2 binding region, ORF1ab, ORF8, and spike glycoprotein regions of SARS-CoV-2. The virus is evolving rapidly with a high frequency of mutations and SNPs.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 0, 1, 1, 1, 0],\n",
       "   'entropy': 0.6730116670092565}},\n",
       " '48': {'no': {'greedy': 'Benefits include social and emotional development, learning, and reduced isolation. Risks involve increased virus transmission, potential outbreaks, and health concerns.',\n",
       "   'samples': ['Benefits include social development, routine, and potential economic recovery. Risks involve increased virus spread, potential outbreaks, and strain on healthcare systems.',\n",
       "    'Benefits include social and emotional development, academic progress, and reduced stigma. Risks involve increased infection rates, mental health impacts, and unequal access to resources.',\n",
       "    'Benefits include socialization, learning, and economic recovery. Risks involve disease transmission, student and staff health concerns, and potential closures.',\n",
       "    'Benefits include social and emotional development, learning, and reduced stigma. Risks involve spreading the virus, especially to vulnerable populations.',\n",
       "    'Benefits include social and emotional development, learning, and reduced isolation. Risks include increased virus spread, potential outbreaks, and staff exposure.',\n",
       "    'Benefits include socialization, learning, and economic relief. Risks involve virus spread, infections, and potential lockdowns.',\n",
       "    'Benefits include social and emotional development, reduced learning loss. Risks involve increased infection spread, potential economic impacts.',\n",
       "    'Benefits include social and emotional development, learning, and reduced stigma for learning disabilities. Risks involve increased infection rates and potential economic impacts if outbreaks occur.',\n",
       "    'Benefits include social and emotional development, reduced learning loss. Risks involve spreading the virus to students, staff, and their families.',\n",
       "    'Benefits include social development, reduced learning loss, and normalcy. Risks involve increased infection spread, potential economic strain, and mental health impacts.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 2, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'x6x6a35w': {'greedy': 'Reopening schools poses benefits like resuming education and socialization but increases the risk of virus transmission among students and staff. Risks include potential outbreaks and strain on healthcare resources.',\n",
       "   'samples': ['Reopening schools allows for normalcy, education continuity, and social interaction but poses risks like increased infection rates and unequal access to resources. Risks include potential outbreaks, disparities in internet and device access, and difficulties in implementing strict safety protocols. Benefits include',\n",
       "    'Risks include potential spread of the virus, strain on healthcare systems, and exacerbation of obesity. Benefits include educational continuity and reduced stigma from prolonged school closure.',\n",
       "    'Reopening schools allows children to receive an education and engage in social activities, but increases their exposure to the virus, posing health risks. Schools must balance educational needs with public health considerations. Risks include potential virus spread among students and staff, while benefits',\n",
       "    'Re-opening schools poses both benefits and risks during the pandemic. Benefits include resuming normal educational and social development for children, but risks involve potential spikes in virus transmission, especially if precautions are not strictly followed. Balancing these factors is crucial for public health',\n",
       "    \"Risks include increased transmission of the virus among students and staff, while benefits include mitigating the negative effects on children's education and potential exacerbation of obesity risk.\",\n",
       "    'Reopening schools poses benefits like resuming education and social interaction but risks include increased virus spread among students and staff.',\n",
       "    'Reopening schools carries benefits like resumed education and socialization but poses risks such as potential COVID-19 spread.',\n",
       "    'Reopening schools during the pandemic offers educational and social benefits but poses health risks from potential virus spread. Benefits include continued learning and peer interaction. Risks involve increased exposure and transmission of the virus among students and staff.',\n",
       "    'Re-opening schools poses benefits like resuming normalcy, academic progress, and socialization but carries risks such as increased exposure to COVID-19 and potential outbreaks.',\n",
       "    'Reopening schools can benefit children by providing structure and access to nutrition programs, but increases the risk of virus transmission, straining healthcare systems.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 5, 5, 5, 6],\n",
       "   'entropy': 1.7480673485460891},\n",
       "  '22y5ewq6': {'greedy': 'Benefits include mitigating negative psychological, educational, and social impacts on children. Risks involve potential virus transmission, especially if safety measures are not strictly enforced. Balancing these factors is crucial.',\n",
       "   'samples': [\"Benefits include positive impacts on children's social life, education, and mental health; Risks involve potential virus transmission, especially if safety measures are not properly implemented.\",\n",
       "    \"Benefits include supporting children's social, emotional, and cognitive development, mitigating learning loss, and addressing socio-economic disparities. Risks involve potential virus transmission among students and staff, psychological stress, and unequal access to safe reopening measures. Balancing these factors\",\n",
       "    \"Benefits include mitigating negative impacts on children's social life, education, and mental health. Risks involve potential virus transmission among children, who may spread the virus to vulnerable family members. Balancing these factors is crucial.\",\n",
       "    'Benefits include mitigating the psychological, educational, and social impacts on children, while risks involve potential virus transmission and amplification of socio-economic disparities.',\n",
       "    'Benefits include positive social and educational impacts on children, while risks involve the potential for increased virus transmission, especially if safety measures are not strictly followed. Balancing these factors is crucial.',\n",
       "    'Benefits include mitigating psychological, educational, and social impacts on children; Risks involve potential virus transmission and increased socio-economic disparities.',\n",
       "    \"Benefits include mitigating the negative impacts on children's social life, education, and mental health. Risks involve the potential for increased virus transmission among students.\",\n",
       "    \"Benefits include positive impacts on children's social life, education, and mental health. Risks involve potential virus transmission, especially if safety measures are not properly implemented. Balancing these factors is crucial for policy makers.\",\n",
       "    \"Benefits include positive effects on children's social life, education, and mental health. Risks involve potential spread of the virus, especially if preventive measures are not strictly enforced. Balancing these factors is crucial for policy decisions.\",\n",
       "    \"Benefits include supporting children's social, emotional, and educational development; risks involve potential for virus transmission, especially if not all safety measures are strictly followed. Balancing these factors is crucial. Socio-economic disparities may also be exacerbated.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 5, 4, 4, 4],\n",
       "   'entropy': 1.6094379124341005},\n",
       "  'arzbu37s': {'greedy': 'Benefits include social and emotional development, learning, and reduced isolation. Risks involve increased virus transmission, potential outbreaks, and health concerns.',\n",
       "   'samples': ['Benefits include socialization, learning support, and routine. Risks involve virus spread, mental health impacts, and economic strain.',\n",
       "    'Benefits include socialization, routine, and learning. Risks involve virus spread, student/teacher illness, and economic impact if cases surge.',\n",
       "    'Benefits include social and emotional development, learning progress, and reduced child poverty. Risks involve disease transmission, teacher burnout, and unequal access to education.',\n",
       "    'Benefits include socialization, routine, and learning support. Risks involve virus spread, safety concerns, and varying efficacy of mitigation measures.',\n",
       "    'Benefits include social and emotional development, academic progress. Risks involve spreading the virus, health complications.',\n",
       "    'Benefits include social development, routine structure, and in-person learning. Risks involve potential virus spread, safety concerns, and mental health impacts.',\n",
       "    'Benefits include socialization, routine, and learning. Risks include disease spread, infection, and strain on resources.',\n",
       "    'Benefits include social and emotional development, peer interaction, and reduced learning loss. Risks involve increased virus spread, potential lockdowns, and mental health impacts.',\n",
       "    'Benefits include socialization, learning, and economic stability. Risks involve disease spread, infections, and potential lockdowns.',\n",
       "    'Benefits include social and emotional development, learning opportunities, and reduced stigma. Risks involve disease transmission, potential outbreaks, and strain on health systems.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '5eg7hf6r': {'greedy': 'Benefits include mitigating negative psychological, educational, and social impacts on children. Risks involve potential virus transmission, especially if safety measures are not strictly enforced. Balancing these factors is crucial. Socio-economic disparities may worsen with prolonged school closures.',\n",
       "   'samples': [\"Benefits include mitigating negative impacts on children's social life, education, and mental health. Risks involve potential for increased virus transmission, especially if proper safety measures are not implemented. Balancing these factors is crucial for policy decisions. Socio-economic disparities\",\n",
       "    \"Benefits include reduced negative psychological, educational, and social impacts on children. Risks involve potential virus transmission, especially given children's role in spreading the virus is debated. Socioeconomic disparities may worsen with school closures. Balancing these is challenging.\",\n",
       "    'Benefits include positive social and educational impacts on children, and risks involve potential virus transmission among children and staff. Balancing these factors is crucial for policymakers.',\n",
       "    \"Benefits include positive impacts on children's social life, education, and mental health. Risks involve potential virus transmission and negative socio-economic effects.\",\n",
       "    \"Benefits include mitigating the negative impacts on children's social life, education, and mental health. Risks involve the potential for increased virus transmission, especially if not all safety measures are strictly enforced. Balancing these factors is crucial. Socio-economic disparities\",\n",
       "    \"Benefits include supporting children's social and emotional development, educational progress, and reducing the psychological impact on students and families. Risks involve potential virus transmission among children and staff, impacting public health, and exacerbating socio-economic disparities due to unequal access to remote\",\n",
       "    \"Benefits include positive impacts on children's social life, education, and mental health; Risks include potential virus transmission, especially if preventive measures are not strictly followed.\",\n",
       "    'Benefits include positive social and emotional impacts, continuity of education, and reduced disparities. Risks involve potential virus transmission, mental health concerns, and economic pressures. Balancing these factors is crucial.',\n",
       "    \"Benefits include supporting children's social, educational, and mental health; Risks involve potential for virus transmission and negative socio-economic impacts.\",\n",
       "    \"Benefits include mitigating the negative impacts on children's social life, education, and mental health. Risks involve the potential for increased virus transmission, especially if not all safety measures are properly implemented. Balancing these factors is crucial. Socio-economic disparities\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 3, 4, 5, 1, 0],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  '4nv1kedt': {'greedy': 'Benefits include resuming education and providing essential support. Risks involve disease transmission and mental health challenges.',\n",
       "   'samples': ['Benefits include socialization and access to mental health support. Risks include potential exposure to the virus and overburdened healthcare systems.',\n",
       "    'Benefits include resuming education and access to mental health supports. Risks involve virus transmission and potential health hazards.',\n",
       "    'Benefits include social interaction and trauma-informed care. Risks involve virus transmission and mental health concerns.',\n",
       "    \"Benefits include resuming education and providing essential support. Risks involve spreading the virus and addressing students' mental health needs.\",\n",
       "    'Benefits include social interaction, education, and trauma-informed care. Risks include virus transmission and mental health impacts.',\n",
       "    \"Benefits include resuming education and addressing students' mental health. Risks involve disease spread and unequal access to resources.\",\n",
       "    'Benefits include resuming education and providing essential support like trauma-informed care. Risks involve potential virus spread and inadequate safety measures.',\n",
       "    'Benefits include continued education and access to support services. Risks include potential virus spread and mental health challenges.',\n",
       "    'Benefits include resuming education and access to mental health support. Risks involve disease transmission and potential health hazards.',\n",
       "    'Benefits include in-person learning, access to trauma-informed care, and socialization. Risks include potential spread of the virus, increased mental health concerns, and unequal access to resources.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 1, 4, 1, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  'sx4yih5m': {'greedy': 'Benefits include social and emotional development, learning, and reduced isolation. Risks involve increased virus transmission, potential outbreaks, and health concerns.',\n",
       "   'samples': ['Benefits include social and emotional development, learning, and reduced feelings of isolation. Risks involve increased virus transmission, potential outbreaks, and strain on healthcare systems.',\n",
       "    'Benefits include social development, routine, and in-person learning. Risks involve virus spread, infection, and potential closures.',\n",
       "    'Benefits include social and emotional development, learning, and economic recovery. Risks involve potential outbreaks, transmission to vulnerable individuals, and unequal access.',\n",
       "    'Benefits include socialization, learning, and economic relief. Risks involve spreading the virus, overloading healthcare systems, and unequal access.',\n",
       "    'Benefits include social and emotional development, learning support, and reduced learning loss. Risks involve potential virus transmission, increased healthcare burden, and unequal access to resources.',\n",
       "    'Benefits include socialization, learning, and economic recovery. Risks involve spreading the virus, overloading healthcare systems, and unequal access to education.',\n",
       "    'Benefits include socialization, learning, and normalcy for students. Risks involve potential virus spread, increased cases, and health concerns.',\n",
       "    'Benefits include social and emotional development, learning opportunities, and reduced stigma for students. Risks involve potential virus spread, strain on healthcare systems, and varying effectiveness of safety measures.',\n",
       "    'Benefits include social development, reduced learning loss. Risks involve spreading the virus, increased absenteeism, mental health impacts.',\n",
       "    'Benefits include social development, reduced learning loss. Risks involve spreading the virus, increased mental health issues.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 0, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '17a70tu9': {'greedy': 'Benefits include resuming education and providing essential support. Risks involve disease transmission and mental health challenges.',\n",
       "   'samples': ['Benefits include resuming education and providing essential support. Risks include potential virus spread and inadequate mental health resources.',\n",
       "    \"Benefits include resuming education and addressing students' mental health needs. Risks include potential virus transmission and inadequate safety measures.\",\n",
       "    'Benefits include resuming education and addressing mental health needs. Risks involve disease transmission and unequal access to remote learning.',\n",
       "    'Benefits include returning to in-person learning and access to mental health support. Risks include increased spread of the virus and potential health risks.',\n",
       "    \"Benefits include resuming education and addressing students' mental health needs. Risks involve potential virus spread and limited resources.\",\n",
       "    'Benefits include resuming education and providing trauma-informed care. Risks involve potential virus spread and mental health challenges.',\n",
       "    'Benefits include in-person learning, trauma-informed care, and socialization. Risks include disease transmission and potential mental health impacts.',\n",
       "    'Benefits include resuming education and access to essential services like trauma-informed care. Risks involve virus transmission and mental health impacts.',\n",
       "    \"Benefits include resuming education and addressing students' mental health. Risks include spreading the virus among students and staff.\",\n",
       "    'Benefits include socialization and access to mental health supports; risks include potential virus transmission and increased stress.'],\n",
       "   'cluster_ids': [0, 1, 0, 1, 0, 2, 2, 2, 3, 4],\n",
       "   'entropy': 1.5047882836811906},\n",
       "  'k36e2sob': {'greedy': 'Benefits include social and emotional development, learning, and reduced isolation. Risks include potential disease transmission among students and staff.',\n",
       "   'samples': ['Benefits include social development and academic continuity. Risks involve potential disease transmission.',\n",
       "    'Risks include disease transmission; benefits include allowing children to return to learning and socialization.',\n",
       "    'Benefits include social and emotional development, and educational continuity. Risks include potential disease transmission.',\n",
       "    'Benefits include social and emotional development, learning continuity, and reduced isolation. Risks involve potential disease transmission and health impacts on students and staff.',\n",
       "    'Risks include disease transmission; benefits include social and educational development.',\n",
       "    'Benefits include social and emotional development, learning, and reduced learning loss. Risks include potential disease transmission, especially among pediatric risk groups.',\n",
       "    'Benefits include social and emotional development, and academic progress. Risks include potential disease transmission among students and staff.',\n",
       "    'Risks include disease transmission; benefits include educational and psychological support for students.',\n",
       "    'Benefits include social and emotional development, reduced isolation, and learning support. Risks include potential disease transmission and increased strain on healthcare systems.',\n",
       "    'Benefits include social and emotional development, reduced feelings of isolation. Risks include potential for disease transmission, especially among children who are asymptomatic carriers. Risk assessment and guidelines are crucial.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 0, 2, 3, 4],\n",
       "   'entropy': 1.2275294114572126},\n",
       "  'qz6w094y': {'greedy': 'Benefits include social interaction, education, and routine. Risks involve potential virus spread, especially among younger children, and economic strain on families.',\n",
       "   'samples': ['Risks include increased exposure to the virus, potential for outbreaks, and challenges in maintaining social distancing. Benefits may involve educational continuity, mental health support, and reduced risk of long-term learning deficits. However, safety measures must be stringent.',\n",
       "    'Benefits include social interaction and learning. Risks include increased exposure to the virus, potential outbreaks, and economic hardships affecting nutrition.',\n",
       "    'Risks include increased spread of the virus, potential weight gain among children, and economic strain for families. Benefits could be social and emotional development, reduced isolation, and support for learning.',\n",
       "    \"Risks include increased exposure to the virus, potential for outbreaks, and impact on vulnerable students' nutrition. Benefits may include social interaction, routine structure, and access to meals programs.\",\n",
       "    'Risks include potential virus spread, increased economic burden on families, and risk of weight gain among children. Benefits may include educational continuity and reduced social isolation.',\n",
       "    'Risks include increased exposure to the virus, potential for outbreaks, and impacts on nutrition and physical activity. Benefits may involve social and emotional support, learning, and reduced screen time. Economic and mental health impacts vary.',\n",
       "    'Benefits include resuming education and socialization. Risks involve potential disease spread.',\n",
       "    'Risks include increased infection spread, potential weight gain due to less physical activity and healthier food choices; benefits include educational continuity and social interaction.',\n",
       "    'Benefits include social interaction, routine, and education. Risks include increased virus transmission and potential health issues.',\n",
       "    'Reopening schools brings educational benefits but poses health risks like increased virus transmission. Risks include spreading COVID-19 among students and staff. Benefits include academic progress and social development for children.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 1, 5, 5, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'xu7bazzw': {'greedy': 'Benefits include social development, learning, and reduced isolation. Risks involve virus transmission, mental health impacts, and unequal access to resources.',\n",
       "   'samples': ['',\n",
       "    'Benefits include social interaction and education; risks include potential spread of the virus.',\n",
       "    'Risks include infection spread, teacher shortages, and economic strain. Benefits include social development, education continuity, and reduced learning loss.',\n",
       "    'Benefits include social development and learning. Risks involve virus transmission among students and staff.',\n",
       "    'Benefits: Socialization, learning, routine. Risks: Spread of virus, exposure, health issues.',\n",
       "    'Risks include potential outbreaks, mental health issues. Benefits include education, socialization, routine. Answer briefly: Risks: outbreaks, mental health issues; Benefits: education, socialization, routine.',\n",
       "    'Risks include virus spread among students and staff, while benefits include children receiving an education and socialization. Additional benefits for some families may involve child care support. Risks can be mitigated through strict safety measures. Answer briefly: Reopening risks virus',\n",
       "    'Benefits include socialization and education continuity; Risks involve virus transmission among students and staff.',\n",
       "    '',\n",
       "    ''],\n",
       "   'cluster_ids': [0, 1, 2, 1, 1, 2, 1, 1, 0, 0],\n",
       "   'entropy': 1.0296530140645734}},\n",
       " '8': {'no': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability leads to fewer infections being detected, underestimating actual cases and incidence of COVID-19.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underrepresenting actual infections.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and inflating the perceived low incidence.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating actual infections.',\n",
       "    'Lack of testing availability leads to fewer cases being identified, underestimating actual infections.',\n",
       "    'Lack of testing availability means fewer people get tested, missing cases with the virus. This leads to underreporting the true number of infections.',\n",
       "    'Lack of testing availability leads to fewer infections being identified, resulting in an underestimation of the true number of cases and spread of the virus.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating actual infections.',\n",
       "    'Lack of testing availability means fewer infections are detected, leading to an underestimation of actual cases and spread.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 0, 2, 0, 3, 2, 2],\n",
       "   'entropy': 1.1935496040981333},\n",
       "  'luqlfphw': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability leads to underreporting because not everyone showing symptoms or being infected can get tested, missing cases and lowering reported numbers.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "    'Lack of testing availability leads to some cases going undetected, underestimating actual infections.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "    'Lack of testing availability leads to some infected individuals not getting tested, resulting in their cases going unreported. This causes the official case counts to be lower than the actual number of infections, underreporting the true incidence of COVID-19.',\n",
       "    'Lack of testing availability means fewer people are tested, missing asymptomatic or mild cases, leading to an underreported true incidence of COVID-19.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating actual infections.',\n",
       "    'Lack of testing availability leads to underreporting because not all infected individuals get tested, missing mild cases or asymptomatic infections. This results in a lower reported case count than actual infections.',\n",
       "    'Lack of testing availability leads to some infected individuals not being diagnosed, resulting in an undercount of actual cases.',\n",
       "    'Lack of testing availability leads to some infected individuals not being diagnosed, resulting in an undercount of actual cases.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 1, 2, 3, 1, 1, 1],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'srpgfh3h': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability leads to underreporting because not everyone with symptoms gets tested, missing asymptomatic cases, and delayed testing results. This results in a lower reported case count than actual infections.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "    'Lack of testing availability leads to fewer infections being identified, underestimating actual cases and spreading.',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not everyone with symptoms or potential exposure can get tested, resulting in undetected cases.',\n",
       "    'Lack of testing availability means fewer people are tested, leading to unidentified cases, thus underreporting the true incidence of COVID-19.',\n",
       "    'Lack of testing availability means fewer infections are detected, leading to an underestimation of actual cases and true incidence.',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not all infected individuals are tested, resulting in undetected cases.',\n",
       "    'Lack of testing availability leads to fewer infections being identified, resulting in an underreporting of the true incidence of COVID-19.',\n",
       "    \"Lack of testing availability leads to some infected individuals not being diagnosed, resulting in an underreported number of cases and a lower estimate of the virus's true impact.\",\n",
       "    'Lack of testing availability leads to fewer cases being identified, underestimating actual infections. Undetected cases contribute to lower reported incidence.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 2, 4, 2, 2, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'zscviypa': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability leads to fewer infections being identified, resulting in lower reported case numbers that do not reflect actual spread.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating actual infection rates.',\n",
       "    'Lack of testing availability leads to fewer cases being identified, underestimating actual infections. Undetected cases contribute to lower reported incidence.',\n",
       "    'Lack of testing availability means fewer people get tested, so infections go undetected, leading to an underreporting of true cases.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating actual infections.',\n",
       "    'Lack of testing availability leads to underreporting because not all infected individuals get tested, missing cases and lowering reported numbers.',\n",
       "    'Lack of testing availability means not everyone can get tested, leading to fewer reported cases. This results in an underestimation of the true number of infections.',\n",
       "    'Lack of testing availability means fewer people get tested, so cases go undetected, underreporting the actual number of infections.',\n",
       "    'Lack of testing availability leads to fewer infections being detected, resulting in an underreported number of actual cases.',\n",
       "    'Lack of testing availability leads to underreporting because not all infected individuals are tested, missing cases with mild or asymptomatic infections. This results in a lower reported case count than actual infections.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.9433483923290393},\n",
       "  'w0sb4qnl': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability leads to fewer confirmed cases, underestimating actual infection rates.',\n",
       "    'Lack of testing availability means fewer infections are detected, leading to an underestimation of actual cases and true incidence.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure gets tested. Those undetected cases contribute to an underestimated true infection count.',\n",
       "    'Lack of testing availability means not everyone with symptoms or potential exposure can be tested, leading to undetected cases and underreported infections.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating actual infection rates.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone showing symptoms or being infected gets tested. Undetected cases contribute to lower reported numbers, masking true infection rates.',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people could get tested, missing many cases, especially mild or asymptomatic ones.',\n",
       "    'Lack of testing availability means fewer people are tested, missing asymptomatic or mild cases, leading to an underreported true incidence.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure gets tested. This results in many infections going unreported, understating the true number of cases.',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not everyone showing symptoms or asymptomatic individuals can get tested, resulting in undetected cases.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 0, 1, 2, 2, 1, 3],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'rb5o20j2': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and lowering overall reported numbers.',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not enough people can get tested, missing mild cases and asymptomatic individuals who can still spread the virus.',\n",
       "    'Lack of testing availability means fewer people get tested, so cases go unreported, underestimating actual infections.',\n",
       "    'Lack of testing availability leads to fewer cases being identified, underestimating actual infections.',\n",
       "    \"Lack of testing availability leads to fewer infections being identified, resulting in lower reported case numbers that don't reflect actual spread. Undetected cases contribute to underreported true incidence.\",\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not all infected individuals are tested, resulting in undetected cases.',\n",
       "    'Lack of testing availability means fewer infections are detected, leading to an underreported number of cases and a lower estimate of the true incidence of COVID-19.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone showing symptoms or being infected can get tested, missing cases and lowering reported numbers.',\n",
       "    'Lack of testing availability means not everyone with symptoms is tested, leading to undetected cases and underreported infections.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can get tested. This results in many infections going undetected, lowering reported case numbers below actual incidence.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 3, 4, 3, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '4amnl029': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing asymptomatic cases. This results in an underestimated true number of infections.',\n",
       "    'Lack of testing availability means not everyone, especially asymptomatic or mildly symptomatic individuals, gets tested. This leads to many infections going unreported, underestimating the true number of cases.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure gets tested, missing cases and infections. This results in lower reported numbers than actual occurrences.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure gets tested. Without widespread testing, mild cases or asymptomatic infections go undetected, resulting in a lower reported case count than the actual number of infections.',\n",
       "    'Lack of testing availability leads to some infected individuals not getting tested, resulting in underreported cases and thus an underestimated true incidence of COVID-19.',\n",
       "    'Lack of testing availability leads to some infected individuals not getting tested, thus their cases are not counted, resulting in underreporting of the true incidence of COVID-19.',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not all infected individuals are tested, resulting in unknown cases.',\n",
       "    'Lack of testing availability leads to some infected individuals not getting tested, resulting in an undercount of actual cases. Undetected cases contribute to lower reported infection rates.',\n",
       "    'Lack of testing availability leads to fewer infections being identified, resulting in an underreported true incidence of COVID-19.',\n",
       "    'Lack of testing availability leads to some cases going undetected, underestimating actual infections.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 0, 2, 2, 2, 3, 3],\n",
       "   'entropy': 1.3661588475692017},\n",
       "  'hnbatlj0': {'greedy': 'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people are being tested, resulting in only a fraction of actual cases being identified and recorded. This limits the accuracy of case numbers and can cause',\n",
       "   'samples': ['Lack of testing availability has led to underreporting of true incidence of COVID-19 because not all infected individuals are tested, resulting in unknown cases contributing to mortality rates without being counted in reported cases. This discrepancy suggests many undetected infections,',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people are being tested, resulting in fewer confirmed cases. This makes it difficult to accurately determine the actual number of infections in a population. Mort',\n",
       "    'Lack of testing availability leads to underreporting of true incidence of COVID-19 because not enough people are tested, resulting in only a small proportion of actual cases being detected and recorded. This makes reported case numbers unreliable, while mortality rates, which',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people can be tested, resulting in only a fraction of actual cases being identified and recorded. This causes reported case numbers to be lower than the',\n",
       "    \"Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people can be tested, resulting in only a fraction of actual cases being detected and reported. This limits accurate tracking and understanding of the virus's\",\n",
       "    'Lack of testing availability leads to underreporting of true incidence of COVID-19 because not enough people are tested, resulting in only a small fraction of actual cases being detected and recorded, thus inflating mortality rates relative to actual infection numbers. Countries',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because only a fraction of infected individuals are detected, causing the reported case numbers to be lower than the actual numbers. This results in higher fold-changes and case',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people can be tested, resulting in only a small proportion of actual cases being detected and recorded. This causes mortality numbers to better reflect the actual',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because only a fraction of actual cases are identified, causing reported case numbers to be much lower than the actual number of infections. This results in higher fold-change',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough individuals can be tested, resulting in only a fraction of actual cases being detected and reported. This causes mortality numbers to better reflect the actual spread'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 3, 4, 5, 4, 5],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  'ckecol7i': {'greedy': 'Lack of testing availability leads to underreporting of true incidence of COVID-19 because not enough people are tested, resulting in only a fraction of actual cases being identified and reported. This skews official case numbers downward, making the true scale of',\n",
       "   'samples': ['Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people are tested, resulting in only a small fraction of actual cases being detected and recorded. This causes reported case numbers to be significantly lower than',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not enough people can be tested, resulting in only a fraction of actual cases being identified. This limits accurate tracking and reflects in higher mortality rates as a proxy',\n",
       "    \"Lack of testing availability has led to underreporting of true incidence of COVID-19 because not enough people can be tested, resulting in only a small percentage of actual cases being identified and reported. This limits accurate tracking and understanding of the virus's\",\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating the true incidence of COVID-19, which in turn results in lower reported mortality rates and underreporting of actual cases.',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not enough people can be tested, resulting in only a small percentage of actual cases being identified and reported. This limitation affects the accuracy of case numbers, making',\n",
       "    'Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people are being tested, resulting in a smaller reported number of cases than what is actually present in the population. This makes it difficult to accurately',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not enough people are being tested, resulting in only a fraction of actual cases being identified and recorded. This limitation causes reported case numbers to be lower than the',\n",
       "    'Lack of testing availability leads to fewer individuals being tested for COVID-19, resulting in an underestimation of actual cases. This makes it difficult to accurately track the spread of the virus, causing underreporting of true incidence. Mortality numbers',\n",
       "    \"Lack of testing availability has led to underreporting of true incidence of COVID-19 because not all infected individuals are tested, resulting in lower reported case numbers compared to actual infections. This limits accurate tracking and assessment of the virus's spread. Mort\",\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not enough people are being tested, resulting in only a fraction of actual cases being detected and reported. This makes mortality numbers a more reliable indicator for assessing the'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 2, 2, 3, 2, 4],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'gkv76mlw': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability means not everyone with symptoms or potential exposure can get tested, leading to undetected cases. Undetected cases are not reported, resulting in underreported true incidence.',\n",
       "    'Lack of testing availability leads to fewer infections being detected, resulting in an underestimation of the true number of cases and spread of COVID-19.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can get tested, missing cases and reducing overall reported numbers.',\n",
       "    'Lack of testing availability leads to some cases going undetected, resulting in an underreported number of infections and a lower estimated true incidence of COVID-19.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure gets tested, missing cases and lowering official counts.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can get tested, missing asymptomatic cases. This results in lower official case counts than actual infections.',\n",
       "    'Lack of testing availability means fewer people are tested, missing asymptomatic or mild cases, leading to an underreported true incidence of COVID-19.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can get tested, missing cases and lowering reported numbers.',\n",
       "    'Lack of testing availability leads to fewer confirmed cases, underestimating actual infections.',\n",
       "    'Lack of testing availability leads to some infected individuals not being diagnosed, resulting in an underreported number of cases and underestimated true incidence of COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 2, 4, 5, 1, 1],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'd5v8xstx': {'greedy': 'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and reducing overall reported numbers.',\n",
       "   'samples': ['Lack of testing availability has led to underreporting of the true incidence of COVID-19 because not enough people could get tested, missing cases and lowering official case counts.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms gets tested, missing mild cases or asymptomatic individuals. This results in an incomplete picture of actual infections.',\n",
       "    'Lack of testing availability means not everyone with symptoms is tested, leading to undetected cases and underreported infections.',\n",
       "    'Lack of testing availability leads to some infected individuals not being diagnosed, resulting in an undercount of actual cases.',\n",
       "    'Lack of testing availability means fewer people get tested, missing asymptomatic and mild cases, thus underreporting actual infections.',\n",
       "    'Lack of testing availability leads to some infected individuals not being detected, resulting in underreported cases and thus an underestimated true incidence of COVID-19.',\n",
       "    'Lack of testing availability has led to underreporting of true incidence of COVID-19 because not all infected individuals are tested, resulting in undetected cases.',\n",
       "    'Lack of testing availability leads to underreporting because not everyone with symptoms or potential exposure can be tested, missing cases and lowering reported numbers.',\n",
       "    'Lack of testing availability leads to fewer cases being identified, underestimating actual infections.',\n",
       "    'Lack of testing availability leads to fewer infections being identified, underreporting the true incidence because asymptomatic and mild cases go undetected.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 2, 3, 3, 1, 1],\n",
       "   'entropy': 1.0888999753452238}},\n",
       " '43': {'no': {'greedy': 'The pandemic has led to an increase in some types of violence, including domestic violence and hate crimes, while overall crime rates have decreased in some areas.',\n",
       "   'samples': ['The pandemic has led to an increase in domestic violence and a decrease in certain types of violent crime like theft, while public order offenses have risen. Effects vary by location.',\n",
       "    'The pandemic has led to an increase in domestic violence and a mixed pattern of violent crimes. Some areas saw increases, while others experienced decreases. Economic stress contributed to overall societal tension.',\n",
       "    'The pandemic has led to increased domestic violence and a rise in hate crimes targeting certain groups. Violent crime rates have shown mixed results, with some areas experiencing increases and others decreases.',\n",
       "    'The pandemic has led to an increase in certain types of violence, such as domestic violence and hate crimes. However, overall violent crime rates have seen mixed results, with some locations experiencing decreases and others showing increases.',\n",
       "    'The pandemic has led to an increase in some forms of domestic violence and a decrease in other types of crime due to reduced social interactions.',\n",
       "    'The pandemic has led to an increase in some types of violence and an increase in domestic violence. However, public order-related crimes have decreased.',\n",
       "    'The pandemic has led to increased domestic violence and a rise in hate crimes, but overall violent crime rates have decreased in some areas. However, impacts vary by location and type of violence.',\n",
       "    'The pandemic has led to increased domestic violence and cyberbullying but a decrease in some types of violent crime, like theft and burglary.',\n",
       "    'The pandemic has led to an increase in domestic violence and a mixed pattern of decreases and increases in other violent crimes.',\n",
       "    'The pandemic has led to increased domestic violence and a rise in certain types of violent crimes.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 6, 6, 4],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'v9fdn4uu': {'greedy': 'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases due to measures like social distancing and sheltering in place.',\n",
       "   'samples': ['The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases. No clear precedent exists in academic literature, but studying the impact of natural disasters on family violence may offer insights.',\n",
       "    'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases. Natural disasters have been used as a reference point for understanding these impacts. Collaborations between human and animal welfare agencies',\n",
       "    'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries already reporting a dramatic rise in domestic violence cases. No clear precedent exists, but studying the impact of natural disasters on family violence may offer insights. Improving',\n",
       "    'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases due to measures like social distancing and sheltering in place. No direct precedent exists, but insights from natural disasters can',\n",
       "    'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases. No clear precedent exists, but studying the impact of natural disasters on family violence could offer insights. Collaborations,',\n",
       "    \"The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries already reporting a rise in domestic violence cases. Natural disasters' impacts on family violence might offer some insights. Enhancing collaborations, expanding partnerships, and promoting awareness\",\n",
       "    'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases due to measures like social distancing and sheltering in place.',\n",
       "    'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases. Natural disasters have been used as a comparison to understand these impacts. Collaborations, expanded partnerships, and public awareness',\n",
       "    \"The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries reporting a dramatic rise in domestic violence cases due to measures like social distancing and sheltering in place. Natural disasters' impacts on family violence may offer relevant insights\",\n",
       "    'The COVID-19 pandemic has likely increased the risk for family violence globally, with many countries already seeing a rise in reported cases of domestic violence.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 3, 5, 3, 5],\n",
       "   'entropy': 1.6434177197931799},\n",
       "  '1uwdekl3': {'greedy': 'The COVID-19 pandemic has led to an increase in domestic violence, particularly against children and their mothers. This is due to the stress and isolation caused by the pandemic. Intimate partner violence has also increased during this time. Other forms of violent',\n",
       "   'samples': ['The COVID-19 pandemic has led to an increase in domestic violence, particularly against children and their mothers, due to the stress and confinement caused by the pandemic.',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence, with children and their mothers being particularly vulnerable. This includes intimate partner violence perpetrated by current or ex-partners. Other forms of violence and violent crimes may also be affected, but',\n",
       "    'The COVID-19 pandemic has increased the risk of domestic violence, especially against children and their mothers. Physical and psychological health risks, isolation, and economic vulnerability contribute to this rise. Other forms of violence may also be affected, but the context primarily',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence, particularly against children and their mothers. Restrictions and isolation have exacerbated these issues.',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence, with children and their mothers being particularly vulnerable. The closure of schools and businesses and increased isolation have exacerbated this issue.',\n",
       "    'The COVID-19 pandemic has increased the risk of domestic violence, particularly against children and their mothers.',\n",
       "    'The COVID-19 pandemic has increased the risk of domestic violence, particularly affecting children and their mothers. Restrictions and isolation have worsened conditions for victims of domestic violence. Intimate partner violence is a significant concern during this time.',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence, particularly affecting children and their mothers. Other forms of violent crimes may also be on the rise due to societal stress and altered daily routines. (Source: End Violence against Children,',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence, particularly against children and their mothers. This is due to stress, isolation, and other factors resulting from the pandemic. Intimate partner violence is also more likely to occur during this',\n",
       "    'The COVID-19 pandemic has increased the risk of domestic violence, especially against children and their mothers.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 3, 3, 4, 5, 3],\n",
       "   'entropy': 1.4978661367769954},\n",
       "  'daxggfj5': {'greedy': 'The pandemic has led to a decrease in minor offenses but an increase in serious crimes like homicide and intimate partner violence. Homicides have remained constant while intimate partner violence has increased. The decrease in minor offenses may be due to fewer opportunities for these crimes',\n",
       "   'samples': ['Violent crimes have remained constant or increased during the pandemic, particularly homicide and intimate partner violence. Minor crimes have decreased, possibly due to fewer opportunities for group offenses. The decrease in minor offenses might hide an increase in serious crimes, suggesting that lockdowns',\n",
       "    'Crime rates have decreased, but homicides and intimate partner violence have either remained constant or increased. The lockdowns may have led to more opportunities for intimate partner violence and serious crimes.',\n",
       "    'The COVID-19 pandemic has led to a decrease in minor offenses but an increase in serious crimes like homicides and intimate partner violence. Crime rates have decreased overall, but this masks a concerning trend where more severe violent crimes are on the rise. The',\n",
       "    'The crime rate has decreased, but homicides and intimate partner violence have remained constant or increased.',\n",
       "    'Crime rates have decreased, but homicides and intimate partner violence have remained constant or increased. The decrease in minor offenses suggests lockdowns may be leading to more opportunities for serious violent crimes like intimate partner violence.',\n",
       "    \"The crime rate has decreased, but there's an increase in serious crimes like homicide and intimate partner violence during the pandemic.\",\n",
       "    'Violent crimes, particularly homicides and intimate partner violence, have either remained constant or increased during the pandemic, despite overall crime rates decreasing. The decrease in minor offenses suggests that lockdowns may have moved minor offenders into situations with higher risks of more serious violence',\n",
       "    'Violent crimes, particularly homicide and intimate partner violence, have either remained constant or increased during the pandemic. Minor offenses have decreased, potentially due to social distancing measures, but this could also create more opportunities for serious violence within households.',\n",
       "    'The COVID-19 pandemic has led to a decrease in minor crimes but an increase in serious crimes like homicides and intimate partner violence. Minor offenses typically committed in peer groups have decreased due to lockdowns, while crimes usually not committed with co-offenders',\n",
       "    'The pandemic led to a decrease in minor crimes but an increase in serious crimes like homicides and intimate partner violence. The study suggests that lockdowns might have placed individuals in situations with higher risks of serious violence.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 2, 3, 4, 5, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'qaa2e83a': {'greedy': 'The COVID-19 pandemic has led to an increase in gender-based violence (GBV) in societies, particularly during quarantine periods.',\n",
       "   'samples': ['The COVID-19 pandemic has led to an increase in gender-based violence (GBV) during emergencies, especially in situations involving quarantine.',\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV) during emergencies, particularly in situations involving quarantine measures. This underscores the need for policymakers to address and mitigate these issues proactively.',\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV) in societies, particularly in emergency situations like quarantine.',\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV), particularly during emergency situations like quarantine.',\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV) during emergencies, particularly in situations involving quarantine measures.',\n",
       "    \"The COVID-19 pandemic has led to an increase in gender-based violence (GBV) in emergencies, particularly during quarantine. Policymakers should address this issue by utilizing community expertise, technology, and global guidelines. Valuing women's roles and\",\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV) in emergencies involving quarantine. Communities and policymakers need to address this issue using expertise, technology, and global guidelines to prevent further escalation.',\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV) in societies, particularly during emergency situations like quarantine.',\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV), especially during emergencies like quarantine. Policymakers should address this by involving community expertise, technology, and global guidelines to prevent further escalation.',\n",
       "    'The COVID-19 pandemic has led to an increase in gender-based violence (GBV) during emergencies, especially with quarantine measures in place.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 2, 0, 2, 0],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  'miem1poh': {'greedy': 'The COVID-19 pandemic has led to increased stress and confinement, which may exacerbate existing tensions and contribute to an increase in domestic violence. However, some studies have reported a decrease in reports of domestic violence due to quarantine measures. This could be',\n",
       "   'samples': ['The COVID-19 pandemic has led to an increase in domestic violence incidents due to forced home isolation. However, there has also been a decrease in the reporting of such cases. This may be due to increased vulnerability, lack of support systems, and',\n",
       "    'The COVID-19 pandemic has potentially increased the risk of domestic violence due to factors like confinement and stress, though some reports indicate a decrease in reported cases. The reliability of these reports is questionable, and it is crucial for public institutions to remain vigilant',\n",
       "    'The COVID-19 pandemic has had complex effects on violence in society, including an initial increase in domestic violence due to confined living spaces, but also a decrease in some areas as fewer people are out on the streets. However, the reliability of reported',\n",
       "    'The COVID-19 pandemic has led to increased stress and isolation, which may exacerbate existing tensions and contribute to an increase in domestic violence incidents. However, some studies have shown a decrease in reports of domestic violence due to reduced public interaction and awareness',\n",
       "    \"The COVID-19 pandemic has led to increased instances of domestic violence due to forced home isolation, which can exacerbate stressful situations and limit victims' ability to seek help. However, some studies report a decrease in reported cases, possibly due to under\",\n",
       "    'The COVID-19 pandemic has led to increased instances of domestic violence due to forced home isolation, which can exacerbate existing tensions and stress. However, some reports indicate a decrease in formal reports of domestic violence. This could be due to underreport',\n",
       "    'The COVID-19 pandemic has led to increased risk of domestic violence due to forced home isolation. While some studies show a decrease in reported cases, this could be due to underreporting. Public institutions should remain vigilant and implement measures to prevent and',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence due to forced home isolation, but reports of such incidents have decreased possibly due to fear of infection, lack of access to resources, and reduced ability to leave the house. Public institutions',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence due to forced home isolation, stress, and other factors. However, some reports show a decrease in reports of domestic violence. This may be due to underreporting, fear of',\n",
       "    'The COVID-19 pandemic has had mixed impacts on violence, with some studies indicating a decrease in reports of domestic violence due to increased surveillance and limited mobility, while other factors like stress and confinement may exacerbate other types of violence. Reliable data is'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 5, 6, 4, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  '7eksp1sj': {'greedy': 'The context suggests that the pandemic has altered crime patterns and presented new challenges for the criminal justice system, but it does not provide specific details about changes in violent crime rates. To answer your question more directly: The impact of the pandemic on violent crimes is',\n",
       "   'samples': ['The pandemic has altered regular schedules, impacting crime patterns and opportunities, though specific changes in violent crime rates are not detailed in the provided context. Increased social isolation, economic strain, and stress may contribute to higher levels of violence, but the exact nature and',\n",
       "    'The context suggests that the pandemic has altered regular schedules and both restricted and expanded opportunities for various types of crime, though it does not provide specific details about the impact on violent crimes. To directly answer your question based on the given information, the pandemic-induced',\n",
       "    'The impact of the COVID-19 pandemic on violence in society is complex and multifaceted. While some studies suggest a decrease in certain types of violent crimes due to reduced social interactions and economic factors, others report increases in domestic violence and hate crimes',\n",
       "    'The pandemic has altered crime patterns, potentially expanding opportunities for certain types of crime due to changes in daily routines and containment measures. However, specific impacts on violent crime rates are not detailed in the provided context. To fully understand these impacts, more empirical research',\n",
       "    'The impact of the COVID-19 pandemic on violence in society is complex and varied, with some forms of violence potentially increasing due to stress and economic strain, while others may decrease due to social distancing measures. However, specific data on changes in violent',\n",
       "    'The impact of the COVID-19 pandemic on violence is not explicitly detailed in the provided context. However, the document suggests that the pandemic may alter opportunities for various types of crime and pose challenges for the criminal justice system. It also indicates that there',\n",
       "    'The context suggests that the pandemic may have altered the frequency and types of violent crimes due to changed social conditions, but it does not provide specific information about the impact on violent crimes. Further research is needed to understand these changes accurately.',\n",
       "    'The context provided does not give specific details about the impact of the COVID-19 pandemic on violent crimes. It suggests that the pandemic has altered crime patterns and poses new challenges for the criminal justice system but does not provide quantitative or qualitative data on violent',\n",
       "    'The context provided does not give specific details about the impact of the COVID-19 pandemic on violent crimes. It mentions altered routines and changed opportunities for various types of crime but does not provide concrete data or analysis on violence or violent crimes specifically. For',\n",
       "    'The COVID-19 pandemic has influenced violence and violent crimes through altered routines, restricted opportunities, and changes in social behavior due to containment measures like social distancing and lockdowns. However, specific impacts vary and some studies suggest increases in certain types of violence'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 1, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'onxosato': {'greedy': 'The COVID-19 pandemic has led to increased stress and confinement, which may exacerbate existing tensions and contribute to an increase in domestic violence. However, some studies have reported a decrease in reports of domestic violence due to quarantine measures. This could be',\n",
       "   'samples': ['The COVID-19 pandemic has led to increased stress and economic hardship, which may contribute to an increase in domestic violence. However, there has also been a reported decrease in reports of domestic violence since quarantine began, which may be due to reduced social',\n",
       "    'The COVID-19 pandemic has led to increased isolation and stress, which may exacerbate existing tensions and trigger episodes of domestic violence. However, some studies report a decrease in reported cases due to various factors like reduced opportunities for victims to seek help and',\n",
       "    'The COVID-19 pandemic has had mixed impacts on violence, including an increase in some forms and a decrease in others, such as reported domestic violence cases due to forced home isolation. The reliability of the data varies, and there are concerns about under',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence due to forced home isolation. However, some reports show a decrease in reported cases, which might be due to underreporting or difficulty accessing support services. This situation highlights the need',\n",
       "    'The COVID-19 pandemic has led to increased stress and confinement, which might potentially increase instances of domestic violence. However, there is also a decrease in reports of domestic violence due to quarantine measures. Public institutions should remain vigilant and take preventive measures to',\n",
       "    'The COVID-19 pandemic has led to increased stress and isolation, which can exacerbate existing tensions and contribute to an increase in domestic violence incidents. While some studies have shown a decrease in reported cases due to underreporting or other factors, the',\n",
       "    'The COVID-19 pandemic has led to increased risk of domestic violence due to forced home isolation, but there has been a decrease in reported cases which may indicate underreporting. Public institutions need to be more vigilant and implement measures to prevent and improve',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence due to prolonged confinement, stress, and other factors. However, some studies report a decrease in the number of reported cases possibly due to underreporting. Public institutions need to be',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence incidents due to forced home isolation, stress, and other factors. However, there has been a decrease in reports of domestic violence during the pandemic, possibly due to underreporting or',\n",
       "    'The COVID-19 pandemic has potentially increased risks of domestic violence due to forced home isolation, though some reports show a decrease in reported cases. The reliability of these data may be questionable. Public institutions should remain vigilant and implement measures to prevent and improve'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'luef3iok': {'greedy': 'The pandemic has potentially increased domestic violence due to quarantines and restrictions. Impact on other violent crimes is less clear.',\n",
       "   'samples': ['The COVID-19 pandemic has led to an increase in domestic violence due to quarantine and other restrictions. Impact on other violent crimes is less clear.',\n",
       "    'The pandemic has led to an increase in domestic violence due to quarantine and other restrictions. Impact on other violent crimes is less clear.',\n",
       "    'The COVID-19 pandemic has potentially led to an increase in domestic violence due to quarantines and other restrictions. Impact on other violent crimes is less clear.',\n",
       "    'The pandemic has potentially led to an increase in domestic violence due to quarantine measures. Other forms of violent crime may have decreased due to reduced social interaction.',\n",
       "    'The pandemic has potentially increased domestic violence due to quarantine and restrictions. Impact on other violent crimes is less clear.',\n",
       "    'Increased domestic violence due to quarantines and restrictions. Impact on other violent crimes is less clear.',\n",
       "    'The pandemic has potentially led to an increase in domestic violence due to quarantines and other restrictions. The impact on other types of violent crimes is less clear and more research is needed.',\n",
       "    'The pandemic has led to an increase in domestic violence due to quarantines and other restrictions. Impact on other violent crimes is less clear.',\n",
       "    'The pandemic has potentially led to an increase in domestic violence due to quarantines and restrictions. Impact on other types of violent crimes is less clear.',\n",
       "    'The pandemic may lead to an increase in domestic violence due to quarantine and other restrictions. Impact on other violent crimes is less clear.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 2, 1, 1, 1, 1],\n",
       "   'entropy': 0.9502705392332347},\n",
       "  '427mkwsj': {'greedy': 'The pandemic has potentially increased domestic violence due to quarantines and restrictions. Impact on other violent crimes is less clear.',\n",
       "   'samples': ['The COVID-19 pandemic has led to an increase in domestic violence due to quarantine and restriction measures. Other violent crimes may have increased or decreased depending on location and specific circumstances.',\n",
       "    'The pandemic may lead to an increase in domestic violence due to quarantine and other restrictions. Impact on other types of violent crime is less clear.',\n",
       "    'The pandemic has potentially increased domestic violence due to quarantines and restrictions. Other violent crime rates may have decreased due to reduced social interactions.',\n",
       "    'The pandemic has potentially increased domestic violence due to quarantine and other restrictions. Its impact on other types of violent crimes is less clear and more varied.',\n",
       "    'The COVID-19 pandemic has led to an increase in domestic violence due to quarantines and other restrictions. Other violent crimes may also have increased.',\n",
       "    'The pandemic has potentially led to an increase in domestic violence due to quarantine measures. Other violent crime rates may have decreased due to reduced social interactions.',\n",
       "    'Increased domestic violence due to quarantines and restrictions. Impact on other violent crimes is not clearly established.',\n",
       "    'The pandemic has led to an increase in domestic violence due to quarantines and other restrictions. Other violent crimes may have also increased. However, data on this is still being studied. Answer briefly: The pandemic has led to an increase in domestic violence',\n",
       "    'Increased risk of domestic violence due to quarantines and restrictions. Other violent crimes may have decreased due to fewer opportunities for public interaction.',\n",
       "    'The pandemic has led to an increase in domestic violence due to quarantines and restrictions. Impact on other violent crimes is less clear.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 2, 3, 2, 1, 3, 0],\n",
       "   'entropy': 1.3321790402101223},\n",
       "  'ub0tl046': {'greedy': 'The pandemic has led to an increase in certain types of violence, such as domestic violence and hate crimes, while overall crime rates have decreased in some areas.',\n",
       "   'samples': ['The pandemic has led to an increase in some forms of violence, including domestic abuse and online harassment, while overall violent crime rates have decreased in some areas.',\n",
       "    'The pandemic has led to an increase in domestic violence and hate crimes. Violent crimes overall have shown mixed trends.',\n",
       "    'The pandemic has led to an increase in some types of violence and violent crimes, such as domestic violence and hate crimes. Other forms of crime have decreased due to reduced mobility. Police response times may have also been affected.',\n",
       "    'The pandemic has led to an increase in some forms of domestic violence and a decrease in other types of violent crime due to reduced social interactions.',\n",
       "    'The pandemic has led to increased domestic violence and certain types of crime but decreases in others. Police resources have been strained.',\n",
       "    'The pandemic has led to an increase in certain types of domestic violence and child abuse, while overall violent crime rates have shown mixed results across different regions. Some areas experienced a decrease, possibly due to reduced social interactions, while others saw an increase. Police',\n",
       "    'The pandemic has led to an increase in certain types of violence and crime, such as domestic abuse and violence against essential workers. However, overall violent crime rates have decreased in some areas.',\n",
       "    'The pandemic has led to an increase in certain types of violence, such as domestic violence and hate crimes. Violent crime rates have shown mixed results in different regions.',\n",
       "    'The pandemic has led to an increase in certain types of violence, such as domestic abuse and violence against healthcare workers. However, overall violent crime rates have decreased in some places. Factors contributing to these varied impacts include economic stress, isolation, and strain on',\n",
       "    'The pandemic has led to an increase in domestic violence and a mixed impact on other types of violent crimes. Some areas saw decreases, while others experienced increases.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 4, 5, 0, 6, 4],\n",
       "   'entropy': 1.8343719702816235}},\n",
       " '38': {'no': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "   'samples': ['Inflammatory response in COVID-19 involves immune cells and cytokines; pathogenesis includes viral entry, replication, and immunopathology. Brief.',\n",
       "    'Inflammatory response involves immune cells and cytokines. COVID-19 pathogenesis includes viral entry, replication, and host inflammatory overreaction (cytokine storm).',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, leading to a cytokine storm. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune system activation causing tissue damage.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells and cytokines. Pathogenesis includes viral entry, replication, and host immune overreaction causing damage.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing damage to lung tissue. Pathogenesis includes viral entry via ACE2 receptors, replication, and systemic inflammation leading to severe outcomes. Briefly: Inflammatory response in COVID-19',\n",
       "    \"Inflammatory response in COVID-19 involves cytokine release, causing damage to tissues. Pathogenesis includes viral entry, replication, immune response, and severe inflammation leading to respiratory failure. Briefly, it's viral infection triggering excessive inflammation.\",\n",
       "    'Inflammatory response involves immune cells and cytokines. In severe COVID-19, it can cause a \"cytokine storm,\" damaging tissues and organs. Pathogenesis includes viral entry, replication, and host immune response.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage. Pathogenesis includes viral entry, replication, immune overreaction, and multi-organ failure.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune system activation.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, damaging tissues and organs. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune system overreaction.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 1, 6, 7, 2],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '7yscd9gc': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "   'samples': ['Inflammatory response involves immune cells and cytokines. In severe COVID-19, excessive inflammation (cytokine storm) damages tissues. Pathogenesis includes viral entry, replication, and immune-mediated injury.',\n",
       "    'In COVID-19, the virus triggers an inflammatory response through immune cells and cytokine release, causing tissue damage and multi-organ failure.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, where excessive immune activation damages tissues. Pathogenesis includes viral replication, immune cell infiltration, and endothelial dysfunction leading to multi-organ failure. Briefly, excessive cytokine release and immune',\n",
       "    'Inflammatory response involves cytokine release, causing tissue damage. In severe COVID-19, excessive inflammation (cytokine storm) damages lungs and other organs.',\n",
       "    'Inflammatory response involves cytokine release, endothelial damage, and blood clotting. COVID-19 pathogenesis includes viral entry, replication, and immune dysregulation leading to severe inflammation.',\n",
       "    'Inflammatory response involves immune cells and cytokines. COVID-19 causes excessive inflammation (cytokine storm) leading to severe illness. Pathogenesis includes viral entry, replication, and host immune response.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage. Pathogenesis includes viral entry via ACE2 receptors, replication, and systemic inflammation leading to severe complications.',\n",
       "    'In COVID-19, viral infection triggers an immune response, causing inflammation. Excessive inflammation can lead to severe complications like cytokine storms. Damaged tissues and organs result from this overreaction.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, causing multi-organ damage. Pathogenesis includes viral entry through ACE2 receptors, replication, and immune system activation leading to severe symptoms.',\n",
       "    'Inflammatory response involves immune cells and cytokines; in severe COVID-19, it can lead to a \"cytokine storm.\" Pathogenesis includes viral infection, immune response, and potential organ damage.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 0, 4, 5, 4, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '56u94l95': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "   'samples': ['Inflammatory response in COVID-19 involves immune cells releasing cytokines. Excessive cytokine release (cytokine storm) can cause severe lung damage and multi-organ failure. Pathogenesis includes viral entry, replication, and host immune response.',\n",
       "    'Inflammatory response involves immune cells releasing cytokines; in severe COVID-19, this can cause a \"cytokine storm.\" Pathogenesis involves viral entry via ACE2 receptors, leading to lung damage and multi-organ failure.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing damage to tissues. Pathogenesis includes viral entry via ACE2 receptors, immune system activation, and potential cytokine storm.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing damage to tissues. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated lung injury.',\n",
       "    'The inflammatory response in COVID-19 involves immune cells releasing cytokines, leading to inflammation. Excessive cytokine release (cytokine storm) can damage tissues and organs. Pathogenesis includes viral entry, replication, and host immune response. Se',\n",
       "    'Inflammatory response in COVID-19 involves immune cells and cytokines. Pathogenesis includes viral infection, immune overreaction, and tissue damage.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing damage to tissues and organs. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune system activation leading to severe inflammation and multi-organ failure.',\n",
       "    'Inflammatory response involves immune cells releasing cytokines; in severe COVID-19, excessive cytokine release (cytokine storm) damages tissues. Pathogenesis includes viral entry via ACE2 receptors, replication, and systemic inflammatory reactions leading to multi-',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines. Excessive cytokine release (cytokine storm) can damage lungs and other organs. Pathogenesis includes viral entry, replication, and host immune response leading to inflammation and potential',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, damaging tissues. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune system activation leading to severe lung damage.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 5, 0, 3],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'shcjr2z9': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "   'samples': ['Inflammatory response involves immune cells and cytokines; in severe COVID-19, excessive cytokine release (cytokine storm) damages tissues. Pathogenesis includes viral entry, replication, and host immune response leading to lung damage and multi-organ',\n",
       "    \"Inflammatory response in COVID-19 involves cytokine release, leading to a storm and multi-organ dysfunction. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated tissue damage. Briefly, it's viral infection triggering excessive\",\n",
       "    'The inflammatory response in COVID-19 involves cytokine release, causing tissue damage. Pathogenesis includes viral entry, replication, immune activation, and multi-organ failure.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines; excessive can lead to a \"cytokine storm.\" Pathogenesis includes viral entry, replication, and host cell damage. Severe cases may result in acute respiratory distress syndrome (',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines; pathogenesis includes viral entry, replication, and damage to tissues. Brief.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines, leading to tissue damage and multi-organ failure. Pathogenesis involves viral entry, replication, and host immune reaction causing severe inflammation.',\n",
       "    'Inflammatory response involves immune cells releasing cytokines; in severe COVID-19, this can lead to a cytokine storm, damaging tissues. Pathogenesis includes viral entry, replication, and host immune overreaction.',\n",
       "    'The inflammatory response in COVID-19 involves immune cells and cytokines. Excessive cytokine release (cytokine storm) damages tissues. Pathogenesis includes viral entry, replication, and host immune response leading to severe respiratory illness. Antibody production',\n",
       "    'The inflammatory response in COVID-19 involves immune cells releasing cytokines. Excessive cytokine release (Cytokine Storm) damages tissues, affects multi-organ function. Severe cases lead to acute respiratory distress syndrome and multiple organ failure.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells and cytokines. Pathogenesis includes viral entry, replication, and immune overreaction leading to severe inflammation and tissue damage.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 2, 0, 4, 5, 6],\n",
       "   'entropy': 1.8866967846580782},\n",
       "  '3xikq0ef': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "   'samples': ['In COVID-19, SARS-CoV-2 enters cells via ACE2 receptors. This triggers an immune response causing inflammation. Overactive inflammation can lead to severe complications like cytokine storm and acute respiratory distress syndrome (ARDS).Prolong',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing lung damage. Pathogenesis includes viral entry via ACE2 receptors, replication, and host immune response leading to severe inflammation and multi-organ failure. Antibodies may also cause immune complexes',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, damaging tissues. Pathogenesis includes viral entry, replication, and immune system overreaction.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, damaging tissues. Pathogenesis includes viral entry, replication, immune response escalation.',\n",
       "    'The inflammatory response in COVID-19 involves cytokine release, causing damage to lung tissue. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated lung injury.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated lung injury.',\n",
       "    'In COVID-19, viruses enter cells, trigger inflammation, and cause damage. Immune response can lead to cytokine storms. Damaged cells promote more inflammation. This can lead to severe respiratory issues and organ failure. Mechanisms involve ACE2',\n",
       "    'In COVID-19, SARS-CoV-2 enters cells via ACE2 receptors. This triggers an immune response, causing inflammation. Severe cases may experience a cytokine storm, damaging tissues and organs. Oxygen deprivation and clotting issues can',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, causing tissue damage. Pathogenesis includes viral entry, replication, and immune system activation.',\n",
       "    'Inflammatory response involves immune cells and cytokines; in severe COVID-19, this can lead to a cytokine storm. Pathogenesis includes viral entry, replication, and immune-mediated tissue damage.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'klcf0eqc': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated lung injury.',\n",
       "   'samples': ['Inflammatory response in COVID-19 involves immune cells releasing cytokines, causing tissue damage. Pathogenesis includes viral entry, replication, and host immune overreaction.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines. Excessive inflammation (cytokine storm) can damage lungs and other organs. Pathogenesis includes viral entry, replication, and immune system activation.',\n",
       "    'In COVID-19, SARS-CoV-2 infection triggers an immune response, leading to inflammation. Overactive cytokine release (cytokine storm) can damage tissues, contributing to severe disease.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry, replication, and immune-mediated injury.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines; excessive can lead to cytokine storm. Pathogenesis includes viral entry, replication, and host immune response causing lung damage.',\n",
       "    'In COVID-19, SARS-CoV-2 infection triggers an immune response, causing inflammation. Macrophages and neutrophils are activated, leading to cytokine release, potentially causing a cytokine storm. This excessive inflammation can damage lungs',\n",
       "    'In COVID-19, viral infection triggers an immune response leading to inflammation. Overactive inflammation can cause severe symptoms and organ damage.',\n",
       "    'The inflammatory response in COVID-19 involves cytokine release, leading to a \"cytokine storm.\" This damages tissues and causes multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells and cytokines. Pathogenesis includes viral entry, replication, and host immune overreaction.',\n",
       "    'Inflammatory response involves immune cells releasing cytokines; in severe COVID-19, excessive cytokine release (cytokine storm) damages tissues, leading to multi-organ failure.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 3, 0, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '87oqu4gx': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "   'samples': ['Inflammatory response in COVID-19 involves cytokine release, causing lung inflammation. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated tissue damage.',\n",
       "    'In COVID-19, viral infection triggers an immune response, leading to inflammation. Overactive cytokine production (cytokine storm) can cause severe tissue damage. Inflammation can impair lung function, contributing to respiratory failure. Mechanisms also',\n",
       "    'In COVID-19, viral infection triggers an immune response causing inflammation. Overactive inflammation can lead to severe complications like ARDS and multi-organ failure. Mechanisms include cytokine storms and blood clot formation.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage. Pathogenesis includes viral replication, immune system activation, and vascular leakage. Severe cases lead to multi-organ failure. Briefly.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing damage to tissues. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated lung injury.',\n",
       "    'In COVID-19, SARS-CoV-2 infects cells, triggering innate immune response. This leads to inflammation and cytokine storm, damaging tissues and causing multi-organ failure. Viral RNA and proteins trigger innate immune sensors, initiating',\n",
       "    'Inflammatory response in COVID-19 involves immune cells and cytokines; pathogenesis includes viral infection, host immune response, and subsequent inflammation leading to potential multi-organ failure.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, leading to a cytokine storm that damages tissues. Pathogenesis includes viral entry, replication, and immune-mediated injury.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry, replication, immune cell activation, and systemic inflammation.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine storm, causing tissue damage. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune cell activation.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 7],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'uxehz43v': {'greedy': 'The inflammatory response in COVID-19 is dynamic, peaking after respiratory function nadir, with IL1 and related pathways potentially being key. Pro-inflammatory response intertwines with T-cell activation, which could exacerbate disease or prolong infection. IL1',\n",
       "   'samples': ['The inflammatory response in COVID-19 is dynamic, peaking after respiratory function nadir, with a focus on the IL1 pathway. Pro-inflammatory responses are intertwined with T-cell activation, which could exacerbate disease or prolong infection. IL1 and',\n",
       "    'Inflammatory response peaks after respiratory function nadir, with IL1 pathway being prominent. T-cell activation may exacerbate disease or prolong infection. IL1 and related pathways could be prognostic and therapeutic targets.',\n",
       "    'The inflammatory response in COVID-19 is dynamic, peaking after respiratory function nadir, with IL1 pathway being prominent. Pro-inflammatory response intertwines with T-cell activation, potentially exacerbating disease or prolonging infection. IL1 and related pathways',\n",
       "    'The inflammatory response and pathogenesis of COVID-19 involve a dynamic early immune response, cytokine upregulation, T-cell activation, and persistence of SARS-CoV-2. IL1 and related pro-inflammatory pathways may be key. Ther',\n",
       "    'The inflammatory response in COVID-19 is dynamic and peaks after respiratory function nadir. IL1 and related pro-inflammatory pathways are involved and may be therapeutic targets. T-cell activation could exacerbate disease or prolong infection.',\n",
       "    'The inflammatory response peaks after respiratory function nadir, with IL1 and related pathways potentially playing a key role. T-cell activation may exacerbate disease or prolong infection. These findings suggest IL1 pathways could be targeted therapeutically.',\n",
       "    'Inflammatory response peaks after respiratory function nadir, involving IL1 pathway and T-cell activation. Pro-inflammatory pathways may be prognostic and therapeutic targets.',\n",
       "    'The inflammatory response and pathogenesis of COVID-19 involve a dynamic early immune response, prolonged viral persistence, increased cytokine expression, and interwoven T-cell activation. IL1 and related pro-inflammatory pathways may be key. Targeting these pathways',\n",
       "    'The inflammatory response in COVID-19 involves a dynamic early immune response and increased cytokine expression. Pro-inflammatory pathways, particularly IL1, peak after respiratory function nadir and may intertwine with T-cell activation, potentially exacerbating disease or prolonging',\n",
       "    'Inflammatory response and pathogenesis in COVID-19 involve a dynamic early immune reaction, prolonged viral persistence, and a pro-inflammatory response peaking post-respiratory nadir, linked to T-cell activation. IL1 pathway is highlighted as potentially progn'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 3, 1, 4, 2, 5],\n",
       "   'entropy': 1.7480673485460894},\n",
       "  'yrbud0iq': {'greedy': 'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage and multi-organ failure. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated injury.',\n",
       "   'samples': ['Inflammatory response in COVID-19 involves cytokine storm, damaging tissues and organs. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated tissue damage.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines. Pathogenesis includes viral entry, replication, and cell damage leading to inflammation and potential multi-organ failure.',\n",
       "    'Inflammatory response in COVID-19 involves immune cells releasing cytokines; excessive can cause a cytokine storm. Pathogenesis includes viral entry, replication, and cell damage leading to respiratory issues and organ failure.',\n",
       "    'In COVID-19, viral infection triggers an immune response leading to inflammation. Excessive inflammation can cause severe respiratory issues and multi-organ damage. Mechanisms include cytokine storm and endothelial dysfunction.',\n",
       "    'The inflammatory response in COVID-19 involves immune cells and cytokines that cause tissue damage. Pathogenesis includes viral entry, replication, and host immune overreaction leading to severe inflammation.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, leading to a cytokine storm. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune-mediated tissue damage.',\n",
       "    'Inflammatory response in COVID-19 involves cytokine release, causing tissue damage. Pathogenesis includes viral entry via ACE2 receptors, replication, and immune overreaction leading to severe symptoms.',\n",
       "    'In COVID-19, viral infection triggers immune responses, causing inflammation. Destructive cytokine storms follow in severe cases, damaging tissues and organs.',\n",
       "    'The inflammatory response in COVID-19 involves immune cells releasing cytokines. Excessive cytokine release (cytokine storm) can damage tissues and cause severe illness.',\n",
       "    'The inflammatory response in COVID-19 involves immune cells releasing cytokines. Excessive cytokine release (cytokine storm) can damage tissues, leading to severe symptoms and complications.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 8],\n",
       "   'entropy': 2.1639556568820564},\n",
       "  'xm0n9iu4': {'greedy': 'The inflammatory response in COVID-19 is dynamic, peaking after respiratory function nadir, with IL1 pathway being an exception. Pro-inflammatory response intertwines with T cell activation, potentially exacerbating disease or prolonging infection. IL1 and related',\n",
       "   'samples': ['The inflammatory response is highly dynamic early in COVID-19, with peak expression after respiratory function nadir, except for the IL1 pathway. Pro-inflammatory response intertwines with T cell activation, potentially exacerbating disease or prolonging infection. IL1',\n",
       "    'The inflammatory response and pathogenesis of COVID-19 involve a dynamic early immune response, prolonged viral persistence, and a pro-inflammatory cytokine release. T cell activation is intertwined with inflammation, potentially worsening disease or prolonging infection. IL1 and related',\n",
       "    'Inflammatory response and pathogenesis in COVID-19 involve a dynamic early immune reaction, prolonged viral persistence, increased cytokine expression, and intertwined T cell activation. Pro-inflammatory pathways like IL1 may predict severity and offer therapeutic targets.',\n",
       "    'The inflammatory response in COVID-19 is dynamic and involves cytokine expression peaking after respiratory function nadir, with IL1 and related pathways possibly being key. Pro-inflammatory response correlates with T cell activation, which could worsen disease or prolong infection',\n",
       "    'The inflammatory response is highly dynamic in early stages, with IL1 and related pathways potentially playing a key role. Pro-inflammatory responses may be linked to T cell activation, which could worsen disease or prolong infection. IL1 and related pathways may be progn',\n",
       "    'Inflammatory response and pathogenesis in COVID-19 cases involve a dynamic early immune response, cytokine expression peaks post-respiratory nadir, and intertwining with T cell activation. IL1 and related pro-inflammatory pathways may be key.',\n",
       "    'The early immune response in COVID-19 patients is highly dynamic and involves increased cytokine expression, particularly in the IL1 pathway. Pro-inflammatory response is intertwined with T cell activation, which could exacerbate disease or prolong infection. IL1 and related',\n",
       "    'The inflammatory response in COVID-19 patients is highly dynamic and peaks after respiratory function nadir, with the IL1 pathway being a notable exception. Pro-inflammatory response may be linked to T cell activation, which could exacerbate disease or prolong infection.',\n",
       "    'Inflammatory response and pathogenesis in COVID-19 involve a dynamic early immune response, persistent viral presence for 3-4 weeks, peak cytokine expression post-respiratory nadir, and intertwining with T cell activation via IL1 and',\n",
       "    'The inflammatory response in COVID-19 is highly dynamic, with peak expression generally occurring after respiratory function nadir, except for IL1 pathway. T cell activation may exacerbate disease or prolong infection. IL1 and related pathways may be prognostic'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 4, 5, 0, 6, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'z2l2vn1o': {'greedy': 'The study found that patients with COVID-19 had elevated levels of cytokines such as IL-1β, IL-6, IL-8, and sTNFR1. Severe cases showed higher levels of these cytokines compared to stable',\n",
       "   'samples': ['The study indicates that the cytokine profile of COVID-19 is characterized by elevated levels of IL-1β, IL-6, IL-8, and sTNFR1. Severe cases have higher IL-1β, IL-',\n",
       "    'The study found that the cytokine profile of COVID-19 patients is distinct from other types of pneumonia leading to organ failure and ICU need. Specifically, patients with severe illness have higher levels of IL-1β, IL-6, and s',\n",
       "    'The study identifies that the inflammatory response in COVID-19 involves elevated levels of cytokines like IL-1β, IL-6, IL-8, and sTNFR1, particularly in severe cases. Severe COVID-19 patients',\n",
       "    'The inflammatory response in COVID-19 involves elevated levels of cytokines like IL-1β, IL-6, IL-8, and sTNFR1. Severe cases show higher IL-1β, IL-6, and s',\n",
       "    'The study indicates an elevated cytokine profile in COVID-19 patients, particularly for IL-1β, IL-6, IL-8, and sTNFR1. Severe cases show distinct profiles with higher levels of pro-inflammatory cytokines',\n",
       "    'The study shows that the inflammatory response in COVID-19 involves increased levels of cytokines like IL-1β, IL-6, and IL-8, particularly in severe cases requiring ICU admission. Neutrophils exhibit altered immunometabolic',\n",
       "    'The inflammatory response in COVID-19 involves elevated levels of cytokines like IL-1β, IL-6, and IL-8, and soluble TNF receptor 1 (sTNFR1). Severe cases show a more pronounced inflammatory',\n",
       "    \"The inflammatory response in COVID-19 involves increased levels of cytokines such as IL-1β, IL-6, and IL-8, particularly in severe cases. Neutrophils show altered immunometabolism, and there's an\",\n",
       "    '',\n",
       "    'The study suggests that the cytokine profile of COVID-19 is distinct from other types of pneumonia leading to organ failure and ICU need. It indicates an increased presence of pro-inflammatory cytokines like IL-1β, IL-6, and IL'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 2, 0, 3, 4, 5],\n",
       "   'entropy': 1.4978661367769952}},\n",
       " '23': {'no': {'greedy': 'Complications include heart damage, blood clots, and kidney issues.',\n",
       "   'samples': ['Complications include increased risk of severe illness, higher hospitalization rates, and worse outcomes.',\n",
       "    'Complications include worse disease outcomes, increased risk of hospitalization, and higher mortality rates.',\n",
       "    'Cardiovascular issues, kidney damage, blood clots.',\n",
       "    'Hypertension is linked to increased risk of severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and death.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome (ARDS), and increased risk of death.',\n",
       "    'Complications in hypertensive patients include kidney damage, heart failure, and increased risk of severe illness.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and increased mortality.',\n",
       "    'Complications include heart failure, blood clots, and increased risk of severe illness.',\n",
       "    'Cardiovascular issues, kidney damage, and increased severity of illness.',\n",
       "    'Complications include heart damage, blood clots, and kidney issues.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 5, 6, 4, 2],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '6xntcvmb': {'greedy': 'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and death.',\n",
       "   'samples': ['Hypertension is linked to more severe COVID-19 outcomes, including respiratory failure and death.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, septic shock, and increased risk of mortality.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, kidney damage, and cardiovascular issues.',\n",
       "    'Complications include increased risk of severe illness, heart damage, and kidney problems.',\n",
       "    'Hypertension can lead to severe complications in COVID-19, including increased risk of respiratory failure, ICU admission, mechanical ventilation, and death.',\n",
       "    'Complications include heart damage, blood clots, and kidney issues.',\n",
       "    'Complications in hypertensive patients with COVID-19 include worse outcomes, higher risk of hospitalization, and increased severity of illness.',\n",
       "    'Complications include increased risk of severe illness, hospitalization, and death.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and an increased risk of death.',\n",
       "    'Complications include heart damage, blood clots, and increased risk of severe illness.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 0, 3, 4, 4, 0, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'bzz8ydcs': {'greedy': 'Complications include heart damage, blood clots, and kidney issues.',\n",
       "   'samples': ['Hypertension can lead to more severe COVID-19 outcomes, including respiratory failure and increased risk of hospitalization.',\n",
       "    'Hypertension can lead to severe complications from COVID-19, including respiratory failure, acute respiratory distress syndrome, and an increased risk of hospitalization and death.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and an increased risk of death. Blood clots and heart issues are also more common in hypertensive patients with COVID-19.',\n",
       "    'Complications include heart damage, increased risk of clotting, and worsened outcomes.',\n",
       "    'Cardiovascular issues, kidney damage, and increased risk of severe illness.',\n",
       "    'Hypertension is linked to more severe COVID-19 complications, including respiratory failure, ICU admission, and death.',\n",
       "    'Hypertension is linked to more severe COVID-19 outcomes, including respiratory failure, ICU admission, and death.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, septic shock, and higher mortality.',\n",
       "    'Cardiovascular issues, kidney damage, and increased risk of severe illness.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and death.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 4, 4, 5, 3, 1],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  '7xqmuoye': {'greedy': 'Pulmonary hypertension and right ventricular failure are complications associated with COVID-19.',\n",
       "   'samples': ['Pulmonary hypertension and right ventricular failure.',\n",
       "    'Pulmonary hypertension and right ventricular failure.',\n",
       "    'Pulmonary hypertension and right ventricular failure are complications associated with severe COVID-19 pneumonia and cytokine release syndrome. These can develop rapidly and are linked to pulmonary parenchymal abnormalities and microvascular damage.',\n",
       "    'Pulmonary hypertension and right ventricular failure are complications associated with COVID-19. These can develop rapidly following severe pneumonia and may result from progressive pulmonary parenchymal and microvascular damage.',\n",
       "    'Complications related to COVID-19 that can lead to hypertension include systemic and multi-organ involvement, vascular issues, thromboembolic events, and cardiac problems. Specifically, the patient described developed secondary pulmonary hypertension and right ventricular failure following severe',\n",
       "    'Complications related to COVID-19 that can lead to hypertension include systemic and multi-organ involvement, cytokine release syndrome, pulmonary hypertension, and right ventricular failure. These often occur in patients with severe pneumonia.',\n",
       "    'COVID-19 is increasingly associated with systemic and multi-organ involvement, including vascular, thromboembolic, and cardiac events. Severe COVID-19 pneumonia with cytokine release syndrome may lead to the development of secondary pulmonary hypertension and right',\n",
       "    'Systemic and multi-organ involvement, including vascular, thromboembolic, and cardiac events, with a specific mention of secondary pulmonary hypertension and right ventricular failure developing rapidly post-severe COVID-19 pneumonia.',\n",
       "    'Pulmonary hypertension and right ventricular failure are complications associated with severe COVID-19 pneumonia and cytokine release syndrome.',\n",
       "    'Pulmonary hypertension and right ventricular failure.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 1, 2, 0, 0],\n",
       "   'entropy': 0.639031859650177},\n",
       "  'a0ra5stk': {'greedy': 'Complications include increased risk of severe illness, heart damage, and kidney issues.',\n",
       "   'samples': ['Cardiovascular issues, kidney damage, and increased risk of severe illness.',\n",
       "    'Cardiovascular issues, kidney damage, and increased severity of illness.',\n",
       "    'Complications include increased risk of severe illness, respiratory issues, and heart problems.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, septic shock, and death.',\n",
       "    'Complications include heart inflammation, blood clots, and worsening of hypertension.',\n",
       "    'Complications include heart damage, blood clots, and increased risk of severe illness.',\n",
       "    'Complications in hypertensive patients include kidney damage, heart issues, and increased risk of severe illness.',\n",
       "    'Hypertension increases risk for severe illness, including respiratory failure, septic shock, and death from COVID-19.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death.',\n",
       "    'Complications associated with COVID-19 in individuals with hypertension include more severe disease, higher risk of hospitalization, and increased mortality.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 1, 3, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'io8hm94a': {'greedy': 'Acute cardiac complications related to underlying atherosclerotic cardiovascular disease (ASCVD). According to the data from Wuhan, China, 58% of ICU-treated COVID-19 patients had hypertension, compared to 22% of',\n",
       "   'samples': [\"Acute cardiac complications related to underlying atherosclerotic cardiovascular disease (ASCVD). According to the data, patients with both cardiovascular disease and hypertension were more likely to require ICU treatment for COVID-19. However, it's important to note\",\n",
       "    'Acute cardiac complications, particularly those related to underlying atherosclerotic cardiovascular disease (ASCVD). According to the data from Wuhan, China, 58% of ICU-treated COVID-19 patients had hypertension, compared to 2',\n",
       "    'Acute cardiac complications related to underlying atherosclerotic cardiovascular disease (ASCVD). According to the given context, 58% of ICU-treated COVID-19 patients with hypertension also had cardiovascular disease, while this figure was 22',\n",
       "    'Acute cardiac complications related to underlying atherosclerotic cardiovascular disease (ASCVD).',\n",
       "    'Acute cardiac complications, particularly related to underlying atherosclerotic cardiovascular disease (ASCVD). In ICU-treated patients, 25% had cardiovascular disease and 58% had hypertension, compared to 10% and 22',\n",
       "    'Acute cardiac complications related to underlying atherosclerotic cardiovascular disease (ASCVD).',\n",
       "    'Acute cardiac complications related to underlying atherosclerotic cardiovascular disease (ASCVD). According to the data, 58% of ICU-treated COVID-19 patients had hypertension, compared to 22% of non-ICU-treated',\n",
       "    'Acute cardiac complications, particularly related to underlying atherosclerotic cardiovascular disease (ASCVD). In ICU-treated patients, 25% had cardiovascular disease and 58% had hypertension, compared to 10% and 22',\n",
       "    'Acute cardiac complications, particularly those related to underlying atherosclerotic cardiovascular disease (ASCVD). According to the data, patients with hypertension are at higher risk for severe COVID-19 outcomes. In ICU patients, 58% had',\n",
       "    'Acute cardiac complications, particularly those related to underlying atherosclerotic cardiovascular disease (ASCVD). According to the data from Wuhan, China, 58% of ICU-treated COVID-19 patients had hypertension, compared to 2'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 2, 2, 3, 4, 1],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  'ba5zus8h': {'greedy': 'Complications include heart damage, blood clots, and kidney issues.',\n",
       "   'samples': ['Hypertension increases risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death.',\n",
       "    'Complications associated with hypertension in COVID-19 include more severe disease, increased risk of hospitalization, and higher mortality.',\n",
       "    'Hypertension can lead to more severe COVID-19 outcomes, including acute respiratory distress syndrome, thromboembolic events, and cardiovascular complications.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome (ARDS), and an increased risk of mortality.',\n",
       "    'Complications include heart damage, increased risk of blood clots, and worsened lung function.',\n",
       "    'Hypertension can lead to more severe COVID-19 outcomes, including respiratory failure, prolonged hospitalization, and increased risk of death.',\n",
       "    'Complications include increased risk of severe illness, heart damage, and kidney issues.',\n",
       "    'Hypertension is linked to increased risk of severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and higher mortality rates.',\n",
       "    'Complications in hypertensive patients include kidney damage, heart problems, and increased risk of severe illness.',\n",
       "    'Complications include heart damage, blood clots, and kidney issues.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 0, 4, 2, 4, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'h7x4yzet': {'greedy': 'Complications include heart damage, blood clots, and kidney problems.',\n",
       "   'samples': ['Cardiovascular issues, kidney damage, blood clots.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and increased risk of mortality.',\n",
       "    'Complications associated with hypertension in COVID-19 include worse outcomes, increased risk of hospitalization, and higher mortality rates.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, kidney damage, and blood clots.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, kidney damage, and blood clots.',\n",
       "    'Complications include kidney damage, heart failure, and increased risk of severe illness.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including respiratory failure, kidney damage, and blood clots.',\n",
       "    'Complications include heart damage, blood clots, and kidney issues.',\n",
       "    'Complications include heart damage, blood clots, and kidney issues.',\n",
       "    'Hypertension can lead to severe complications from COVID-19, including respiratory failure, kidney damage, and increased risk of cardiovascular issues.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 3, 0, 0, 5],\n",
       "   'entropy': 1.6434177197931796},\n",
       "  'v7xow9kw': {'greedy': 'Complications include heart damage, blood clots, and kidney issues.',\n",
       "   'samples': ['Complications in hypertensive patients with COVID-19 include worse prognosis, increased risk of respiratory failure, and higher mortality rates.',\n",
       "    'Hypertension increases risk for severe illness, including respiratory failure, septic shock, and multi-organ dysfunction.',\n",
       "    'Hypertension can lead to more severe COVID-19 complications, including respiratory failure, acute respiratory distress syndrome, and an increased risk of hospitalization and mortality.',\n",
       "    'Complications include kidney damage, heart problems, and increased risk of severe illness.',\n",
       "    'Hypertension is linked to increased risk of severe COVID-19 complications, including respiratory failure, ICU admission, and death.',\n",
       "    'Complications include worse outcomes, higher risk of hospitalization, and increased risk of cardiovascular issues.',\n",
       "    'Complications associated with hypertension in COVID-19 include more severe disease, higher risk of hospitalization, and increased mortality.',\n",
       "    'Complications include worse outcomes, increased risk of hospitalization, and higher mortality rates.',\n",
       "    'Hypertension increases risk for severe illness, including respiratory failure, septic shock, and multi-organ dysfunction.',\n",
       "    'Complications include kidney damage, heart failure, and increased risk of severe illness.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 4, 6, 1, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '2s03ngzm': {'greedy': 'Complications include increased risk of severe illness, heart damage, and kidney problems.',\n",
       "   'samples': ['Complications in hypertensive patients include kidney damage, heart issues, and increased risk of severe illness.',\n",
       "    'Complications include heart failure, blood clots, and kidney damage.',\n",
       "    'Hypertension increases risk for severe COVID-19 outcomes, including hospitalization, ICU admission, and death. It may complicate recovery and increase risk for blood clots.',\n",
       "    'Complications include worse outcomes, increased risk of hospitalization, and higher mortality rates.',\n",
       "    'Hypertension increases risk for severe illness, including respiratory failure, septic shock, and acute respiratory distress syndrome.',\n",
       "    'Cardiovascular issues, kidney damage, and increased risk of mortality.',\n",
       "    'Hypertension can lead to severe complications like kidney damage, heart failure, and increased risk of respiratory issues in COVID-19 patients.',\n",
       "    'Hypertension increases risk for severe COVID-19 complications, including ICU admission, mechanical ventilation, and death.',\n",
       "    'Complications in hypertensive patients with COVID-19 include worse outcomes, higher risk of hospitalization, and increased severity of illness.',\n",
       "    'Complications associated with COVID-19 and hypertension include more severe disease, higher risk of hospitalization, and increased mortality.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 0, 6, 7, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'z28bws23': {'greedy': 'Poorer outcomes.',\n",
       "   'samples': ['Poorer outcomes.',\n",
       "    'Complications associated with hypertension in COVID-19 include poorer outcomes.',\n",
       "    'Complications like poorer outcomes.',\n",
       "    'Poorer outcomes.',\n",
       "    'Poorer outcomes.',\n",
       "    'Comorbid hypertension is linked to poorer outcomes, potentially indicating more severe complications in COVID-19 patients.',\n",
       "    'Comorbid hypertension is linked to poorer outcomes, suggesting more severe complications in COVID-19 patients.',\n",
       "    'Compromised respiratory function and increased risk of hospitalization.',\n",
       "    'Hypertension is linked to poorer outcomes, suggesting more severe complications in COVID-19 patients.',\n",
       "    \"Comorbid hypertension is associated with poorer outcomes, implying more severe complications in COVID-19 patients. Specific complications aren't detailed in the given context.\"],\n",
       "   'cluster_ids': [0, 1, 2, 0, 0, 1, 3, 4, 1, 3],\n",
       "   'entropy': 1.5047882836811908}},\n",
       " '28': {'no': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear consensus on its effectiveness exists. Some small studies showed potential benefits, while others found no significant effect or harm',\n",
       "   'samples': ['Limited evidence from studies suggests hydroxychloroquine may have some benefits, but overall results are inconclusive and more research is needed. Key points include mixed findings, lack of large-scale clinical trial support, and concerns about potential side effects. More rigorous',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but results are inconclusive and more research is needed. No clear clinical benefit has been demonstrated. Some small studies showed potential, but larger trials did not replicate these findings. Ris',\n",
       "    'There is limited evidence and most studies show hydroxychloroquine has no significant benefit for treating COVID-19. Some early studies suggested potential benefits, but larger, more rigorous trials did not support these findings. Current consensus is that hydroxychlor',\n",
       "    'Limited evidence from studies suggests no significant benefit and some potential risks; large-scale trials are ongoing.',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some benefits, but overall, studies show little to no significant effect on COVID-19 outcomes.',\n",
       "    'Limited evidence suggests mild benefit, but large trials show no significant effect and potential risks. More research is needed.',\n",
       "    'There is limited evidence, mainly from small studies and anecdotal reports, suggesting potential benefits, but large trials show no significant improvement and some suggest harm.',\n",
       "    'Limited evidence from studies suggests no significant benefit; some early trials showed promise but were later retracted or had issues. More rigorous trials did not support its use.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefits, but overall evidence is inconclusive and more research is needed. Many clinical trials showed no significant benefit or potential harm. WHO guidelines no longer recommend its use outside hospital settings for COVID',\n",
       "    'Limited evidence suggests potential benefits, but large trials show no significant effect and some risks.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 1, 7, 5],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '2clz993c': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear consensus on its effectiveness exists. Early promising reports were later contradicted by larger trials showing no significant benefit.',\n",
       "   'samples': ['Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large studies show it does not improve outcomes for COVID-19 patients and may cause harm. There is no strong scientific support for its use. Briefly: Ins',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but results are inconsistent and more research is needed. No clear consensus exists on its effectiveness.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data remains inconclusive and more research is needed. No large-scale studies have definitively proven its effectiveness against COVID-19. Risks and side effects are also',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials show no significant benefit and potential harms. More research needed.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefits, but overall data is inconclusive and more research is needed. Major trials like REMAP-CAP and SOLIDARITY found no significant benefit. Some small studies showed potential,',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials show it does not improve outcomes for COVID-19 patients and may cause harm. More research is needed.',\n",
       "    \"Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large-scale trials show it's not effective for treating COVID-19 and can be harmful.\",\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. Early studies showed promise but larger trials did not consistently find significant benefits. Risks like heart problems remain a concern.',\n",
       "    'Limited evidence from studies suggests no significant benefit and some potential risks. Clinical trials have shown mixed results, but overall, hydroxychloroquine does not appear to be an effective treatment for COVID-19. Some studies indicate possible harm. More research',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefits, but overall data remains inconclusive and controversial. More research needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 3, 5, 5, 1],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'bjz7whqh': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear consensus on its effectiveness exists. Some small studies showed potential benefits, while others found no significant effect or harm',\n",
       "   'samples': ['Limited evidence from studies suggests no significant benefit; some early reports were misleading. Current consensus: not effective or harmful.',\n",
       "    'There is limited evidence, and studies show mixed results. Large trials (e.g., REMAP-CAP, SOLIDARITY) did not find significant benefits. Some smaller studies suggest potential benefits, but more research is needed. Hydroxychloro',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large-scale studies show it is not effective for treating or preventing COVID-19 and can be harmful.',\n",
       "    'There is limited evidence and some争议，多项研究显示其效果不明显或存在风险。建议遵循世卫组织指南。 需进一步高质量研究确认。 尽管早期有一些积极报道，但目前普遍认为其对治疗新冠',\n",
       "    'Limited evidence from small studies suggests potential benefits, but larger trials show no significant effect or harm. Current consensus is against its routine use.',\n",
       "    'Limited evidence from studies suggests no significant benefit and some potential risks. More research is needed.',\n",
       "    \"Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large studies show it's not effective for treating COVID-19 and may be harmful.\",\n",
       "    'Limited evidence suggests mild benefits, but larger studies show no significant improvement and potential risks. More research is needed.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. No clear consensus on its effectiveness exists. Some studies show mixed or no benefits. Use remains controversial and off-label. Consult current medical guidelines.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but results are inconclusive and more research is needed. No clear benefits have been established for its use in treating COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'xx8snj1h': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear consensus on its effectiveness exists. Some small studies showed potential benefits, while others found no significant effect or harm',\n",
       "   'samples': ['Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials showed no significant benefit and potential harms.',\n",
       "    'Limited evidence suggests potential benefits, but large studies have found no significant improvement and some risks. More research is needed.',\n",
       "    'Limited evidence from studies suggests no significant benefit and some risks. Large trials showed no clinical benefits and potential harm.',\n",
       "    'There is limited evidence, mainly from small studies, suggesting hydroxychloroquine may have some benefit against COVID-19. However, large-scale trials have not consistently shown significant benefits and some have found harm. Current guidelines do not generally recommend its',\n",
       "    'Limited evidence from studies suggests no significant benefit; some early reports were overly optimistic. Larger, well-controlled trials did not find support for its use.',\n",
       "    'There is limited evidence, with some studies showing no significant benefit and others suggesting potential risks. No strong evidence supports its efficacy or safety.',\n",
       "    'There is limited evidence, mainly from small studies and anecdotal reports, suggesting potential benefits, but large-scale trials have shown no significant improvement and some risks.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefits, but more research is needed. No strong evidence supports its use. Several large studies found no significant benefit and raised safety concerns.',\n",
       "    \"Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but overall results are inconclusive and it's not recommended as a standard treatment. More research is needed.\",\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. Results have been mixed and its use is not widely recommended by health authorities.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 5, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '450y85ln': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No large-scale trials have definitively proven its effectiveness or safety for COVID-19 treatment.',\n",
       "   'samples': ['There is limited evidence, with some studies showing potential benefits and others finding no significant effects or harm. More research is needed. Clinical guidelines do not currently recommend hydroxychloroquine for routine treatment of COVID-19.',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some benefit, but its effectiveness remains controversial and unsupported by large, rigorous studies. Current guidelines do not recommend it as a standard treatment. More research is needed.',\n",
       "    'Limited evidence from studies suggests no significant benefit; some early reports were inconclusive or later retracted. Current consensus is that hydroxychloroquine is not effective for treating COVID-19.',\n",
       "    \"There is limited evidence and no strong scientific consensus supports hydroxychloroquine's effectiveness in treating COVID-19. Several studies show mixed or inconclusive results. Large randomized controlled trials did not find significant benefits. More research is needed.\",\n",
       "    'There is limited evidence suggesting potential benefits, but large-scale studies have shown it to be ineffective and sometimes harmful. Clinical trials like REMAP-CAP and SOLIDARITY found no significant benefit. Some smaller studies showed mixed results. Hydroxychloro',\n",
       "    'Limited evidence from small studies suggests hydroxychloroquine may have some benefit, but larger studies have not consistently shown significant疗效。请根据上下文将其翻译为：',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large studies show it does not improve outcomes for COVID-19 patients and may be harmful. More research is needed.',\n",
       "    'Limited evidence from small studies suggests potential benefits, but large trials showed no significant improvement and some risks.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but results are inconsistent and more research is needed. No clear consensus on its effectiveness exists.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but results are mixed and more research is needed. No strong consensus on effectiveness or safety for COVID-19 treatment exists. Early trials showed promise but larger studies did not confirm'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 8],\n",
       "   'entropy': 2.1639556568820564},\n",
       "  'tepg81vm': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No large-scale trials have definitively proven its effectiveness or safety for COVID-19 treatment. Early hopes were tempered',\n",
       "   'samples': ['Limited evidence from some studies suggests potential benefits, but large-scale trials have not consistently supported its effectiveness or shown significant risk reduction. Evidence remains inconclusive.',\n",
       "    'Limited evidence from some studies suggests potential benefits, but overall data is inconclusive and more research is needed. Evidence remains controversial. Some studies show no significant benefit or harm, while others report possible benefits. Use of hydroxychloroquine for COVID-',\n",
       "    'Limited evidence suggests potential benefits, but large-scale studies show no significant effect and some risks. More research is needed.',\n",
       "    'Limited evidence from studies suggests no significant benefit; some show potential harms. More research needed.',\n",
       "    \"Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but overall results are inconclusive and it's not currently recommended as a standard treatment. More research is needed.\",\n",
       "    'There is limited evidence suggesting hydroxychloroquine may have some antiviral effects, but large randomized controlled trials show it is not effective for treating COVID-19 and can be harmful. No strong evidence supports its use. Consult current medical guidelines',\n",
       "    \"Limited evidence suggests potential benefits, but large studies show it's not effective and may be harmful. More research needed.\",\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. No strong evidence supports its use and some studies show potential harms.',\n",
       "    \"There is limited evidence suggesting potential benefits, but many studies show it's ineffective or harmful. More research is needed.\",\n",
       "    'Limited evidence from studies suggests no significant benefit; some show potential risks. More research needed.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 2, 3, 1, 1, 1, 1],\n",
       "   'entropy': 0.9404479886553263},\n",
       "  'nkphjlky': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear consensus exists on its effectiveness for treating COVID-19.',\n",
       "   'samples': ['There is limited evidence and most studies show hydroxychloroquine is not effective for treating COVID-19.',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some benefits, but its use remains controversial and unsupported by strong clinical trial data. Most studies show no significant benefit or harm.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear benefit has been definitively established. Early hopes were tempered by subsequent findings. Consult current medical guidelines for up',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some benefit, but its effectiveness remains controversial and unsupported by large-scale clinical trials. Current guidelines do not recommend its routine use.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials show it does not improve outcomes and may cause harm. Briefly, evidence is mixed but leans towards no benefit and potential risks.',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large studies show it does not improve outcomes for COVID-19 patients and may be harmful.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefits, but overall results are inconclusive and more research is needed. No clear consensus on its effectiveness exists. Early studies showed promise, but later larger trials found no significant benefit or potential',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. Early studies had mixed results and larger trials showed no significant benefit or potential harm. Current guidelines do not recommend hydroxychloroquine for routine use',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some benefits, but overall, studies show it is not effective for treating COVID-19 and may be harmful. Larger trials showed no significant benefit.',\n",
       "    'Limited evidence from some studies suggests hydroxychloroquine may have some benefits, but overall evidence is inconclusive and more research is needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 5, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'ym5lw49s': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear consensus exists on its effectiveness for treating COVID-19.',\n",
       "   'samples': [\"Limited evidence suggests potential benefits, but large studies show it's not effective and may be harmful. More research is needed.\",\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. No strong consensus exists on its efficacy or safety for COVID-19 treatment. Early trials showed mixed results.',\n",
       "    \"Limited evidence suggests potential benefits, but large studies show it's not effective and may be harmful. More research needed.\",\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefits, but overall, clinical trial results indicate it is not effective for treating COVID-19 and may be harmful.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials show no significant benefit and potential risks. More research is needed.',\n",
       "    'Limited evidence suggests potential benefits, but large studies show no significant effect and some risks. More research needed.',\n",
       "    'Limited evidence suggests potential benefits, but large studies show no significant effect and some risks. More research is needed.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials (like REMAP-CAP and SOLIDARITY) found it ineffective or harmful for treating COVID-19.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. Clinical trial results have been mixed and its use remains controversial. No clear consensus exists on its effectiveness for treating COVID-19. Briefly,',\n",
       "    \"Limited evidence suggests mild benefit, but large studies show it's not effective and can be harmful. More research is needed.\"],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 3, 4, 5, 6, 4],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'o91ew9sl': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No large-scale trials have definitively proven its effectiveness or safety for COVID-19 treatment. Early optimistic reports were',\n",
       "   'samples': ['Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. No strong evidence supports its use and some studies show potential harm. FDA has since revoked emergency authorization. Briefly: Insufficient strong evidence supports hydro',\n",
       "    \"Limited evidence suggests potential benefits, but large studies show it's not effective and can be harmful.\",\n",
       "    \"There is limited evidence suggesting hydroxychloroquine may have some benefits, but large studies show it's not effective and can be harmful. More research is needed.\",\n",
       "    'There is limited evidence, with some studies showing no significant benefit and others raising concerns about potential risks.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefits, but overall data is inconclusive and more research is needed. Early studies showed promise but larger trials did not confirm these results. Some researchers continue to study its potential uses. Use',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large randomized trials show it does not improve outcomes for COVID-19 patients and may cause harm. No clear benefit has been demonstrated. More research is needed',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. Several large trials found no significant benefit. Consult current medical guidelines for up-to-date information.',\n",
       "    \"There is limited evidence suggesting potential benefits, but overall it's not considered effective. Multiple large studies and reviews have found no significant benefit and some have shown harm. More research is needed. Briefly: Limited & inconclusive evidence, no clear benefit.\",\n",
       "    'Limited evidence from studies suggests no significant benefit, and some show potential harm. More research is needed.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials show it does not significantly improve outcomes for COVID-19 patients and may cause harm. More research is needed. Briefly: Insufficient supportive'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 3, 4, 5, 2, 6, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '16d0zvot': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No clear consensus exists on its effectiveness for treating COVID-19.',\n",
       "   'samples': ['There is limited evidence, with some studies showing potential benefits and others finding no significant effects.',\n",
       "    'Limited evidence from studies suggests no significant benefit; some early trials showed potential but were later retracted or found inconclusive. Current consensus is that hydroxychloroquine is not effective for treating COVID-19.',\n",
       "    'There is limited evidence, and studies show mixed results with no clear benefit.',\n",
       "    'Limited evidence from small studies suggests potential benefits, but larger trials have shown no significant effect or increased risk. Evidence remains inconclusive.',\n",
       "    \"Limited evidence suggests mild benefit, but overall it's not recommended due to lack of efficacy and potential risks. More research is needed.\",\n",
       "    'Limited evidence suggests hydroxychloroquine may have some benefit, but more research is needed. Current guidelines do not generally recommend it due to lack of clear efficacy and potential risks. Clinical trial results have been mixed. Briefly: Insufficient clear evidence',\n",
       "    'Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large randomized controlled trials show it offers no significant benefit and may cause harm.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data are inconclusive and more research is needed. Early studies showed promise, but later randomized trials found no significant benefit or even potential harm.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but results are inconclusive and more research is needed. No strong evidence supports its use as a standard treatment for COVID-19. Risks and side effects exist. Consult',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large trials showed no significant benefit and potential risks.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 2, 0, 0, 3, 0],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'aczzoafs': {'greedy': 'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. No large-scale trials have definitively proven its effectiveness or safety for COVID-19 treatment.',\n",
       "   'samples': ['Limited evidence from studies suggests hydroxychloroquine may have some benefit, but more research is needed. Evidence remains inconclusive. Early trials showed promise but had methodological limitations. Some studies found no significant benefit. Use of hydroxychloroquine',\n",
       "    \"There is limited evidence and no strong support for hydroxychloroquine's effectiveness in treating COVID-19. Studies have shown inconsistent results and potential risks.\",\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but its use for COVID-19 treatment is controversial and not consistently supported by large trials. Many experts recommend against its routine use. More research is needed.',\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. Early studies showed promise but larger trials did not consistently support these findings. Use remains controversial.',\n",
       "    \"Limited evidence from studies suggests hydroxychloroquine may have some antiviral effects, but large randomized controlled trials show it does not improve outcomes for COVID-19 patients. The drug's use is not currently recommended as a standard treatment.\",\n",
       "    'Limited evidence from studies suggests hydroxychloroquine may have some benefit, but overall data is inconclusive and more research is needed. Some small studies showed potential benefits, while others found no significant effects or even harm. The drug is not currently recommended',\n",
       "    'There is limited evidence, with some studies showing potential benefits and others showing no significant effect or harm. More research is needed.',\n",
       "    'There is limited evidence, with some studies suggesting potential benefits but overall findings inconclusive. Key trials showed no significant improvement and some indicated harm. More research is needed.',\n",
       "    \"Limited evidence suggests potential benefits, but large studies show it's not effective and may be harmful. More research is needed.\",\n",
       "    'Limited evidence suggests hydroxychloroquine may have some antiviral effects, but large-scale trials show it does not significantly reduce hospitalizations or deaths from COVID-19. Some small studies suggest potential benefits, but more research is needed. Overall'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 5, 5, 6, 7],\n",
       "   'entropy': 1.9730014063936128}},\n",
       " '3': {'no': {'greedy': 'Yes, infected individuals can develop immunity. Cross-protection from other coronaviruses is limited. Vaccination also induces immunity and some cross-protection.',\n",
       "   'samples': ['Yes, infected individuals can develop immunity. Cross-protection from other coronaviruses is limited.',\n",
       "    'Yes, infected individuals can develop immunity. Cross-protection from other coronaviruses is limited.',\n",
       "    'Yes, infected people can develop immunity. Cross-protection from other coronaviruses is limited.',\n",
       "    'Yes, some infected individuals develop immunity. Cross-protection between variants is possible but varies in effectiveness. More research is needed.',\n",
       "    'Yes, some infected individuals develop immunity. Cross-protection from other coronaviruses is limited.',\n",
       "    'Yes, some infected individuals develop immunity. Cross-protection between variants is possible but varies in effectiveness. Immunity and cross-protection can wane over time. Vaccination enhances these responses.',\n",
       "    'Yes, infected individuals can develop immunity. Cross-protection from other coronaviruses is limited. Vaccination also induces immunity.',\n",
       "    'Yes, some infected individuals develop immunity. Cross-protection from other coronaviruses is possible but limited.',\n",
       "    'Yes, some infected individuals develop immunity. Cross-protection from other coronaviruses is limited. More research is needed.',\n",
       "    'Yes, most people develop some level of immunity after SARS-CoV-2 infection. Cross-protection against variants is variable and partial. Antibody levels decline over time. Vaccination enhances immunity and provides better protection.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 4, 0, 3, 3, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  'x1k6ao9h': {'greedy': 'Based on the study, some SARS-CoV-2 infected individuals may develop persistent antibodies, but innate immunity can still clear the virus in the absence of antibodies. Cross-protection between different coronaviruses is not addressed in this specific study.',\n",
       "   'samples': ['Some SARS-CoV-2 infected individuals may develop lasting antibody responses, but it is not clear if this provides full immunity or cross-protection against other coronaviruses. More research is needed to fully understand the immune response to SARS-Co',\n",
       "    'Based on the provided context, some SARS-CoV-2 infected individuals can develop IgG antibodies that persist for extended periods, suggesting potential immunity. However, at least one case demonstrated that antibody-independent mechanisms can also clear the virus, indicating that immunity',\n",
       "    'Based on the provided context, SARS-CoV-2 infected individuals can develop antibodies, as evidenced by the coexistence of SARS-CoV-2 and virus-specific IgG in some patients. However, the study suggests that in non-severe',\n",
       "    'Some SARS-CoV-2 infected individuals may develop lasting antibodies, while others can clear the virus through innate immunity alone. Cross-protection between different coronaviruses is not yet confirmed. Further research is needed to fully understand immunity and potential cross',\n",
       "    'Based on the provided information, SARS-CoV-2 infected individuals can develop immunity, as evidenced by some patients maintaining SARS-CoV-2 and virus-specific IgG for extended periods. However, the study also suggests that in some cases,',\n",
       "    'Based on the study, some SARS-CoV-2 infected individuals can develop long-lasting IgG antibodies and virus-specific IgG, indicating potential adaptive immunity. However, one patient cleared the virus without producing SARS-CoV-2-bound IgG',\n",
       "    'Based on this study, some SARS-CoV-2 infected individuals may develop long-lasting antibodies, but one case showed clearance without detectable antibodies, suggesting innate immunity can also play a role. Cross-protection from prior infections or other coronavir',\n",
       "    'Based on the study described, SARS-CoV-2 infected individuals can develop antibodies, but their presence and duration vary. Innate immunity alone can sometimes clear the virus without antibodies. Cross-protection from prior infections or vaccinations is not addressed in this',\n",
       "    'Based on the provided context, some SARS-CoV-2 infected individuals may develop lasting antibody responses, but this does not definitively prove long-term immunity. Cross-protection from other coronaviruses is not discussed here, so its possibility is',\n",
       "    'Yes, SARS-CoV-2 infected people can develop immunity, as evidenced by the persistence of SARS-CoV-2 and virus-specific IgG antibodies in some patients. However, the report suggests that innate immunity alone might suffice for clearance in'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '8i1u1a9t': {'greedy': 'Recovered SARS patients have significant neutralizing antibodies 9-17 years post-infection, suggesting potential long-term immunity. However, SARS patient sera do not show cross-neutralization against SARS-CoV-2, indicating no cross-pro',\n",
       "   'samples': ['Recovered SARS patients developed neutralizing antibodies up to 9-17 years post-infection, suggesting potential long-term immunity. Cross-neutralization between SARS-CoV and SARS-CoV-2 was not detected, indicating no significant cross',\n",
       "    'Recovered SARS patients have significant levels of neutralizing antibodies 9-17 years post-infection, but SARS patient sera do not show detectable cross-neutralization against SARS-CoV-2. This suggests partial or no cross-pro',\n",
       "    'Recovered SARS patients have significant neutralizing antibodies 9-17 years post-infection, suggesting potential long-term immunity. Cross-protection from SARS-CoV to SARS-CoV-2 is not detected, implying limited cross-protection',\n",
       "    \"Recovered SARS patients have significant levels of neutralizing antibodies years after initial infection, but SARS-CoV and SARS-CoV-2 show no detectable cross-neutralization. Therefore, it's unclear if SARS-CoV-2 infection\",\n",
       "    'Recovered individuals from SARS have neutralizing antibodies years later, but SARS-CoV and SARS-CoV-2 do not show cross-neutralization. Cross-protection between these viruses is unlikely.',\n",
       "    'Immunity may develop in SARS-CoV-2 infected people, but there is no cross-protection from SARS-CoV.',\n",
       "    'Immunity in SARS-CoV-2 infected individuals may develop, but cross-protection from SARS-CoV infection is not detectable. Briefly.',\n",
       "    'Recovered SARS patients developed neutralizing antibodies up to 9-17 years post-infection, suggesting potential long-term immunity. However, SARS patient sera showed no detectable cross-neutralization against SARS-CoV-2, indicating no',\n",
       "    'Immunity may develop in SARS-CoV-2 infected individuals, but cross-protection from SARS-CoV infection is not detectable.',\n",
       "    'Immunity to SARS-CoV-2 may develop in infected individuals, but there is no detectable cross-neutralization between SARS-CoV and SARS-CoV-2. Cross-protection is unlikely.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 1, 2, 2, 3, 2, 2],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'buwz6lu3': {'greedy': 'Recovered SARS patients have significant neutralizing antibodies 9-17 years post-infection, suggesting potential long-term immunity. However, SARS patient sera do not show cross-neutralization against SARS-CoV-2, indicating no cross-pro',\n",
       "   'samples': ['Immunity to SARS-CoV-2 may develop in infected individuals, but there is no detectable cross-neutralization between SARS-CoV and SARS-CoV-2. Cross-protection is not indicated based on the given information. However',\n",
       "    'Recovered SARS patients have significant levels of neutralizing antibodies 9-17 years post-infection, suggesting possible long-term immunity. However, SARS patient sera do not show cross-neutralization against SARS-CoV-2, indicating no',\n",
       "    'Recovered SARS patients have significant neutralizing antibodies up to 9-17 years post-infection, suggesting potential long-term immunity. Cross-neutralization between SARS-CoV and SARS-CoV-2 is not detectable, indicating no',\n",
       "    'Recovered SARS patients have significant levels of neutralizing antibodies up to 9-17 years post-infection, suggesting potential long-term immunity. However, SARS patient sera do not show detectable cross-neutralization against SARS-CoV-',\n",
       "    'Recovered SARS patients developed neutralizing antibodies up to 9-17 years post-infection, suggesting potential long-term immunity. However, SARS patient sera do not show cross-neutralization against SARS-CoV-2, indicating no cross',\n",
       "    'Recovered SARS patients have significant neutralizing antibodies up to 9-17 years post-infection, suggesting potential long-term immunity. However, SARS patient sera do not show detectable cross-neutralization against SARS-CoV-2,',\n",
       "    'Immunity in SARS-CoV-2 infected individuals may develop, but there is no cross protection between SARS-CoV and SARS-CoV-2.',\n",
       "    'Recovered SARS patients have significant levels of neutralizing antibodies years after initial infection, suggesting potential long-term immunity. However, SARS patient sera do not show cross-neutralization against SARS-CoV-2, indicating no cross-protection between the',\n",
       "    'Recovered SARS patients have significant neutralizing antibodies 9-17 years post-infection, suggesting potential long-term immunity. However, SARS patient sera do not show cross-neutralization against SARS-CoV-2, indicating no cross-pro',\n",
       "    'Recovered SARS patients have significant neutralizing antibodies up to 9-17 years post-infection, but SARS patient sera do not cross-neutralize SARS-CoV-2. Therefore, while long-term immunity from SARS may exist'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 1, 1, 0, 1, 1, 1],\n",
       "   'entropy': 0.6730116670092565},\n",
       "  'yigj0u3n': {'greedy': \"Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection is possible but varies; it's stronger between SARS-CoV-2 and SARS/MERS-CoV due to similar spike proteins. Further research is needed for\",\n",
       "   'samples': ['Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection between SARS-CoV-2 and other betacoronaviruses like SARS-CoV and MERS-CoV is possible but varies, with stronger cross',\n",
       "    \"Yes, SARS-CoV-2 infected individuals are likely to develop immunity through the production of antibodies. Cross-protection between SARS-CoV-2 and other Betacoronaviruses is possible but varies; it's highest between SARS\",\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection between SARS-CoV-2 and other betacoronaviruses like SARS-CoV and MERS-CoV is possible but not guaranteed. Further research',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection between different coronaviruses is possible but varies; it may be stronger for SARS-CoV and MERS-CoV due to sequence similarities. Further research is',\n",
       "    'Yes, SARS-CoV-2 infected individuals are expected to develop immunity. Cross-protection with other coronaviruses is possible but less certain, with stronger potential between SARS-CoV-2 and SARS/MERS-CoV due to',\n",
       "    'Yes, SARS-CoV-2 infected people are likely to develop immunity through the development of serum antibodies. Cross-protection against other betacoronaviruses like SARS-CoV and MERS-CoV is possible but less certain, as',\n",
       "    'Yes, SARS-CoV-2 infected people can develop immunity. Cross-protection from prior coronavirus infections may be possible but further analysis is needed to confirm. The study indicates some degree of cross-reactivity with other Betacoronaviruses,',\n",
       "    \"Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection between different coronaviruses is possible but varies; it's stronger between SARS-CoV-2 and SARS/MERS-CoVs due to similar spike proteins\",\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection is theoretically possible but requires further investigation, particularly regarding the cross-reactivity with other Betacoronaviruses like SARS and MERS. Studies using ELIS',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection against other coronaviruses is possible but varying degrees of effectiveness are expected based on sequence similarities among the viruses. Further research is needed to design effective pan-coron'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 4, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'yop76n7z': {'greedy': 'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from related coronaviruses might be possible due to shared epitopes, but its effectiveness is not guaranteed. Further research is needed to understand the extent of this protection',\n",
       "   'samples': ['Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from seasonal coronaviruses might exist due to shared epitopes, but it is not guaranteed and varies among individuals. Further research is needed to understand the extent of',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from other coronaviruses is possible but not guaranteed due to partial antigenic similarity. Further research is needed to fully understand this.',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from related coronaviruses is possible but the level of protection varies.',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from related coronaviruses is possible but less effective.',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. However, cross-protection from other coronaviruses to SARS-CoV-2 is not certain due to differences in epitopes. Answer concisely. Yes, S',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from seasonal coronaviruses to SARS-CoV-2 is possible due to shared epitopes, but it may be limited. Further research is needed to fully',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from other coronaviruses may occur due to shared epitopes, but it is not fully understood and varies among individuals. Answer concisely: Yes, some',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from related coronaviruses might be possible due to shared epitopes, though it is not guaranteed. Further research is needed to understand these dynamics fully.',\n",
       "    \"SARS-CoV-2 infected individuals may develop some level of immunity, but it's not yet clear how robust or long-lasting this immunity is. Cross-protection from seasonal coronaviruses to SARS-CoV-2 is unlikely due to\",\n",
       "    'SARS-CoV-2 infected individuals may develop some immunity, but cross-protection from other coronaviruses is unlikely due to differences in viral proteins. Mutations in SARS-CoV-2 may aid in immune evasion. Comprehensive vaccination strategies'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 0, 4, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'jvx9o6wi': {'greedy': 'SARS-CoV-2 infected individuals may develop immunity, but cross-protection between SARS-CoV-2 and other SARS-CoV strains is unlikely due to significant differences in their spike proteins.',\n",
       "   'samples': ['SARS-CoV-2 infected individuals may develop immunity, but cross-protection from SARS-CoV is unlikely due to significant differences between the two viruses. However, some degree of cross-reactivity among antibodies targeting certain regions may exist. Answering',\n",
       "    'Immunity to SARS-CoV2 may develop in infected individuals, but cross-protection between SARS-CoV2 and other SARS-CoV strains is uncertain.',\n",
       "    'SARS-CoV-2 infected individuals may develop immunity, but cross-protection from SARS-CoV is unlikely due to significant genetic differences between the viruses. However, some level of cross-reactivity with certain antibodies might be possible.',\n",
       "    'Immunity development and cross-protection against SARS-CoV2 are not addressed in the provided text about SARS-CoV. However, generally, viral infections can lead to some level of immunity, and cross-protection between related viruses is possible but',\n",
       "    'SARS-CoV-2 infected individuals may develop immunity, but cross-protection between SARS-CoV-2 and other SARS-CoV strains is unlikely due to significant differences in their spike proteins.',\n",
       "    'SARS-CoV-2 infected people may develop immunity, but cross-protection between SARS-CoV-2 and other SARS-CoV strains is uncertain.',\n",
       "    'SARS-CoV-2 infected individuals may develop immunity, but cross-protection between SARS-CoV-2 and SARS-CoV is unlikely due to significant differences between the viruses.',\n",
       "    'SARS-CoV-2 infected individuals may develop immunity, but cross-protection from SARS-CoV is unlikely due to significant differences between the two viruses. Answering the second part briefly: Cross-protection from SARS-CoV to SARS',\n",
       "    'SARS-CoV-2 infected individuals may develop immunity, but cross-protection between SARS-CoV-2 and SARS-CoV is unlikely due to significant differences in their Spike protein structures.',\n",
       "    'SARS-CoV-2 infected individuals may develop immunity, but cross-protection from SARS-CoV is unlikely due to significant differences between the two viruses. However, some level of cross-reactivity might be possible with certain antibodies targeting conserved regions'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 0, 2, 3, 2, 0],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'fi1ldwe8': {'greedy': 'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from other coronaviruses is not well-established, but some level of partial protection may exist. Further research is needed to understand the extent and duration of immunity.',\n",
       "   'samples': ['SARS-CoV-2 infected people may develop some level of immunity, but the extent and duration are not yet fully understood. Cross-protection against variants is uncertain and more research is needed. Immunity and cross-protection differ among individuals and ages',\n",
       "    'Yes, infected individuals may develop immunity. Cross-protection from related coronaviruses is possible but not guaranteed. More research is needed to understand the full extent of immunity and potential cross-protection against SARS-CoV-2.',\n",
       "    '',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from prior infections or vaccines is possible but varies and more research is needed.',\n",
       "    'Yes, SARS-CoV-2 infected people can develop immunity. Cross-protection against variants is partially possible but varies. Further research is needed.',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity, but cross-protection from other coronaviruses is limited. Further research is needed to fully understand immunity and potential cross-protection against SARS-CoV-2.',\n",
       "    'SARS-CoV-2 infected individuals may develop some level of immunity, but the extent and duration are not fully understood. Cross-protection against different variants is also uncertain. Further research is needed.',\n",
       "    '',\n",
       "    'Yes, SARS-CoV-2 infected people can develop immunity. Cross protection against other coronaviruses is possible but not definitive for SARS-CoV-2. Further research is needed.',\n",
       "    'Yes, SARS-CoV-2 infected individuals can develop immunity. Cross-protection from other coronaviruses is unlikely. Further research is needed to fully understand the duration and effectiveness of this immunity.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 1, 1, 2, 1, 4],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'y6a4u0vh': {'greedy': 'The study suggests that some individuals can clear SARS-CoV-2 infection without antibody-mediated adaptive immunity, indicating that both innate and adaptive immunity play roles in clearance. Cross-protection from other coronaviruses is not addressed in this specific study,',\n",
       "   'samples': ['The study suggests that some individuals can clear SARS-CoV-2 infection without antibody-mediated adaptive immunity, implying that immunity can develop. Cross-protection from other coronaviruses is not discussed in this specific context but is an area of ongoing research',\n",
       "    'The study suggests that some patients can clear SARS-CoV-2 without antibody-mediated adaptive immunity, implying that both adaptive and innate immunity play roles in clearance. Cross-protection between different coronaviruses is possible but not guaranteed; further research is',\n",
       "    'The study suggests that some SARS-CoV-2 infected individuals can clear the virus without antibody-mediated adaptive immunity, relying on innate immunity. Antibody development varies, with some patients maintaining SARS-CoV-2 and virus-specific IgG for extended',\n",
       "    'The presence of antibodies does not guarantee immunity, as some patients cleared the virus without producing SARS-CoV-2-bound IgG. Cross-protection from other coronaviruses is not confirmed but is being studied. Further research on both innate and',\n",
       "    'The study suggests that some individuals may develop SARS-CoV-2 and virus-specific IgG antibodies that persist for extended periods, indicating potential adaptive immune response. However, another case showed successful viral clearance without detectable antibodies, suggesting innate immunity can also',\n",
       "    'The presence of SARS-CoV-2 and virus-specific IgG antibodies for extended periods suggests potential for immunity, but this report does not conclusively determine immunity or cross-protection. Further research is needed to fully understand the role of both innate and',\n",
       "    'Based on the provided context, some SARS-CoV-2 infected individuals may develop IgG antibodies and maintain them for extended periods, suggesting potential for adaptive immunity. However, one case showed successful clearance without detectable antibodies, indicating innate immunity can also',\n",
       "    'The study suggests that some individuals can clear SARS-CoV-2 infection without producing antibodies, indicating that immunity might involve both adaptive and innate immune responses. Cross-protection between different coronaviruses is not addressed in this specific study, but it',\n",
       "    'Immunity development in SARS-CoV2-infected people is suggested by the report, with some individuals maintaining detectable antibodies for extended periods. However, the report also indicates that in at least one case, viral clearance occurred without detectable antibody response',\n",
       "    'The study indicates that some SARS-CoV-2 infected individuals can develop long-lasting IgG antibodies, but it also shows that clearance of the virus is possible without antibodies, relying on innate immunity. Cross-protection from other coronaviruses is'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 0, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '5wpq72vy': {'greedy': 'SARS-CoV-2 infection may not lead to robust immunity, as evidenced by poor induction and response to innate immunity, which can result in ineffective neutralization by antibodies. Cross-protection from other coronaviruses is also unlikely due to significant',\n",
       "   'samples': [\"Understanding of SARS-CoV-2's interaction with host immunity is limited, but initial data suggest partial immunity and low cross-protection between different coronaviruses. Further research is needed. Answer as briefly as possible. Yes, some immunity may\",\n",
       "    'It is not clear whether SARS-CoV2 infected people will develop immunity or if cross protection is possible. More research is needed to understand the immune response to SARS-CoV-2 and its potential for developing immunity and cross protection.',\n",
       "    'SARS-CoV-2 infection may not fully induce robust innate immune responses, potentially leading to less efficient antibody production. Cross-protection between SARS-CoV-2 and other coronaviruses is not well established and would require further investigation.',\n",
       "    'Understanding the development of immunity and potential cross-protection against SARS-CoV-2 is complex. Immunity in infected individuals can develop, but the extent and duration are still being studied. Cross-protection from other coronaviruses is possible but',\n",
       "    'SARS-CoV-2 infection may not provide strong immunity, and cross-protection against different variants is uncertain. Further research is needed to fully understand immunity and potential cross-protection.',\n",
       "    'It is uncertain if SARS-CoV2 infected people will develop strong immunity, and cross-protection against other coronaviruses is unlikely. More research is needed to fully understand the immune response to SARS-CoV-2.',\n",
       "    \"Understanding immunity to SARS-CoV-2 and potential cross-protection is complex. While infected individuals typically develop some immunity, it's not clear how long-lasting or complete this might be. Cross-protection against related coronaviruses is theoretically possible\",\n",
       "    'Understanding the development of immunity to SARS-CoV-2 and potential for cross-protection involves several key points:',\n",
       "    'SARS-CoV-2 infection may not lead to robust immunity, as shown by poor induction and response to innate immunity, resulting in ineffective neutralization by antibodies. Cross-protection between SARS-CoV-2 and other coronaviruses is',\n",
       "    \"Understanding SARS-CoV-2's interaction with the immune system is complex. While infected individuals may develop some immunity, there's no definitive proof of long-term immunity or cross-protection against other coronaviruses. Ongoing research is necessary to\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 1, 3, 4, 5, 3],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  '7jwhypgs': {'greedy': 'Yes, SARS-CoV-2 infected individuals may develop immunity, and there is potential for cross-protection against related coronaviruses like SARS-CoV. However, further research is needed to fully understand the extent of this protection.',\n",
       "   'samples': ['',\n",
       "    'Yes, SARS-CoV-2 infected people may develop immunity. Cross-protection against related coronaviruses is possible based on observed cross-neutralization responses. However, further research is needed to fully understand and exploit these findings for vaccine development.',\n",
       "    'Yes, SARS-CoV-2 infected individuals may develop immunity. Cross-protection from SARS-CoV infection to SARS-CoV-2 has been observed but its extent varies. Further research is needed to determine the effectiveness of such cross-pro',\n",
       "    'Yes, SARS-CoV-2 infected people may develop immunity, and there is potential for cross-protection against related coronaviruses like SARS-CoV. Further research is needed to fully understand the extent of this immunity and cross-protection',\n",
       "    \"Yes, SARS-CoV-2 infected individuals may develop immunity, and cross-protection against related coronaviruses, including SARS-CoV, is possible based on the study's findings. However, more research is needed to fully understand the\",\n",
       "    'Yes, SARS-CoV-2 infected individuals may develop immunity, and there is potential for cross-protection against other coronaviruses, including SARS-CoV, based on the findings of cross-reactive neutralizing antibodies. However, further',\n",
       "    'Yes, SARS-CoV-2 infected individuals may develop immunity. Cross-protection against related coronaviruses, like SARS-CoV, is observed but effectiveness against SARS-CoV-2 is not definitively established. More research is',\n",
       "    \"Yes, SARS-CoV-2 infected individuals may develop immunity, and cross-protection against related coronaviruses like SARS-CoV is possible based on the study's findings. However, further research is needed to fully understand the extent and\",\n",
       "    'Yes, SARS-CoV-2 infected individuals may develop immunity, and there is potential for cross-protection against related coronaviruses, as evidenced by cross-neutralizing responses in convalescent sera from SARS-CoV patients and immunized',\n",
       "    'Yes, SARS-CoV-2 infected people may develop immunity, and there is potential for cross-protection against related coronaviruses. However, further research is needed to fully understand the extent and duration of this immunity and cross-protection.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 1, 1, 2, 3, 4, 5],\n",
       "   'entropy': 1.6094379124341003}},\n",
       " '5': {'no': {'greedy': 'Remdesivir, chloroquine, and hydroxychloroquine have shown some activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "   'samples': ['Remdesivir, chloroquine, and hydroxychloroquine have shown some activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir, chloroquine, and hydroxychloroquine have shown some activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir, chloroquine, and hydroxychloroquine have shown activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir, chloroquine, hydroxychloroquine.',\n",
       "    'Remdesivir, chloroquine, and hydroxychloroquine have shown some activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir, chloroquine, and hydroxychloroquine have shown some activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir, chloroquine, and hydroxychloroquine have shown activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir, chloroquine, and hydroxychloroquine have shown potential in animal studies against SARS-CoV or SARS-CoV-2.',\n",
       "    'Remdesivir, chloroquine, hydroxychloroquine, and lopinavir/ritonavir have shown activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir, chloroquine, and hydroxychloroquine have shown activity against SARS-CoV or SARS-CoV-2 in animal studies. Other drugs like lopinavir/ritonavir and interferons'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 0, 0, 1, 1, 3, 3],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'ywaefpe8': {'greedy': 'The text does not specify which drugs have been active against SARS-CoV or SARS-CoV-2 in animal studies. It only mentions plans to test the most active antivirals identified from in vitro studies in appropriate animal models. No',\n",
       "   'samples': ['The document does not specify which drugs have been active against SARS-CoV or SARS-CoV-2 in animal studies; it focuses on the ongoing in vitro tests and plans for future animal model testing. No specific drug results are provided. To',\n",
       "    'The text does not provide specific information about which drugs have been active against SARS-CoV or SARS-CoV-2 in animal studies. It focuses on comparing currently available drugs to identify effective antivirals for further testing, both in animal',\n",
       "    'The text does not specify which drugs have been found active against SARS-CoV or SARS-CoV-2 in animal studies. It only mentions plans to test the most active antivirals identified from in vitro studies in appropriate animal models.',\n",
       "    'The text does not mention any specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. It only describes ongoing efforts to test various drugs and combinations in vitro and plans to move to animal models for further',\n",
       "    'The text does not provide specific information about which drugs have been active against SARS-CoV or SARS-CoV-2 in animal studies. It only mentions the intention to test the most active antivirals identified from in vitro experiments in adequate',\n",
       "    'The text does not mention any specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. The study described is focused on testing a variety of drugs and combinations in vitro, and plans to move to animal',\n",
       "    'The text does not provide specific information about which drugs have been active against SARS-CoV or SARS-CoV-2 in animal studies. The study described is focused on testing a variety of drugs and drug combinations for antiviral activity in vitro',\n",
       "    'The text does not specify which drugs have been active against SARS-CoV or SARS-CoV-2 in animal studies. The researchers are testing various drugs and combinations in vitro and plan to move to animal models next, but no specific results are',\n",
       "    'The document does not mention any specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. It describes an ongoing effort to test various drugs and combinations for antiviral activity in vitro and plans to move',\n",
       "    'The text does not provide specific details on which drugs have been active against SARS-CoV or SARS-CoV-2 in animal studies. It focuses on ongoing research to identify active antivirals through in vitro testing and plans to test promising'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 2, 0, 3, 4, 3, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'm7dwbheg': {'greedy': 'Azithromycine, Opipramol, Quinidine, and Omeprazol have shown antiviral potency against SARS-CoV-2 in vitro. No specific drugs for SARS-CoV are mentioned in the given',\n",
       "   'samples': ['Azithromycine, Opipramol, Quinidine, and Omeprazol have shown antiviral potency against SARS-CoV-2 in cell-based assays. The study did not mention specific animal studies but provides preliminary',\n",
       "    'Azithromycin, quinidine, and remdesivir have shown activity against SARS-CoV or SARS-CoV-2 in animal studies. (Note: While not mentioned in the provided context, these drugs are commonly cited in',\n",
       "    'Azithromycine, Opipramol, Quinidine, and Omeprazol have shown antiviral potency against SARS-CoV-2 in cell-based assays. The study did not specifically mention animal studies but these findings',\n",
       "    'Azithromycin, quinidine, and chloroquine have shown some activity against SARS-CoV or SARS-CoV-2 in animal studies. However, the specific details of these studies are not provided in the given context. This',\n",
       "    'Azithromycine, Opipramol, Quinidine, and Omeprazol have shown antiviral potency against SARS-CoV-2 in vitro, but the provided context does not mention any specific animal studies. To',\n",
       "    'Azithromycine, Opipramol, Quinidine, and Omeprazol have shown antiviral potency against SARS-CoV-2 in vitro. While the text does not explicitly mention animal studies, these in vitro',\n",
       "    'Azithromycine, Opipramol, Quinidine, or Omeprazol have shown antiviral potency against SARS-CoV-2 in vitro. Note that this does not necessarily mean they are effective in vivo or',\n",
       "    'Azithromycine, Opipramol, Quinidine, or Omeprazol have shown antiviral potency against SARS-CoV-2 in vitro, but specific animal studies are not mentioned in the given context. Answer',\n",
       "    'The study screened the Prestwick Chemical Library® and identified several drugs with antiviral potency against SARS-CoV-2, including Azithromycine, Opipramol, Quinidine, and Omeprazol. However',\n",
       "    'The provided context does not mention any specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. The study described focuses on identifying potential antiviral drugs from a library of approved compounds using a cell-based'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 3, 4, 3, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'e9fjo7tl': {'greedy': 'Hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, and merfloquine hydrochloride have been identified as active against SARS',\n",
       "   'samples': ['In the study described, 24 FDA approved compounds were found to be active against SARS-CoV-2, including previously reported drugs like hydroxychloroquine, amlodipine, arbidol hydrochloride, tilor',\n",
       "    'Hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, and merfloquine hydrochloride.',\n",
       "    'The passage does not mention any specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. Instead, it describes a screen of FDA-approved drugs to identify potential antiviral agents for SARS-CoV',\n",
       "    'The passage mentions several FDA approved drugs that have shown activity against SARS-CoV-2 in this study, including hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl,',\n",
       "    'In the study described, the researchers identified 24 FDA-approved drugs that were active against SARS-CoV-2, including some previously reported compounds like hydroxychloroquine and new ones with a wide therapeutic window. However, specific details about',\n",
       "    'The passage mentions that the study identified 24 anti-SARS-CoV-2 drugs, including previously reported compounds like hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl',\n",
       "    'The study identified 24 anti-SARS-CoV-2 drugs, including some previously reported such as hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl, droned',\n",
       "    'Hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, and merfloquine hydrochloride have shown activity against SARS-CoV',\n",
       "    'Hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, and merfloquine hydrochloride have been identified as active against SARS',\n",
       "    'Hydroxychloroquine, amlodipine, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, and merfloquine hydrochloride have shown activity against SARS-CoV'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 5, 1, 1, 1],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'jbc74lcu': {'greedy': 'Chloroquine and chlorpromazine have been shown to protect mice from clinical disease in an animal study using a mouse-adapted SARS-CoV model.',\n",
       "   'samples': ['Chloroquine and chlorpromazine have been shown to be active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Chloroquine and chlorpromazine have shown activity against SARS-CoV-2 in animal studies.',\n",
       "    'Chloroquine and chlorpromazine have been shown to protect mice from clinical disease in an animal study using a mouse-adapted SARS-CoV model.',\n",
       "    'Chloroquine and chlorpromazine have been found to protect mice from clinical disease in an animal study using a mouse-adapted SARS-CoV model.',\n",
       "    'Chloroquine and chlorpromazine have shown activity against SARS-CoV-2 in animal studies.',\n",
       "    'Chloroquine and chlorpromazine have been shown to be active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Chloroquine and chlorpromazine have been shown to protect mice from clinical disease in an in vivo study using a mouse-adapted SARS-CoV model.',\n",
       "    'Chloroquine and chlorpromazine have shown activity against SARS-CoV-2 in animal studies.',\n",
       "    'Chloroquine and chlorpromazine have been found to protect mice from clinical disease in an in vivo mouse-adapted SARS-CoV model.',\n",
       "    'Chloroquine and chlorpromazine have been found to protect mice from clinical disease in an in vivo mouse-adapted SARS-CoV model.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '7ln7p715': {'greedy': 'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "   'samples': ['Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'In animal studies, interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytopl',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells, and nucleocytoplasmic',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells, and nucleocytoplasmic',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'In animal studies, interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytopl',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells, and nucleocytoplasmic',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 1, 0, 0, 0, 0],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'el7d8lck': {'greedy': 'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "   'samples': ['Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells, and nucleocytoplasmic',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells, and nucleocytoplasmic',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking',\n",
       "    'Interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors, viral entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the SARS-CoV-2 RNA genome, natural killer cells and nucleocytoplasmic trafficking'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  'hchioraj': {'greedy': 'The text does not provide information about drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. It only mentions the identification of potential inhibitors through computational methods and the recommendation of 41 drugs for further experimental',\n",
       "   'samples': ['The context does not provide information about drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. Instead, it describes the use of QSAR models and molecular docking to identify potential inhibitors of Mpro from S',\n",
       "    'The text does not mention any specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. The study described focuses on identifying potential inhibitors through virtual screening and QSAR modeling, and recommends 41 drugs',\n",
       "    'The text does not provide specific information about drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. Instead, it describes a study that used computational methods to identify potential inhibitors of the Mpro enzyme from S',\n",
       "    'Based on the given context, no specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies are mentioned. However, the study identified 41 potential agents that could act as inhibitors of Mpro from',\n",
       "    'The text does not provide information about drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. It focuses on using existing data and models to identify potential inhibitors of Mpro from SARS-CoV-2',\n",
       "    'The text does not mention any specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. It describes the development of QSAR models and virtual screening of compounds from DrugBank to identify potential inhibitors of M',\n",
       "    'The text does not provide information about drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. It only mentions the identification of potential inhibitors through computational methods and recommends 41 drugs as potential agents against S',\n",
       "    'Based on the provided context, the study focused on identifying potential inhibitors through computational methods rather than reporting on specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. Therefore, no drugs are mentioned as having',\n",
       "    'The context provided does not specify any drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. The study described focused on identifying potential drug candidates through QSAR models and virtual screening but did not mention results from',\n",
       "    'The text does not provide information about drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. It only mentions the identification of 41 potential inhibitors of Mpro from the DrugBank database and that ten'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'xb5p25gk': {'greedy': 'Remdesivir and chloroquine have shown promise in animal studies against SARS-CoV and SARS-CoV-2.',\n",
       "   'samples': ['Remdesivir and chloroquine have been active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have been active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have been active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have shown activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have been active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have been active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have been active against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have shown activity against SARS-CoV or SARS-CoV-2 in animal studies.',\n",
       "    'Remdesivir and chloroquine have shown promise in animal studies against SARS-CoV and SARS-CoV-2.',\n",
       "    'Remdesivir and chloroquine have shown promise in animal studies against SARS-CoV and SARS-CoV-2.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 0, 0, 1, 0, 0],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'zbpk7sh0': {'greedy': \"In the provided context, nitazoxanide, remdesivir, amodiaquine, and umifenovir have shown significant synergy against SARS-CoV-2 in vitro. However, it does not specifically mention any drug's activity\",\n",
       "   'samples': ['In the provided context, nitazoxanide, remdesivir, amodiaquine, and umifenovir have shown significant synergy against SARS-CoV-2 in vitro. However, specific mentions of animal study results are not provided',\n",
       "    'Nitazoxanide, remdesivir, amodiaquine, and umifenovir have shown significant synergy against SARS-CoV-2 in in vitro studies. Remdesivir and hydroxychloroquine demonstrated strong antagonism',\n",
       "    'Based on the provided context, nitazoxanide, remdesivir, amodiaquine, and umifenovir have shown activity against SARS-CoV-2 in in vitro studies. However, specific animal study results are not mentioned',\n",
       "    'In the given context, the drugs that have shown activity against SARS-CoV-2 in vitro include nitazoxanide, remdesivir, amodiaquine, and umifenovir. However, specific mentions of drugs tested in',\n",
       "    'In the given context, no specific drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies are mentioned. The passage discusses the identification of synergistic and antagonistic drug combinations through in silico approaches and in',\n",
       "    'In the provided context, the drugs nitazoxanide, remdesivir, amodiaquine, and umifenovir have shown notable synergy against SARS-CoV-2 in in vitro testing. While the text does not specifically mention',\n",
       "    'The passage does not provide information on drugs that have been active against SARS-CoV or SARS-CoV-2 in animal studies. Instead, it discusses in vitro testing of drug combinations against SARS-CoV-2. The specific drugs mentioned',\n",
       "    'In the provided context, no specific drugs are mentioned as having been active against SARS-CoV or SARS-CoV-2 in animal studies. The text focuses on identifying synergistic drug combinations using in vitro methods and does not discuss animal studies explicitly',\n",
       "    'Based on the provided context, nitazoxanide combined with remdesivir, amodiaquine, and umifenovir have shown significant synergy against SARS-CoV-2 in vitro. However, the information does not specifically mention any',\n",
       "    'Based on the information provided, the following drugs have shown potential activity against SARS-CoV-2 in vitro:'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 0, 4, 5, 0, 6],\n",
       "   'entropy': 1.7480673485460891},\n",
       "  '5f95gve3': {'greedy': 'Niclosamide and ciclesonide have been identified as potentially effective against SARS-CoV-2 in animal studies. They will be tested further in appropriate animal models. No specific drugs from the initial screening have been reported as active against SARS',\n",
       "   'samples': ['Niclosamide and ciclesonide have been noted for their antiviral efficacy against SARS-CoV-2 in preliminary screenings, and they will be tested in an appropriate animal model for further evaluation. No specific drugs from the initial screening that',\n",
       "    'Niclosamide and ciclesonide have shown antiviral efficacy against SARS-CoV-2 in animal studies. They will be further tested for their antiviral activities.',\n",
       "    'Niclosamide and ciclesonide have shown antiviral efficacy against SARS-CoV-2 in preclinical screening assays and will be tested in an appropriate animal model for their antiviral activities. However, no drugs have been reported to',\n",
       "    'Niclosamide and ciclesonide have been identified as potentially active against SARS-CoV-2 in preliminary screening assays and will be tested in animal models for their antiviral activities. No drugs have shown activity in animal studies yet based on',\n",
       "    'Niclosamide and ciclesonide have shown antiviral efficacy against SARS-CoV-2 in preclinical screening. They will be tested in an appropriate animal model for further evaluation of their antiviral activities. These drugs could potentially be',\n",
       "    'Niclosamide and ciclesonide have been noted for their potential antiviral efficacy against SARS-CoV-2 and will be tested in an appropriate animal model. However, no drugs have been reported as active in animal studies so far.',\n",
       "    'Niclosamide and ciclesonide have been identified as potentially effective against SARS-CoV-2 in preclinical screening and are scheduled for testing in an appropriate animal model. No specific drugs active against SARS-CoV in animal studies are mentioned',\n",
       "    \"Niclosamide and ciclesonide have been identified as potential antiviral drug candidates against SARS-CoV-2 and will be tested in an appropriate animal model for their antiviral activities. However, it's important to note that these\",\n",
       "    'Niclosamide and ciclesonide have been noted as potentially effective in preclinical screens against SARS-CoV-2. Further testing is required to confirm their activity in animal models.',\n",
       "    'Niclosamide and ciclesonide have been noted as potentially active against SARS-CoV-2 in preliminary screenings and warrant further testing in animal models. However, specific mention of activity in animal studies is not provided in the context given. Further'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 2, 4, 5, 3, 4],\n",
       "   'entropy': 1.7480673485460896}},\n",
       " '24': {'no': {'greedy': 'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and infections.',\n",
       "   'samples': ['Diabetes patients may experience more severe COVID-19 complications, including respiratory issues, multi-organ failure, and higher mortality rates.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and hospitalization. They may also experience poor wound healing and increased susceptibility to infections.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. Poorly controlled blood sugar can also lead to delayed recovery.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and increased susceptibility to infections.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. High glucose levels can impair immune function and blood flow, exacerbating infection. Other complications include kidney damage, cardiovascular issues, and longer',\n",
       "    'Diabetes patients are at higher risk for severe COVID-19 complications, including respiratory failure, pneumonia, and increased mortality.',\n",
       "    'Diabetic patients may experience more severe complications, including pneumonia, acute respiratory distress syndrome (ARDS), and higher risk of hospitalization and mortality. Cardiovascular issues and kidney damage are also more common.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. Other complications may involve cardiovascular issues, kidney damage, and poor wound healing.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. They may also experience poorer glycemic control and delayed wound healing.',\n",
       "    'Increased risk of severe illness, hospitalization, and death.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 0, 0, 0, 0, 2],\n",
       "   'entropy': 0.639031859650177},\n",
       "  'b7m5go9y': {'greedy': 'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and increased susceptibility to infections.',\n",
       "   'samples': ['Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, septic shock, and death. High blood sugar can also impair immune function.',\n",
       "    'Diabetic patients may experience more severe respiratory issues, higher risk of hospitalization, and increased likelihood of developing blood clots.',\n",
       "    'Diabetic patients may experience more severe COVID-19 complications, including respiratory issues, hospitalization, and death. High血糖水平可能增加重症、住院和死亡的风险。 (Translation: High blood sugar levels may increase the risk of severe illness,',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. High blood sugar levels can also impair immune function.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications like pneumonia, respiratory failure, and death. Poor glycemic control worsens outcomes. Other complications include thrombotic events and acute kidney injury.',\n",
       "    'Diabetes patients may experience more severe complications, including pneumonia, respiratory failure, and higher mortality rates from COVID-19.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, acute respiratory distress syndrome, and increased mortality.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death. Poorly controlled blood sugar can exacerbate symptoms. Common complications include pneumonia, acute respiratory distress syndrome, and thrombotic events.',\n",
       "    'Diabetic patients may experience more severe respiratory issues, higher risk of ICU admission, and increased mortality from COVID-19.',\n",
       "    'Increased risk of severe illness, respiratory issues, and hospitalization.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 2, 4, 5, 6, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '02ua1qyj': {'greedy': 'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and increased susceptibility to infections.',\n",
       "   'samples': ['Increased risk of severe illness, hospitalization, and death.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications like pneumonia, respiratory failure, and death. Poorly controlled blood sugar can worsen outcomes. Complications may also include kidney damage, blood clots, and infections. Managing blood sugar is crucial.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, sepsis, and death.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and hospitalization. Other complications may include cardiovascular issues and poor wound healing.',\n",
       "    'Diabetic patients may experience more severe respiratory issues, higher risk of hospitalization, and increased likelihood of developing blood clots.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and an increased likelihood of hospitalization and death. High blood sugar levels can also impair immune function and wound healing.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including respiratory failure, septic shock, and death. High blood sugar can also impair immune function.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, septic shock, and increased mortality.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, acute respiratory distress syndrome, and higher mortality rates.',\n",
       "    'Diabetes patients are at higher risk for severe COVID-19 complications, including respiratory failure, septic shock, and death. They may also experience poor wound healing and increased susceptibility to infections.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 2, 2, 5, 2],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  '6duc06et': {'greedy': 'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. High blood sugar can also impair immune function.',\n",
       "   'samples': ['Diabetes increases risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death.',\n",
       "    'Diabetes patients may experience more severe complications, including respiratory issues, acute kidney injury, and higher risk of hospitalization and death from COVID-19.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications like pneumonia, respiratory failure, and death. High血糖增加患COVID-19严重并发症（如肺炎、呼吸衰竭和死亡）的风险。',\n",
       "    'Increased risk of severe illness, respiratory failure, and death.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications like pneumonia, respiratory failure, and death. Poorly controlled blood sugar can worsen outcomes.',\n",
       "    'Diabetes increases risk for severe illness, including pneumonia, respiratory failure, sepsis, and death from COVID-19.',\n",
       "    'Increased risk of severe illness, respiratory issues, hospitalization, and death.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and hospitalization. High blood sugar can also impair immune response.',\n",
       "    'Increased risk of severe illness, respiratory issues, and complications like diabetic ketoacidosis.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications, including pneumonia, ICU admission, mechanical ventilation, and death. High blood sugar can also impair immune response.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 0, 0, 1, 2, 3, 4],\n",
       "   'entropy': 1.4184836619456562},\n",
       "  'xlxfex1j': {'greedy': 'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and infections.',\n",
       "   'samples': ['Diabetic patients may experience more severe COVID-19 complications, including respiratory failure, sepsis, and multi-organ dysfunction.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. High blood sugar can also impair immune function.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death. High blood sugar can also impair immune response.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, acute respiratory distress syndrome, and hospitalization. They also have increased risk of death.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and increased mortality. High blood sugar levels can also impair immune response and healing.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, acute respiratory distress syndrome, and multi-organ failure.',\n",
       "    'Diabetes patients face higher risks of severe complications from COVID-19, including pneumonia, respiratory failure, and increased mortality.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications like pneumonia, respiratory failure, and ICU admission. Poorly controlled blood sugar may also worsen outcomes.',\n",
       "    'Diabetes patients are at higher risk for severe COVID-19 complications, including pneumonia, acute respiratory distress syndrome, and multi-organ failure. They also have increased hospitalization and mortality rates.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. High blood sugar levels can also impair immune function.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 0, 3, 4, 3, 1],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  '33c85eaa': {'greedy': 'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and infections.',\n",
       "   'samples': ['Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death. They may also experience poor wound healing and increased infections.',\n",
       "    'Diabetic patients may experience more severe complications, including pneumonia, acute respiratory distress syndrome, and higher risk of hospitalization and death.',\n",
       "    'Increased risk of severe illness, respiratory failure, and death.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications like pneumonia, respiratory failure, and death. Poor glycemic control worsens outcomes.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, sepsis, and multi-organ dysfunction.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, acute respiratory distress syndrome, septic shock, and death. They may also experience poor wound healing and increased risk of infections.',\n",
       "    'Diabetic patients may experience more severe COVID-19 complications, including pneumonia, respiratory failure, and increased risk of mortality.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications like pneumonia, ICU admission, mechanical ventilation, and death. Poorly controlled blood sugar can worsen outcomes.',\n",
       "    'Diabetic patients may experience more severe complications from COVID-19, including pneumonia, respiratory failure, and higher mortality rates. High blood sugar can also impair immune response.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. High blood sugar can also impair immune response.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 4, 4, 2, 5, 5],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  'zn5iutfu': {'greedy': 'Diabetes increases risk for severe COVID-19 complications like pneumonia, respiratory failure, and death. Poorly controlled blood sugar can also lead to longer recovery times.',\n",
       "   'samples': ['Diabetes patients may experience more severe complications, including respiratory failure, septic shock, and acute kidney injury, when infected with COVID-19.',\n",
       "    'Increased risk of severe illness, respiratory issues, and hospitalization.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including respiratory failure, sepsis, and death. They may also experience hyperglycemia or difficulty managing blood sugar levels during infection.',\n",
       "    'Diabetes patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and increased mortality. They may also experience poor glycemic control and delayed wound healing.',\n",
       "    'Increased risk of severe illness, respiratory issues, and hospitalization.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including respiratory failure, septic shock, and death.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and ICU admission.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. They may also experience hyperglycemia or hypoglycemia due to the virus.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and increased susceptibility to infections.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including respiratory failure, sepsis, and death. They may also experience poor wound healing and increased risk of infections.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 2, 1, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '36pf3e7w': {'greedy': 'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, respiratory failure, and death. High blood sugar can also impair immune function.',\n",
       "   'samples': ['Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and increased mortality. Cardiovascular issues and kidney damage are also more common.',\n",
       "    'Diabetes patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and multi-organ dysfunction.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death.',\n",
       "    'Increased risk of severe illness, respiratory issues, and hospitalization.',\n",
       "    'Diabetes increases risk for severe illness, including respiratory failure, septic shock, and death. Other complications include kidney damage, blood clots, and poor wound healing.',\n",
       "    'Increased risk of severe illness, respiratory failure, hospitalization, and death.',\n",
       "    'Diabetes patients may experience more severe complications from COVID-19, including respiratory issues, higher risk of hospitalization, and longer recovery times.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including respiratory failure, septic shock, and death. They may also experience prolonged viral shedding and a delayed immune response.',\n",
       "    'Increased risk of severe illness, respiratory issues, and hospitalization.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 0, 3, 2, 4, 2],\n",
       "   'entropy': 1.4184836619456564},\n",
       "  'nx74j7ao': {'greedy': 'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and infections.',\n",
       "   'samples': ['Diabetes patients face higher risk of severe complications, including pneumonia, respiratory failure, and death. Other issues may involve kidney damage, blood clots, and poor wound healing.',\n",
       "    'Diabetes patients are at higher risk for severe complications from COVID-19, including pneumonia, acute respiratory distress syndrome, and increased likelihood of hospitalization and death.',\n",
       "    'Diabetes increases risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death. High blood sugar can also impair immune response.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death. Common issues include impaired immune response and poorer outcomes due to pre-existing organ damage.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, ICU admission, and death. High blood sugar can also impair immune function.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including respiratory failure, septic shock, and multi-organ failure. They may also experience poor wound healing and increased susceptibility to infections.',\n",
       "    'Increased risk of severe illness, respiratory issues, and hospitalization.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and increased mortality. They may also experience poor wound healing and infections.',\n",
       "    'Diabetic patients may experience more severe COVID-19 complications, including pneumonia, respiratory failure, and an increased risk of death. High blood sugar levels can also impair immune function.',\n",
       "    'Diabetes patients may experience more severe complications, including respiratory issues, acute kidney injury, and higher risk of death.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 3, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'javx1luo': {'greedy': 'Diabetic patients are at higher risk for severe COVID-19 complications, including pneumonia, respiratory failure, and death. They may also experience poor wound healing and infections.',\n",
       "   'samples': ['Increased risk of severe illness, hospitalization, and death.',\n",
       "    'Diabetic patients may experience more severe COVID-19 complications, including respiratory failure, septic shock, and acute kidney injury. High blood sugar can also impair immune function.',\n",
       "    'Diabetes patients may experience more severe complications from COVID-19, including pneumonia, respiratory failure, and increased risk of hospitalization.',\n",
       "    'Diabetic patients are at higher risk for severe complications from COVID-19, including respiratory failure, septic shock, and multi-organ dysfunction.',\n",
       "    'Diabetes patients are at higher risk for severe COVID-19 complications, including respiratory failure, septic shock, and death. Other issues may involve kidney damage, heart complications, and blood clotting.',\n",
       "    'Increased risk of severe illness, respiratory issues, hospitalization, and death.',\n",
       "    'Diabetic patients may experience more severe complications from COVID-19, including respiratory failure, septic shock, and acute respiratory distress syndrome.',\n",
       "    'Increased risk of severe illness, respiratory issues, and hospitalization.',\n",
       "    'Diabetic patients are at higher risk for severe COVID-19 complications, including respiratory failure, sepsis, and multi-organ dysfunction.',\n",
       "    'Increased risk of severe illness, hospitalization, and death. Common complications include respiratory issues, acute kidney injury, and blood clots.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 2, 3, 4],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '25v7qies': {'greedy': 'Pancreatic damage and stress hyperglycemia.',\n",
       "   'samples': ['Pancreatic damage, stress hyperglycaemia.',\n",
       "    'Pancreatic damage, stress hyperglycemia, increased vulnerability due to immune defects, and complications associated with pre-existing conditions like hypertension, heart disease, and chronic renal disease. Hospitalized diabetics may require insulin management.',\n",
       "    'Pancreatic damage, stress hyperglycemia.',\n",
       "    'Diabetes-related complications from COVID-19 include immune defects making individuals more susceptible to infections, potential pancreatic damage, and stress hyperglycemia requiring insulin. Hospitalization may necessitate early diabetes-specific nutrition and close monitoring.',\n",
       "    'Pancreatic damage, stress hyperglycaemia, increased susceptibility to infections, and worsening of pre-existing conditions like hypertension, heart disease, and chronic renal disease. Hospitalized diabetics may require insulin.',\n",
       "    'Pancreatic damage, stress hyperglycemia, increased susceptibility to infections, and potential need for insulin.',\n",
       "    'Pancreatic damage and stress hyperglycemia.',\n",
       "    'Pancreatic damage, stress hyperglycaemia, increased vulnerability due to immune defects, and higher risk for complications like heart disease and chronic renal disease. Hospitalized diabetics may require insulin management.',\n",
       "    'Pancreatic damage and stress hyperglycaemia.',\n",
       "    'Pancreatic damage, stress hyperglycaemia.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 1, 1, 1, 2, 2, 0],\n",
       "   'entropy': 1.0296530140645734}},\n",
       " '12': {'no': {'greedy': 'Wash hands frequently, wear masks, disinfect surfaces, maintain distance, limit visitors, stay in designated rooms.',\n",
       "   'samples': ['Wash hands frequently, wear masks, disinfect surfaces, maintain distance, limit visitors, stay home when sick.',\n",
       "    'Wash hands, wear masks, disinfect surfaces, limit visitors, stay isolated.',\n",
       "    'Wash hands frequently, wear masks, disinfect surfaces, isolate patients, restrict visitors, monitor temperatures, follow healthcare guidelines.',\n",
       "    'Wash hands, wear masks, disinfect surfaces, avoid close contact, stay in designated areas.',\n",
       "    'Wash hands, wear masks, disinfect surfaces, limit visitors, stay in designated rooms.',\n",
       "    '',\n",
       "    'In hospitals, maintain strict protocols, dedicated spaces, PPE, and regular disinfection. At home, isolate in a separate room, limit contact, wear masks, disinfect surfaces, and practice good hygiene.',\n",
       "    '',\n",
       "    'In hospitals, maintain strict access control, thorough sanitization, and use of personal protective equipment (PPE). At home, limit movement to one area, wear a mask, sanitize frequently, and practice good hygiene.',\n",
       "    ''],\n",
       "   'cluster_ids': [0, 1, 1, 1, 2, 3, 2, 4, 5, 4],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'mtpbzgr9': {'greedy': '',\n",
       "   'samples': ['',\n",
       "    'Best practices include routine hand washing, use of appropriate barriers like gloves, gowns, and masks, and isolation of patients based on known methods of transmission. At home, similar measures apply with a focus on hygiene and minimizing contact with sick individuals.',\n",
       "    '',\n",
       "    'Best practices include hand washing, using appropriate barriers (gloves, gowns, eye protection), and isolating infected patients based on known transmission methods.',\n",
       "    '',\n",
       "    '',\n",
       "    '',\n",
       "    '',\n",
       "    'Routine hand washing is the most effective nosocomial infection control intervention. In both hospitals and homes, use appropriate barriers such as gloves, gowns, and masks. Isolate patients based on known methods of transmission when necessary. Regular cleaning and disinfection',\n",
       "    'Best practices include hand hygiene, use of personal protective equipment like gloves, gowns, and masks, and following standard precautions for all patients. Isolation measures should be implemented based on the known methods of transmission. At home, focus on hygiene, social'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 0, 0, 0, 0, 3, 4],\n",
       "   'entropy': 1.2275294114572126},\n",
       "  'hdbbgee2': {'greedy': 'Best practices include activating quarantine units, proper staffing, accurate charting/admission, symptom monitoring, infection control, and client management. Regular exercises and drills are also important to maintain readiness. At home, individuals should follow public health guidelines for isolation and quarantine',\n",
       "   'samples': ['Best practices include activating quarantine units, staffing them adequately, charting and admitting patients efficiently, monitoring symptoms and infection control, and managing clients properly. Regular exercises and training improve preparedness. At home, follow official guidelines, isolate, wear masks, sanitize',\n",
       "    'Best practices include activating quarantine units, proper staffing, accurate charting/admission, effective symptom monitoring and infection control, and client management. Regular exercises enhance readiness and address gaps in preparedness. At home, isolation protocols, regular monitoring, and adherence to',\n",
       "    'Best practices include efficient management of physical resources, staffing, charting/admission, symptom monitoring, infection control, and client management. Regular exercises and drills can help identify and address gaps in preparedness. Additionally, good communication and leadership are crucial. At',\n",
       "    'Best practices include efficient management of resources, proper integration and practice of quarantine-specific emergency response plans, regular training and drills, ensuring adequate supplies, maintaining good communication, and following strict infection control procedures. At home, individuals should follow public health guidelines, isolate',\n",
       "    'Best practices in hospitals include efficient management of physical plants, personnel, and materials, integrating and practicing specific emergency response plans and protocols, activating the quarantine unit, proper staffing, charting/admission, symptom monitoring, infection control, and client management. At',\n",
       "    'Best practices include activating quarantine units, staffing them appropriately, efficiently charting and admitting patients, monitoring symptoms and infection control, and managing clients. Regular exercises and drills improve readiness. At home, isolate sick individuals, limit contact with others, monitor their condition',\n",
       "    'Best practices include activating quarantine units efficiently, ensuring proper staffing and charting/admission processes, effective symptom monitoring and infection control measures, and managing clients appropriately. Regular exercises and drills improve readiness. At home, isolate individuals showing symptoms, maintain hygiene, limit',\n",
       "    'Best practices include activating quarantine units, staffing them appropriately, charting and admitting patients accurately, monitoring symptoms and infection control effectively, and managing clients properly. Regular exercises and drills are crucial for maintaining readiness. At home, proper isolation, regular cleaning, hand',\n",
       "    'Best practices include activating quarantine units, staffing them adequately, properly charting and admitting patients, monitoring symptoms and infection control, and managing clients effectively. Regular exercises improve preparedness. At home, isolate sick individuals, limit contact with others, clean and disin',\n",
       "    'Best practices include efficient management of resources, proper staffing, accurate charting/admission, symptom monitoring, infection control, and client management. Regular exercises and drills are essential for maintaining disaster readiness. At home, individuals should follow local health guidelines, limit contact'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 5, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'bu617h9z': {'greedy': 'Best practices include clear communication, support for mental health, financial assistance, and monitoring of health status.',\n",
       "   'samples': ['Best practices include clear communication, support for economic stability, regular monitoring, and ensuring access to healthcare. At home, maintain hygiene, stay informed, and follow health guidelines strictly. In hospitals, isolate patients, provide care, and ensure staff safety.',\n",
       "    'Best practices include clear communication, resource provision, mental health support, and financial assistance for quarantined individuals. Hospitals should coordinate with public health officials and local resources to ensure compliance and well-being. Home quarantine requires a supportive environment with adequate supplies and information',\n",
       "    'Best practices include clear communication, financial support, mental health resources, and regular monitoring.',\n",
       "    'Best practices include clear communication, regular monitoring, provision of necessary supplies, mental health support, and addressing economic concerns for quarantined individuals. Hospitals should establish protocols for containment and care, while homes should ensure safe isolation with separate living areas if possible.',\n",
       "    'Best practices include clear communication, resources for support (like food and supplies delivery), mental health services, financial assistance programs, and regular check-ins with health authorities.',\n",
       "    '',\n",
       "    'Best practices include clear communication, support for economic stability, mental health resources, and adherence to public health guidelines.',\n",
       "    'Best practices include clear communication, support for mental health, regular check-ins, and assistance with essential needs like food and medicine. Hospitals should have isolation protocols, while homes need designated areas, personal protective equipment, and access to healthcare. Financial planning and community',\n",
       "    'Best practices include clear communication, financial support for quarantined individuals, monitoring health status, ensuring access to necessary supplies, and providing mental health resources. Hospitals should coordinate with public health authorities and local resources to support both patients and community members in voluntary quarantine',\n",
       "    'Best practices include strict adherence to quarantine guidelines, regular communication with health authorities, monitoring symptoms, practicing good hygiene, and addressing economic impacts through support programs.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 1, 2, 1, 0],\n",
       "   'entropy': 1.5047882836811906},\n",
       "  '9rn8kzst': {'greedy': 'Best practices include thorough cleaning with detergents and disinfectants, especially on frequently touched surfaces, to reduce the risk of pathogen transmission. Tailor cleaning practices to clinical risk and scientifically evaluate effectiveness. Regularly clean high-touch areas in both hospitals',\n",
       "   'samples': ['Best practices include thorough cleaning with detergents and disinfectants, focusing on frequently touched surfaces, and evaluating cleaning methods scientifically. For home quarantine, follow similar guidelines, emphasizing cleanliness in living spaces and high-contact areas. Regular hand hygiene is crucial in',\n",
       "    'Best practices include thorough cleaning with detergents and disinfectants, especially on frequently touched surfaces, to prevent the spread of hospital and household pathogens. Tailor cleaning practices to clinical and environmental risks. Regularly clean high-touch areas in both settings.',\n",
       "    'Best practices include thorough cleaning and disinfection of frequently touched surfaces, proper hand hygiene, and isolating ill individuals to prevent the spread of pathogens. At home, maintain good hygiene and clean high-touch areas regularly. In hospitals, tailor cleaning practices to clinical',\n",
       "    '',\n",
       "    'Best practices include thorough cleaning with detergents and disinfectants, especially on frequently touched surfaces, to reduce the risk of pathogen transmission. Tailor cleaning practices to clinical risk and scientifically evaluate effectiveness. At home, maintain good hygiene practices and clean',\n",
       "    'Best practices in hospitals and at home for maintaining quarantine include thorough cleaning and disinfection of surfaces, especially those frequently touched, using a combination of detergent and disinfectant. Tailor cleaning practices to clinical risk and scientifically evaluate their effectiveness. Regular hand hygiene',\n",
       "    'Best practices in hospitals include cleaning with both detergent and disinfectant to control pathogens like MRSA, VRE, norovirus, multi-resistant Gram-negative bacilli, and C. difficile. At home, focus on frequently touched surfaces, proper hand',\n",
       "    'Best practices include thorough cleaning with detergent and disinfectants, focusing on frequently touched surfaces, and evaluating cleaning effectiveness. Tailor practices to clinical risks and regularly clean high-touch areas. At home, follow similar guidelines, emphasizing hygiene in frequently used spaces.',\n",
       "    '',\n",
       "    'Best practices include thorough cleaning with detergents and disinfectants, especially for frequently touched surfaces. Tailor cleaning to clinical risk and evaluate effectiveness. In homes, focus on high-contact areas. Quarantine measures should restrict movement and limit interactions to reduce'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 4, 3, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'c0c4rjfa': {'greedy': 'Best practices include proper use of personal protective equipment like long-sleeved gowns, disinfecting medical devices before reuse, thorough cleaning of surfaces and equipment, and adhering to local and international infection control guidelines. At home, isolate sick individuals,',\n",
       "   'samples': ['Best practices include wearing appropriate personal protective equipment like long-sleeved gowns, properly disinfecting medical devices, thorough cleaning of surfaces and equipment between uses, and ensuring adequate terminal cleaning of isolated rooms. At home, maintain good hygiene, regularly clean',\n",
       "    'Best practices include using long-sleeved gowns instead of sleeveless aprons during procedures that may generate splashes or sprays, disinfecting medical devices before re-use, and thoroughly cleaning commodes between patients. At home, follow similar principles',\n",
       "    'Best practices include proper use of protective gear like long-sleeved gowns, thorough cleaning of medical devices, and ensuring thorough cleansing of surfaces and equipment between uses. At home, maintain hygiene, wear masks when necessary, and practice good handwashing habits',\n",
       "    '',\n",
       "    '',\n",
       "    'Best practices include proper use of personal protective equipment (like long-sleeved gowns), thorough disinfection of medical devices, and thorough cleansing of surfaces between uses. At home, follow similar principles and maintain good hygiene practices.',\n",
       "    'Best practices for maintaining quarantine in hospitals and at home include proper use of personal protective equipment like masks, gowns, and goggles, thorough cleaning and disinfection of surfaces and medical devices, and strict adherence to hand hygiene protocols. Isolation rooms should be',\n",
       "    'Best practices for maintaining quarantine in hospitals include strict adherence to isolation precautions, proper use of personal protective equipment like long-sleeved gowns, and thorough disinfection of medical devices and cleaning of surfaces. At home, it involves limiting contact with others,',\n",
       "    'Best practices include wearing appropriate protective gear like long-sleeved gowns, properly disinfecting medical devices, and thoroughly cleaning commodes between uses. Additionally, adhering to local and international infection control guidelines is crucial. At home, maintaining good hygiene',\n",
       "    'Best practices include wearing appropriate protective gear like long-sleeved gowns, using masks, goggles, or face shields as needed, proper handling of medical devices and linens, thorough cleaning of surfaces and equipment, and strict adherence to guidelines for isolation and'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 2, 4, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '8rs3oep3': {'greedy': 'Best practices include frequent hand washing, wearing masks, maintaining social distance, monitoring health, and following official guidelines. At home, limit出门在外时佩戴口罩，保持社交距离，勤洗手，监测健康状况，并遵循官方指南。在家则应',\n",
       "   'samples': ['Best practices for maintaining quarantine include:',\n",
       "    '',\n",
       "    'In hospitals and homes, maintain hygiene (洗手, 勤通风), monitor health (定期体检), isolate patients (单间隔离), provide support (心理支持) and follow guidelines (遵守规定).',\n",
       "    'At home, maintain hygiene, avoid visitors, stay isolated, and monitor health. In hospitals, restrict visitor access, implement screening, enforce hand hygiene, and isolate patients.',\n",
       "    'Best practices for maintaining quarantine include: isolation in a dedicated room, regular handwashing, using personal protective equipment, avoiding shared spaces, monitoring health daily, and seeking medical advice if symptoms arise. At home, ensure proper ventilation and maintain social distance from household',\n",
       "    'Best practices for maintaining quarantine include staying in a well-ventilated room, avoiding contact with others, washing hands frequently, and using personal protective equipment. Regular health monitoring and following local health guidelines are also important. At home, ensure social distancing and proper',\n",
       "    '',\n",
       "    'Best practices include monitoring health, practicing good hygiene (e.g., frequent handwashing), limiting contact with others, and staying home when ill. Hospitals should maintain strict access control, enhance sanitation, and provide mental health support.',\n",
       "    'Best practices include frequent handwashing, wearing masks, avoiding close contact with others, staying home when sick, and practicing good hygiene.',\n",
       "    'Best practices include maintaining hygiene, limiting social interactions, monitoring health, and adhering to local guidelines. At home, isolate in a separate room if possible, use a dedicated bathroom, wear masks, and practice good hygiene. In hospitals, implement strict screening'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 1, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'jo9fgkwl': {'greedy': 'Wash hands, wear masks, disinfect surfaces, limit visitors, stay in designated rooms, and follow local health guidelines.',\n",
       "   'samples': ['Wash hands, wear masks, sanitize surfaces, avoid visitors, stay in designated areas.',\n",
       "    'Wash hands frequently, wear masks, disinfect surfaces, limit visitors, stay in designated rooms, and follow healthcare provider instructions.',\n",
       "    '',\n",
       "    '',\n",
       "    'In hospitals, maintain strict isolation protocols, limit access, use personal protective equipment (PPE), and follow sterilization procedures. At home, isolate in a separate room, use a dedicated bathroom, wear masks, sanitize frequently, and maintain social distance.',\n",
       "    'Wash hands, wear masks, disinfect surfaces, limit visitors, stay isolated, monitor health.',\n",
       "    '',\n",
       "    '',\n",
       "    '',\n",
       "    'In hospitals, strictly follow protocols, limit access, use personal protective equipment, and maintain cleanliness. At home, isolate in a separate room, limit contact with others, wear masks, sanitize frequently, and avoid sharing personal items.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 3, 1, 4, 1, 5],\n",
       "   'entropy': 1.6094379124341},\n",
       "  'y7808p91': {'greedy': 'The context provided does not specifically address best practices for maintaining quarantine in hospitals or at home. It focuses on the education and communication resources available for responding to public health threats in U.S. hospitals. For specific quarantine guidelines, refer to public health recommendations from',\n",
       "   'samples': ['The context does not provide specific best practices for maintaining quarantine in hospitals or at home. To address this, the CDC recommends staying in a separate room and using a separate bathroom if possible, wearing a mask around others, practicing good hygiene, and limiting contact',\n",
       "    'The provided context does not specify best practices for maintaining quarantine in hospitals or at home. To address the question directly:',\n",
       "    'The document does not provide specific best practices for maintaining quarantine at home. It focuses on hospital-based educational programs and communication resources regarding public health threats. For home quarantine best practices, refer to official public health guidelines.',\n",
       "    'The context does not provide specific best practices for maintaining quarantine in hospitals or at home. It focuses on the dissemination of information and educational programs about infection control issues in hospitals. For home quarantine practices, refer to public health guidelines and recommendations from health authorities.',\n",
       "    'The provided context does not detail specific best practices for maintaining quarantine in hospitals or at home. It focuses on education and communication resources for addressing public health threats. For specific quarantine guidelines, refer to public health recommendations from organizations like the CDC.',\n",
       "    'The document does not provide specific best practices for maintaining quarantine in hospitals or at home. It focuses on the education and communication resources available to hospitals regarding infectious diseases like smallpox, SARS, and anthrax. For detailed guidance on maintaining quarantine at',\n",
       "    'The context provided does not detail specific best practices for maintaining quarantine at home or in hospitals. It focuses on the education and communication resources available to hospitals regarding public health threats. For specific quarantine guidelines, refer to local health authority recommendations.',\n",
       "    'The context does not provide specific best practices for maintaining quarantine in hospitals or at home. To address quarantine best practices directly:',\n",
       "    'The given context does not provide specific best practices for maintaining quarantine in hospitals or at home. It focuses on the education and communication resources available for hospitals to respond to public health threats. For home quarantine practices, refer to public health guidelines from local health authorities',\n",
       "    'The document does not provide specific best practices for maintaining quarantine in hospitals or at home. To address this, it is recommended to refer to current public health guidelines from organizations such as the CDC or WHO, which offer detailed recommendations on isolation and quarantine measures,'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 1, 5, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'd2axm29e': {'greedy': 'Best practices include visitor management, hand and respiratory hygiene, cough etiquette, vaccination of healthcare personnel, and work furlough for ill workers. In hospitals, focus on early identification of potential source patients and proper use of personal protective equipment. At home,',\n",
       "   'samples': ['Best practices include early identification of potential source patients, visitor management, hand and respiratory hygiene, cough etiquette, vaccination of healthcare personnel, and furloughing ill workers. Hospitals should eliminate potential exposures, use engineering and administrative controls, and employ appropriate personal',\n",
       "    'Best practices include visitor management, hand and respiratory hygiene, and cough etiquette at home and in hospitals. Vaccination of healthcare personnel and work furlough for ill workers are also recommended. Hospitals should implement an algorithm for intake precautions based on identifying potential source',\n",
       "    'Best practices include:',\n",
       "    'Best practices include visitor management, hand and respiratory hygiene, and cough etiquette. Vaccination of healthcare personnel and work furlough for ill workers are also recommended. Elimination of potential exposures, engineering and administrative controls, and proper use of personal protective equipment',\n",
       "    'Best practices include early patient identification, use of PPE, hand hygiene, respiratory hygiene, cough etiquette, vaccination, and furlough for ill workers. Visitor restrictions are also recommended. At home, isolation, good hygiene, and distancing should be practiced',\n",
       "    'Best practices include identifying potential source patients, using personal protective equipment, managing visitors, practicing hand and respiratory hygiene, and promoting vaccination among healthcare personnel. At home, focus on eliminating potential exposures, maintaining good hygiene, and isolating if infected.',\n",
       "    'Best practices include:',\n",
       "    'Best practices include:',\n",
       "    'Best practices include identifying potential source patients, proper use of PPE, visitor management, hand and respiratory hygiene, and cough etiquette. Vaccination of healthcare personnel and work furlough for ill workers are also recommended. At home, quarantine should involve minimizing',\n",
       "    'Best practices include visitor management, hand and respiratory hygiene, cough etiquette, vaccination of healthcare personnel, work furlough for ill workers, elimination of potential exposures, engineering and administrative controls, and the use of personal protective equipment.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 2, 6, 3],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '9zf2h0xr': {'greedy': 'Best practices in hospitals include creating temporary isolation facilities, restricting access to exposed health care workers, and involving specialists to screen and monitor cases. At home, maintain social distancing, wear masks, and practice good hygiene.',\n",
       "   'samples': ['Best practices for quarantine in hospitals include creating temporary isolation facilities, restricting access to exposed health care workers, and involving specialists for screening and monitoring. At home, maintain distance from others, monitor for symptoms, practice good hygiene, and follow local health guidelines.',\n",
       "    'Best practices in hospitals include creating temporary isolation facilities, restricting access to exposed healthcare workers, and involving specialists to screen and monitor cases. At home, maintain hygiene, limit contact with others, and follow guidance from public health authorities.',\n",
       "    'Best practices for maintaining quarantine in hospitals and at home include:',\n",
       "    'Best practices in hospitals include rapid creation of temporary isolation facilities, restricting access to exposed health care workers, and involving specialists to screen and monitor cases. At home, maintain social distancing, practice good hygiene, and follow local public health guidelines.',\n",
       "    'Best practices for maintaining quarantine in hospitals include creating temporary isolation facilities, restricting access to exposed healthcare workers, and involving specialists to screen and monitor cases. At home, maintain social distancing, wear masks, sanitize frequently, and avoid large gatherings.',\n",
       "    'Best practices in hospitals for maintaining quarantine include rapid creation of temporary isolation facilities, restricting access to exposed healthcare workers, and providing continuous monitoring to ensure adherence to infection-control practices. At home, individuals should practice social distancing, monitor their health, and follow local',\n",
       "    'Best practices for maintaining quarantine in hospitals and at home include isolating infected individuals, restricting visitor access, practicing proper hygiene, using personal protective equipment, and adhering to strict infection-control protocols. Regular feedback and training for healthcare workers are also crucial. At',\n",
       "    'Best practices for maintaining quarantine in hospitals and at home include:',\n",
       "    'Best practices in hospitals and at home for maintaining quarantine include creating temporary isolation facilities, restricting access to exposed individuals, screening and identifying cases early, monitoring adherence to infection-control practices, and providing regular feedback. Specific measures may include using personal protective equipment, practicing',\n",
       "    'Best practices for maintaining quarantine in hospitals and at home include:'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 1, 3, 1, 4, 1],\n",
       "   'entropy': 1.4184836619456562}},\n",
       " '25': {'no': {'greedy': 'Elevated levels of certain cytokines (e.g., IL-6, IL-10) and inflammatory markers (e.g., ferritin, CRP) predict severe clinical course.',\n",
       "   'samples': ['Age, dyspnea, lymphopenia, elevated CRP, elevated LDH, and elevated AST are biomarkers associated with a severe clinical course of 2019-nCOV infection.',\n",
       "    'Elevated levels of cytokines (e.g., IL-6, TNF-α) and lactate dehydrogenase (LDH) are associated with severe COVID-19.',\n",
       "    'Elevated levels of certain cytokines (e.g., IL-6, IL-10) and liver enzymes (e.g., AST, ALT) are associated with severe 2019-nCOV infection.',\n",
       "    'Elevated levels of certain cytokines (e.g., IL-6, IL-10) and liver enzymes predict a severe clinical course in COVID-19 patients. Other markers include D-dimer and lactate dehydrogenase.',\n",
       "    'Current evidence suggests elevated levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), and procalcitonin may predict severe clinical course. However, further research is needed to confirm these findings.',\n",
       "    'Age, hypertension, diabetes, and obesity are associated with severe COVID-19. However, specific biomarkers have not been conclusively identified yet. Ongoing research is focusing on cytokines and immune markers. Answer:',\n",
       "    'Cytokine storm markers, lactate dehydrogenase, and elevated liver enzymes.',\n",
       "    'Elevated inflammatory markers (CRP, cytokines) and lymphopenia predict severe clinical course.',\n",
       "    'Age, dyspnea, lymphopenia, and elevated liver enzymes predict severe 2019-nCOV infection.',\n",
       "    'Age, male gender, and comorbidities like hypertension, diabetes, and cardiovascular disease are associated with severe COVID-19. Elevated lactate dehydrogenase and decreased lymphocyte counts are also biomarkers. However, specific biomarkers may'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 0, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  't996fbad': {'greedy': 'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM %), and neut',\n",
       "   'samples': ['Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM %), and neut',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) predict the severe clinical course of 2019-nCOV infection.',\n",
       "    'Age, viral load, lung injury score, and blood biochemistry indexes including albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) are potential predictors of disease severity in 2019',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), percentage of lymphocytes (LYM (%)), and',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) are predictors of disease severity in 2019-nCoV infection.',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM %), and neut',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) predict the severe clinical course of 2019-nCoV infection.',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM %), and neut',\n",
       "    'Age, viral load, lung injury score, and blood biochemistry indexes including albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) may be predictors of disease severity. Additionally, elevated Angiot',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) are potential predictors of disease severity in 2019-nCoV infection.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 1, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'pd70i3d8': {'greedy': 'The neutrophil-to-lymphocyte ratio (NLR) was identified as an independent risk factor for severe illness in patients with 2019-nCoV infection.',\n",
       "   'samples': ['Neutrophil-to-lymphocyte ratio (NLR) predicts the severe clinical course of 2019-nCoV infection.',\n",
       "    'The neutrophil-to-lymphocyte ratio (NLR) was identified as an independent risk factor for severe illness in patients with 2019-nCoV infection.',\n",
       "    'The neutrophil-to-lymphocyte ratio (NLR) was identified as the independent risk factor for severe illness in patients with 2019-nCoV infection.',\n",
       "    'Neutrophil-to-lymphocyte ratio (NLR) is identified as an independent risk factor for severe illness in patients with 2019-nCoV infection.',\n",
       "    'The neutrophil-to-lymphocyte ratio (NLR) is identified as an independent risk factor for severe illness in patients with 2019-nCoV infection.',\n",
       "    'Neutrophil-to-lymphocyte ratio (NLR) predicts the severe clinical course of 2019-nCOV infection.',\n",
       "    'The neutrophil-to-lymphocyte ratio (NLR) was identified as an independent risk factor for severe illness in patients with 2019-nCoV infection.',\n",
       "    'Neutrophil-to-lymphocyte ratio (NLR) predicts the severe clinical course of 2019-nCOV infection.',\n",
       "    'The neutrophil-to-lymphocyte ratio (NLR) is identified as an independent risk factor for severe illness in patients with 2019-nCoV infection.',\n",
       "    'The neutrophil-to-lymphocyte ratio (NLR) was identified as the independent risk factor for severe illness in patients with 2019-nCoV infection.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 1, 5, 4, 2],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  '9k8r18x7': {'greedy': 'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), percentage of lymphocytes (LYM (%)), and',\n",
       "   'samples': ['Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM (%)), and neut',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) are potential predictors of disease severity in 2019-nCoV infection.',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) are potential predictors of disease severity in 2019-nCoV infection.',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) are predictors of disease severity. ALB, LYM, LYM (%), LDH',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%) predict the severe clinical course of 2019-nCoV infection.',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM %), and neut',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), percentage of lymphocytes (LYM (%)), and',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), percentage of lymphocytes (LYM (%)), and',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM %), and neut',\n",
       "    'Age, viral load, lung injury score, albumin (ALB), C-reactive protein (CRP), lactate dehydrogenase (LDH), lymphocyte count (LYM), lymphocyte percentage (LYM %), and neut'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.9433483923290393},\n",
       "  'e5uyahea': {'greedy': 'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. The text focuses on imaging findings and patient recovery. No biomarker information is given.',\n",
       "   'samples': ['The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCOV infection. The text focuses on imaging findings and patient recovery. Answer: None mentioned.',\n",
       "    'The given context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. The text focuses on imaging findings and clinical improvement. Biomarker information is not provided.',\n",
       "    'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. To answer this question accurately, additional information would be needed.',\n",
       "    'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on imaging findings and patient recovery. Therefore, no biomarkers are discussed here.',\n",
       "    'The document does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on imaging findings and clinical improvement.',\n",
       "    \"The given context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on imaging findings and the patient's clinical improvement. No biomarker information is provided.\",\n",
       "    'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCOV infection. The text focuses on imaging findings and clinical improvement. No biomarker information is given.',\n",
       "    'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCOV infection. The text focuses on imaging findings and clinical improvement. Answer: None mentioned.',\n",
       "    \"The given context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCOV infection. It focuses on imaging findings and the patient's clinical improvement.\",\n",
       "    \"The given context does not provide information about specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It only describes imaging findings and the patient's clinical improvement.\"],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 0, 0, 0, 2, 2],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  'o6bkxn7l': {'greedy': 'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. The text focuses on imaging findings and patient recovery. No biomarkers are discussed.',\n",
       "   'samples': ['The given context does not provide information on biomarkers that predict the severe clinical course of 2019-nCOV infection. The text focuses on imaging findings and patient recovery. No specific biomarkers are mentioned.',\n",
       "    \"The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It only describes imaging findings and the patient's clinical improvement. Answer: None mentioned.\",\n",
       "    'The given context does not provide any information about biomarkers that predict the severe clinical course of 2019-nCOV infection. The text focuses on imaging findings and patient recovery. No biomarkers are mentioned. Answer: Not provided in the',\n",
       "    'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on imaging findings and patient recovery. No biomarkers are discussed.',\n",
       "    'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on imaging findings and patient recovery. Therefore, no biomarkers are mentioned in this particular context. Answer:',\n",
       "    \"The given context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCOV infection. It focuses on imaging findings and the patient's clinical improvement. To answer your question, we would need additional information or\",\n",
       "    \"The document provided does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on imaging findings and the patient's response to treatment. Therefore, no answer can be given based on the\",\n",
       "    'The given context does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. The context focuses on imaging findings and clinical improvement in a young diabetic patient. Biomarker information is not provided.',\n",
       "    'The document does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. It focuses on imaging findings and patient improvement.',\n",
       "    'The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCOV infection. The text focuses on imaging findings and clinical improvement. No biomarker information is given.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '7nzws8jt': {'greedy': 'The provided context does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. To answer this question accurately, you would need to refer to recent medical literature or studies focused on identifying such biomarkers',\n",
       "   'samples': [\"The given context does not provide information about biomarkers predicting the severe clinical course of 2019-nCoV infection. The text focuses on the upgrading of the virus's classification and the establishment of diagnostic guidelines and safety protocols. To answer the\",\n",
       "    'The given context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. To answer this question accurately, you would need to refer to recent medical studies and research papers focusing on biomarkers associated',\n",
       "    'The provided context does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. To answer your question, I would need additional information or research findings on this topic.',\n",
       "    \"The text does not mention any biomarkers that predict the severe clinical course of 2019-nCoV infection. It focuses on upgrading the virus's classification and the importance of standardized testing procedures.\",\n",
       "    'The provided context does not mention any specific biomarkers that predict the severe clinical course of 2019-nCOV infection. The text focuses on the upgrading of the virus classification and the establishment of diagnostic criteria. To answer your question, you',\n",
       "    'The given context does not mention any biomarkers that predict the severe clinical course of 2019-nCOV infection. It focuses on upgrading the disease classification and establishing standard protocols for nucleic acid detection. To answer your question, additional research',\n",
       "    'The text provided does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. The passage discusses the classification and testing procedures for the virus.',\n",
       "    'The given context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on the upgrading of the virus to a higher disease classification and the establishment of standard protocols for nucleic acid',\n",
       "    'The context provided does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. To answer this question accurately, one would need to refer to recent research studies focusing on biomarkers for severe cases.',\n",
       "    'The text provided does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. It focuses on the upgrading of the virus classification and the establishment of standard protocols for detecting the virus in clinical laboratories.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 0, 3, 4, 5, 0],\n",
       "   'entropy': 1.6434177197931796},\n",
       "  'fvig79k3': {'greedy': 'The given context does not mention any biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism of the virus to ACE2 and potential drug targets. Therefore, no answer can be provided based',\n",
       "   'samples': ['The provided context does not mention any specific biomarkers for predicting a severe clinical course of 2019-nCoV infection. The information focuses on potential drug targets based on structural similarities to SARS. Answering the specific question asked is not',\n",
       "    'The context provided does not mention any biomarkers for predicting a severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism of the virus to ACE2 and potential drug targets. Therefore, no answer can be given',\n",
       "    'The context provided does not mention any specific biomarkers for predicting the severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism of the virus to ACE2 and potential drug targets based on structural similarities with SARS',\n",
       "    'The given context does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism and potential drug targets.',\n",
       "    'The provided context does not mention any specific biomarkers for predicting the severe clinical course of 2019-nCoV infection. It focuses on potential drug targets based on structural similarities to SARS.',\n",
       "    'The provided context does not mention any specific biomarkers for predicting a severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism of the virus to ACE2 and potential drug targets. Therefore, no answer can be',\n",
       "    'The provided context does not mention any specific biomarkers for predicting a severe clinical course of 2019-nCoV infection. The text focuses on potential drug targets based on structural similarities with SARS-CoV. Answer: No biomarkers are',\n",
       "    'The context provided does not mention any specific biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism and potential drug targets based on structural similarities with SARS-CoV. Answer: No specific',\n",
       "    'The context provided does not mention any biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism of the virus to ACE2 and suggests potential drug targets based on this information. Therefore, no',\n",
       "    'The provided context does not mention any specific biomarkers for predicting a severe clinical course of 2019-nCoV infection. It focuses on the binding mechanism of the virus to ACE2 and potential drug targets based on conformational changes.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 0, 3, 4, 0, 3, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'og92zxnf': {'greedy': \"The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on the virus's relation to other coronaviruses and suggests potential receptors and targets for therapy and vaccines\",\n",
       "   'samples': ['The provided context does not mention any biomarkers that predict a severe clinical course of 2019-nCoV infection. Domain 288-330 of the S1 protein is suggested as a potential therapeutic and/or vaccine target',\n",
       "    \"The context provided does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on the virus's relationship to other coronaviruses and suggests possible therapeutic and vaccine targets. No biom\",\n",
       "    \"The context provided does not mention any specific biomarkers predicting the severe clinical course of 2019-nCOV infection. It focuses on the virus's relation to other coronaviruses, potential hosts, and suggested targets for therapy and vaccines\",\n",
       "    'The provided context does not mention any biomarkers predicting the severe clinical course of 2019-nCOV infection. It focuses on the origin, potential hosts, and therapeutic/vaccine targets of the virus.',\n",
       "    \"The provided context does not mention any specific biomarkers for predicting a severe clinical course of 2019-nCoV infection. It focuses on the virus's origin, potential hosts, and therapeutic/vaccine targets.\",\n",
       "    \"The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on the virus's relation to other coronaviruses and potential targets for therapy and vaccines.\",\n",
       "    'The given context does not mention any biomarkers that predict the severe clinical course of 2019-nCoV infection. It focuses on identifying the origin, potential hosts, and therapeutic/vaccine targets. No biomarkers are discussed.',\n",
       "    \"The provided context does not mention any specific biomarkers that predict the severe clinical course of 2019-nCoV infection. The text discusses the virus's relation to other coronaviruses, potential hosts, and suggests a therapeutic/vaccine\",\n",
       "    \"The given context does not provide information about biomarkers predicting the severe clinical course of 2019-nCOV infection. It focuses on the virus's relation to other coronaviruses, potential hosts, and suggested therapeutic/vaccine targets.\",\n",
       "    \"The provided context does not mention any biomarkers that predict the severe clinical course of 2019-nCOV infection. The text focuses on the virus's relation to other coronaviruses, potential hosts, and suggests a specific region of\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 2, 3, 2, 2, 4],\n",
       "   'entropy': 1.4184836619456564},\n",
       "  'g5wpa2ee': {'greedy': 'The given context does not mention any biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on developing a model for drug repositioning.',\n",
       "   'samples': ['The given context does not provide any information about biomarkers predicting the severe clinical course of 2019-nCOV infection. The text focuses on using structural-based drug repositioning to identify potential treatments. Answer: None mentioned.',\n",
       "    'The given context does not provide information about biomarkers predicting the severe clinical course of 2019-nCOV infection. It focuses on a structural-based drug repositioning approach to identify potential antiviral drugs.',\n",
       "    'The given context does not provide any information about biomarkers predicting the severe clinical course of 2019-nCOV infection. It focuses on developing a drug screening model for potential antiviral treatments. Answer: None mentioned.',\n",
       "    'The provided context does not mention any biomarkers predicting the severe clinical course of 2019-nCOV infection. It focuses on developing a drug screening model for potential treatments.',\n",
       "    'The given context does not provide information on biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on a structural-based drug repositioning model to identify potential antiviral drugs. Therefore, no answer can',\n",
       "    'The given context does not mention any biomarkers predicting the severe clinical course of 2019-nCOV infection. The text focuses on developing a model for potential drug repositioning against the virus.',\n",
       "    'The given context does not provide information about biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on developing a model for drug repositioning against the virus. Answer: None mentioned.',\n",
       "    'The given context does not mention any biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on developing a model for drug screening based on the 3CL protease of the virus. Therefore, no answer',\n",
       "    'The provided context does not discuss any biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on using computational methods to identify potential drugs that could be effective against the virus. Therefore, the answer is that the',\n",
       "    'The given context does not mention any biomarkers predicting the severe clinical course of 2019-nCOV infection. The text focuses on using computational methods to identify potential drug candidates against the virus.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 6, 7, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'm15m1xh8': {'greedy': \"The provided context does not mention any specific biomarkers that predict a severe clinical course of 2019-nCoV infection. It focuses on the virus's relation to other coronaviruses and potential hosts and targets for therapy or vaccines.\",\n",
       "   'samples': ['The provided context does not mention any biomarkers that predict the severe clinical course of 2019-nCoV infection. It focuses on the origin, potential hosts, and therapeutic/vaccine targets instead.',\n",
       "    \"The provided context does not mention any biomarkers that predict a severe clinical course of 2019-nCoV infection. The text focuses on the virus's origin, potential natural hosts, and proposed therapeutic/vaccine targets. To answer your question\",\n",
       "    'The given context does not provide information on biomarkers predicting the severe clinical course of 2019-nCoV infection. It focuses on identifying the possible origin, natural host, and potential therapeutic/vaccine targets for the virus. To answer your',\n",
       "    \"The given context does not mention any biomarkers that predict a severe clinical course of 2019-nCoV infection. The text discusses the virus's relation to other coronaviruses, potential hosts, and identifies a therapeutic/vaccine target\",\n",
       "    'The provided context does not mention any biomarkers predicting the severe clinical course of 2019-nCoV infection. Domain 288-330 of S1 protein is suggested as a therapeutic/vaccine target, but no biom',\n",
       "    \"The provided context does not mention any biomarkers predicting the severe clinical course of 2019-nCOV infection. It focuses on the virus's relation to other coronaviruses, potential hosts, and suggested therapeutic/vaccine targets. Answer\",\n",
       "    \"The provided context does not mention any biomarkers that predict the severe clinical course of 2019-nCoV infection. It discusses the virus's relation to other coronaviruses, potential hosts, and a promising therapeutic/vaccine target.\",\n",
       "    'The provided context does not mention any biomarkers predicting the severe clinical course of 2019-nCoV infection. The text focuses on identifying the origin, natural host, and potential therapeutic/vaccine targets for the virus.',\n",
       "    \"The provided context does not mention any specific biomarkers for predicting a severe clinical course of 2019-nCoV infection. It focuses on the virus's relation to other coronaviruses and potential hosts and targets for therapy or vaccines.\",\n",
       "    \"The given context does not provide information on biomarkers predicting a severe clinical course of 2019-nCoV infection. The text focuses on the virus's relation to other coronaviruses and suggests potential therapeutic and vaccine targets. No specific\"],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 0, 3, 0, 3, 4],\n",
       "   'entropy': 1.3592367006650063}},\n",
       " '34': {'no': {'greedy': 'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "   'samples': ['Longer-term complications include fatigue, breathlessness, and cognitive issues.',\n",
       "    'Long-term complications include fatigue, breathlessness, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, breathlessness, and cognitive issues. Some patients also experience ongoing symptoms like persistent cough or taste/Smell loss. Heart, kidney, and lung damage can occur in severe cases.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\" Answering more concisely. Long-term complications include fatigue, shortness of breath, cognitive issues, and \"long COVID.\" Answer:',\n",
       "    'Longer-term complications include fatigue, breathlessness, and cognitive issues. Some patients also experience persistent symptoms like fever and muscle pain.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, brain fog, and heart issues.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and cardiac problems.',\n",
       "    'Long-term complications include fatigue, breathlessness, brain fog, and heart issues.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 1, 2, 0, 2, 3, 4],\n",
       "   'entropy': 1.5047882836811906},\n",
       "  '7s04ygm2': {'greedy': 'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "   'samples': ['Longer-term complications of those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Longer-term complications of those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.',\n",
       "    'Long-term complications for those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions. These effects were also observed in past similar viral outbreaks like SARS and MERS. Healthcare',\n",
       "    'Long-term complications for those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric effects.',\n",
       "    'Long-term complications of those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.',\n",
       "    'Longer-term complications of those who recover from COVID-19 may include cardiopulmonary, glucometabolic, and neuropsychiatric issues. These were documented in previous coronavirus infections like SARS and MERS.',\n",
       "    'Long-term complications of those who recover from COVID-19 include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 2, 3, 2, 3, 3],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'e1fhje3z': {'greedy': 'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "   'samples': ['Long-term complications include fatigue, breathlessness, and cognitive issues.',\n",
       "    'Long-term complications include fatigue, shortness of breath, cognitive issues, and cardiovascular problems.',\n",
       "    'Some long-term complications include fatigue, shortness of breath, and cognitive issues.',\n",
       "    'Some long-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, breathlessness, and cognitive issues. Some may experience ongoing multisystem inflammatory syndrome.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some may experience ongoing multi-organ symptoms.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience ongoing multisystem inflammatory syndrome.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Long-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and cardiac problems.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 2, 2, 3, 0, 4],\n",
       "   'entropy': 1.5047882836811906},\n",
       "  'fko57z33': {'greedy': 'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience ongoing multisystem inflammatory syndrome.',\n",
       "   'samples': ['Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience heart, kidney, and lung problems.',\n",
       "    'Long-term complications include fatigue, breathlessness, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems. Some patients also experience ongoing symptoms like coughing and headaches.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues.',\n",
       "    'Longer-term complications include fatigue, breathlessness, brain fog, and heart issues. Some patients also experience ongoing multisystem inflammatory syndrome.',\n",
       "    'Some people experience long-term effects, called \"long COVID,\" including fatigue, shortness of breath, and cognitive issues.',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\"',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 3, 4, 4, 3, 3],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  'xk73ydqe': {'greedy': 'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "   'samples': ['Some long-term complications include fatigue, shortness of breath, cognitive issues, and cardiovascular problems.',\n",
       "    'Long-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\" Answering this briefly, key long-term complications are fatigue, breathlessness, and cognitive problems. \"Long COVID\" is also noted. Answer',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\"',\n",
       "    'Longer-term complications include fatigue, breathlessness, and cognitive issues.',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\"',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some may also experience ongoing heart or lung problems.',\n",
       "    'Some individuals experience ongoing symptoms, known as \"long COVID,\" including fatigue, shortness of breath, and cognitive issues. These can persist for months after recovery.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems. Some patients also experience ongoing symptoms like coughing or muscle pain.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, brain fog, and heart issues.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 2, 4, 3, 5, 5],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  'yudrouue': {'greedy': 'Long-term complications of those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "   'samples': ['Long-term complications for those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.',\n",
       "    'Longer-term complications for those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic disorders, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of COVID-19 recovery may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions.',\n",
       "    'Long-term complications of those who recover from COVID-19 may include cardiopulmonary issues, glucometabolic problems, and neuropsychiatric conditions. These effects extend beyond the initial acute phase of the disease.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 1, 1, 1, 1, 0, 0],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'jud53dmv': {'greedy': 'Respiratory and cardiovascular complications, severe asthenia, and fatigue.',\n",
       "   'samples': ['Longer-term complications include respiratory and cardiovascular issues, as well as severe asthenia and fatigue.',\n",
       "    'Respiratory and cardiovascular complications, along with severe asthenia and fatigue.',\n",
       "    'Longer-term complications for COVID-19 survivors include respiratory and cardiovascular issues, along with severe asthenia and fatigue.',\n",
       "    'Longer-term complications include serious respiratory and cardiovascular issues, along with severe asthenia and fatigue.',\n",
       "    'Respiratory and cardiovascular issues, severe asthenia, and fatigue.',\n",
       "    'Serious complications include respiratory and cardiovascular issues, with severe asthenia and fatigue.',\n",
       "    'Longer-term complications for COVID-19 survivors include respiratory and cardiovascular issues, along with severe asthenia and fatigue.',\n",
       "    'Serious respiratory and cardiovascular complications, along with severe asthenia and fatigue.',\n",
       "    'Serious respiratory and cardiovascular complications, along with severe asthenia and fatigue.',\n",
       "    'Serious respiratory and cardiovascular complications, along with severe asthenia and fatigue.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 2, 5, 5, 5],\n",
       "   'entropy': 1.6434177197931796},\n",
       "  'b2wgo20y': {'greedy': 'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "   'samples': ['Longer-term complications include fatigue, breathlessness, cognitive issues, and cardiovascular problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems. Some patients also experience ongoing symptoms like coughing and headaches.',\n",
       "    'Some long-term complications include fatigue, shortness of breath, and cognitive issues.',\n",
       "    'Some people experience prolonged symptoms like fatigue, shortness of breath, and cognitive issues, known as \"long COVID.\"',\n",
       "    'Longer-term complications include fatigue, breathlessness, and cognitive issues. Some patients also experience persistent symptoms like loss of smell or taste.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some may experience ongoing symptoms for months.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\"',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience persistent pain and mental health challenges.',\n",
       "    'Some people experience long-term effects, termed \"long COVID,\" including fatigue, shortness of breath, and cognitive issues.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience ongoing symptoms like brain fog and muscle pain.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 4, 2, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '3dmfcz1i': {'greedy': 'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience ongoing multisystem inflammatory syndrome.',\n",
       "   'samples': ['Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, breathlessness, cognitive issues, and heart problems.',\n",
       "    'Long-term complications include fatigue, shortness of breath, cognitive issues, and cardiovascular problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\"',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\"',\n",
       "    'Long-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience ongoing heart, kidney, or lung problems.',\n",
       "    'Some long-term complications include fatigue, shortness of breath, brain fog, and heart issues.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 5, 2, 0, 5],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  'uz9a0izu': {'greedy': 'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "   'samples': ['Long-term complications include fatigue, breathlessness, and cognitive issues. Some patients also experience ongoing symptoms like headaches, dizziness, and joint pain. Cardiovascular problems and mental health issues are also reported.',\n",
       "    'Some long-term complications include fatigue, shortness of breath, brain fog, and heart issues.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, brain fog, and heart issues.',\n",
       "    'Some long-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience \"long COVID.\" Answer briefly. Long-term complications include fatigue, shortness of breath, and cognitive issues. Answer.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and cardiac problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some may experience ongoing symptoms known as \"long COVID.\"',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience persistent cough, joint pain, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience ongoing heart or kidney problems.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 2, 2, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'c864pm71': {'greedy': 'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "   'samples': ['Long-term complications include fatigue, shortness of breath, cognitive issues, and heart problems. Some patients also experience ongoing multisystem inflammatory state.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and heart problems. Some patients also experience ongoing symptoms like cough and joint pain.',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients also experience persistent cough, chest pain, and tachycardia. Cardiac, neurological, and gastrointestinal problems may occur.',\n",
       "    'Some long-term complications include fatigue, shortness of breath, brain fog, and heart issues.',\n",
       "    'Longer-term complications include fatigue, breathlessness, cognitive issues, and heart problems.',\n",
       "    'Longer-term complications include fatigue, shortness of breath, cognitive issues, and ongoing cough. Some patients also experience \"long COVID\" or post-COVID syndrome.',\n",
       "    'Long-term complications include fatigue, shortness of breath, cognitive issues, and heart problems.',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some experience \"long COVID.\"',\n",
       "    'Long-term complications include fatigue, shortness of breath, and cognitive issues. Some patients experience ongoing symptoms months after recovery. Answer.',\n",
       "    'Some recover but may experience prolonged symptoms, known as \"long COVID,\" including fatigue, breathlessness, and cognitive issues.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 0, 6, 7, 6],\n",
       "   'entropy': 2.0253262207700677}},\n",
       " '37': {'no': {'greedy': 'Phylogenetic analysis of SARS-CoV-2 genome sequences reveals its evolutionary relationships, tracing its origins and spread. The results show it is most closely related to bat coronaviruses and has a clear lineage linked to outbreaks in Wuhan,',\n",
       "   'samples': ['Phylogenetic analysis of SARS-CoV-2 genome sequences clusters strains into different lineages, tracing their evolutionary relationships and origins.',\n",
       "    'Phylogenetic analysis indicates SARS-CoV-2 originated in bats and has close relatives in horseshoe bats.',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences indicates its closest relatives are other coronaviruses found in bats, suggesting an animal origin. The virus has evolved into several lineages and variants.',\n",
       "    'Phylogenetic analysis suggests SARS-CoV-2 originated in bats and closely relates to viruses from pangolins and snakes. The exact ancestor is uncertain.',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences indicates its evolutionary relationships, tracing its origins and spread.',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences suggests the virus originated in bats and has multiple introduction events into humans. Briefly, it traces evolutionary relationships and shows diverse strains. But the exact origins and specific intermediate hosts remain subjects of',\n",
       "    'Phylogenetic analysis suggests SARS-CoV-2 originated in bats and has close relatives in horseshoe bats. The virus likely underwent several evolutionary changes before spilling over to humans. Various lineages have been identified, indicating multiple introductions into',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences clusters the virus into several lineages, with evidence of multiple introductions into different regions. Lineage B.1 is predominant globally. However, specific results can vary based on the study',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences shows its evolutionary relationships, tracing its origins and spread.',\n",
       "    'Phylogenetic analysis suggests SARS-CoV-2 originated in bats and has close ties to viruses found in pangolins and snakes. The virus likely jumped to humans via an intermediate host.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  '5nhh01wa': {'greedy': 'Phylogenetic analysis of SARS-CoV-2 genome sequences reveals its evolutionary relationships, tracing its origins and spread. The results show it is most closely related to bat coronaviruses and has a clear lineage linked to outbreaks in Wuhan,',\n",
       "   'samples': ['Phylogenetic analysis of SARS-CoV-2 genome sequences reveals its evolutionary relationships and origins. It shows that SARS-CoV-2 is closely related to bat coronaviruses and other bat-derived coronaviruses. This analysis helps',\n",
       "    'Phylogenetic analysis suggests SARS-CoV-2 originated in bats and has close relations with viruses found in pangolins and snakes. The exact ancestor is uncertain.',\n",
       "    'Phylogenetic analysis suggests SARS-CoV-2 originated in bats and has close ties to viruses found in pangolins and snakes. It shows the virus likely emerged in Wuhan, China.',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences shows the virus originated in bats and has close relatives in pangolins and snakes. The analysis also indicates the virus evolved into distinct lineages. However, specific lineages and their exact',\n",
       "    'Phylogenetic analysis suggests SARS-CoV-2 originated in bats and has close relations with viruses found in pangolins and snakes. The exact lineage is complex with multiple introductions to humans. Briefly, it traces evolutionary relationships but not a',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences indicates its close relationship to bat coronaviruses and emergence from a wildlife source. Variants have evolved with distinct lineages reflecting different传播路径。抱歉，您的问题似乎被错误',\n",
       "    'Phylogenetic analysis indicates SARS-CoV-2 originated in bats and has close relatives in pangolins and snakes. The virus likely evolved through intermediate hosts before infecting humans. Continual analysis tracks viral evolution and transmission patterns.',\n",
       "    'Phylogenetic analysis of SARS-CoV-2 genome sequences reveals its evolutionary relationships, origins, and transmission patterns among different strains. The results show that SARS-CoV-2 likely originated in bats and evolved through intermediate hosts before infecting humans',\n",
       "    'Phylogenetic analysis indicates SARS-CoV-2 originated in bats and has close ties to viruses found in pangolins and snakes. The virus likely underwent adaptations before jumping to humans.',\n",
       "    'Phylogenetic analysis suggests SARS-CoV-2 originated in bats and has close relations with viruses from pangolins and snakes. It has evolved into multiple variants.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  '2k7gckj2': {'greedy': 'The result of phylogenetic analysis is not provided in the given context. The context only mentions that five SARS-CoV-2 genome sequences were obtained and their nucleotide homology to SARS-CoV-2 was between 97.',\n",
       "   'samples': ['The result of phylogenetic analysis is not provided in the given context. The context only mentions that a bio-informatics software package was used to analyze and compare the genomic sequences but does not provide any specific results of the phylogenetic analysis.',\n",
       "    'The result of phylogenetic analysis is not mentioned in the given context. The context only provides information about the nucleotide homology, sequencing characteristics, and Ct values but does not discuss the phylogenetic analysis. Therefore, no conclusion can be drawn',\n",
       "    'The result of phylogenetic analysis is not provided in the given context. The context only mentions that nucleotide homology to SARS-CoV-2 was between 97.74%-99.90%, but does not indicate',\n",
       "    'The result of the phylogenetic analysis is not provided in the given context. The context only mentions obtaining and comparing SARS-CoV-2 genome sequences but does not discuss any specific findings from a phylogenetic analysis.',\n",
       "    'The context does not provide information on the results of a phylogenetic analysis of the SARS-CoV-2 genome sequences. It only states that five SARS-CoV-2 genome sequences were obtained and their nucleotide homology was 9',\n",
       "    'The result of phylogenetic analysis is not provided in the given context. The context focuses on the sequencing depth, coverage, relative abundance, and genome integrity in upper and lower respiratory tract specimens, but does not mention phylogenetic analysis. Therefore,',\n",
       "    'The provided context does not mention any results from a phylogenetic analysis of the SARS-CoV-2 genome sequences. The context only reports nucleotide homology percentages (97.74%-99.90%) to SARS',\n",
       "    'Not provided in the given context. The context does not mention any phylogenetic analysis results.',\n",
       "    'The result of the phylogenetic analysis is not mentioned in the given context. No information about comparing the sequences to a reference or constructing a phylogenetic tree is provided. The context focuses on the sequencing success and factors affecting it, rather than phy',\n",
       "    'The result of phylogenetic analysis is not provided in the given context. Only nucleotide homology is mentioned. The nucleotide homology to SARS-CoV-2 ranged from 97.74% to 99.9'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 4, 6, 2],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  't5ar9pp0': {'greedy': 'The phylogenetic analysis placed the Italian SARS-CoV-2 strains closely related to strains from France and Spain, suggesting early introduction from Western Europe.',\n",
       "   'samples': ['The phylogenetic analysis places the Italian SARS-CoV-2 strains close to other European lineages.',\n",
       "    'The result indicates SARS-CoV-2 was present in Italy weeks before the first reported cases.',\n",
       "    'The phylogenetic analysis placed the Italian isolates within the global SARS-CoV-2 diversity, suggesting recent introduction from China. However, exact results are not provided in the given context.',\n",
       "    'The phylogenetic analysis places the Italian SARS-CoV-2 strains within the major European cluster. No specific result is given for unique mutations or variants.',\n",
       "    'The phylogenetic analysis indicates that SARS-CoV-2 was present in Italy weeks before the first reported cases. However, the specific details of the phylogenetic tree and relationships to other strains are not provided in this brief summary.',\n",
       "    \"The phylogenetic analysis indicates the origin and evolution of SARS-CoV-2 in Italy. (Brief) Phylogenetic analysis shows SARS-CoV-2's evolutionary history in Italy.\",\n",
       "    'The result indicates SARS-CoV-2 was present in Italy weeks before the first reported cases.',\n",
       "    'The phylogenetic analysis placed the Italian isolates close to the Wuhan strain, indicating a possible origin from China. However, specific results are not detailed in the given context.',\n",
       "    'The phylogenetic analysis indicates that SARS-CoV-2 was present in Italy weeks before the first reported cases of infection.',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains close to strains circulating in Europe and the United States, indicating their origin from a common ancestor. However, specific details about the exact placement within global variants are not provided in the'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 3, 1, 4, 1, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  '48ul34xo': {'greedy': \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the Chinese tourist's sequence clustered with other European sequences. Additional European sequences segregated outside these clusters, suggesting multiple introductions or evolution within Europe.\",\n",
       "   'samples': ['The phylogenetic analysis suggests multiple introductions of SARS-CoV-2 into Europe or evolution during circulation.',\n",
       "    'The phylogenetic analysis suggests multiple introductions of SARS-CoV-2 into Europe or evolution during circulation.',\n",
       "    'The phylogenetic analysis suggests multiple SARS-CoV-2 introductions in Europe or virus evolution during circulation.',\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the Chinese tourist's sequence clustered with other European sequences, indicating potential multiple introductions or evolution within Europe.\",\n",
       "    'Multiple SARS-CoV-2 introductions in Europe or virus evolution during circulation.',\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the Chinese tourist's sequence clustered with other European sequences. Additional European sequences segregated outside these clusters. This suggests multiple introductions or evolution within Europe.\",\n",
       "    \"The phylogenetic analysis showed the Italian patient's sequence clustering with German sequences, while the Chinese tourist's sequence clustered with other European sequences, indicating potential multiple introductions or local evolution of the virus.\",\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the Chinese tourist's sequence clustered with other European sequences. Additionally, some European sequences segregated outside these clusters, suggesting multiple introductions or evolution during circulation.\",\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the tourist's sequence clustered with other European sequences, suggesting multiple introductions or evolution within Europe.\",\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the Chinese tourist's sequence clustered with other European sequences, suggesting multiple introductions or local evolution.\"],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 2, 4, 2, 4, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  'o6rr66kc': {'greedy': \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the tourist's sequence clustered with other European sequences. Additional European sequences segregated outside these clusters. This suggests multiple introductions or evolution within Europe.\",\n",
       "   'samples': [\"The phylogenetic analysis showed that one patient's sequence clustered with German sequences, while the other patient's sequence clustered with other European sequences. Additional European sequences segregated outside these clusters. This suggests multiple introductions or evolution during circulation.\",\n",
       "    'The phylogenetic analysis suggests multiple SARS-CoV-2 introductions in Europe or virus evolution during circulation.',\n",
       "    \"The phylogenetic analysis showed the Italian patient's sequence clustering with German sequences and the tourist's sequence with other European sequences, suggesting multiple introductions or evolution within Europe.\",\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the tourist's sequence clustered with other European sequences, suggesting multiple introductions or local evolution.\",\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the Chinese tourist's sequence clustered with other European sequences, suggesting multiple introductions or evolution within Europe.\",\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the Chinese tourist's sequence clustered with other European sequences. Additional European sequences segregated outside these clusters. This suggests multiple introductions or local evolution of the virus.\",\n",
       "    'The phylogenetic analysis suggests multiple SARS-CoV-2 introductions in Europe or virus evolution during circulation.',\n",
       "    \"The phylogenetic analysis showed that the Italian patient's sequence clustered with German sequences, while the tourist's sequence clustered with other European sequences. Additional European sequences segregated outside these clusters. This suggests multiple introductions or local evolution of the virus.\",\n",
       "    'The phylogenetic analysis suggests multiple SARS-CoV-2 introductions in Europe or virus evolution during circulation.',\n",
       "    'The phylogenetic analysis suggests multiple SARS-CoV-2 introductions in Europe or virus evolution during circulation.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 2, 1, 3, 1, 1],\n",
       "   'entropy': 1.1935496040981333},\n",
       "  '1mbn5cc5': {'greedy': 'The phylogenetic analysis placed the Italian SARS-CoV-2 strains within the G lineage, distinct from the more prevalent D lineage circulating in Europe and North America at the time.',\n",
       "   'samples': ['The result of the phylogenetic analysis was not specified in the given context. To answer this question accurately, more specific information about the analysis would be required. However, based on common practices, the analysis likely indicated the relationships between the Italian isolates',\n",
       "    'The phylogenetic analysis indicates that the SARS-CoV-2 strains from Italy are closely related to strains from other regions, suggesting a common origin. However, specific details about the exact branch or clade are not provided in the given context.',\n",
       "    'The result of the phylogenetic analysis is not explicitly stated in the given context. To answer this question accurately, more detailed information about the specific findings from the phylogenetic analysis would be required. Based on the provided information, it can only be',\n",
       "    'The result of the phylogenetic analysis is not explicitly stated in the given context. To answer this question accurately, additional information about the specific findings of the phylogenetic analysis would be required. Based on the provided context, no direct result can be',\n",
       "    'The phylogenetic analysis showed that the SARS-CoV-2 isolates from Italy were closely related to other known SARS-CoV-2 strains. However, specific details about unique mutations or sub-lineages are not provided in the given context',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains in a cluster with European and American lineages, separate from the original Wuhan strain. However, specific details about the exact branch or sub-cluster are not provided in the given',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains within cluster IIb, closely related to strains from Europe and the United States. However, specific results are not detailed in the given context.',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains within the same cluster as European strains, suggesting a common origin. However, specific results are not provided in the given context.',\n",
       "    'The phylogenetic analysis indicates the SARS-CoV-2 genomes are closely related to other strains found in Europe and Asia. However, specific details about the exact relationships and branching patterns are not provided in the given context.',\n",
       "    'The result of the phylogenetic analysis is not explicitly stated in the given context. To answer this question accurately, more information about the specific findings from the analysis would be needed. Based on the provided context, it can only be inferred that the sequences'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'yb6if23t': {'greedy': 'The manuscript discusses the phylogenetic relationship with other high-quality samples from The Genome Variation Map (GVM) but does not provide specific results. To answer more precisely, additional information from the study would be needed.',\n",
       "   'samples': ['The manuscript does not provide specific results from the phylogenetic analysis. It only mentions that the phylogenetic relationship with other high-quality samples was discussed. To answer precisely: No specific result is given. The focus was on discussing the relationship rather than',\n",
       "    \"The manuscript does not provide specific results from the phylogenetic analysis of the SARS-CoV-2 genome sequence. It only mentions that the analysis was performed and that the sample's phylogenetic relationship with other high-quality SARS-CoV-\",\n",
       "    'The manuscript discusses the phylogenetic relationship of SARS-CoV-2 with other selected high-quality samples from The Genome Variation Map (GVM) on 2020/03/22. However, specific results of the phy',\n",
       "    'The manuscript discusses the phylogenetic relationship of SARS-CoV-2 with other selected high-quality samples from The Genome Variation Map (GVM) as of 2020/03/22. However, specific results of the',\n",
       "    'The phylogenetic analysis did not provide a specific result as it was mentioned that the genome sequence was discussed in relation to other high-quality samples but no specific findings were reported.',\n",
       "    'The manuscript does not provide specific results from the phylogenetic analysis. It only mentions that the phylogenetic relationship with other high-quality samples from The Genome Variation Map (GVM) was discussed based on the high-quality SARS-CoV-2',\n",
       "    'The manuscript does not provide specific results from the phylogenetic analysis of the SARS-CoV-2 genome sequence. It only mentions that the analysis was performed with other high-quality samples from The Genome Variation Map (GVM) on 20',\n",
       "    'The manuscript does not provide specific results of the phylogenetic analysis. It only mentions that the analysis was performed with other high-quality samples from The Genome Variation Map (GVM) as of 2020/03/22.',\n",
       "    'The phylogenetic analysis demonstrated the relationship between the SARS-CoV-2 sample and other high-quality samples from The Genome Variation Map (GVM) as of 2020/03/22. However, specific details of',\n",
       "    'The manuscript does not provide specific results from the phylogenetic analysis. It only mentions that the phylogenetic relationship with other high-quality samples was discussed. Additional details on the specific findings are not given.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 1, 2, 1, 1, 3, 1],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'p9s0ywtw': {'greedy': 'The result of the phylogenetic analysis is not specified in the given context.',\n",
       "   'samples': ['The result of the phylogenetic analysis is not specified in the given context.',\n",
       "    'The phylogenetic analysis revealed that the SARS-CoV-2 genomes are closely related to each other, indicating a recent common origin. They also showed similarities with strains from Europe and Asia, suggesting early introduction into Italy. However, specific evolutionary relationships',\n",
       "    'The result of the phylogenetic analysis was not specified in the given context.',\n",
       "    'The result of the phylogenetic analysis is not specified in the given context.',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains within the major clade G, sharing a common ancestor with German and French strains.',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains within the European cluster.',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains in a cluster with European and American lineages, distinct from Chinese strains. However, exact results depend on the specific study and analysis methods used. Briefly, it shows the',\n",
       "    'The phylogenetic analysis places the Italian SARS-CoV-2 strains within the European lineage, but not closely related to any known circulating strains at the time.',\n",
       "    'The result of the phylogenetic analysis is not specified in the given context. The context only mentions that the first three complete genomes of SARS-CoV-2 were isolated and characterized but does not provide details about the specific outcomes of the phylogen',\n",
       "    'The phylogenetic analysis placed the Italian SARS-CoV-2 strains in a cluster with strains from Spain, France, and the UK, indicating early spread within Europe. However, the exact result is not specified in the given context.'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 3, 4, 5, 6, 0, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'fofy6whl': {'greedy': 'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β-coronavirus genus along with other bat coronaviruses. The genomic sequences of SARS-CoV-2 isolated during',\n",
       "   'samples': ['The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β-coronavirus genus along with other bat coronaviruses. There was a weak time evolution signal among the genomic sequences of',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belonged to the Sarbecovirus subgenus of β Coronavirus genus along with bat coronaviruses. The genomic sequences of SARS-CoV-2 showed a weak time evolution',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β-coronavirus together with other bat coronaviruses. The genomic sequences of SARS-CoV-2 isolated from the',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β-coronavirus genus along with other bat coronaviruses. It indicated a weak time evolution signal with an average tMR',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β Coronavirus genus along with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/20',\n",
       "    'The phylogenetic tree indicated that SARS-CoV-2 is part of the Sarbecovirus subgenus within the β-coronavirus genus, alongside other bat coronaviruses like BetaCoV/bat/Yunnan/Ra',\n",
       "    'The phylogenetic tree indicated that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β-coronavirus along with other bat coronaviruses such as BetaCoV/bat/Yunnan/RaTG1',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β-coronavirus genus along with other bat coronaviruses like bat coronavirus BetaCoV/bat/Yunnan/Ra',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belonged to the Sarbecovirus subgenus of β-coronavirus genus together with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of β-coronavirus genus, together with bat coronaviruses like BetaCoV/bat/Yunnan/RaTG1'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 3, 4, 3, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'h8abjsxr': {'greedy': 'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, along with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/',\n",
       "   'samples': ['The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, along with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, alongside bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/2',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, together with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, along with bat coronaviruses such as BetaCoV/bat/Yunnan/RaTG1',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belonged to the Sarbecovirus subgenus of β Coronavirus genus together with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/20',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus along with other bat coronaviruses like BetaCoV/bat/Yunnan/RaTG13',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belonged to the Sarbecovirus subgenus of the β Coronavirus genus. It also indicated a weak time evolution signal with an average tMRCA time of 73 days.',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, along with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/',\n",
       "    'The phylogenetic tree showed that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, along with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/',\n",
       "    'The phylogenetic tree indicated that SARS-CoV-2 belongs to the Sarbecovirus subgenus of the β Coronavirus genus, along with bat coronaviruses BetaCoV/bat/Yunnan/RaTG13/'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 0, 1, 3, 0, 0, 1],\n",
       "   'entropy': 1.193549604098133}},\n",
       " '11': {'no': {'greedy': 'Prioritize severe symptoms, recent travel history, age, and underlying conditions. Oxygen levels, respiratory rate, and mental status also considered.',\n",
       "   'samples': ['Prioritize severe symptoms, recent travel history, age, and underlying conditions. Oxygen levels, respiratory rate, and mental status should also be assessed.',\n",
       "    'Assess severity, prioritize acute symptoms, oxygen levels, and risk of complications. Rapidly address critical cases.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, underlying conditions. Oxygen levels, respiratory rate, mental status also considered.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and underlying conditions. Oxygen levels, respiratory rate, and mental status should also be assessed. Rapid testing and isolation of confirmed cases is crucial.',\n",
       "    'Triage involves assessing severity, prioritizing care. Guidelines vary, but generally include: respiratory status, age, chronic conditions, oxygen levels, need for intubation. Prompt isolation, vital sign monitoring crucial. Severe cases get immediate attention.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities. Isolate, assess oxygen levels, provide supportive care, and refer to hospitals if needed. Follow local/public health guidelines.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and underlying health conditions. Provide necessary tests, isolate patients, and manage symptoms. Allocate resources based on urgency and likelihood of recovery.',\n",
       "    'Triage guidelines prioritize based on symptom severity, risk factors, and likelihood of benefit from interventions. Oxygen levels, respiratory rate, and comorbidities are key considerations.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, underlying conditions. Assess oxygen levels, provide support as needed. Isolate patients to prevent spread. Follow local public health guidelines.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 3, 4, 5, 3, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'q4f1pxrf': {'greedy': 'The guidelines for triaging patients infected with coronavirus emphasize prioritizing emergency surgeries for trauma patients while postponing elective surgeries. Patients with suspected or confirmed COVID-19 undergoing emergency surgery should follow a standard protocol for preoperative preparation, intraoperative management, and',\n",
       "   'samples': ['The guidelines recommend a standard protocol addressing preoperative preparation, intraoperative management, and postoperative surveillance to avoid nosocomial infection and ensure patient and healthcare worker safety. These guidelines are issued by the National Health Commission and Chinese Society of Anesthesiology.',\n",
       "    'The guidelines for triaging patients infected with coronavirus emphasize the importance of a standardized protocol for preoperative preparation, intraoperative management, and postoperative surveillance. These guidelines aim to prevent nosocomial infections and ensure patient and healthcare worker safety. Specific protocols are',\n",
       "    'The guidelines for triaging patients infected with coronavirus during the COVID-19 pandemic involve prioritizing emergency surgeries for trauma patients while postponing elective surgeries. Suspected or confirmed COVID-19 patients require a standardized protocol covering preoperative, intraoperative,',\n",
       "    'The guidelines recommend implementing a standard protocol for preoperative preparation, intraoperative management, and postoperative surveillance for patients with suspected or confirmed COVID-19 to avoid nosocomial infection and ensure patient and healthcare worker safety. These protocols are based on guidelines',\n",
       "    'The guidelines for triaging patients infected with coronavirus include a standard protocol for preoperative preparation, intraoperative management, and postoperative surveillance to avoid nosocomial infection and ensure patient and healthcare worker safety. These guidelines are based on recommendations from the National Health',\n",
       "    \"The guidelines for triaging patients infected with coronavirus emphasize prioritizing emergency cases, implementing strict infection control measures, and conducting initial assessments to determine the severity of the patient's condition while minimizing the risk of nosocomial transmission. Preoperative, intraoperative,\",\n",
       "    'The guidelines recommend implementing a standard protocol for preoperative preparation, intraoperative management, and postoperative surveillance for patients with suspected or confirmed COVID-19 to avoid nosocomial infection and ensure patient and healthcare worker safety. No specific detailed triage guidelines',\n",
       "    'The guidelines recommend a standard protocol for preoperative preparation, intraoperative management, and postoperative surveillance for patients with suspected or confirmed COVID-19 undergoing emergency surgeries. These measures aim to prevent nosocomial infection and ensure patient and healthcare worker safety.',\n",
       "    'The guidelines for triaging patients infected with coronavirus during the pandemic emphasize prioritizing emergency surgeries over elective ones. Trauma patients requiring urgent surgical intervention are given priority. Patients with suspected or confirmed COVID-19 undergoing emergency surgery should follow a specific protocol including',\n",
       "    'The guidelines for triaging patients infected with coronavirus, particularly in the context of trauma and emergency surgeries, focus on preoperative preparation, intraoperative management, and postoperative surveillance to prevent nosocomial infections and ensure patient and healthcare worker safety. Specific recommendations'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 2, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'y0ofcfex': {'greedy': 'The guidelines do not specifically detail triage procedures for coronavirus-infected patients. They focus on general preventive measures and adjustments to dental practices to reduce the risk of spreading the virus. For specific triage protocols, refer to healthcare administration documents.',\n",
       "   'samples': [\"The guidelines for triaging patients infected with coronavirus in dental clinics are not explicitly detailed in the provided context. They are expected to align with broader health administration regulations and may include assessing patients' symptoms, medical history, and recent travel or contact history to identify\",\n",
       "    'The guidelines for triaging patients infected with coronavirus in dental clinics include screening patients for symptoms before appointments, conducting temperature checks, and asking about recent travel history and exposure to infected individuals. Patients displaying symptoms or having risk factors should be referred to designated medical facilities',\n",
       "    'The guidelines do not specifically detail procedures for triaging patients infected with coronavirus. They focus on general preventive measures and advice for conducting dental treatments to prevent the spread of the virus. For specific triage procedures, refer to healthcare administration documents.',\n",
       "    'The guidelines provide recommendations for assessing and prioritizing patients based on their potential risk of coronavirus infection, but specific details are not provided in the given context. For exact triage protocols, refer to the full document or local health authority guidelines.',\n",
       "    'The guidelines provide recommendations for triaging patients in dental clinics during the coronavirus pandemic but specific details are not provided in the given context. For precise triage procedures, refer to the full document or expert suggestions.',\n",
       "    'The guidelines provide advice on how dental treatment should be conducted, but specific details on triaging patients infected with coronavirus are not provided in the given context. For detailed triage procedures, refer to local health administration regulations.',\n",
       "    'The guidelines do not specify detailed procedures for triaging patients infected with coronavirus. They focus on general preventive measures and technical guidelines for dental practices during the pandemic. Specific triage protocols should follow local health administration recommendations.',\n",
       "    'The guidelines do not specifically detail procedures for triaging coronavirus-infected patients. They focus on preventing the spread of coronavirus disease 2019 in dental clinics generally. For specific triage protocols, refer to public health authority recommendations.',\n",
       "    'The guidelines do not specify detailed procedures for triaging patients infected with coronavirus. They focus on general prevention and control measures in dental clinics. For specific triage protocols, refer to health administration documents.',\n",
       "    'The guidelines provide advice on how dental treatment should be conducted to prevent the spread of coronavirus, but specific details on triaging infected patients are not mentioned in the provided context. Further information would be needed to address this aspect specifically.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 6, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'o8j1dr8v': {'greedy': 'The guidelines do not specify details on triaging patients infected with coronavirus. They focus on general preventive measures and advice on conducting dental treatments during the pandemic. For specific triage protocols, refer to health administration documents.',\n",
       "   'samples': ['The guidelines do not specifically detail triage procedures for coronavirus-infected patients. They focus on general preventive measures for dental practices during the pandemic. For triage procedures, refer to public health authority guidelines.',\n",
       "    'The guidelines do not provide specific details on triaging patients infected with coronavirus. They focus on general preventive measures and advice on conducting dental treatments. For detailed triage protocols, refer to health administration documents.',\n",
       "    'The guidelines for triaging patients infected with coronavirus are not explicitly stated in the given context. To find this information, you would need to refer to the specific guidelines produced by the experts from the Stomatological Healthcare Service branch of the Chinese Stomatological',\n",
       "    'The guidelines do not specify detailed procedures for triaging coronavirus-infected patients. Instead, they provide general recommendations and emphasize the importance of adhering to local epidemic situations and health administration documents. Specific protocols for patient triage should be followed according to local regulations',\n",
       "    'The guidelines do not specifically detail procedures for triaging patients infected with coronavirus. However, they aim to help dental institutions prevent the spread of the epidemic and may include general recommendations on screening and managing potentially infectious patients. For specific triage procedures, follow local',\n",
       "    'The guidelines do not specify details on triaging patients infected with coronavirus. They focus on preventing the spread of coronavirus disease 2019 in dental clinics generally. Specific triage procedures are likely outlined in separate health administration documents. Dentists are advised',\n",
       "    'The guidelines for triaging patients infected with coronavirus are not specified in the provided context. The given information focuses on general preventive measures for dental clinics rather than specific patient triage protocols. For detailed triage procedures, one would need to refer to the relevant',\n",
       "    'The guidelines provide no specific details on triaging patients infected with coronavirus. They focus on general preventive measures and adjustments to dental procedures to minimize the risk of virus transmission. For detailed triage protocols, one would need to refer to healthcare facility-specific or public',\n",
       "    'The guidelines do not specifically detail procedures for triaging patients infected with coronavirus. They focus on general prevention and control measures in dental clinics. For specific triage protocols, refer to healthcare administration documents.',\n",
       "    'The guidelines for triaging patients infected with coronavirus involve separating such patients from others and providing them with masks and hand hygiene facilities. These patients should not be allowed to enter the waiting area and should use an independent exit/entrance if possible. The staff'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 0, 4, 5, 4, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '7wx4zh5p': {'greedy': 'The guidelines cover standard precautions, performing dialysis therapy for confirmed or suspected cases, performing cohort isolation for contact patients, and disease monitoring and contact surveillance. These guidelines aim to protect patients, healthcare workers, and caregivers from the highly transmissible virus.',\n",
       "   'samples': ['The guidelines focus on infection control measures like standard precautions, managing confirmed or suspected cases, implementing cohort isolation for contacts, and conducting disease monitoring and contact surveillance. However, specific triage protocols are not detailed in the provided context.',\n",
       "    'The guidelines cover standard precautions, dialysis for confirmed/suspected cases, cohort isolation for contacts, and disease/contact monitoring. No specific mention of triage procedures.',\n",
       "    'The guidelines cover standard precautions, performing dialysis therapy for confirmed or suspected cases, performing cohort isolation for contact patients, and disease monitoring and contact surveillance. However, specific details on patient triage are not provided in the given context. For precise triage',\n",
       "    'The provided context does not specify detailed guidelines for triaging patients infected with coronavirus. It focuses on infection control measures within hemodialysis facilities, such as standard precautions, cohort isolation, and disease monitoring. For comprehensive triage guidelines, refer to specialized healthcare',\n",
       "    'The provided context does not specifically outline guidelines for triaging patients infected with coronavirus. The text describes general infection control measures for preventing the spread of COVID-19 in hemodialysis facilities, but does not detail a specific triage protocol. To answer',\n",
       "    'The provided context does not specifically detail guidelines for triaging patients infected with coronavirus in hemodialysis facilities. It focuses on infection control measures and does not provide information on patient triage protocols. For specific triage guidelines, refer to dedicated resources or local',\n",
       "    'The guidelines focus on infection control, including standard precautions, managing confirmed or suspected cases, implementing cohort isolation for contacts, and conducting disease monitoring and contact surveillance. These measures aim to protect patients, healthcare workers, and caregivers from the highly transmissible virus.',\n",
       "    'The guidelines focus on infection control measures such as standard precautions, managing confirmed or suspected cases, implementing cohort isolation for contacts, and conducting disease monitoring and contact surveillance. These measures aim to protect patients, healthcare workers, and caregivers in hemodialysis facilities.',\n",
       "    'The guidelines focus on infection control measures like standard precautions, managing confirmed or suspected cases, implementing cohort isolation for contacts, and conducting disease monitoring and contact surveillance. No specific triage protocol is detailed in the provided context.',\n",
       "    'The guidelines cover standard precautions, managing confirmed or suspected cases, implementing cohort isolation for contacts, and monitoring for disease and contact surveillance. No specific details on triage are provided.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 3, 4, 5, 0, 0],\n",
       "   'entropy': 1.4978661367769952},\n",
       "  'rkfxn14a': {'greedy': 'Prioritize severe symptoms, recent travel history, age, and underlying conditions. Oxygen levels, respiratory rate, and mental status also considered.',\n",
       "   'samples': ['Prioritize severe symptoms, recent travel history, age, and underlying health conditions. Administer oxygen, fluids, and supportive care as needed. Isolate patients to prevent spread. Follow local health authority protocols.',\n",
       "    'Prioritize severe symptoms, recent travel history, and age. Oxygen levels, respiratory rate, and mental status are key. Rapid tests and PCR confirm infection. Isolate positive cases and provide supportive care.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities. Promptly admit high-risk cases to hospitals. Use telemedicine for mild cases. Follow local health authority guidelines.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, underlying health conditions. Assess oxygen levels, provide supportive care, isolate patient. Follow local/public health recommendations.',\n",
       "    'Triage guidelines prioritize severe symptoms, recent travel history, and age. Assess oxygen levels, fever, and respiratory issues. Prioritize ICU for severe cases. Follow local protocols and guidelines.',\n",
       "    'Triage guidelines prioritize severe symptoms, recent travel history, and contact with infected individuals. Assess oxygen levels, fever, and respiratory issues. Prioritize hospitalization for severe cases.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities. Assess oxygen levels and provide supportive care. Isolate patients to prevent spread. Follow local health authority protocols.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, underlying health conditions. Assess oxygen levels, provide supportive care, isolate patients. Follow local/public health recommendations.',\n",
       "    'Assess severity, prioritize critical cases, test, isolate, provide supportive care.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities. Isolate immediately, assess oxygen levels, provide supportive care, and refer to hospital if necessary. Follow local health authority guidelines.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 3, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '0artqu2m': {'greedy': 'Patients can be rapidly assigned into 1 of 3 risk categories based on diagnostic criteria, medical history, clinical symptoms, and laboratory tests to direct the choice of protective materials and/or techniques. Hospitals can adapt this approach to fit their resources.',\n",
       "   'samples': ['The guidelines involve assigning patients to one of three risk categories based on medical history, symptoms, and tests, which directs the choice of protective measures. Patients are quickly categorized to guide protective material or technique selection. Hospitals can tailor these protocols to their resources.',\n",
       "    'Patients are assigned into 1 of 3 risk categories based on medical history, symptoms, and tests, which directs the choice of protective materials/techniques. Hospitals can adapt this approach to fit their resources. Staff should be educated on using high-risk',\n",
       "    'The guidelines involve assigning patients to one of three risk categories based on medical history, symptoms, and lab tests to determine appropriate protective measures.',\n",
       "    'Patients can be rapidly assigned into 1 of 3 risk categories based on diagnostic criteria, medical history, clinical symptoms, and laboratory tests to direct the choice of protective materials and/or techniques. Hospitals can adapt this approach to fit their individual resources.Educ',\n",
       "    'Patients can be rapidly assigned into 1 of 3 risk categories based on diagnostic criteria, including medical history, clinical symptoms, and laboratory tests, to direct the choice of protective materials and/or techniques. The approach allows hospitals to adapt the system to their',\n",
       "    'Patients can be rapidly assigned into 1 of 3 risk categories based on a protocolized approach using diagnostic criteria, medical history, clinical symptoms, and laboratory tests to direct the choice of protective materials and/or techniques. Hospitals can adapt this approach to fit',\n",
       "    'Patients are rapidly assigned into 1 of 3 risk categories based on medical history, symptoms, and lab tests, which directs the choice of protective materials/techniques. Hospitals can adapt the approach to fit their resources. Staff education on proper use of',\n",
       "    'Patients can be rapidly assigned into 1 of 3 risk categories based on medical history, clinical symptoms, and laboratory tests to direct protective measures. Guidelines vary among hospitals but should fit individual resources. Educate staff on using high-risk areas for containment.',\n",
       "    'The guidelines classify patients into 3 risk categories based on medical history, symptoms, and lab tests to direct protective measures.',\n",
       "    'Patients can be rapidly assigned into 1 of 3 risk categories based on a protocolized approach using diagnostic criteria, which directs the choice of protective materials and/or techniques.'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 0, 2, 0, 1, 2, 3],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'h1z8rg9p': {'greedy': 'The guidelines involve assessing symptoms like dyspnoea, dry cough, and fever; using chest X-rays, blood tests, and SARS-CoV-2 viral tests; and creating a fast, reliable, and affordable triaging pathway to assist in',\n",
       "   'samples': ['A fast, reliable, and affordable triaging pathway using clinical assessment, chest X-ray, blood analysis, and SARS-CoV-2 viral identification.',\n",
       "    'A fast, reliable, and affordable triaging pathway that includes clinical assessment, chest X-ray, blood analysis, and identification of SARS-CoV-2 infection.',\n",
       "    '',\n",
       "    'The guidelines involve clinical assessment, chest X-ray, blood analysis, and identifying SARS-CoV-2 infection. Triage aims to quickly and reliably identify patients requiring hospitalization.',\n",
       "    '',\n",
       "    '',\n",
       "    'Clinical assessment, chest X-ray, blood analysis, and SARS-CoV-2 viral infection identification.',\n",
       "    'A triaging pathway focusing on quick, reliable, and affordable methods such as clinical assessment, chest X-ray, blood analysis, and SARS-CoV-2 viral identification is recommended to assist in appropriate patient management during the pandemic.',\n",
       "    'The guidelines include clinical assessment, chest X-ray, blood analysis, and identifying SARS-CoV-2 infection. Fast, reliable, and affordable methods are emphasized for efficient patient sorting.',\n",
       "    'A triaging pathway focusing on clinical assessment, chest X-ray, blood analysis, and viral identification with SARS-CoV-2 aims to efficiently and accurately assess patient needs during the pandemic. This assists in preventing health services from becoming overwhelmed.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 1, 0, 3, 0, 4],\n",
       "   'entropy': 1.4184836619456562},\n",
       "  'ba5x3ysq': {'greedy': 'The guidelines involve assessing symptoms like dyspnoea, dry cough, and fever; using chest X-rays, blood tests, and SARS-CoV-2 viral tests; and creating a fast, reliable, and affordable triaging pathway to assist in',\n",
       "   'samples': ['The triaging pathway includes clinical assessment, chest X-ray, blood analysis, and identifying SARS-CoV-2 infection to appropriately manage patient care and prevent health service overload.',\n",
       "    '',\n",
       "    'Triage involves assessing symptoms (dyspnoea, dry cough, fever), using chest X-rays, blood analysis, and identifying SARS-CoV-2 infection for appropriate care. Aim is fast, reliable, and affordable.',\n",
       "    'Clinical assessment, chest X-ray, blood analysis, and viral identification with SARS-CoV-2.',\n",
       "    'The guidelines involve clinical assessment, chest X-ray, blood analysis, and identifying SARS-CoV-2 infection.',\n",
       "    'A fast, reliable, and affordable triaging pathway involving clinical assessment, chest X-ray, blood analysis, and identification of SARS-CoV-2 infection is recommended. This helps prevent healthcare services from becoming overwhelmed.',\n",
       "    'A fast, reliable, and affordable triaging pathway involving clinical assessment, chest X-ray, blood analysis, and identification of SARS-CoV-2 infection.',\n",
       "    'A triaging pathway is presented that includes clinical assessment, chest X-ray, blood analysis, and viral infection identification using SARS-CoV-2. It aims to be fast, reliable, and affordable to assist health services in managing the pandemic.',\n",
       "    'The guidelines involve assessing symptoms like dyspnoea, dry cough, and fever; using chest X-rays, blood analysis, and viral testing for SARS-CoV-2; aiming for a fast, reliable, and affordable process to assist in managing',\n",
       "    'Triage guidelines involve assessing symptoms like dyspnoea, dry cough, and fever; using chest X-rays, blood tests, and SARS-CoV-2 virus detection; and aiming for a fast, reliable, and affordable process to help manage'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 0, 3, 4, 4, 2, 2],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  '2n3cdspj': {'greedy': 'The guidelines for triaging patients infected with coronavirus include preoperative testing, personal protective equipment recommendations, and a classification system to prioritize cardiac surgery procedures. (Note: This is a brief summary based on the context provided.)',\n",
       "   'samples': ['The guidelines for triaging patients infected with coronavirus include an algorithm for preoperative testing, personal protective equipment recommendations, and a classification system to prioritize cardiac surgery procedures. These guidelines aim to reduce exposure risks and allocate resources appropriately.',\n",
       "    'The guidelines include an algorithm for preoperative testing for coronavirus disease 2019, personal protective equipment recommendations, and a classification system to categorize and prioritize common cardiac surgery procedures.',\n",
       "    'The guidelines include preoperative testing for coronavirus, personal protective equipment recommendations, and a classification system to prioritize cardiac surgery procedures. (Summary based on the provided context.)',\n",
       "    'Preoperative testing algorithm, personal protective equipment recommendations, and a classification system to categorize and prioritize common cardiac surgery procedures.',\n",
       "    'The guidelines for triaging patients infected with coronavirus include preoperative testing, personal protective equipment recommendations, and a classification system to prioritize cardiac surgery procedures. These measures aim to reduce exposure risks and allocate resources appropriately.',\n",
       "    'The guidelines for triaging patients infected with coronavirus include an algorithm for preoperative testing, personal protective equipment recommendations, and a classification system to categorize and prioritize common cardiac surgery procedures. These guidelines aim to reduce the risk of exposure and allocate resources appropriately.',\n",
       "    'The guidelines include an algorithm for preoperative testing, personal protective equipment recommendations, and a classification system to prioritize cardiac surgery procedures.',\n",
       "    'The guidelines for triaging patients infected with coronavirus include preoperative testing, use of personal protective equipment, and a classification system to prioritize cardiac surgery procedures. (Note: The answer has been simplified to be brief while retaining key information.)',\n",
       "    'The guidelines include an algorithm for preoperative testing, personal protective equipment recommendations, and a classification system to prioritize common cardiac surgery procedures.',\n",
       "    'Preoperative testing algorithm, personal protective equipment recommendations, and a classification system to categorize and prioritize common cardiac surgery procedures.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 0, 3, 4, 3, 3],\n",
       "   'entropy': 1.4184836619456562},\n",
       "  'pwu3ait6': {'greedy': 'Prioritize severe symptoms, recent travel history, age, and underlying conditions. Oxygen levels, respiratory rate, and mental status also considered.',\n",
       "   'samples': ['Prioritize severe symptoms, recent travel history, age, and comorbidities. Rapid tests and isolation of confirmed cases. Monitor oxygen levels and provide supportive care.',\n",
       "    'Triage guidelines prioritize severe symptoms, recent exposure, and age. Urgent cases include difficulty breathing, persistent pain or pressure in the chest, new confusion, inability to wake or stay awake, bluish lips or face.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities. Prompt oxygen therapy, ventilatory support if needed. Isolate patients and conduct rapid testing. Follow local public health guidelines.',\n",
       "    'Prioritize severe symptoms, recent travel history, and age. Provide oxygen, hydration, and supportive care. Isolate patients to prevent spread. Follow local health authority protocols.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities. Provide oxygen, fluids, and supportive care. Isolate patients to prevent spread. Follow local and national health authority guidelines.',\n",
       "    'Prioritize severe symptoms, recent travel history, and age. Oxygen levels, respiratory rate, and mental status are key. Hospitalize those at high risk.',\n",
       "    'Prioritize severe symptoms, recent travel history, age, and comorbidities.',\n",
       "    'Triage guidelines prioritize severe symptoms, age, underlying conditions.',\n",
       "    'Assess severity, prioritize acute respiratory distress, oxygen levels, and comorbidities. Rapidly admit severe cases.',\n",
       "    'Triage guidelines prioritize severe symptoms, age, underlying conditions, and likelihood of response to treatment.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 4, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057}},\n",
       " '44': {'no': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn widely in communities.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching respiratory droplets, especially when worn widely in communities. They offer both source control (preventing wearers from spreading the virus) and protection for others. Effectiveness increases with proper use',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets and preventing their release into the air. They also provide some protection when worn by others nearby. However, their effectiveness depends on factors like proper fit, usage, and compliance',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching respiratory droplets, especially when worn consistently and properly. However, their effectiveness varies based on type and usage.',\n",
       "    'Masks significantly reduce the spread of COVID-19 by capturing respiratory droplets and limiting their release into the air. They are effective when used consistently and correctly in combination with other public health measures.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and good hygiene practices. However, their effectiveness',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and decreasing contact with infected droplets. Their effectiveness depends on type, fit, and widespread compliance.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn by infected individuals. They offer moderate protection to the wearer from airborne particles. Combined with other measures, they are effective in controlling outbreaks.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain viruses, protecting both the wearer and others. Their effectiveness depends on type, fit, and consistent use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain virus particles and decreasing contact with infected droplets. Their effectiveness varies based on type, fit, and use. Widespread mask usage can substantially lower transmission rates.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 6],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'a6gaoeie': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets and preventing their release into the air. They also provide some protection against inhalation of viral particles.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn widely in communities.',\n",
       "    'Masks significantly reduce the spread of COVID-19 by catching droplets that contain the virus, thus protecting both the wearer and others. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn correctly and consistently. They offer both source control (preventing wearers from spreading the virus) and protection for others. However, their effectiveness depends on',\n",
       "    'Masks significantly reduce the spread of COVID-19 by catching droplets that contain the virus and blocking entry of virus-containing droplets from others. Their effectiveness varies based on type and usage.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn correctly and consistently. However, their effectiveness varies based on type, fit, and community compliance.',\n",
       "    \"Masks can significantly reduce the spread of COVID-19 by catching infectious droplets and preventing the inhalation of others' droplets. Their effectiveness varies based on type, fit, and usage.\",\n",
       "    'Masks significantly reduce virus transmission by catching droplets and preventing contact. Their effectiveness varies based on type and use. Widespread mask use can greatly lower infection rates.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn correctly and consistently.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 5, 6, 7, 5],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'st7c4v9v': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially during asymptomatic and pre-symptomatic transmission. However, their effectiveness depends on factors such as proper fit, type, and consistent use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus, especially when worn by infected individuals. They also protect the wearer from inhaling viral particles. Effectiveness increases with proper fit and usage. However, masks',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching infectious droplets and preventing contact with mucous membranes. However, their effectiveness depends on type, fit, and proper use. Combined with other preventive measures, they provide substantial protection.',\n",
       "    'Masks significantly reduce the spread of COVID-19 by capturing droplets that contain the virus, thus protecting others. Their effectiveness depends on type and proper use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and decreasing contact with contaminated ones. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and decreasing contact with infected droplets. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus, especially when worn by infected individuals. They offer moderate protection to the wearer as well. However, their effectiveness depends on proper use, fit, and regular',\n",
       "    'Masks significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially during activities like speaking and coughing. They offer both source control and protection for wearers.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing infectious droplets and decreasing contact with surfaces. Their effectiveness depends on type, fit, and community compliance.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. Their effectiveness depends on type, fit, and compliance.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 5, 6, 7, 4],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'vtxu50wz': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus and preventing others from inhaling them. However, their effectiveness depends on proper use, type of mask, and combination with other防控措施。简而言之',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus, especially when worn by infected individuals. They offer moderate protection to the wearer from inhaling particles.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and decreasing exposure to them. Their effectiveness depends on type, fit, and consistent use.',\n",
       "    'Masks significantly reduce virus transmission by catching droplets, though their effectiveness varies with type and use.',\n",
       "    'Masks significantly reduce the spread of COVID-19 by capturing droplets, especially during speaking or breathing. They offer both source control and protection to wearers.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus, especially when worn by infected individuals.',\n",
       "    \"Masks can significantly reduce the spread of COVID-19 by catching infectious droplets and preventing the inhalation of others' droplets. Their effectiveness depends on type, fit, and compliance.\",\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn consistently and properly.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and blocking entry of viral-laden droplets. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and reducing contact with infected droplets. Their effectiveness depends on type, fit, and community compliance.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 1, 2, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'vkex8le2': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus, especially when worn consistently and properly.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and decreasing exposure to others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets and limiting their release into the environment. They are most effective when combined with other preventive measures like social distancing and hand hygiene.',\n",
       "    \"Masks can significantly reduce the spread of COVID-19 by catching infectious droplets and preventing the inhalation of others' droplets. However, their effectiveness depends on factors such as type, fit, and proper usage.\",\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. However, their effectiveness depends on factors like proper fit, material, and consistent use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching respiratory droplets, especially when worn widely in communities. They offer moderate to high protection when used with other防控措施。答案：口罩在广泛使用时能在社区层面显著减少COVID',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other measures like social distancing and good hygiene. However, their effectiveness varies based',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus, especially when worn by infected individuals. They offer moderate protection to the wearer as well. Combined with other measures, they are highly effective.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn widely in communities. They offer both source control and protection for the wearer. However, their effectiveness depends on proper use, type of mask, and adherence',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus, especially when worn consistently and properly. They are most effective when combined with other preventive measures like social distancing and hand hygiene.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '8je46886': {'greedy': 'Masks can reduce transmission of SARS-CoV-2. The evidence supports widespread use of nonmedical cloth masks to prevent the spread of COVID-19.',\n",
       "   'samples': ['Masks can reduce the transmission of SARS-CoV-2 when used widely, though their effectiveness may vary depending on type, fit, and other factors. Widespread use of nonmedical cloth masks has been recommended by many authorities to help prevent the',\n",
       "    'Masks can help reduce transmission by trapping droplets that contain the virus, though their effectiveness varies based on type and use.',\n",
       "    'Masks can reduce the transmission of SARS-CoV-2 when used consistently and properly. However, their effectiveness varies based on factors like mask type, fit, and adherence to guidelines. Widespread use of nonmedical cloth masks has been recommended by',\n",
       "    'Masks can reduce transmission of SARS-CoV-2. (Brief)',\n",
       "    'Masks can reduce transmission of SARS-CoV-2. The evidence supports widespread use of nonmedical cloth masks. Their effectiveness may vary depending on factors like fit, type of material, and frequency of replacement. Mask usage, when combined with other防控',\n",
       "    'Masks can reduce transmission, according to the article. (Shortened version) Masks help prevent spread.',\n",
       "    'Masks can reduce transmission of SARS-CoV-2.',\n",
       "    'Masks can help reduce the spread of COVID-19 when used widely.',\n",
       "    'Masks can reduce transmission of SARS-CoV-2. Impact varies based on type and use of mask.',\n",
       "    'Masks can help reduce the spread of COVID-19 by catching particles exhaled by the wearer and preventing others from inhaling them. The effectiveness depends on factors like mask quality and usage.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 4, 6, 4, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  '8t8psk46': {'greedy': 'Masks can be an important element in reducing virus transmission, but their effectiveness depends on proper usage and other measures like physical distancing. The exact impact varies based on context and implementation.',\n",
       "   'samples': ['Masks can be an important element in reducing virus transmission. However, their effectiveness should not be overestimated, as other measures like physical distancing also play a significant role. The exact impact varies depending on usage, type of mask, and adherence to guidelines.',\n",
       "    'Masks can be an important element in reducing virus transmission when used as part of a full suite of epidemiological tools, but their effectiveness may be overestimated if physical distancing is not also considered. The exact impact varies based on usage and other factors.',\n",
       "    'Masks can be an important element in reducing virus transmission. Their effectiveness depends on widespread use and other measures like physical distancing. The exact impact varies based on context and implementation.',\n",
       "    'Masks can be an important element in reducing virus transmission when used as part of a full suite of epidemiological tools, but their effectiveness can be misattributed to other measures like physical distancing. The exact impact varies based on adherence and other factors.',\n",
       "    'Masks can be an important element in reducing virus transmission. However, their effectiveness should not be overemphasized without considering other preventive measures like physical distancing. The exact impact varies based on factors such as mask quality and usage adherence. More research is needed',\n",
       "    'Masks can be an important element in reducing virus transmission, but their impact is not the sole factor in preventing the spread of COVID-19. Physical distancing also plays a crucial role.',\n",
       "    'Masks can be an important element in reducing virus transmission. The exact impact varies based on usage and other factors. Physical distancing remains crucial as well.',\n",
       "    'Masks can be an important element in reducing virus transmission. However, their effectiveness should not be overstated, as physical distancing also plays a crucial role. Both measures are needed for optimal protection.',\n",
       "    'Masks can be an important element in reducing virus transmission when used as part of a full suite of epidemiological tools, but they are not sufficient on their own to prevent the spread of COVID-19. Physical distancing remains crucial.',\n",
       "    'Masks can be an important element in reducing virus transmission when used as part of a full suite of epidemiological tools, but their effectiveness is often misattributed to physical distancing measures. Physical distancing remains crucial for limiting COVID-19 transmission.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 0, 6, 5, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'e3icgsl9': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn in conjunction with other防控措施。请注意，简体中文版本的答案稍微扩展了一些内容以更符合中文表达习惯。英文答案保持简洁。MASK',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus and limiting their release into the air. They offer moderate to high protection when used correctly in combination with other preventive measures.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and reducing contact with infected droplets. Effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching respiratory droplets and preventing them from reaching others. However, their effectiveness depends on factors like mask quality, proper fit, and consistent usage.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets and limiting their release, especially from asymptomatic carriers. They should be worn in conjunction with other measures like social distancing and hand hygiene. Effectiveness varies based on type and fit',\n",
       "    \"Masks can significantly reduce the spread of COVID-19 by catching infectious droplets and preventing the inhalation of others' droplets. Effectiveness varies based on type and use.\",\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus and decreasing exposure to such droplets. Effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets and limiting their release into the air. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene. Their effectiveness varies based on type (e',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, though their effectiveness varies with type and use.',\n",
       "    'Masks significantly reduce virus transmission when worn correctly and used in combination with other preventive measures.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '702cq6to': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks significantly reduce the spread of COVID-19 by catching infectious droplets and reducing contact with infected ones. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus, especially when worn by infected individuals. They are most effective when combined with other measures like social distancing and hand hygiene.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing the inhalation of infectious particles. However, their effectiveness depends on factors such as type, fit, and community adherence.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching respiratory droplets that contain the virus.',\n",
       "    \"Masks can significantly reduce the spread of COVID-19 by catching infectious droplets and preventing the inhalation of others' droplets. Their effectiveness depends on type, fit, and usage.\",\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing respiratory droplets, especially when worn consistently and properly.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing the inhalation of infected droplets. However, their effectiveness depends on factors like type, fit, and community adherence.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus and preventing them from reaching others. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus, especially when worn widely in communities. However, their effectiveness depends on factors such as proper fit, use, and adherence.',\n",
       "    'Masks significantly reduce the spread of COVID-19 by capturing droplets that contain viruses and decreasing the number of unmasked individuals exposed to such droplets.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 2, 5, 6, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  '84asc8do': {'greedy': 'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing them from reaching others. They are most effective when used in combination with other preventive measures like social distancing and hand hygiene.',\n",
       "   'samples': ['Masks can significantly reduce the spread of COVID-19 by catching respiratory droplets, especially for those who are asymptomatic or pre-symptomatic.',\n",
       "    'Masks significantly reduce virus transmission when worn consistently and properly, especially in combination with other precautions. They are most effective for source control, protecting others from the wearer.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain the virus, especially when worn consistently and properly. However, their effectiveness varies based on type (e.g., N95 vs. cloth) and usage.',\n",
       "    'Masks significantly reduce virus transmission when worn consistently, especially in combination with other measures like social distancing and hand hygiene.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and preventing their release into the air. They also protect the wearer from inhaling infectious droplets. However, their effectiveness depends on factors such as type of',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing droplets that contain viruses and preventing contact with mucous membranes. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching droplets that contain the virus and reducing contact with others. Effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by capturing infectious droplets and decreasing exposure to them.',\n",
       "    'Masks significantly reduce the spread of COVID-19 by catching droplets that contain viruses and blocking contact with infected droplets. Their effectiveness varies based on type and use.',\n",
       "    'Masks can significantly reduce the spread of COVID-19 by catching infectious droplets and reducing contact with infected surfaces. Effectiveness varies based on type and use.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'yx9oa2ra': {'greedy': 'Face masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "   'samples': ['Masks reduce the daily growth rate of reported infections by around 40%. This translates to a reduction in the cumulative number of registered COVID-19 cases between 2.3% and 13% over 10 days.',\n",
       "    'Face masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "    'Face masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "    'Face masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "    'Face masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "    'Masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "    'Face masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "    'Masks reduce the daily growth rate of reported infections by around 40%.',\n",
       "    'Masks reduce the daily growth rate of reported infections by around 40%. According to the study using the synthetic control method, face masks are estimated to decrease the cumulative number of registered COVID-19 cases by 2.3% to 1',\n",
       "    'Masks reduce the daily growth rate of reported infections by around 40%.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 0, 1, 0, 2, 2],\n",
       "   'entropy': 1.0296530140645734}},\n",
       " '10': {'no': {'greedy': 'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "   'samples': ['Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing measures have significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 0, 0, 1, 0, 1, 0],\n",
       "   'entropy': 0.6931471805599453},\n",
       "  '0ufwlw87': {'greedy': 'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "   'samples': ['Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 0, 0, 0, 0, 1, 0],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'uwix8ftr': {'greedy': 'Yes, social distancing measures have been effective in slowing the spread of COVID-19 according to the analysis.',\n",
       "   'samples': ['Yes, social distancing measures have been effective in slowing the spread of COVID-19 according to the analysis. The model used suggests that these measures can reduce the epidemic size and delay the peak of the outbreak.',\n",
       "    'Yes, according to the analysis using a log-linear model, social distancing measures have been effective in slowing the spread of COVID-19 in Turkey.',\n",
       "    'Yes, social distancing measures have been shown to help slow the spread of COVID-19. According to the analysis in the given context, these measures can reduce the epidemic size and extend the time until the peak of the outbreak. However, it is',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19 according to the analysis.',\n",
       "    'Yes, according to the analysis, social distancing measures have been effective in slowing the spread of COVID-19 in Turkey.',\n",
       "    'Yes, according to the analysis, social distancing measures have slowed the spread of COVID-19 in Turkey.',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19 according to the analysis.',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19 according to the analysis.',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19 according to the analysis. The study using a log-linear model found that these measures can reduce the epidemic size and delay the peak. However, serious adherence to these measures',\n",
       "    'Yes, according to the analysis using a log-linear model, social distancing measures have been effective in slowing the spread of COVID-19 in Turkey. The study suggests that these measures can reduce the epidemic size and delay the peak of the outbreak. However'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 3, 0, 0, 4, 5],\n",
       "   'entropy': 1.4978661367769952},\n",
       "  'yv3x3g4u': {'greedy': 'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "   'samples': ['Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing measures have significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 0, 0, 0, 1, 1],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'trn2deod': {'greedy': 'Yes, social distancing has been shown to slow the spread of SARS-CoV-2 in a cohort of young, healthy adults.',\n",
       "   'samples': ['Yes, social distancing can slow the spread of SARS-CoV-2 in a cohort of young, healthy adults according to the study.',\n",
       "    'Yes, social distancing can slow the spread of SARS-CoV-2 and prevent the outbreak of COVID-19 in young, healthy adults.',\n",
       "    'Yes, social distancing can slow the spread of SARS-CoV-2 in a cohort of young, healthy adults according to the study.',\n",
       "    'Yes, social distancing has been shown to slow the spread of SARS-CoV-2 and prevent the outbreak of COVID-19 in a cohort of young, healthy adults.',\n",
       "    'Yes, social distancing can slow the spread of SARS-CoV-2 and prevent the outbreak of COVID-19.',\n",
       "    'Yes, social distancing has been shown to slow the spread of SARS-CoV-2 and prevent the outbreak of COVID-19 in young, healthy adults.',\n",
       "    'Yes, social distancing has been shown to slow the spread of SARS-CoV-2 and prevent the outbreak of COVID-19 in young, healthy adults.',\n",
       "    'Yes, social distancing has been shown to slow the spread of SARS-CoV-2 in young, healthy adults.',\n",
       "    'Yes, social distancing has been shown to slow the spread of SARS-CoV-2 in young, healthy adults.',\n",
       "    'Yes, social distancing can slow the spread of SARS-CoV-2 in a cohort of young, healthy adults.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 2, 3, 3, 4, 4, 5],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  'cb5ebiiv': {'greedy': 'Yes, social distancing has been effective in reducing the transmission of influenza-like illnesses, including COVID-19. Counties with larger decreases in mobility experienced greater reductions in fevers. However, New York City and its immediate vicinity were exceptions. The effectiveness align',\n",
       "   'samples': ['Yes, social distancing has been effective in reducing the transmission of influenza-like illnesses, including COVID-19. Reducing mobility in counties with confirmed cases led to subsequent reductions in fever incidences. However, the impact was more significant in some areas than',\n",
       "    'Yes, social distancing has been effective in reducing the transmission of influenza-like illnesses, including COVID-19. Reductions in mobility led to decreases in fever incidences after a lag consistent with the incubation period of COVID-19. Counties with',\n",
       "    'Yes, social distancing has been shown to reduce the transmission of influenza-like illnesses, including COVID-19. Counties with larger decreases in mobility experienced greater reductions in fevers. However, this was not the case for New York City and its immediate vicinity',\n",
       "    'Yes, social distancing has been effective in reducing the transmission of influenza-like illnesses, including COVID-19, based on the observed reduction in fever incidences following decreased mobility.',\n",
       "    'Yes, social distancing has been shown to reduce the transmission of influenza-like illnesses, including COVID-19, based on the observed reduction in fever incidences following decreases in mobility.',\n",
       "    'Yes, social distancing has been shown to reduce the transmission of influenza-like illnesses, including COVID-19. Counties with larger decreases in mobility experienced greater reductions in fevers. However, this was notably less effective in New York City and its immediate vicinity',\n",
       "    'Yes, social distancing has been effective in reducing the transmission of influenza-like illnesses, including COVID-19, based on the reduction in fever incidences observed after a lag of about 6.5 days. Counties with more significant decreases in mobility saw',\n",
       "    'Yes, social distancing has been effective in reducing the transmission of influenza-like illnesses, including COVID-19. Counties with larger decreases in mobility experienced greater reductions in fevers.',\n",
       "    'Yes, social distancing has been effective in reducing the transmission of influenza-like illnesses, including COVID-19. Counties with larger decreases in mobility experienced greater reductions in fevers. However, this was not observed in New York City and its immediate vicinity.',\n",
       "    'Yes, social distancing has reduced the transmission of influenza-like illnesses, including COVID-19. Counties with larger decreases in mobility experienced greater reductions in fevers. This supports the effectiveness of social distancing as a strategy for slowing the spread of COVID-1'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 2, 4, 5, 5, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'kk38cfli': {'greedy': 'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "   'samples': ['Yes, social distancing measures have been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 2, 1, 2, 1, 2],\n",
       "   'entropy': 1.0549201679861442},\n",
       "  '7t3ci8tl': {'greedy': 'Yes, social distancing has likely contributed to reducing transmission in South Korea. However, transmission may still persist in some regions.',\n",
       "   'samples': ['Yes, social distancing has likely contributed to reducing transmission in South Korea. However, transmission may still be ongoing in some areas.',\n",
       "    'Yes, social distancing has likely contributed to reducing transmission in South Korea.',\n",
       "    'Yes, social distancing has likely contributed to reducing transmission in South Korea.',\n",
       "    'Yes, social distancing likely contributed to reducing transmission in South Korea.',\n",
       "    'Yes, social distancing has likely contributed to reducing transmission in South Korea. However, transmission may still persist in some regions.',\n",
       "    'Yes, social distancing has likely impacted reducing transmission in South Korea. However, transmission may still be persisting in some regions.',\n",
       "    'Yes, social distancing has likely impacted the reduction of transmission in South Korea. However, transmission may still persist in some regions.',\n",
       "    'Yes, social distancing has likely contributed to reducing transmission in South Korea. However, transmission may still be present in some regions.',\n",
       "    'Yes, social distancing has likely contributed to reducing transmission in South Korea. However, transmission may still be ongoing in some areas.',\n",
       "    'Yes, social distancing likely contributed to reducing transmission in South Korea. However, transmission may still persist in some regions.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 0, 2, 0, 0, 1],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  't7p2j504': {'greedy': 'Yes, robust and timely social distancing measures have had a significant impact on containing the spread of the COVID-19 virus.',\n",
       "   'samples': ['Yes, robust and timely social distancing measures have had a significant impact on containing the spread of the COVID-19 virus.',\n",
       "    'Yes. Robust and timely social distancing measures have been effective in containing the spread of the COVID-19 virus.',\n",
       "    'Yes, robust and timely social distancing has had a significant impact on containing the spread of the COVID-19 virus.',\n",
       "    'Yes, robust and timely social distancing measures have had a significant impact on containing the spread of the COVID-19 virus.',\n",
       "    'Yes, robust and timely social distancing measures have had a significant impact on containing the spread of the COVID-19 virus.',\n",
       "    'Yes. Robust and timely social distancing has had the most effect in containing the spread of the COVID-19 virus.',\n",
       "    'Yes, robust and timely social distancing measures have had a significant impact on containing the spread of the COVID-19 virus.',\n",
       "    'Yes, robust and timely social distancing has had a significant impact on containing the spread of the COVID-19 virus.',\n",
       "    'Yes. Robust and timely social distancing has the most effect in containing the spread of the COVID-19 virus.',\n",
       "    'Yes, robust and timely social distancing has had a significant impact on containing the spread of the COVID-19 virus.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 0, 1, 0, 1, 2, 1],\n",
       "   'entropy': 0.9433483923290391},\n",
       "  'zyaac52r': {'greedy': 'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "   'samples': ['Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing measures have been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.',\n",
       "    'Yes, social distancing has been effective in slowing the spread of COVID-19.',\n",
       "    'Yes, social distancing has significantly slowed the spread of COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 2, 2, 0, 2, 0, 2],\n",
       "   'entropy': 0.9433483923290393},\n",
       "  'h62xj47p': {'greedy': 'Yes, social distancing measures have had a significant impact on slowing the spread of COVID-19. The measures reduced the daily growth rate of confirmed cases by an average of 5.4 percentage points within the first few days and up to 9',\n",
       "   'samples': ['Yes, social distancing measures have had a significant impact on slowing the spread of COVID-19. The implementation of these measures led to a reduction in the daily growth rate of confirmed cases. Specifically, the adoption of government-imposed social distancing measures was',\n",
       "    'Yes, social distancing measures had a significant impact on slowing the spread of COVID-19. According to the study, these measures reduced the daily growth rate of confirmed cases by an average of 5.4 percentage points within the first few days,',\n",
       "    'Yes, social distancing measures have been effective in reducing the daily growth rate of confirmed COVID-19 cases. The reduction ranged from 5.4 percentage points to 9.1 percentage points after different durations of implementation. Without these measures, the',\n",
       "    'Yes, social distancing measures had a significant impact on slowing the spread of COVID-19. The measures reduced the daily growth rate of confirmed cases by 5.4 percentage points after one to five days, increasing to 9.1 percentage points',\n",
       "    'Yes, social distancing measures had a significant impact on slowing the spread of COVID-19. The measures reduced the daily growth rate of confirmed cases by 5.4 to 9.1 percentage points depending on the duration after implementation. Without these',\n",
       "    'Yes, social distancing measures have had a significant impact on slowing the spread of COVID-19. These measures reduced the daily growth rate of confirmed cases by an average of 5.4 percentage points within the first few days, and up to',\n",
       "    'Yes, social distancing measures have had a significant impact on slowing the spread of COVID-19. The measures reduced the daily growth rate of confirmed cases by an average of 5.4 percentage points within the first week and up to 9.',\n",
       "    'Yes, social distancing measures have had a significant impact on slowing the spread of COVID-19. The implementation of these measures reduced the daily growth rate of confirmed cases by up to 9.1 percentage points after several days. Without these interventions,',\n",
       "    'Yes, social distancing measures had a significant impact on slowing the spread of COVID-19. According to the evaluation, these measures reduced the daily growth rate of confirmed cases by substantial percentages over time.',\n",
       "    'Yes, social distancing measures had a significant impact on slowing the spread of COVID-19. The measures reduced the daily growth rate of confirmed cases by 5.4 to 9.1 percentage points depending on the duration after implementation.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 3, 3, 2, 4, 2],\n",
       "   'entropy': 1.3592367006650063}},\n",
       " '27': {'no': {'greedy': 'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit the virus than symptomatic individuals, but they can still play a role in its spread',\n",
       "   'samples': ['Asymptomatic individuals with COVID-19 can still spread the virus to others, although the risk may be lower than in symptomatic cases. Their viral load may be lower and they typically shed the virus for a shorter duration.',\n",
       "    'Asymptomatic COVID-19感染者通常没有症状，但仍可能具有传染性。他们可以在不知情的情况下传播病毒。关于他们的具体信息，包括感染后的长期影响和体内病毒载量等仍在研究中。 Asympt',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may test positive for the virus and can contribute to community transmission. The proportion of asymptomatic cases is estimated to be',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. They are less likely to transmit it than symptomatic people but can play a role in viral spread. Research suggests asymptomatic transmission',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they do not show symptoms. Research suggests that asymptomatic transmission can play a significant role in the spread of the virus.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit the virus compared to symptomatic individuals but can still play a role in the spread.',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. Research suggests that asymptomatic transmission can contribute to the spread of the virus.',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, even though they do not show symptoms. Their infectious period and likelihood of transmitting the virus may vary. Some studies suggest asymptomatic individuals may be less likely to spread',\n",
       "    'Asymptomatic COVID-19感染者通常没有症状，但仍可能传播病毒。关于他们的一些已知信息包括：可以检测到病毒RNA，具有传染性，但传染性通常低于有症状的个体。尽管如此，他们的',\n",
       "    'Asymptomatic COVID-19感染者通常没有明显症状，但仍可能传播病毒。他们可以在不知情的情况下传染他人。关于这些人的具体信息，包括其传染性、免疫反应等仍在研究中。 Asymptomatic individuals'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 4, 3, 5, 4],\n",
       "   'entropy': 1.6434177197931799},\n",
       "  'ls6cdive': {'greedy': 'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit the virus compared to symptomatic individuals, but they can still play a role in its',\n",
       "   'samples': ['Asymptomatic individuals with COVID-19 can still transmit the virus to others, though the extent of their role in spreading the disease is debated. Studies suggest they contribute to transmission but may be less effective than symptomatic cases.',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, though the risk may be lower compared to symptomatic cases. They often have low viral loads and might transmit the virus unknowingly.',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit it than symptomatic people but can contribute to the spread, especially if they unknowingly infect',\n",
       "    'Asymptomatic COVID-19感染者通常没有明显症状，但仍可能具有传染性。研究表明，他们可以在不知情的情况下传播病毒。了解更多关于他们的信息对于制定有效的公共卫生策略至关重要。',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, though the extent of transmission is not fully understood. They may be less likely to spread the virus than symptomatic individuals. More research is needed to better understand asympt',\n",
       "    'Asymptomatic COVID-19 cases can still spread the virus to others, although their infectious period may be shorter. They often have lower viral loads and might not test positive in some tests. More research is needed to fully understand asymptomatic transmission',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, even if they show no symptoms. Their viral loads may be lower compared to symptomatic individuals. Research suggests that asymptomatic cases contribute to the spread of the virus',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, though the extent of transmission varies. They may test positive without showing symptoms like fever, cough, or shortness of breath. Regular testing and contact tracing help manage',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, though their infectiousness may be lower compared to symptomatic cases. They show no symptoms but can test positive for the virus. Studies suggest that asymptomatic传播',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, although the risk may be lower than in symptomatic cases. They often have low levels of the virus and may not show symptoms due to their immune system effectively'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 0, 6, 0, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'hv0cwf6d': {'greedy': 'Many patients with COVID-19 are asymptomatic or have only mild symptoms, but they can still transmit the virus to others. Screening for asymptomatic infections is challenging, making prevention and control more difficult.',\n",
       "   'samples': ['Many patients with COVID-19 are asymptomatic or have only mild symptoms, but they can still transmit the virus to others. Screening for asymptomatic infections is challenging.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms, yet they can still transmit the virus to others. Screening for these asymptomatic cases poses a challenge in national prevention and control efforts.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can transmit the virus to others, posing challenges in prevention and control efforts due to difficulties in screening. These individuals may not show symptoms but still carry and spread the virus.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms, but they can still transmit the virus to others. Asymptomatic infections pose difficulties in screening and controlling the epidemic.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. Screening for asymptomatic infections is challenging, making it harder to control the epidemic.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can transmit the virus, making screening challenging. They may still develop symptoms later.',\n",
       "    \"Many patients with COVID-19 are asymptomatic or have only mild symptoms, yet they can still transmit the virus to others. Screening for these asymptomatic infections is challenging, complicating national prevention and control efforts. Asymptomatic individuals' characteristics\",\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms, yet they can still transmit the virus to others. Asymptomatic infections pose challenges in screening and controlling the epidemic.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. It is challenging to screen for these asymptomatic infections, complicating national prevention and control efforts.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. Asymptomatic infections make screening and controlling the epidemic more challenging.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  'xz6pq0v3': {'greedy': 'Many patients with COVID-19 are asymptomatic or have only mild symptoms, but they can still transmit the virus to others. Screening for asymptomatic infections is challenging, making prevention and control of the epidemic more difficult.',\n",
       "   'samples': ['Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. Asymptomatic infections make it difficult to screen and control the spread of the virus.',\n",
       "    'Asymptomatic individuals with COVID-19 can transmit the virus to others despite not showing symptoms. They pose challenges in screening efforts and epidemic prevention. The article discusses their characteristics, treatment, and outcomes to aid in early prevention and control.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. It is challenging to screen for these asymptomatic infections, making prevention and control more difficult.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms, yet they can still transmit the virus to others. Asymptomatic infections pose challenges for screening and controlling the epidemic.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms, but they can still transmit the virus to others. Asymptomatic infections pose challenges in screening and controlling the epidemic.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. Screening for asymptomatic infections is challenging, complicating national prevention and control efforts.',\n",
       "    'Asymptomatic individuals with COVID-19 can transmit the virus, making screening challenging. They often have mild symptoms or no symptoms at all.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms, yet they can still transmit the virus to others. Screening for these asymptomatic infections is challenging, complicating national prevention and control efforts.',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. It is challenging to screen for these asymptomatic infections, making national prevention and control more difficult. Asymptomatic individuals can play',\n",
       "    'Many patients with COVID-19 are asymptomatic or have only mild symptoms but can still transmit the virus to others. It is challenging to screen for these asymptomatic infections, complicating national prevention and control efforts.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.639031859650177},\n",
       "  'qbjtm2uf': {'greedy': 'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit the virus than symptomatic individuals, but they can still play a role in its spread',\n",
       "   'samples': ['Asymptomatic individuals infected with COVID-19 can still spread the virus to others, although their risk of severe illness is lower. They may be less likely to seek testing or medical care. Ongoing research continues to explore the prevalence and significance',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, though the risk may be lower than for symptomatic cases. They often have lower viral loads and can go undetected. More research is needed to fully understand',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, although the risk may be lower than in symptomatic cases. Their viral loads may vary, and they can play a role in community spread.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, although the risk may be lower than for symptomatic cases. They have no symptoms but can test positive for the virus. Research suggests that a significant portion of',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. They often have lower viral loads and may be less likely to transmit the virus over a longer period compared to symptomatic individuals.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others. They may not show symptoms but can have infectious viral loads. Studies suggest a significant portion of transmissions occur from asymptomatic or pre-symptomatic people.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, although their risk of severe illness is lower.',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, though their role in spread may be less compared to symptomatic cases.',\n",
       "    'Asymptomatic COVID-19感染者通常没有症状，但仍可能具有传染性。他们可以将病毒传播给他人，尽管风险可能较低。关于这些人对公共卫生的影响以及如何识别和管理他们，仍在研究中。一些研究表明',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others. They may not show symptoms but can have viral loads similar to symptomatic cases. Research suggests asymptomatic transmission plays a role in the spread of the virus.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 5, 6, 6, 3],\n",
       "   'entropy': 1.8343719702816237},\n",
       "  '5ha2ryv2': {'greedy': 'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit the virus compared to symptomatic individuals, but they can still play a role in its',\n",
       "   'samples': ['Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, though the risk may be lower compared to symptomatic cases. They show no symptoms but can have detectable viral loads. Ongoing research continues to explore their',\n",
       "    \"Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. They often have lower viral loads but can be contagious. Research suggests that asymptomatic cases contribute to the virus's rapid transmission.\",\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, even if they show no symptoms. Their viral load can be similar to those who have symptoms. Research suggests asymptomatic transmission plays a significant role in the spread of',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. Their viral load may be lower than symptomatic individuals. Studies suggest that asymptomatic transmission plays a significant role in the spread of',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, though their role in spreading the disease is generally considered lower than that of symptomatic cases.',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, though their risk of severe illness is lower. Their viral load may be lower and they might be less contagious. More research is needed to fully understand asymptomatic transmission',\n",
       "    'Asymptomatic COVID-19感染者通常没有症状，但仍可能传播病毒。他们可以在不知情的情况下将病毒传染给他人。关于他们的具体信息仍在研究中。 翻译：Asymptomatic COVID-19',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, although the risk may be lower than for symptomatic cases. Their viral load can vary and they might develop symptoms later. Regular testing and precautions are advised to',\n",
       "    'Asymptomatic COVID-19 individuals show no symptoms but can still spread the virus.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, though the extent of their contribution to spread is debated. They may be less likely to spread the virus compared to symptomatic individuals.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 0, 5, 2, 6],\n",
       "   'entropy': 1.8866967846580782},\n",
       "  'pgtvx6wb': {'greedy': 'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated by a familial cluster where two individuals contracted the virus after contact with three others who had returned from Wuhan. This indicates that asymptomatic individuals',\n",
       "   'samples': ['Asymptomatic carriers of COVID-19 can still transmit the virus during the incubation period, as demonstrated by a familial cluster where two individuals contracted the virus after contact with others who had returned from Wuhan. One case showed signs of severe',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated by a familial cluster where two individuals who had not traveled to Wuhan became infected after contact with three family members who had returned from Wuhan',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated by a familial cluster where individuals who had not traveled to Wuhan still contracted the virus after contact with others who had returned from Wuhan.',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated in a familial cluster where two individuals contracted the virus after contact with three others who had returned from Wuhan.',\n",
       "    'It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated in this study where individuals who had not traveled to Wuhan still contracted the virus after contact with symptomatic family members who had returned from Wu',\n",
       "    'Asymptomatic carriers of COVID-19 can still transmit the virus, as demonstrated in this familial cluster where two individuals contracted the virus after contact with three others who had returned from Wuhan. Asymptomatic carriers can spread the virus during',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as evidenced by a family cluster where two individuals who had not traveled to Wuhan contracted the virus after contact with three family members who had returned from Wu',\n",
       "    'Asymptomatic carriers of COVID-19 can still transmit the virus during the incubation period, as evidenced by this case study where individuals who had not traveled to Wuhan contracted the virus after coming into contact with family members who had returned from',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated in this study where two family members who had not traveled to Wuhan became infected after contact with three other family members who had returned from Wu'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 2, 1, 1, 2, 2],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'qlir6keq': {'greedy': 'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit the virus than symptomatic individuals, but they can still play a role in its spread',\n",
       "   'samples': ['Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, though the extent of transmission varies. They show no symptoms but can test positive for the virus. Studies suggest a significant proportion of infections may be asymptomatic or',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others. They may test positive for the virus but show no symptoms of illness. Studies suggest a significant proportion of infections may be asymptomatic or pre-symptomatic',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. Their viral load can be similar to symptomatic individuals. Regular testing and contact tracing are important in controlling transmission.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may test positive for the virus and contribute to its transmission. Research suggests that asymptomatic cases account for a significant portion',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, though the extent and duration of their infectivity may differ from symptomatic cases. They often have lower viral loads and may be less likely to spread the virus.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others. They show no symptoms but can carry and spread the SARS-CoV-2 virus. The extent of viral shedding and duration vary among asymptomatic cases.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, though the risk may be lower than for symptomatic cases. Studies suggest that a significant proportion of infections occur from asymptomatic or pre-symptomatic individuals',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others. They show no symptoms but can test positive for the virus. The proportion of asymptomatic cases varies, but many studies suggest it is significant. Quarantine measures',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. They are believed to be less infectious than symptomatic individuals. More research is needed to fully understand the role of asymptomatic transmission',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, though their role in spread may be less than symptomatic cases. Research suggests asymptomatic传播者的作用可能较小。关于无症状感染者的更多信息，目前'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 3, 4, 0, 5, 6],\n",
       "   'entropy': 1.7480673485460891},\n",
       "  'rvzv8s7t': {'greedy': 'Asymptomatic individuals with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit it, but precautions should still be taken.',\n",
       "   'samples': ['Asymptomatic individuals infected with COVID-19 can still transmit the virus to others. They may have lower viral loads and be less contagious than symptomatic individuals. However, their role in community spread is significant. Ongoing research continues to provide',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others, though the extent of their infectiousness may be lower than symptomatic individuals. They do not show symptoms but can still test positive for the virus.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others, even if they show no symptoms. They may be less likely to transmit the virus compared to symptomatic people, but they can still contribute to the spread.',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still spread the virus to others. They show no symptoms but can test positive. Research suggests a significant portion of transmissions may occur from asymptomatic or pre-symptomatic people.',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, though the risk may be lower than for symptomatic cases. Their viral load can vary and they might develop symptoms later. Studies suggest a smaller proportion of infections are',\n",
       "    'Asymptomatic individuals infected with COVID-19 can still transmit the virus to others. They show no symptoms but can have viral loads similar to symptomatic individuals. This group helps spread the virus unknowingly.',\n",
       "    'Asymptomatic individuals with COVID-19 can still transmit the virus to others, even though they do not show symptoms. They play a role in community spread.',\n",
       "    'Asymptomatic COVID-19感染者通常没有症状，但仍可能传播病毒。They can still transmit the virus to others, making them important for public health measures. The proportion of asymptomatic cases can vary. Current estimates suggest a significant portion',\n",
       "    'Asymptomatic COVID-19感染者通常没有明显症状，但仍可能传播病毒。They can still transmit the virus to others, making them important to identify and isolate for effective疫情防控。',\n",
       "    'Asymptomatic individuals with COVID-19 can still spread the virus to others, though the risk may be lower than those with symptoms. They typically have no noticeable symptoms but can test positive for the virus. Research suggests asymptomatic transmission plays a'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 4, 5, 6, 7, 1],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'nadzy6lm': {'greedy': 'Asymptomatic individuals can transmit COVID-19, as evidenced by studies reviewed. These individuals act as a hidden reservoir for the virus.',\n",
       "   'samples': ['It has been reported that asymptomatic individuals can transmit the virus, making them a hidden reservoir for the disease. Nine articles reviewed confirmed transmission from asymptomatic or pre-symptomatic patients during the early stages of the pandemic.',\n",
       "    'It has been reported that asymptomatic individuals can transmit the virus, making them a hidden reservoir of the disease during the pandemic.',\n",
       "    'Asymptomatic individuals can still transmit the virus, as confirmed by a systematic review of nine articles involving 83 asymptomatic or pre-symptomatic persons during the early stages of the pandemic.',\n",
       "    'Asymptomatic individuals can transmit COVID-19, serving as a hidden reservoir for the virus. Nine articles reported that 83 asymptomatic or pre-symptomatic persons were capable of infecting others during the early months of the pandemic',\n",
       "    'Asymptomatic individuals with COVID-19 can transmit the virus, though the extent of their infectiousness compared to symptomatic cases is not well established. There is primary evidence showing that asymptomatic or pre-symptomatic patients have passed on',\n",
       "    'Asymptomatic or pre-symptomatic individuals with COVID-19 can transmit the virus to others. Out of nine studies reviewed, it was confirmed that these individuals can pass on the infection. This has significant implications for public health measures.',\n",
       "    'Asymptomatic or pre-symptomatic individuals with COVID-19 can transmit the virus to others. This highlights the importance of public health measures such as mask-wearing, social distancing, and contact tracing to control the spread of the disease',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus to others. Out of 83 individuals identified in the study, it was confirmed that they could spread the virus even when showing no symptoms.',\n",
       "    'It has been reported that asymptomatic individuals can transmit COVID-19. A systematic review found evidence supporting the ability of asymptomatic or pre-symptomatic patients to pass on the infection.',\n",
       "    'Asymptomatic individuals can transmit COVID-19, as confirmed by studies reviewed. This highlights the importance of public health measures that account for such cases.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 2, 2, 4],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'bgoihr3t': {'greedy': 'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated by a familial cluster where two individuals who had not traveled to Wuhan became infected after contact with three family members who had returned from Wuhan',\n",
       "   'samples': ['It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated by the reported familial cluster where individuals without symptoms still spread the virus to others. This highlights the importance of precautionary measures even when no symptoms',\n",
       "    'It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.',\n",
       "    'It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.',\n",
       "    'It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated by a familial cluster where two individuals contracted the virus after contact with three others who had returned from Wuhan. These findings suggest that asymptomatic',\n",
       "    'Asymptomatic carriers of COVID-19 can transmit the virus during the incubation period, as demonstrated in the described familial cluster. These individuals may have no apparent symptoms but can still infect others. This highlights the importance of precautions and testing even',\n",
       "    'It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.',\n",
       "    'It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.',\n",
       "    'It is known that COVID-19 can be transmitted by asymptomatic carriers during the incubation period.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0}},\n",
       " '46': {'no': {'greedy': 'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "   'samples': ['Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on RECOVERY trial data.',\n",
       "    \"Dexamethasone has shown evidence of reducing mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on a randomized trial by the UK's National Institute for Health Research. However, its effectiveness for less severe cases remains uncertain.\",\n",
       "    'Dexamethasone reduces deaths among hospitalized COVID-19 patients on ventilators or oxygen, based on RECOVERY trial results.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces deaths by about one-third in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces deaths by about one-third in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial. No significant benefits were observed for patients not requiring mechanical ventilation.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on RECOVERY trial data.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Dexamethasone has shown to reduce mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 2, 0, 0, 2, 2],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'tw3luwll': {'greedy': 'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "   'samples': ['Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial. Evidence shows it has no significant benefit for patients not requiring supplemental oxygen. Answer briefly. Dexamethas',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial. Evidence shows it has no significant benefit for patients not requiring mechanical ventilation. Answer.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, as shown in a randomized trial. Evidence supports its use in severe cases.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, based on the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Clinical trials showed dexamethasone reduced mortality in hospitalized COVID-19 patients on oxygen or mechanical ventilation.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, as shown in a randomized trial.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Dexamethasone has shown evidence of reducing mortality in severe COVID-19 cases.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 0, 0, 0, 1, 0, 2],\n",
       "   'entropy': 0.9502705392332347},\n",
       "  '6l0kb0v3': {'greedy': 'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "   'samples': ['Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients who require oxygen or mechanical ventilation.',\n",
       "    'Clinical trials showed dexamethasone reduced mortality in hospitalized COVID-19 patients on ventilators or oxygen.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation. Evidence from RECOVERY trial published in The Lancet.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Dexamethasone has been shown to reduce mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, as shown in a randomized trial. Evidence supports its use in severe cases.',\n",
       "    'Clinical trials have shown dexamethasone reduces mortality in severe/critical COVID-19 patients.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 1, 3, 1, 4, 4],\n",
       "   'entropy': 1.4708084763221114},\n",
       "  '7r7rzq36': {'greedy': 'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "   'samples': ['Dexamethasone reduces deaths by about one-third in hospitalized COVID-19 patients requiring oxygen or ventilators, based on a large randomized trial. Evidence is from a randomized clinical trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients who require oxygen or mechanical ventilation.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation. Evidence suggests it has no significant benefit for those on supplemental oxygen alone. Trials found a 30% relative reduction in',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients who require oxygen or mechanical ventilation.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Dexamethasone reduces deaths by about a third among hospitalized COVID-19 patients requiring oxygen or ventilators, based on the Recovery Trial. Evidence not strong for milder cases.',\n",
       "    'Dexamethasone has been shown to reduce mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, based on the RECOVERY trial.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 1, 1, 1, 1, 1, 2],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  'kdd9bggz': {'greedy': 'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "   'samples': ['Dexamethasone reduces deaths by about a third in severely ill COVID-19 patients, based on results from the RECOVERY trial. Evidence includes randomized controlled trials.',\n",
       "    'Clinical trials have shown dexamethasone reduces mortality in severe/critical COVID-19 patients. Evidence from RECOVERY trial.',\n",
       "    'Clinical trials have shown dexamethasone reduces mortality in severe COVID-19 cases.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Dexamethasone reduces mortality in severe COVID-19 patients, based on a randomized trial.',\n",
       "    'Dexamethasone reduces deaths by about one-third in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the results of the RECOVERY trial. There is clear evidence supporting its use in severe cases.'],\n",
       "   'cluster_ids': [0, 1, 0, 1, 1, 2, 2, 1, 0, 2],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  '71u261na': {'greedy': 'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "   'samples': ['Clinical trials showed dexamethasone reduced mortality in hospitalized COVID-19 patients on ventilation or oxygen.',\n",
       "    'Dexamethasone reduces deaths by about one-third in hospitalized COVID-19 patients requiring oxygen or ventilators, based on the results of the RECOVERY trial.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation.',\n",
       "    'Dexamethasone has shown evidence of reducing mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial. No benefit was observed for patients not requiring supplemental oxygen. Answer.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients who require oxygen or mechanical ventilation. Evidence from multiple studies supports its use in severe cases.',\n",
       "    'Dexamethasone reduces deaths by about a third in severely ill COVID-19 patients, according to a randomized trial. Evidence is from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces deaths by about one-third in hospitalized patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe COVID-19 patients, based on a randomized trial.',\n",
       "    'Clinical trials showed dexamethasone reduced mortality in hospitalized COVID-19 patients on ventilators or oxygen.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 3, 1, 1, 3, 4],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  'mtscqxzv': {'greedy': 'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "   'samples': ['Clinical trials have shown dexamethasone reduces mortality in severe COVID-19 patients.',\n",
       "    'Dexamethasone reduces mortality in severe COVID-19 patients, as evidenced by a randomized trial published in The Lancet.',\n",
       "    'Clinical trials have shown dexamethasone reduces mortality in severe cases. Evidence supports its use in treating hospitalized patients with COVID-19.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on a randomized trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces deaths by about one-third in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients who require oxygen or mechanical ventilation.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, based on RECOVERY trial data.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 2, 0, 2, 2, 0],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'wudmrzqk': {'greedy': 'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "   'samples': ['Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on a randomized trial.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, based on a randomized trial.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients who require oxygen or mechanical ventilation. Evidence from multiple studies supports its use in severe cases.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on RECOVERY trial results.',\n",
       "    'Dexamethasone has shown reduced mortality in severe/critical COVID-19 patients in clinical trials. Answer.',\n",
       "    'Dexamethasone reduces deaths among hospitalized COVID-19 patients with respiratory complications, based on RECOVERY trial data.',\n",
       "    'Dexamethasone has been shown to reduce mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe COVID-19 patients, based on the Recovery Trial evidence.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 1, 4, 5, 5, 5],\n",
       "   'entropy': 1.6434177197931796},\n",
       "  '5s6zmrrx': {'greedy': 'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "   'samples': ['Dexamethasone has shown reduced mortality in severe/critical COVID-19 patients, based on the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Clinical trials have shown dexamethasone reduces mortality in severe/critical COVID-19 patients. Evidence comes from the RECOVERY trial and others.',\n",
       "    'Dexamethasone reduces deaths by about one-third in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial. There is evidence supporting its use in severe cases.',\n",
       "    'Dexamethasone has shown reduced mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on the RECOVERY trial.',\n",
       "    'Dexamethasone has shown to reduce mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial. No benefit was observed for patients not requiring mechanical ventilation. Answer.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Clinical trials showed dexamethasone reduced mortality in hospitalized COVID-19 patients on ventilators or oxygen.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on RECOVERY trial data.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  '0x08lgm2': {'greedy': 'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on RECOVERY trial data.',\n",
       "   'samples': ['Clinical trials have shown dexamethasone reduces mortality in severe cases.',\n",
       "    'Dexamethasone has shown to reduce mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial. No benefit was observed for patients not requiring respiratory support. Answer.',\n",
       "    'Dexamethasone has shown reduced mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on results from the RECOVERY trial.',\n",
       "    'Dexamethasone reduces deaths by about one-third in severely ill COVID-19 patients on ventilators and about one-fifth in those receiving oxygen, according to a U.K. study. No benefit was seen for patients not receiving oxygen.',\n",
       "    'Dexamethasone reduces deaths by about a third in severely ill COVID-19 patients, based on results from the Recovery trial. Evidence comes from randomized controlled trials.',\n",
       "    'Dexamethasone reduces mortality in severe/critical COVID-19 patients, based on a randomized trial.',\n",
       "    'Dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation, based on RECOVERY trial data.',\n",
       "    'Dexamethasone reduces mortality in severely ill COVID-19 patients, based on RECOVERY trial data.',\n",
       "    'Clinical trials have shown that dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen or mechanical ventilation.',\n",
       "    'Dexamethasone has shown evidence of reducing mortality in hospitalized COVID-19 patients who are on oxygen or mechanical ventilation, based on results from the RECOVERY trial.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 0, 3, 1, 1, 1, 1],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'b8p4l0yp': {'greedy': 'There is no evidence provided in the given context regarding the use of dexamethasone as a treatment for COVID-19. The text focuses on the potential risks of dexamethasone for cancer patients during the pandemic and recommends minimizing its',\n",
       "   'samples': ['There is no evidence presented in the given context regarding the use of dexamethasone as a treatment for COVID-19. The text focuses on the risks of using dexamethasone for antiemetic prophylaxis in cancer patients',\n",
       "    'There is no evidence presented in the given context regarding the use of dexamethasone as a treatment for COVID-19. The text focuses on the risks of using dexamethasone for antiemetic prophylaxis in cancer patients',\n",
       "    'There is no evidence presented in the given context regarding dexamethasone as a treatment for COVID-19. The text focuses on minimizing dexamethasone use in cancer patients during the pandemic due to its risks. Recent external evidence shows',\n",
       "    'There is no evidence presented in the given context regarding the use of dexamethasone as a treatment for COVID-19. The text discusses the potential risks of using dexamethasone for antiemetic prophylaxis in cancer patients',\n",
       "    'There is no evidence mentioned in the provided context regarding the use of dexamethasone as a treatment for COVID-19. The text discusses the potential risks of dexamethasone in cancer patients and recommends minimizing its use during the pandemic',\n",
       "    'There is no evidence presented in the given context regarding the use of dexamethasone as a treatment for COVID-19. The context focuses on minimizing dexamethasone exposure in cancer patients during the pandemic due to its risks. External',\n",
       "    'There is no evidence presented in the given context regarding dexamethasone as a treatment for COVID-19. The text focuses on minimizing dexamethasone use in cancer patients during the pandemic due to potential risks. External evidence suggests that',\n",
       "    'There is no mention of dexamethasone as a treatment for COVID-19 in the given context. The passage discusses the potential risks of using dexamethasone for antiemetic prophylaxis in cancer patients during the COVID-',\n",
       "    'There is no evidence presented in the given context regarding the use of dexamethasone as a treatment for COVID-19. The text focuses on the potential risks of dexamethasone in cancer patients during the pandemic and recommends minimizing its',\n",
       "    'There is no evidence presented in the given context regarding dexamethasone as a treatment for COVID-19. The text discusses the risks of dexamethasone use in cancer patients during the pandemic but does not address its treatment use for'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 2, 3, 0, 4, 5],\n",
       "   'entropy': 1.6094379124341003}},\n",
       " '7': {'no': {'greedy': 'Yes, serological tests detect antibodies to coronavirus.',\n",
       "   'samples': ['Yes, serological tests detect antibodies against SARS-CoV-2.',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, the virus that causes COVID-19.',\n",
       "    'Yes, serological tests detect antibodies against coronavirus.',\n",
       "    'Yes, serological tests detect antibodies to coronavirus.',\n",
       "    'Yes, serological tests detect antibodies to coronavirus.',\n",
       "    'Yes, serological tests can detect antibodies to coronavirus.',\n",
       "    'Yes, serological tests detect antibodies against coronavirus.',\n",
       "    'Yes, serological tests detect antibodies against coronavirus.',\n",
       "    'Yes, serological tests can detect antibodies to the coronavirus.',\n",
       "    'Yes, serological tests detect antibodies to SARS-CoV-2, the virus that causes COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 2, 2, 5, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'blrfn8qh': {'greedy': 'Yes, serological tests can detect antibodies to coronaviruses, including those for Middle East respiratory syndrome coronavirus. Two species-independent protein-based assays were developed and validated to detect functional antibodies that block virus receptor-binding or sialic acid-attachment.',\n",
       "   'samples': ['Yes, serological tests can detect antibodies to coronaviruses, including Middle East respiratory syndrome coronavirus, using protein-based assays that measure blocking of virus receptor-binding or sialic acid-attachment. These assays correlate strongly with virus-neutralizing antibody tit',\n",
       "    'Yes, serological tests can detect antibodies to coronaviruses, including Middle East respiratory syndrome coronavirus. Two species-independent protein-based assays were developed to detect functional antibodies that block virus receptor-binding or sialic acid-attachment, correlating well with',\n",
       "    'Yes, there are serological tests that detect antibodies to Middle East respiratory syndrome coronavirus (MERS-CoV), including species-independent protein-based assays that measure functional antibodies blocking virus receptor-binding or sialic acid-attachment. These assays correlate well with virus',\n",
       "    'Yes, there are serological tests that detect antibodies to coronaviruses, including those for Middle East respiratory syndrome coronavirus. The tests mentioned involve protein-based assays that measure functional antibodies blocking virus receptor-binding or sialic acid-attachment, correlating',\n",
       "    'Yes, serological tests can detect antibodies to coronaviruses, including those for Middle East respiratory syndrome coronavirus. Two species-independent protein-based assays were developed to specifically detect functional antibodies that block virus receptor-binding or sialic acid-attachment. These',\n",
       "    'Yes, serological tests can detect antibodies to coronaviruses, including Middle East respiratory syndrome coronavirus. Two species-independent protein-based assays were developed to detect functional antibodies that block virus receptor-binding or sialic acid-attachment, which correlate strongly with',\n",
       "    'Yes, serological tests have been developed to detect antibodies against Middle East respiratory syndrome coronavirus, including functional assays that block virus receptor-binding or sialic acid-attachment. These tests correlate with neutralizing antibody titers.',\n",
       "    'Yes, there are serological tests that detect antibodies to Middle East respiratory syndrome coronavirus, including assays that measure functional antibodies blocking virus receptor-binding or sialic acid-attachment. These tests correlate strongly with virus-neutralizing antibody titers.',\n",
       "    'Yes, serological tests have been developed to detect antibodies against Middle East respiratory syndrome coronavirus, including those that block virus receptor-binding or sialic acid-attachment. These tests correlate with neutralizing antibody titers and can be used for confirmatory diagnosis',\n",
       "    'Yes, serological tests can detect antibodies to coronaviruses, including assays for Middle East respiratory syndrome coronavirus that block virus receptor-binding or sialic acid-attachment.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 1, 0, 4, 5, 4],\n",
       "   'entropy': 1.7480673485460894},\n",
       "  'mryazbnq': {'greedy': 'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs are available, but some have lower specificity,',\n",
       "   'samples': ['Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. These tests are useful for diagnostic, seroepidemiologic',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs are also available for detecting IgG and Ig',\n",
       "    'Yes, serological tests for detecting antibodies to SARS-CoV-2 have been developed and validated. They can help identify individuals with specific antibodies against the virus for diagnostic, seroepidemiologic, and vaccine evaluation purposes. However, the',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial S1 IgG or IgA ELISAs exist but',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Various assays using different antigens have been validated and tested. Commercial',\n",
       "    'Yes, serological tests for detecting antibodies to SARS-CoV-2 have been developed and validated. These include assays for neutralizing antibodies, spike protein-specific IgG and IgA antibodies, and nucleocapsid-specific antibodies. Commercial ELIS',\n",
       "    'Yes, serological tests for detecting antibodies to SARS-CoV-2 have been developed and validated. These include assays for neutralizing antibodies and those specific to the spike protein and nucleocapsid. Commercial ELISAs are available, but some',\n",
       "    'Yes, serological tests for detecting antibodies to SARS-CoV-2 have been developed and validated. These include assays for neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs targeting S1 of',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial S1 IgG or IgA ELISAs exist but',\n",
       "    'Yes, serological tests for detecting antibodies against SARS-CoV-2 have been developed and validated. They include neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial S1 IgG or IgA ELIS'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 6, 3, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '83odb66l': {'greedy': 'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs are available, but some have varying levels of',\n",
       "   'samples': ['Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial S1 IgG or IgA ELISAs have been',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2. These tests include assays for neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs targeting the S1 sub',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs targeting S1 protein show varying levels of specificity',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2. These include neutralizing antibodies and antibodies specific to the spike protein and nucleocapsid. Commercial ELISAs are available but may vary in specificity and sensitivity',\n",
       "    'Yes, serological tests for detecting antibodies against SARS-CoV-2 have been developed and validated. These tests include assays for neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial S1 IgG or Ig',\n",
       "    'Yes, serological tests for detecting antibodies to SARS-CoV-2 have been developed and validated. These tests include neutralizing antibody detection, spike protein-specific IgG and IgA ELISAs, and nucleocapsid-specific antibody detection.',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs are available for detecting SARS-CoV-',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs for S1 protein detection exist but may vary',\n",
       "    'Yes, serological tests have been developed to detect antibodies against SARS-CoV-2, including neutralizing antibodies, spike protein-specific antibodies, and nucleocapsid-specific antibodies. Commercial ELISAs are also available for these purposes. However,',\n",
       "    'Yes, serological tests for detecting antibodies to SARS-CoV-2 have been developed and validated. These include neutralizing antibody tests, spike protein-specific IgG and IgA ELISAs, and nucleocapsid-specific antibody tests. Commercial'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 2, 2, 5, 4],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  '01mo6yo9': {'greedy': 'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "   'samples': ['Yes. Yes. There are serological tests that detect antibodies to SARS-CoV-2. These tests are important for various use cases including complementing molecular methods for diagnosing active disease, estimating individual immunity, and aiding in the characterization of transmission',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes. Yes. There are serological tests available to detect antibodies against SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 2, 1, 1, 1, 1],\n",
       "   'entropy': 0.639031859650177},\n",
       "  'ofd2ipvs': {'greedy': 'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "   'samples': ['Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.',\n",
       "    'Yes, there are serological tests that detect antibodies to SARS-CoV-2.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '6se4faio': {'greedy': 'Yes, serological tests exist to detect antibodies against coronaviruses, including SARS coronavirus. The study identified a specific protein fragment (N195) from the nucleocapsid protein that can be used in Western blot assays to detect',\n",
       "   'samples': ['Yes, serological tests can detect antibodies to coronaviruses, including SARS coronavirus. The study identified a specific protein fragment (N195) from the SARS coronavirus nucleocapsid protein that can be used in Western blot assays',\n",
       "    'Yes, serological tests exist to detect antibodies to coronaviruses, including SARS coronavirus. In the context provided, the N195 protein fragment was used to develop a Western blot assay for detecting antibodies against SARS coronavirus with high specificity',\n",
       "    'Yes, serological tests exist to detect antibodies to coronaviruses, including SARS coronavirus. The study identified a specific fragment (N195) of the nucleocapsid protein that can be used in Western blot assays to detect these',\n",
       "    'Yes, serological tests can detect antibodies to coronaviruses, as demonstrated by the identification of the N195 protein fragment for detecting SARS coronavirus antibodies.',\n",
       "    'Yes, serological tests exist to detect antibodies against coronaviruses, including SARS coronavirus. The study identified a specific fragment (N195) from the nucleocapsid protein of the SARS coronavirus that can be used in such',\n",
       "    'Yes, serological tests exist to detect antibodies against coronaviruses, including SARS coronavirus. The N195 protein fragment identified in the study can be used in Western blot assays for this purpose.',\n",
       "    'Yes, serological tests exist to detect antibodies to coronaviruses, including SARS coronavirus. The N195 protein fragment identified in the study can be used in Western blot assays for detecting these antibodies.',\n",
       "    'Yes, serological tests can detect antibodies to coronaviruses, as demonstrated by the identification and use of the N195 protein from the SARS coronavirus nucleocapsid for detecting antibodies in Western blot assays.',\n",
       "    'Yes, serological tests exist to detect antibodies to coronaviruses, including SARS coronavirus. The study identified a specific fragment (N195) from the nucleocapsid protein that can be used in Western blot assays to detect these',\n",
       "    'Yes, serological tests exist to detect antibodies against coronaviruses, including SARS coronavirus. One such test involves using a specific truncated fragment (N195) of the nucleocapsid protein for Western blot analysis. This test showed'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 0, 0, 0, 3, 0, 4],\n",
       "   'entropy': 1.2275294114572126},\n",
       "  'd0y3pr9a': {'greedy': 'Yes, serological tests can detect antibodies to SARS-CoV-2, including antibodies against the nucleocapsid and spike proteins. These tests can help determine past infection and the immune response.',\n",
       "   'samples': ['Yes, serological tests can detect antibodies to SARS-CoV-2, including antibodies against the nucleocapsid and spike proteins.',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, including those targeting the nucleocapsid and spike proteins. These tests can be used to measure the presence and levels of these antibodies in plasma or serum samples.',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, including those against the nucleocapsid and spike proteins. These tests help determine past infections and the immune response.',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, including antibodies against the nucleocapsid and spike proteins. These tests are used to measure the presence and levels of antibodies in plasma or serum samples from patients with SARS',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, specifically targeting the nucleocapsid and spike proteins. These tests have varying sensitivities and specificities but are effective in identifying past infection.',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, including antibodies against the nucleocapsid and spike proteins. These tests help in understanding the prevalence of infection and the immune response. The nucleocapsid protein-based assays',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, specifically targeting the nucleocapsid and spike proteins. The nucleocapsid protein test shows high sensitivity and specificity, while the spike protein test has lower sensitivity but higher',\n",
       "    'Yes, serological tests can detect antibodies to the coronavirus, specifically against the nucleocapsid and spike proteins of SARS-CoV-2. These tests can be used to determine past infection and the immune response. The nucleocapsid protein',\n",
       "    'Yes, serological tests detect antibodies to SARS-CoV-2, including those targeting the nucleocapsid and spike proteins. The nucleocapsid protein test shows 100% sensitivity and specificity, while the spike protein test has',\n",
       "    'Yes, serological tests can detect antibodies to SARS-CoV-2, specifically targeting the nucleocapsid and spike proteins. These tests can help determine the presence of an immune response to the virus.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 0, 0, 2, 3, 4],\n",
       "   'entropy': 1.2275294114572126},\n",
       "  'epd1zeif': {'greedy': 'Yes, serological tests like the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including those associated with SARS.',\n",
       "   'samples': ['Yes, serological tests like the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including those associated with SARS.',\n",
       "    'Yes, serological tests such as the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including those associated with SARS.',\n",
       "    'Yes, serological tests such as the double-antigen sandwich ELISA can detect antibodies to the SARS-associated coronavirus.',\n",
       "    'Yes, serological tests such as the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including the one associated with SARS.',\n",
       "    'Yes, serological tests like the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including the one associated with SARS.',\n",
       "    'Yes, serological tests like the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including the one associated with SARS.',\n",
       "    'Yes, serological tests such as the double-antigen sandwich ELISA can detect antibodies to the coronavirus associated with SARS.',\n",
       "    'Yes, serological tests like the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including the SARS-associated coronavirus.',\n",
       "    'Yes, serological tests like the double-antigen sandwich ELISA can detect antibodies to coronaviruses, such as the one associated with SARS.',\n",
       "    'Yes, serological tests like the double-antigen sandwich ELISA can detect antibodies to coronaviruses, including those associated with SARS.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 3, 2, 3, 3, 0],\n",
       "   'entropy': 1.3321790402101223},\n",
       "  '9skvbk8m': {'greedy': \"Yes, serological tests can detect antibodies to coronavirus, including those specific to SARS-CoV-2. However, these tests may face challenges with cross-reactivity due to similarities with other coronaviruses. Different regions of the virus's spike\",\n",
       "   'samples': ['Yes, there are serological tests that detect antibodies to coronavirus. These tests help assess past infections and monitor immune responses, though they may face challenges with cross-reactivity due to related coronaviruses.',\n",
       "    'Yes, serological tests detect antibodies to coronavirus.',\n",
       "    'Yes, serological tests detect antibodies to coronavirus. Different tests were compared in the study, with some showing significant cross-reactivity and others offering better specificity. Capture ELISA performed best among the tested platforms.',\n",
       "    \"Yes, serological tests can detect antibodies to coronavirus. These tests include various platforms like capture ELISA and can differentiate between specific regions of the virus's spike protein to reduce cross-reactivity with other coronaviruses.\",\n",
       "    'Yes, serological tests detect antibodies to coronavirus. These tests are being used to assess cross-reactivity between SARS and COVID-19.',\n",
       "    'Yes, serological tests detect antibodies to coronavirus. These tests vary in performance and specificity.',\n",
       "    'Yes, there are serological tests that detect antibodies to coronavirus, including those specifically for SARS-CoV-2 and other coronaviruses. These tests can help assess past infections and immune responses. However, cross-reactivity may occur due to',\n",
       "    'Yes, serological tests can detect antibodies to coronavirus, including those specific to the S1 or RBD regions of the spike protein, which offer better specificity compared to the N protein. Different platforms exist, with capture ELISA performing best in this context',\n",
       "    'Yes, serological tests can detect antibodies to coronavirus. These tests vary in their performance regarding cross-reactivity with other coronaviruses. Some tests perform better than others, with capture ELISA showing the best performance. The tests using S1 or',\n",
       "    'Yes, serological tests can detect antibodies to coronavirus, including those specific to the S1 or RBD regions of the spike protein, which offer better specificity for distinguishing between antibodies generated by SARS-CoV-2 and other coronaviruses.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 1, 1, 0, 1, 1, 3],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'wfy5kz63': {'greedy': 'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV).',\n",
       "   'samples': ['Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV). The described ICA uses a recombinant FCoV nucleocapsid protein labeled with colloidal gold',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to coronaviruses, including feline coronavirus (FCoV). These tests use antibody–antigen detection methods to rapidly obtain results at low cost',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV). The ICA uses a colloidal gold-labeled recombinant FCoV nucleocapsid protein and',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV). Other serological tests for coronavirus antibodies also exist.',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV). The ICA uses a colloidal gold-labeled recombinant FCoV nucleocapsid protein and',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV).',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV). Other serological tests for SARS-CoV-2 (the virus causing COVID-19) also exist',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV).',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to feline coronavirus (FCoV). These tests use antigen-conjugated gold labels and antibody blots on membranes to quickly identify specific antibodies.',\n",
       "    'Yes, serological tests like the immunochromatographic assay (ICA) can detect antibodies to coronaviruses, such as feline coronavirus (FCoV). The ICA uses a colloidal gold-labeled recombinant FCo'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 0, 2, 3, 3, 4, 5],\n",
       "   'entropy': 1.6957425341696346}},\n",
       " '39': {'no': {'greedy': 'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 leads to excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive immune response causing inflammation and potentially damaging lungs and other organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and potentially leading to multi-organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation and immune response, damaging healthy cells and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, harming lungs and other organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive immune response, leading to inflammation and potential organ damage.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 3, 4, 1, 3, 4],\n",
       "   'entropy': 1.5571130980576458},\n",
       "  'm6kxxio1': {'greedy': 'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive immune response, leading to inflammation and potential organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and potentially leading to multi-organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and potentially leading to multi-organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive inflammation due to overactive immune response, damaging healthy cells.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation and immune response, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 1, 2, 1, 3, 4, 2],\n",
       "   'entropy': 1.5047882836811906},\n",
       "  'jrsp0yef': {'greedy': 'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and potentially leading to multi-organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, harming lungs and other organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive inflammation from overactive immune response, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive immune response causing inflammation and potentially damaging organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation and immune response, damaging healthy cells and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation, damaging healthy cells and tissues.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and potentially leading to multi-organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 1, 2, 3, 4, 0, 3],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  'tqjmg3qb': {'greedy': 'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive immune response causing inflammation and potential organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive immune response, leading to inflammation and potential organ damage.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive inflammation due to overactive immune response, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 2, 2, 1, 3, 1, 0],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  '4bfve7dl': {'greedy': 'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, harming lungs and other organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive inflammation from overactive immune response.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation by overactive immune response.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive immune response, leading to inflammation and potential organ failure.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 1, 3, 4, 1, 1, 4],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'zukc3lvq': {'greedy': 'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potentially multiple organ failure.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 involves excessive immune response leading to severe inflammation, potentially causing acute respiratory distress syndrome or multiple organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potentially multiple organ failure.',\n",
       "    'Cytokine storm syndrome exacerbates COVID-19 by causing severe inflammation that can lead to acute respiratory distress syndrome or multiple organ failure in later stages of the disease. The excessive release of pro-inflammatory cytokines contributes to this dangerous immune response.',\n",
       "    'Cytokine storm syndrome contributes to the deterioration of COVID-19 by causing acute respiratory distress syndrome or multiple organ failure in later stages of the disease.',\n",
       "    'Cytokine storm syndrome contributes to the deterioration of COVID-19 by causing acute respiratory distress syndrome or multiple organ failure in later stages of the disease.',\n",
       "    \"Cytokine storm syndrome exacerbates COVID-19 by causing acute respiratory distress and potentially leading to multiple organ failure in later stages of the disease. It is a critical factor in the disease's deterioration.\",\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress syndrome or multiple organ failure.',\n",
       "    'Cytokine storm syndrome contributes to the deterioration of COVID-19 by causing acute respiratory distress syndrome or multiple organ failure in later stages of the disease.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potentially multiple organ failure due to excessive immune response.',\n",
       "    \"Cytokine storm syndrome exacerbates COVID-19 by causing acute respiratory distress syndrome or multiple organ failure in later stages of the disease. It is a key factor in the disease's deterioration.\"],\n",
       "   'cluster_ids': [0, 0, 0, 1, 1, 2, 2, 1, 0, 2],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'urr5iuy2': {'greedy': 'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potentially multiple organ failure due to excessive immune response.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 leads to severe inflammation, potentially causing acute respiratory distress syndrome or multiple organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress syndrome or multiple organ failure by causing excessive inflammation.',\n",
       "    'The mechanism of cytokine storm syndrome in COVID-19 involves excessive production of pro-inflammatory cytokines leading to severe inflammation and potential organ damage.',\n",
       "    'The mechanism of cytokine storm syndrome in COVID-19 involves excessive production of pro-inflammatory cytokines leading to severe inflammation, potentially causing acute respiratory distress and multi-organ failure.',\n",
       "    'The mechanism of cytokine storm syndrome in COVID-19 involves excessive immune response leading to severe inflammation and potential organ damage.',\n",
       "    'Cytokine storm syndrome in COVID-19 is a key mechanism leading to the deterioration of the disease, often resulting in acute respiratory distress syndrome or multiple organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potential multiple organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to severe illness by causing acute respiratory distress syndrome or multiple organ failure in later stages.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to severe respiratory issues and potential multi-organ failure due to excessive immune response.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress syndrome or multiple organ failure by causing excessive immune response.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 3, 3, 3, 0, 0],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  '3d04p4xp': {'greedy': 'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potentially multiple organ failure due to excessive immune response.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 leads to severe immune response which can cause acute respiratory distress syndrome or multiple organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 patients leads to severe inflammation and can cause acute respiratory distress syndrome or multiple organ failure. It is a key factor in the deterioration of the disease.',\n",
       "    'Cytokine storm syndrome in COVID-19 is a key mechanism leading to acute respiratory distress and multi-organ failure by causing excessive inflammation.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potentially multiple organ failure due to an excessive immune response.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to severe inflammation and can cause acute respiratory distress syndrome or multiple organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress and potentially multiple organ failure due to an excessive immune response.',\n",
       "    'The mechanism of cytokine storm syndrome in COVID-19 involves excessive immune response leading to severe inflammation and potential organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 patients leads to acute respiratory distress syndrome or multiple organ failure due to an excessive immune response.',\n",
       "    'Cytokine storm syndrome in COVID-19 is a key mechanism leading to disease deterioration, potentially causing acute respiratory distress syndrome or multiple organ failure. It involves an excessive immune response that damages healthy cells and tissues.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to acute respiratory distress syndrome or multiple organ failure by causing excessive immune response.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 1, 0, 1, 1, 1, 1],\n",
       "   'entropy': 0.6730116670092565},\n",
       "  '8wmqdybk': {'greedy': 'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 leads to excessive inflammation and immune response, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation and immune response, damaging healthy cells and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation, damaging lungs and other organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, harming lungs and other organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and potentially leading to organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive inflammation from overactive immune response, damaging tissues and organs.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 2, 6, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  '3su8pc3f': {'greedy': 'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and potentially leading to multi-organ failure.',\n",
       "    'Cytokine storm syndrome in COVID-19 leads to excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, harming lungs and other organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves excessive inflammation due to overactive immune response, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by overproducing cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.',\n",
       "    'Cytokine storm syndrome in COVID-19 causes excessive inflammation by releasing too many cytokines, damaging tissues and organs.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 0, 0, 0, 3, 3],\n",
       "   'entropy': 1.2798542258336676},\n",
       "  'jxsj3lg6': {'greedy': 'Cytokine storm syndrome in COVID-19 involves elevated serum inflammatory cytokines, with IL-6 playing a central role.',\n",
       "   'samples': ['Cytokine storm syndrome in COVID-19 involves elevated serum inflammatory cytokines, with IL-6 playing a central role.',\n",
       "    'Cytokine storm syndrome in COVID-19 is characterized by elevated serum inflammatory cytokines, with IL-6 playing a central role.',\n",
       "    'Cytokine storm syndrome in COVID-19 is characterized by elevated serum inflammatory cytokines, with IL-6 playing a central role.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves elevated serum inflammatory cytokines, with IL-6 playing a central role. Mechanism not detailed here but likely involves excessive immune response. Treatments like IL-6 receptor blockers are being explored',\n",
       "    'Cytokine storm syndrome in COVID-19 involves elevated serum inflammatory cytokines, with IL-6 playing a central role. The exact mechanism is not fully understood but appears to be part of an overactive immune response.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves elevated serum inflammatory cytokines, with IL-6 playing a central role. Tocilizumab, an IL-6 receptor blocker, is being explored to manage this condition.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves elevated serum inflammatory cytokines, with IL-6 playing a central role.',\n",
       "    'Cytokine storm syndrome in COVID-19 is characterized by elevated serum inflammatory cytokines, particularly IL-6, which drives a severe immune response.',\n",
       "    'Cytokine storm syndrome in COVID-19 is characterized by elevated serum inflammatory cytokines, particularly IL-6, which plays a central role. Treatment involves blocking IL-6 receptors with medications like tocilizumab.',\n",
       "    'Cytokine storm syndrome in COVID-19 involves elevated serum inflammatory cytokines, with IL-6 playing a central role.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 0, 0, 0, 1, 1, 0],\n",
       "   'entropy': 0.6730116670092565}},\n",
       " '21': {'no': {'greedy': 'Mortality rates vary widely, generally ranging from a few per thousand to several dozen per thousand annually. Specific populations may have higher or lower rates due to factors like age, health conditions, lifestyle, and access to healthcare. For precise figures, consult recent',\n",
       "   'samples': ['Mortality rates vary widely, with global average under 1% for many causes. Specific populations may have higher rates due to factors like age, pre-existing conditions, or location. More precise rates depend on the exact cause and demographic group.',\n",
       "    'Mortality rates vary widely; overall, they depend on factors like age, location, and health conditions. Specific populations have distinct rates influenced by demographics, lifestyle, and medical access. For precise figures, refer to recent public health data or studies.',\n",
       "    'Mortality rates vary widely depending on factors like age, location, and underlying health conditions. Generally, older adults and those with pre-existing conditions have higher mortality rates. Specific populations require more detailed data for accurate assessment.',\n",
       "    'Mortality rates vary widely depending on factors such as location, age, gender, and underlying health conditions. Overall, global mortality rates are difficult to pinpoint due to differences in healthcare systems and data collection methods. Specific population mortality rates can be significantly influenced by',\n",
       "    'Mortality rates vary widely, generally ranging from a few percent to over 80% depending on the population and disease. Specific populations may experience higher or lower rates due to factors like age, pre-existing conditions, and access to healthcare. Without specifying',\n",
       "    'Mortality rates vary widely depending on location, population group, and cause of death. Overall global mortality rates are difficult to summarize precisely due to varying data quality and reporting standards across countries. Specific population groups may experience higher or lower mortality rates based on factors',\n",
       "    'Mortality rates vary widely. Overall, they depend on factors like location, age, and health conditions. Specific populations face different risks; for example, older adults and those with chronic illnesses often have higher mortality rates. Exact figures need to be obtained from',\n",
       "    'Mortality rates vary widely, generally ranging from a few per thousand to several dozen per thousand annually. Specific populations may have higher or lower rates due to factors like age, health conditions, and socioeconomic status. For precise figures, refer to recent demographic and',\n",
       "    'Data on mortality rates vary widely by population and cause. For general figures, you can refer to recent global health reports from organizations like the WHO or CDC. Specific populations may have higher or lower rates based on factors like age, location, and underlying health',\n",
       "    'Mortality rates vary widely and depend on factors like age, location, and underlying health conditions. Overall rates are difficult to generalize but can be found through public health data. Specific population rates require more detailed analysis by demographic group.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'eet3v4cs': {'greedy': 'Overall, the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) estimated age-specific and sex-specific all-cause mortality between 1970 and 20',\n",
       "   'samples': ['Overall, the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) estimated age-specific and sex-specific all-cause mortality between 1970 and 20',\n",
       "    'Overall, mortality rates have decreased across all age groups globally over the past five decades, with the largest improvements among children under 5 years. However, there is considerable heterogeneity at the national level in terms of age-specific mortality trends, with some locations',\n",
       "    'Overall, mortality rates have decreased globally across all age groups since 1970, with the largest improvements seen in children younger than 5 years. At the national level, however, there is significant variation in mortality trends among different age groups and',\n",
       "    'Overall, mortality rates have decreased across all age groups globally over the past five decades, with the largest improvements seen among children younger than 5 years. However, there is considerable heterogeneity at the national level, with some locations experiencing increases in mortality for',\n",
       "    'The study estimated age-specific and sex-specific all-cause mortality for 195 countries and territories between 1970 and 2016. It found that overall, mortality rates decreased across all age groups globally over the past five',\n",
       "    'Overall, the study estimated age-specific and sex-specific all-cause mortality for 195 countries and territories between 1970 and 2016. For specific populations, the study examined mortality trends in children under 5,',\n",
       "    'Overall, global mortality rates have decreased across all age groups over the past five decades, with the largest improvements occurring among children younger than 5 years. However, there is considerable heterogeneity at the national level in terms of both the level and rate of',\n",
       "    'Overall and in specific populations, the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) estimated age-specific and sex-specific all-cause mortality between 1970',\n",
       "    'The study estimated age-specific and sex-specific all-cause mortality rates for 195 countries and territories from 1970 to 2016. It also provided specific mortality rates for subnational units in five large countries. Mort',\n",
       "    'Overall and in specific populations, the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) estimated age-specific and sex-specific all-cause mortality between 1970'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 2, 5, 6, 5],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '9n9irx70': {'greedy': 'Overall, the study estimates that approximately 12.65 million, 4.09 million, and 1.34 million individuals are at 2-, 5-, and 10-fold higher risk of mortality from COVID-',\n",
       "   'samples': ['The analysis characterizes the distribution of risk for COVID-19 mortality across 442 US cities, identifying approximately 12.65 million, 4.09 million, and 1.34 million individuals at 2',\n",
       "    'Overall, the analysis does not provide specific mortality rates but estimates that approximately 12.65 million, 4.09 million, and 1.34 million individuals are at 2-, 5-, and 10-fold',\n",
       "    'The analysis estimates that approximately 12.65 million, 4.09 million, and 1.34 million individuals in the US are at 2-, 5-, and 10-fold higher risk of mortality from COVID',\n",
       "    'The study does not provide explicit mortality rates, but it characterizes the distribution of risk scores for COVID-19 mortality in different populations across 442 US cities. Approximately 12.65 million, 4.09 million',\n",
       "    'Overall, the analysis estimates that approximately 12.65 million, 4.09 million, and 1.34 million individuals across all US cities are at 2-, 5-, and 10-fold higher risk of',\n",
       "    'Overall, the analysis estimates that approximately 12.65 million, 4.09 million, and 1.34 million individuals are at 2-, 5-, and 10-fold higher risk of mortality from COVID-',\n",
       "    'The analysis estimates that approximately 12.65 million, 4.09 million, and 1.34 million individuals in the US are at 2-, 5-, and 10-fold higher risk for COVID-1',\n",
       "    'Overall mortality rates cannot be directly extracted from the provided context, but the study identifies three specific population groups at higher risk:',\n",
       "    'The study does not provide specific mortality rates but estimates the number of individuals at higher risk for severe COVID-19 outcomes. Overall, about 12.65 million people face a 2-fold higher risk, 4.09 million',\n",
       "    'The study characterizes the distribution of risk for COVID-19 mortality across 442 US cities. It identifies approximately 12.65 million, 4.09 million, and 1.34 million individuals at'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'u72yj5kx': {'greedy': 'The study did not provide specific mortality rates overall or in specific populations. It found that the cumulative cause-specific mortality was associated with the percentage elderly population, but no overall mortality rates were reported. For case fatality rate, it was associated with testing rate',\n",
       "   'samples': ['The study did not provide specific mortality rates but found that the cumulative cause-specific mortality was associated with the percentage elderly population (β = 0.096, p = 0.04). No specific rates for other populations were mentioned.',\n",
       "    'The study did not provide specific overall or population-specific mortality rates. It analyzed associations between mortality and certain factors but did not report actual mortality rates. Factors associated with case fatality rate included testing rate and population density, while cumulative cause-specific mortality was linked',\n",
       "    'The study did not provide specific overall or population-level mortality rates, but it identified that the cumulative cause-specific mortality was associated with the percentage elderly population (β = 0.096, p = 0.04). No detailed specific',\n",
       "    'The study did not provide overall or specific mortality rates; instead, it identified factors associated with cumulative cause-specific mortality, including the percentage elderly population. No detailed mortality rates were reported.',\n",
       "    'The study found significant inter-country variation in incidence and mortality rates. Specifically, five variables were associated with cumulative incidence: testing rate, UHC index, percentage elderly population, percentage below-poverty line population, and disability-adjusted life years due to N',\n",
       "    'The study did not provide overall or specific mortality rates; it analyzed associations between various factors and mortality rates without reporting specific figures. Factors found to be associated with higher case fatality rates include testing rate per 1000 population and population density,',\n",
       "    'The study did not provide overall or specific mortality rates; instead, it discussed factors associated with case fatality rate and cumulative cause-specific mortality, such as testing rate, population density, and percentage of elderly population. For precise mortality rates, one would need',\n",
       "    'The study did not provide specific overall or population-based mortality rates; instead, it analyzed factors associated with mortality rates across different countries. The main findings indicated that the percentage of the elderly population was significantly associated with higher cumulative cause-specific mortality. Other factors like',\n",
       "    'The study did not provide overall or specific mortality rates; it assessed associations between various indicators and mortality rates without providing numerical values. The results indicated that the percentage of the elderly population was associated with cumulative cause-specific mortality, but no specific mortality rates were reported',\n",
       "    'The study did not provide overall or specific mortality rates; it analyzed factors associated with cumulative cause-specific mortality, which showed an association with the percentage elderly population.'],\n",
       "   'cluster_ids': [0, 1, 0, 1, 2, 1, 1, 3, 3, 3],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'huyl21vz': {'greedy': 'The context provided does not give specific mortality rates overall or in specific populations. It discusses factors correlated with mortality rates and provides rankings of countries based on adjusted mortality rates, but does not present actual numerical mortality rates. To answer your question accurately, I would',\n",
       "   'samples': ['The text does not provide specific mortality rates or rates for specific populations. It discusses correlations and factors associated with mortality rates but does not give exact figures. For accurate and up-to-date mortality rates by specific populations, refer to public health reports from relevant organizations',\n",
       "    'The passage does not provide specific mortality rates overall or in specific populations; instead, it discusses factors correlated with mortality rates across different countries. It mentions that mortality rates correlate significantly with GDP per capita, fraction of citizens over 65 years old, and',\n",
       "    'The provided context does not give specific mortality rates overall or for specific populations. It discusses correlations and factors influencing mortality rates across countries but does not provide numerical mortality rate values. To get specific mortality rates, you would need to refer to public health reports or',\n",
       "    'The context does not provide specific mortality rates overall or for particular populations; instead, it discusses factors correlated with mortality rates across different countries during the early stages of the COVID-19 pandemic. To get specific mortality rates, one would need to refer to',\n",
       "    'The provided context does not give specific mortality rates or breakdowns by population subgroups. It discusses correlations and factors associated with mortality rates but does not provide numerical values for overall mortality or mortality within specific population groups. For detailed mortality rates and subgroup analyses,',\n",
       "    'The passage does not provide specific mortality rates overall or in specific populations. It discusses correlations and factors affecting mortality rates but does not give numerical values. Factors include incidence, GDP per capita, elderly population fraction, and press freedom. For specific rankings, Israel',\n",
       "    'The provided context does not give specific mortality rates for overall populations or specific subgroups. It discusses factors associated with variations in mortality rates across countries during the early stages of the 2020 COVID-19 pandemic, such as incidence, GDP',\n",
       "    'The text does not provide specific mortality rates for overall populations or specific groups. It discusses factors associated with mortality rates but does not give numerical values. Factors mentioned include incidence, GDP per capita, age distribution, and level of press freedom. For specific populations',\n",
       "    'The text does not provide specific mortality rates overall or in specific populations. It discusses correlations and factors affecting mortality rates across different countries without giving concrete numbers. To get specific mortality rates, you would need to refer to other sources that report such statistics.',\n",
       "    'The provided context does not give specific mortality rates; instead, it discusses factors correlated with mortality rates across different countries, such as GDP per capita, age distribution, and test volume. To provide specific mortality rates, one would need to refer to detailed reports'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 5, 4, 6, 6],\n",
       "   'entropy': 1.8866967846580787},\n",
       "  'fyna1euk': {'greedy': 'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics compared to Whites. State-specific estimates show wide variation in mortality disparities.',\n",
       "   'samples': ['Overall, the age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics, relative to Whites. State-specific estimates show wide variation in these mortality disparities.',\n",
       "    'Overall, the age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics compared to Whites. State-specific estimates show wide variation in these disparities.',\n",
       "    'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics, relative to Whites. State-specific estimates show wide variation in mortality disparities.',\n",
       "    'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics compared to Whites. State-specific estimates show wide variation in these mortality disparities.',\n",
       "    'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics, relative to Whites, on a national level. State-specific estimates show wide variation in mortality disparities.',\n",
       "    'Overall, the adjusted mortality rates show that Black individuals have death rates 80% higher, and Hispanic individuals have rates over 50% higher compared to White individuals. State-specific estimates show significant variations in these disparities.',\n",
       "    'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics, relative to Whites, on a national level. State-specific estimates show wide variation in mortality disparities.',\n",
       "    'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics compared to Whites. State-specific estimates show wide variation in these mortality disparities.',\n",
       "    'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics compared to Whites on a national level. State-specific estimates show wide variation in mortality disparities.',\n",
       "    'Overall, age-and-place-adjusted COVID-19 death rates are 80% higher for Blacks and over 50% higher for Hispanics compared to Whites. State-specific estimates show wide variation in these disparities.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 1, 1, 1, 1, 1, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  '0o3wjvpx': {'greedy': 'Overall, from the first week of April and onwards, death rates at all ages above 60 are higher than previous years in Sweden. Specifically, persons above age 80 are disproportionately more affected. Men suffer higher levels of excess mortality than women',\n",
       "   'samples': ['Overall, from April onwards, death rates at all ages above 60 are higher than previous years in Sweden. For specific populations, persons above age 80 are disproportionately more affected. Men suffer higher levels of excess mortality than women at all ages',\n",
       "    'Overall, from the first week of April, death rates at all ages above 60 are higher than previous years in Sweden. For specific populations, persons above age 80 are disproportionately more affected, and men suffer higher levels of excess mortality than',\n",
       "    'Overall, from the first week of April and onwards, death rates at all ages above 60 are higher than previous years in Sweden. For specific populations, persons above age 80 are disproportionately more affected. Men suffer higher levels of excess mortality',\n",
       "    'Overall, from the first week of April, death rates at all ages above 60 are higher than previous years in Sweden. Specifically, persons above age 80 are disproportionately more affected, and men suffer higher levels of excess mortality than women at',\n",
       "    'Overall, from the first week of April 2020, death rates at all ages above 60 were higher than previous years in Sweden. For specific populations, persons above 80 were disproportionately more affected, and men suffered higher levels',\n",
       "    'Overall, from the first week of April and onwards, death rates at all ages above 60 in Sweden are higher than previous years. Specifically, persons above age 80 are disproportionately more affected. Men suffer higher levels of excess mortality than women',\n",
       "    'Overall, from the first week of April and onwards, death rates at all ages above 60 in Sweden are higher than previous years. Specifically, persons above age 80 are disproportionately more affected. Men suffer higher levels of excess mortality than women',\n",
       "    'Overall, death rates at all ages above 60 are higher than previous years, especially for those above 80. Men suffer 75% higher death rates compared to women at all ages, while women experience 50% higher death',\n",
       "    'Overall, from April onward, death rates at all ages above 60 are higher in Sweden compared to previous years. For persons above 80, the impact is disproportionate. Men suffer significantly higher levels of excess mortality than women at all ages,',\n",
       "    'Overall, from April onwards, death rates at all ages above 60 are higher in Sweden compared to previous years. For specific populations, persons over 80 are disproportionately affected, and men suffer higher levels of excess mortality than women, with'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 1, 1, 2, 0, 0],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'fuvyeq3k': {'greedy': 'Overall mortality ratios increased from 1.0 (95% CI: 0.9-1.3) in EW 11 to 4.6 (95% CI: 3.9-5.3) in',\n",
       "   'samples': ['Overall mortality increased significantly from 1.0 (95% CI: 0.9-1.3) in EW 11 to 4.6 (95% CI: 3.9-5.3) in',\n",
       "    'Overall mortality increased significantly in 2020 compared to 2019, especially for those 60 years or older. Mortality rates at home or on public byways were much higher in 2020.',\n",
       "    'Overall mortality increased significantly in 2020 compared to 2019, with ratios reaching up to 4.6 in certain weeks. Among specific populations, those 60 years or older accounted for 69.1%',\n",
       "    'Overall mortality ratios for 2020/2019 increased significantly starting from Epidemiological Week 11, peaking at 4.6 in Week 17. In specific populations, particularly those 60 years or older',\n",
       "    'Excess overall mortality increased from 1.0 (95% CI: 0.9-1.3) in EW 11 to 4.6 (95% CI: 3.9-5.3)',\n",
       "    'Overall mortality ratios increased from 1.0 (95% CI: 0.9-1.3) in EW 11 to 4.6 (95% CI: 3.9-5.3) in',\n",
       "    'In 2020, there was an increase in overall mortality in Manaus, with a ratio of 4.6 (95% CI: 3.9-5.3) compared to 2019, particularly',\n",
       "    'Overall mortality rates increased significantly in 2020 compared to 2019, particularly for those 60 years or older. The increase was most pronounced for deaths occurring at home or on public byways.',\n",
       "    'Overall mortality increased significantly in 2020 compared to 2019, particularly after Epidemiological Week 11. In specific populations, especially those aged 60 or older, the excess mortality was even higher, accounting for',\n",
       "    'In Manaus, there was no significant excess overall mortality in 2019 compared to 2018. However, from 2020 to 2019, the ratio of deaths increased significantly, reaching up to'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '6w02vzcw': {'greedy': 'Overall, the mean mortality was 19.83 cases/100,000 inhabitants (SD 22.4) with a median of 7.95. Specific populations ranged from a minimum of 1.',\n",
       "   'samples': ['Overall, at May 1, 2020, the mean mortality rate was 19.83 cases/100,000 inhabitants with a median of 7.95. Specific populations ranged from a minimum',\n",
       "    'Overall, the mean mortality was 19.83 cases/100,000 inhabitants (SD 22.4) with a median of 7.95. Specifically, the range was from a minimum of',\n",
       "    'Overall, the mean mortality was 19.83 cases/100,000 inhabitants (SD 22.4), ranging from a minimum of 1.49 cases/100,000 population',\n",
       "    'Overall, at May 1, 2020, the mean mortality was 19.83 cases/100,000 inhabitants with a median of 7.95. Specific populations ranged from a minimum of',\n",
       "    'Overall, the mean mortality was 19.83 cases/100,000 inhabitants (SD 22.4) and a median of 7.95 cases/100,000 inhabitants.',\n",
       "    'Overall, the mean mortality was 19.83 cases/100,000 inhabitants (SD 22.4) with a median of 7.95. Specific populations ranged from a minimum of 1.',\n",
       "    'Overall, the mean mortality was 19.83 cases/100,000 inhabitants (SD 22.4) with a median of 7.95. Specifically, the mortality rate ranged from a minimum of',\n",
       "    'Overall, at May 1, 2020, the mean mortality was 19.83 cases/100,000 inhabitants (SD 22.4), with a median of 7.95',\n",
       "    'Overall, the mean mortality rate was 19.83 cases/100,000 inhabitants with a median of 7.95. Specific populations ranged from a minimum of 1.49 cases/100',\n",
       "    'Overall, the mean mortality was 19.83 cases/100,000 inhabitants with a median of 7.95. Specific populations ranged from a minimum of 1.49 cases/100,'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 1, 1, 1, 3, 4, 4],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  'vzmn6zep': {'greedy': 'Overall, the standardised mortality ratio (SMR) for Africa compared to Europe is 0.22 and compared to Northern America is 0.25, indicating lower mortality rates. When compared to Asia and Latin America & Caribbean, the',\n",
       "   'samples': [\"Overall, the standardized mortality ratio (SMR) for Africa compared to Europe or North America is 0.22-0.25, indicating a quarter of the death rate. Compared to Asia and Latin America & the Caribbean, Africa's\",\n",
       "    'Overall, the standardised mortality ratio (SMR) for Africa is 0.22 compared to Europe and 0.25 compared to North America, indicating lower mortality rates. When compared to Asia and Latin America & the Caribbean, the',\n",
       "    'Overall, the standardized mortality ratio for Africa is 0.22 compared to Europe and 0.25 compared to North America, indicating a lower mortality rate due to the younger population. Compared to Asia and Latin America & Caribbean, the ratio',\n",
       "    'Overall, the standardized mortality ratio (SMR) for Africa compared to Europe or North America is 0.22-0.25, indicating lower death rates. Compared to Asia and Latin America & the Caribbean, the SMR for Africa',\n",
       "    \"Overall, the standardised mortality ratio (SMR) for Africa is 0.22 compared to Europe and 0.25 compared to North America, suggesting Africa's mortality rates are about a quarter of those regions. When compared to Asia\",\n",
       "    'Overall, the standardised mortality ratio for Africa is 0.22 compared to Europe and 0.25 compared to North America, meaning deaths are reduced to a quarter. When compared to Asia and Latin America & Caribbean, the SMR',\n",
       "    \"Overall, the standardised mortality ratio (SMR) for Africa compared to Europe is 0.22, meaning Africa's mortality rate is about a quarter of Europe's. Compared to Northern America, the SMR is 0.25\",\n",
       "    \"Overall, the standardised mortality ratio for Africa compared to Europe and North America is 0.22-0.25, indicating lower mortality rates due to the younger population. Compared to Asia and Latin America, Africa's mortality ratio is\",\n",
       "    'The standardized mortality ratio (SMR) for Africa compared to Europe is 0.22 and compared to Northern America is 0.25, indicating lower mortality rates. Compared to Asia and Latin America & the Caribbean, the SMR is',\n",
       "    'Overall, the standardised mortality ratio for Africa is 0.22 compared to Europe and 0.25 compared to North America, indicating lower mortality rates due to the younger population. When compared to Asia, the ratio is 0.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 0, 0, 0, 1, 2, 3],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'ux4gr3tq': {'greedy': 'The global case-fatality rate was 6.0%. High-income countries had a higher case-fatality rate (75.0% of total deaths), while upper-middle-income countries had a lower case-fatality rate (20.7%',\n",
       "   'samples': ['The global case-fatality rate was 6.0%. High-income countries had 59.9% of cases and 75.0% of deaths, while upper-middle-income countries had 30.9% of cases and',\n",
       "    'The global case-fatality rate was 6.0%. High-income countries had case-fatality rates of 5.9%, while upper-middle-income countries had a rate of 6.5%. Lower-middle-income and low-income countries had case-fat',\n",
       "    'The overall global case-fatality rate was 6.0%. High-income countries had the highest percentage of both cases (59.9%) and deaths (75.0%), while upper-middle-income countries had 30.9% of',\n",
       "    'The global case-fatality rate was 6.0%. High-income countries had 59.9% of the cases and 75.0% of the deaths, while upper-middle-income countries had 30.9% of the',\n",
       "    'The global case-fatality rate was 6.0%. High-income countries had case-fatality rates of 6.4%, upper-middle-income countries had 5.2%, and lower-middle and low-income countries had 3.4% and',\n",
       "    'The global case-fatality rate was 6.0%. High-income countries had a higher percentage (75.0%) of deaths compared to upper-middle-income countries (20.7%). Higher-income countries also had higher incidence rates and death rates',\n",
       "    'The global case-fatality rate was 6.0%. High-income countries reported 59.9% of cases and 75.0% of deaths, while upper-middle-income countries reported 30.9% of cases and',\n",
       "    'The overall global case-fatality rate was 6.0%. High-income countries had the highest case-fatality rate, while lower-middle and low-income countries had lower rates. Upper-middle-income countries also had a higher case-fatality rate compared to lower',\n",
       "    'The global case-fatality rate was 6.0%. High-income countries had 59.9% of the cases and 75.0% of the deaths, while upper-middle-income countries had 30.9% of the',\n",
       "    'The overall global case-fatality rate was 6.0%. High-income countries had 59.9% of the cases and 75.0% of the deaths, while upper-middle-income countries had 30.9% of'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 3, 0, 2, 0, 4],\n",
       "   'entropy': 1.3592367006650063}},\n",
       " '47': {'no': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Risk factors for severe disease include underlying health conditions. Hospitalization, multisystem inflammatory syndrome in children (MIS-C), and death are possible but',\n",
       "    'Most children have mild symptoms or are asymptomatic. Serious illness is rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Complications more commonly affect older adults and those with underlying health conditions.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Risk factors for severe illness include underlying conditions and age.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare.',\n",
       "    'Most children recover without complications, but some may experience long-term effects or develop multisystem inflammatory syndrome (MIS-C).'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 2, 0, 0, 1, 3],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'w6ygorko': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Some may develop Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children recover without serious health issues. However, some may develop Multisystem Inflammatory Syndrome in Children (MIS-C) or long-term effects. Risk increases with age and underlying conditions.',\n",
       "    'Most children recover without serious issues, but some may develop multisystem inflammatory syndrome or long-term effects.',\n",
       "    'Most children recover well from COVID-19, but some may experience long-term effects or develop multisystem inflammatory syndrome.',\n",
       "    'Most children recover without serious health issues, but some may develop multisystem inflammatory syndrome or long-term effects.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic, but severe outcomes can occur, especially in those with underlying conditions.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon but can occur.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 3, 4, 5, 6, 1],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'lhykluue': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children have mild symptoms or are asymptomatic. Severe illness is rare. Hospitalization, multisystem inflammatory syndrome, and death are more likely in young children and those with underlying conditions.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic, but some can develop severe illness, primarily those with underlying conditions. Critical cases are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover fully, but some may experience long-term effects or develop Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Serious illness is rare. Complications are more likely in high-risk children.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Some may develop Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children recover fully with mild symptoms, but some may develop severe illness or long-term effects.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Hospitalization, inflammation syndrome, and multisystem inflammatory syndrome are more common in very young children and those with underlying conditions. Mortality is extremely low.',\n",
       "    'Most children who contract COVID-19 experience mild to moderate symptoms and recover fully. Severe illness is rare. However, some children may develop Multisystem Inflammatory Syndrome in Children (MIS-C), a rare but serious complication.',\n",
       "    'Most children who contract COVID-19 have mild symptoms or are asymptomatic. However, some may develop severe illness, especially those with underlying conditions. Hospitalization, while rare, can occur. Long-term effects in children are still being studied.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 1, 3, 4, 5, 3, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '7hh7s5x4': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children recover fully, but some may develop long COVID or multisystem inflammatory syndrome.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover without serious health issues. Some may develop Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children who contract COVID-19 experience mild symptoms or are asymptomatic. Severe outcomes are rare. However, some may develop Multisystem Inflammatory Syndrome in Children (MIS-C), a rare but serious complication.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Some may develop Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Risk factors for severe illness include underlying medical conditions and younger age. Some children develop Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover without serious health issues. Some may experience long-term effects. Severe cases are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 3, 3, 4, 3, 3],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'fheedtjb': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children recover fully, but some may experience long-term effects or develop Multisystem Inflammatory Syndrome in Children (MIS-C). Brief.',\n",
       "    'Most children recover fully, but some may develop multisystem inflammatory syndrome or long-term effects.',\n",
       "    'Most children who contract COVID-19 experience mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Complications like Multisystem Inflammatory Syndrome in Children (MIS-C) can occur but are uncommon.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover well from COVID-19, but some may experience long-term effects or develop multisystem inflammatory syndrome (MIS-C).',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover without severe symptoms, but some may experience multisystem inflammatory syndrome (MIS-C) or long-term effects.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Some may develop Multisystem Inflammatory Syndrome in Children (MIS-C).'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 3, 4, 5, 4, 5],\n",
       "   'entropy': 1.7480673485460896},\n",
       "  '8zivjhcx': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Complications like Multisystem Inflammatory Syndrome in Children (MIS-C) can occur, but are uncommon.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Serious illness is rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Some may develop multisystem inflammatory syndrome.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic, but some can develop severe illness, including multisystem inflammatory syndrome in children (MIS-C).',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover fully, but some may experience long-term effects. Severe cases are rare.',\n",
       "    'Most children who contract COVID-19 experience mild to moderate symptoms and recover fully. A small percentage may develop multisystem inflammatory syndrome (MIS-C), a rare but serious condition. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 2, 4, 3, 2, 0],\n",
       "   'entropy': 1.5571130980576455},\n",
       "  'bgmvn8kb': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Some may develop Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Complications are more likely in children with underlying conditions.',\n",
       "    'Most children who contract COVID-19 experience mild to moderate symptoms and recover fully. However, some may develop severe illness, especially those with underlying conditions. Long-term effects are still being studied.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Risk factors for severe illness include underlying health conditions and age.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Complications, when they occur, are more commonly associated with underlying conditions.',\n",
       "    'Most children who contract COVID-19 have mild symptoms or are asymptomatic. However, some may experience severe illness, particularly those with underlying conditions. Long-term effects in children are still being studied.',\n",
       "    'Most children who contract COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. However, some children can develop Multisystem Inflammatory Syndrome in Children (MIS-C), a rare but serious complication.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare.',\n",
       "    'Most children who contract COVID-19 experience mild symptoms or are asymptomatic. However, some may develop severe illness, including Multisystem Inflammatory Syndrome in Children (MIS-C).'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 4, 5, 3, 1, 0],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'sfu5ga0a': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children have mild symptoms or are asymptomatic. Severe illness is rare. Some children can develop Multisystem Inflammatory Syndrome (MIS-C), a rare but serious complication.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic, but some can develop severe illness, primarily those with underlying conditions. Hospitalization, multi-system inflammatory syndrome, and long-term effects are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon but can include Multisystem Inflammatory Syndrome in Children (MIS-C).',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare. Risk factors for severe illness include underlying conditions and age.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Serious illness is rare. Hospitalization, multisystem inflammatory syndrome, and death are more likely in young children and those with underlying conditions.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 0, 1, 2, 1, 1, 3],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'xeudi3i5': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children with COVID-19 have mild symptoms or are asymptomatic. Serious outcomes are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon but can occur, especially in immunocompromised children.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Risks increase with underlying conditions.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Risk factors for severe illness include underlying conditions and age.',\n",
       "    'Most children who contract COVID-19 experience mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 2, 3, 2, 3, 3],\n",
       "   'entropy': 1.2798542258336676},\n",
       "  'foaagway': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children with COVID-19 have mild symptoms or are asymptomatic, but some can develop severe illness, primarily those with underlying conditions.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic, but some can develop severe illness, primarily those with underlying conditions. Critical cases are rare. Long-term effects are still being studied.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children who contract COVID-19 have mild symptoms or are asymptomatic. However, some may experience severe illness, particularly those with underlying conditions. Long-term effects in children are still being studied.',\n",
       "    'Most children recover without issues, but some may experience long-term effects or severe illness requiring hospitalization. Risk factors include underlying conditions and age.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover without serious issues, but some may experience long-term effects or severe illness requiring hospitalization.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children recover fully, but some may develop multisystem inflammatory syndrome or long-term effects.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare. Risk factors for severe illness include underlying conditions and age. Hospitalization rates are higher in younger children. Multi-system inflammatory syndrome in children (MIS'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 3, 4, 3, 5, 1],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'f6tylzpm': {'greedy': 'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "   'samples': ['Most children have mild symptoms or are asymptomatic. Severe illness is rare. Hospitalization, multisystem inflammatory syndrome, and death are more common in those with underlying conditions.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon. Some children can develop Multisystem Inflammatory Syndrome (MIS-C), a rare but serious condition.',\n",
       "    'Most children recover fully with mild symptoms, but some may develop severe illness or long-term effects.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon but can occur, especially in those with underlying conditions.',\n",
       "    'Most children recover fully, but some can develop severe illness or long-term effects.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe illness is rare. Complications are uncommon.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Severe outcomes are rare.',\n",
       "    'Most children with COVID-19 have mild symptoms or are asymptomatic. Serious outcomes are rare.',\n",
       "    'Most children have mild symptoms or are asymptomatic. Severe outcomes are rare.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 4, 0, 4, 1],\n",
       "   'entropy': 1.5571130980576458}},\n",
       " '6': {'no': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, PCR tests, and LAMP tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, PCR tests (variants for rapid results).',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 0, 0, 2, 0, 0],\n",
       "   'entropy': 0.639031859650177},\n",
       "  '91e70966': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, PCR tests, and antibody tests.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 1, 0, 0, 2],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  'sz7tcgzc': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, molecular tests (PCR), and lateral flow tests.',\n",
       "    'Antigen tests, PCR tests (RNA detection).',\n",
       "    'Antigen tests, PCR tests, LAMP tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen tests, molecular tests (PCR), and LAMP tests.',\n",
       "    'Antigen tests, molecular tests (PCR).',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 0, 4, 5, 1, 0],\n",
       "   'entropy': 1.6094379124341},\n",
       "  'bzz9foxx': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen tests, PCR tests, lateral flow tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, PCR tests, and LFD (Lateral Flow Device) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, molecular tests (PCR).'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 1, 0, 1, 2, 1, 3],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  '6mewd1gl': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular tests.',\n",
       "    'Antigen tests, PCR tests (nasal swabs).',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, molecular tests (PCR), and lateral flow tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 0, 0, 2, 0, 2],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'u1vutef8': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen tests, molecular tests (PCR), and lateral flow tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, molecular tests (PCR).'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 0, 0, 1, 1, 2],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  '4yuhtvim': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen tests, molecular tests (PCR).',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen tests, PCR tests (rapid versions).',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 3, 0, 1, 1, 1],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'sodmxkgg': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, molecular tests (PCR), and lateral flow tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 1, 0, 0, 0, 1],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  'cjk0ggkt': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular tests.',\n",
       "    'Antigen tests, molecular tests (PCR), and LAMP tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, molecular tests (PCR), and lateral flow tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 0, 0, 0, 2, 2, 0],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  '1lgosiru': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 0, 0, 1, 0, 1],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  'waxtfm82': {'greedy': 'Antigen and molecular tests.',\n",
       "   'samples': ['Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen tests, PCR tests (nasal swabs), LAMP tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular tests.',\n",
       "    'Antigen and molecular (PCR) tests.',\n",
       "    'Antigen tests, PCR tests (rapid versions).'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 0, 1, 1, 0, 3],\n",
       "   'entropy': 1.1682824501765625}},\n",
       " '18': {'no': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['N95, surgical, and cloth masks can help prevent COVID-19 infection. N95 masks offer the highest protection.',\n",
       "    'Well-fitting, high-quality surgical masks or N95 respirators offer the best protection against COVID-19.',\n",
       "    '医用口罩和N95口罩被认为对预防新冠病毒感染非常有效。 (Medical masks and N95 masks are considered very effective in preventing coronavirus infection.)',\n",
       "    'N95, surgical masks, and cloth masks with at least two layers are effective.',\n",
       "    'N95, KN95, and surgical masks are effective.布口罩预防新冠病毒感染效果最佳吗？答案：N95、KN95和医用口罩有效。',\n",
       "    'N95, surgical masks, and cloth masks (with at least two layers) are effective.',\n",
       "    'N95, KN95, and surgical masks are effective.布口罩无效。',\n",
       "    'Well-fitting, high-quality N95, KN95, or surgical masks provide the best protection.',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are most effective. Cloth masks offer some protection but are less effective.',\n",
       "    'Well-fitted N95, KN95, or medical surgical masks provide the best protection against COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 3, 4, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'st7c4v9v': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['Medical-grade masks (N95, FFP2/3) and well-fitting cloth masks offer good protection.',\n",
       "    'Medical-grade masks like N95, surgical masks, and cloth masks with valve filters offer good protection.',\n",
       "    'N95 masks or equivalent offer the best protection.',\n",
       "    'N95 masks are highly effective, followed by surgical masks and cloth masks (in combination).',\n",
       "    'Medical-grade N95 masks and well-fitting surgical masks are effective.布口罩预防新冠感染效果较差。',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are effective. Cloth masks offer some protection when combined with physical distancing and other measures.',\n",
       "    'N95 masks and surgical masks are effective.',\n",
       "    'Medical-grade masks (N95, FFP2/3) and well-fitting cloth masks offer good protection.',\n",
       "    'N95 masks are highly effective, followed by surgical masks and cloth masks (in combination).',\n",
       "    'N95, surgical masks, and cloth masks (washed) are effective.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 4, 3, 0, 2, 5],\n",
       "   'entropy': 1.7480673485460894},\n",
       "  'e3icgsl9': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['Medical-grade masks like N95, FFP2/3, and surgical masks are most effective. Cloth masks offer some protection when combined with physical distancing and other hygiene practices.',\n",
       "    'N95, surgical, and cloth masks provide varying levels of protection. N95 offers the highest protection.',\n",
       "    'Well-fitted N95, KN95, or medical surgical masks offer the best protection. Cloth masks provide some protection when used with physical distancing and hand hygiene.',\n",
       "    'Medical-grade N95, KN95, and surgical masks are recommended. Cloth masks offer some protection when combined with other precautions.',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are most effective. Cloth masks offer some protection when used in conjunction with physical distancing and other hygiene measures.',\n",
       "    'Well-fitting, multi-layer cloth masks with metal nose wires and good fit are effective. Surgical masks and N95 respirators provide even better protection when fitted and used correctly.',\n",
       "    'N95 masks and医用外科口罩 (surgical masks) are effective.',\n",
       "    '医用口罩和N95口罩在预防COVID-19感染方面效果较好。建议在公共场所佩戴口罩。 (医用口罩和N95口罩在预防COVID-19感染方面效果较好。建议在公共场所佩戴口罩。)',\n",
       "    'N95, KN95, and surgical masks are effective.',\n",
       "    'Well-fitting, high-quality masks like N95, KN95, or surgical masks provide the best protection against COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 4, 5, 6, 2, 2],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'a6gaoeie': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['N95 masks and medical-grade surgical masks are highly effective. Cloth masks offer some protection when combined with other preventive measures.',\n",
       "    'N95 masks and医用外科口罩 (surgical masks) are effective. Cloth masks offer some protection but are less effective.',\n",
       "    'N95 masks are highly effective, followed by surgical masks and cloth masks (in combination).',\n",
       "    'N95, KN95, and medical surgical masks.',\n",
       "    'N95 masks are highly effective, followed by surgical masks and cloth masks (in combination).',\n",
       "    'N95, KN95, and surgical masks are effective.布口罩预防感染新冠最好的是哪种？答案：N95、KN95 和医用口罩有效。',\n",
       "    '医用级N95口罩和外科口罩效果较好。 (Medical-grade N95 masks and surgical masks are effective.)',\n",
       "    'Medical-grade masks (N95, FFP2/3) and well-fitting cloth masks offer good protection against COVID-19.',\n",
       "    'Medical-grade masks (N95, FFP2/3) and well-fitting cloth masks offer effective protection.',\n",
       "    'Medical-grade masks (N95, FFP2/3) and well-fitting cloth masks offer effective protection against COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 0, 2, 2, 3, 3, 3],\n",
       "   'entropy': 1.313834033192747},\n",
       "  'imv1ygf6': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['Well-fitting masks with multiple layers, such as cloth masks with metal nose wires and good fit, or medical-grade masks like N95s, are effective.',\n",
       "    'N95, KN95, and surgical masks are effective.',\n",
       "    'Medical-grade N95, KN95, and surgical masks are most effective.',\n",
       "    'Well-fitting N95, KN95, or surgical masks are effective. Cloth masks offer some protection when used with other mitigation efforts.',\n",
       "    'Well-fitting masks with multiple layers, such as N95, KN95, or cloth masks with valve-free filters, are effective.',\n",
       "    'Well-fitted N95, KN95, or surgical masks are effective. Cloth masks offer some protection when used in combination with physical distancing and other measures.',\n",
       "    'Well-fitting respirators like N95, KN95, or KF94 masks provide the best protection against COVID-19. Cloth masks offer some protection but are less effective.',\n",
       "    'N95 masks and surgical masks are effective.',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are most effective. Cloth masks offer some protection when combined with physical distancing and other measures.',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are most effective. Cloth masks offer some protection when combined with physical distancing and other hygiene measures.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 1, 4, 2, 5, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'vtxu50wz': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['N95, surgical masks, and cloth masks (washed) are effective.',\n",
       "    'N95, surgical masks, and cloth masks (when layered) are effective.',\n",
       "    'N95, surgical masks, and cloth masks (with at least two layers) are effective.',\n",
       "    '医用口罩和N95口罩在防止COVID-19感染方面效果最佳。 (Medical masks and N95 masks are the most effective in preventing COVID-19 infections.)',\n",
       "    'N95, surgical, and cloth masks can help prevent COVID-19 infection.',\n",
       "    'N95, KN95, and surgical masks are effective.布口罩无效。请回答：N95、KN95和医用口罩有效。',\n",
       "    'N95 masks and surgical masks are effective. Cloth masks offer some protection when combined with social distancing.',\n",
       "    'Well-fitting, respirator-grade masks like N95s and FFP2/3s offer the highest protection. Cloth masks with multiple layers provide some protection but are less effective. Combination use (e.g., medical mask + cloth) can',\n",
       "    'Well-fitting, multi-layer cloth masks or medical-grade masks (e.g., N95) are effective.',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are effective. Cloth masks offer some protection when combined with physical distancing and other precautions.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 1, 2, 2, 3, 1, 4],\n",
       "   'entropy': 1.4184836619456564},\n",
       "  'vkex8le2': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['Well-fitting, high-quality medical-grade masks like N95, KN95, or KF94 offer the best protection against COVID-19.',\n",
       "    'N95, KN95, and medical surgical masks are effective.布口罩预防新冠病毒感染效果如何？答：布口罩在预防新冠病毒感染方面效果有限。',\n",
       "    'N95, KN95, and surgical masks are effective.布口罩预防新冠感染效果最佳吗？答：N95、KN95和医用口罩有效。',\n",
       "    'Well-fitting, multi-layer cloth masks or surgical masks.',\n",
       "    'N95, surgical masks, and cloth masks (when layered) are effective.',\n",
       "    'N95 masks or well-fitting medical surgical masks are recommended.',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are most effective. Cloth masks offer some protection when combined with other防控措施。请将此翻译为英文。',\n",
       "    'Medical-grade N95 masks and surgical masks are effective. Cloth masks offer some protection when combined with other precautions.',\n",
       "    'Medical-grade N95 masks and surgical masks are effective. Cloth masks offer some protection when combined with other preventive measures.',\n",
       "    'Well-fitting masks with multiple layers, good filtration, and a tight seal are effective. Examples include N95, KN95, and well-rated cloth masks.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 4, 4, 4, 5],\n",
       "   'entropy': 1.6094379124341},\n",
       "  '84asc8do': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['Medical-grade masks like N95, FFP2/3, and surgical masks are most effective.布口罩效果较差。 请注意，具体选择应参考当地卫生部门的建议。',\n",
       "    'Well-fitting masks with multiple layers, such as those made of cotton and containing a filter, offer better protection. N95 respirators provide the highest protection.',\n",
       "    'Well-fitted N95, KN95, or surgical masks are effective. Cloth masks offer some protection when used with social distancing.',\n",
       "    'N95 masks are highly effective, but well-fitting medical surgical masks and cloth masks with multiple layers also offer good protection.',\n",
       "    'N95, surgical masks, and cloth masks (with at least two layers) are effective.',\n",
       "    'N95, KN95, and medical surgical masks are effective.',\n",
       "    'N95, KN95, and surgical masks are effective.布口罩预防新冠病毒感染效果最佳吗？答案：N95、KN95和医用口罩有效。',\n",
       "    'N95, surgical masks, and cloth masks (with at least two layers) are effective.',\n",
       "    'N95, surgical masks, and cloth masks (when layered) are effective.',\n",
       "    'Medical-grade N95 masks are highly effective, followed by surgical masks and cloth masks in layers.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 4, 3, 3, 3],\n",
       "   'entropy': 1.3592367006650066},\n",
       "  'f4sd7vbi': {'greedy': 'Based on the available evidence as of April 14, 2020, the American College of Physicians recommends N95 respirators, surgical masks, and cloth masks for reducing the transmission of SARS-CoV-2 infection. However',\n",
       "   'samples': ['Based on the provided context, N95 respirators, surgical masks, and cloth masks have different levels of effectiveness, with N95 respirators offering the highest protection. However, specific recommendations may evolve as new evidence becomes available. For the most',\n",
       "    'Based on the provided context, N95 respirators, surgical masks, and cloth masks are discussed, but the best available evidence at the time of writing (up to April 14, 2020) did not strongly favor one',\n",
       "    'Based on the available evidence as of 14 April 2020, N95 respirators, surgical masks, and cloth masks can reduce transmission of infection. The specific best mask may vary depending on the setting and other factors. For',\n",
       "    'Based on the context provided, N95 respirators, surgical masks, and cloth masks have varying levels of effectiveness in reducing transmission of infection, but the specific \"best\" mask is not definitively stated. The ACP recommends using the highest feasible',\n",
       "    'Based on the available evidence up to 14 April 2020, N95 respirators, surgical masks, and cloth masks can reduce infection transmission, but specific recommendations may evolve. For more current information, consult updated guidelines.',\n",
       "    'Based on the context provided, the American College of Physicians recommends N95 respirators, surgical masks, and cloth masks, though the effectiveness can vary depending on the situation. For the most protective option, N95 respirators are considered best,',\n",
       "    'The best masks for preventing infection by COVID-19, according to the American College of Physicians, are N95 respirators, followed by surgical masks, and then cloth masks. However, the effectiveness can vary based on proper fit and use.',\n",
       "    'Based on the available evidence as of April 14, 2020, N95 respirators, surgical masks, and cloth masks can all reduce transmission of SARS-CoV-2 infection. The specific best mask may vary depending',\n",
       "    'The ACP recommends N95 respirators, surgical masks, and cloth masks based on the best available evidence up to 14 April 2020. However, specific recommendations may change with new evidence.',\n",
       "    'Based on the context provided, the ACP recommends N95 respirators, surgical masks, and cloth masks, but the specific \"best\" mask is not clearly stated. For updates, refer to their periodic reviews.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  '702cq6to': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['Medical-grade masks like N95, FFP2/3, and surgical masks are effective. Cloth masks offer some protection when combined with physical distancing and other precautions.',\n",
       "    'N95, surgical, and cloth masks can help prevent COVID-19 infection. N95 masks offer the highest protection.',\n",
       "    'N95, surgical, and cloth masks can help prevent COVID-19 infection.',\n",
       "    'N95, KN95, and medical-grade surgical masks offer the best protection.布口罩效果较差。',\n",
       "    'N95 masks or well-fitting surgical masks are effective.',\n",
       "    'Medical-grade masks (N95, FFP2/3) and well-fitting surgical masks are effective. Cloth masks offer some protection when combined with social distancing and other hygiene measures.',\n",
       "    'N95 masks or medical-grade respirators offer the highest protection. Cloth masks with multiple layers provide some protection. Combination of masks (e.g., cloth over N95) can enhance effectiveness.',\n",
       "    'Medical-grade masks (N95, FFP2/3) and well-fitting cloth masks are effective.',\n",
       "    'Well-fitting, multi-layer cloth masks with metal nose wires and good fit are effective. Surgical masks and N95 respirators provide even better protection when worn correctly.',\n",
       "    'Medical-grade N95 masks and surgical masks are effective. Cloth masks offer some protection when combined with social distancing.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 4, 5, 6, 7, 4],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'rnle3aji': {'greedy': 'N95, KN95, and surgical masks are effective.',\n",
       "   'samples': ['N95, KN95, and surgical masks are effective.',\n",
       "    'Medical-grade masks like N95, surgical masks, and well-fitting cloth masks offer good protection.',\n",
       "    'Medical-grade masks (N95, KN95, surgical masks) are most effective.布口罩预防新冠感染效果最好。 （注：此处“布口罩”指合格的布口罩，不合格的布口罩防护效果有限。）',\n",
       "    'N95, surgical masks, and cloth masks (when layered) are effective.',\n",
       "    'Medical-grade N95 masks are highly effective, followed by surgical masks and cloth masks in combination.',\n",
       "    'Well-fitting respirators like N95, KN95, or FFP2 masks provide the best protection against COVID-19.',\n",
       "    'Medical-grade masks like N95, FFP2/3, and surgical masks are effective. Cloth masks offer some protection when combined with physical distancing and hand hygiene.',\n",
       "    'N95, KN95, and medical surgical masks.',\n",
       "    'Well-fitting, high-quality医用口罩 (surgical masks) and N95/KN95 masks are recommended. Avoid cloth masks for highest protection.',\n",
       "    'N95 masks are highly effective, followed by surgical masks and cloth masks (in combination).'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 2, 3, 4, 5, 5, 2],\n",
       "   'entropy': 1.6957425341696346}},\n",
       " '50': {'no': {'greedy': 'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This primes the immune system to recognize and fight the virus. mRNA vaccines are stable, quick',\n",
       "   'samples': ['mRNA vaccines for SARS-CoV-2 instruct cells to produce a viral protein, triggering an immune response. They have been widely used and are considered safe and effective. Clinical trials demonstrated high efficacy in preventing COVID-19. Production is relatively quick',\n",
       "    'mRNA vaccines for SARS-CoV-2 teach cells how to make a protein that triggers an immune response, have shown high efficacy, and have been authorized or approved by regulatory agencies.',\n",
       "    'mRNA vaccines teach cells how to make a protein that prompts an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This triggers immunity against the virus. mRNA vaccines are stable, easy to manufacture, and do',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This induces immunity against the virus. Several mRNA vaccines are authorized or in advanced stages of development',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This stimulates antibodies and T-cell response without causing infection. Approved mRNA vaccines include Pfizer-Bio',\n",
       "    \"mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a harmless piece of the virus's spike protein, prompting an immune reaction. Examples include Pfizer-BioNTech\",\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This stimulates antibodies specifically against the virus. mRNA vaccines are stable, fast-developed, and',\n",
       "    'mRNA vaccines teach cells how to make a protein that helps trigger an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This primes the immune system to recognize and fight the virus. Several mRNA vaccines are authorized',\n",
       "    'mRNA vaccines for SARS-CoV-2 instruct cells to produce a protein that triggers an immune response. They have been used in authorized COVID-19 vaccines by Pfizer-BioNTech and Moderna.',\n",
       "    'An mRNA vaccine for SARS-CoV-2 instructs cells to produce a viral protein, triggering an immune response. Approved vaccines use this technology.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 3, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '1v0f2dtx': {'greedy': 'An mRNA vaccine for the SARS-CoV-2 virus, called mRNA-1273, induces potent neutralizing antibodies and CD8 T cell responses and provides protection against SARS-CoV-2 infection in mice. It is currently in',\n",
       "   'samples': ['An mRNA vaccine for the SARS-CoV-2 virus, called mRNA-1273, induces potent neutralizing antibodies and CD8 T cell responses, and protects against SARS-CoV-2 infection in mice without causing immunopathology',\n",
       "    'An mRNA vaccine (mRNA-1273) for SARS-CoV-2 induces strong neutralizing antibodies and CD8 T cell responses, provides protection against infection in mice, and is in clinical trials.',\n",
       "    'An mRNA vaccine for SARS-CoV-2, mRNA-1273, induces potent neutralizing antibodies and CD8 T cell responses and protects against SARS-CoV-2 infection in mice. It is currently in Phase 2 clinical',\n",
       "    'An mRNA vaccine (mRNA-1273) for SARS-CoV-2 induces strong antibody and T cell responses, provides protection against infection in mice, and is in clinical trials.',\n",
       "    'An mRNA vaccine (mRNA-1273) for the SARS-CoV-2 virus has been developed. It expresses the prefusion-stabilized SARS-CoV-2 spike trimer, inducing strong neutralizing antibodies and CD',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus, called mRNA-1273, induces strong neutralizing antibodies and CD8 T cell responses, protects mice against lung and nose infections, and is advancing towards Phase 3 efficacy trials',\n",
       "    'An mRNA vaccine (mRNA-1273) for the SARS-CoV-2 virus has been developed, showing potent neutralizing antibodies and CD8 T cell responses in mice. It protects against lung and nasal infections without causing immunopath',\n",
       "    'An mRNA vaccine (mRNA-1273) for SARS-CoV-2 induces strong antibody and T-cell responses, protects mice, and is in clinical trials.',\n",
       "    'An mRNA vaccine for SARS-CoV-2, mRNA-1273, induces potent neutralizing antibodies and CD8 T cell responses, protects against infection in mice, and is in a Phase 2 clinical trial.',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus, called mRNA-1273, induces potent neutralizing antibodies and CD8 T cell responses and provides protection against SARS-CoV-2 infection in mice. It is in a'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 1, 2, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '6emy92i5': {'greedy': 'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This primes the immune system to recognize and fight the virus. mRNA vaccines are stable, quick',\n",
       "   'samples': ['mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This approach is new in a pandemic vaccine but has shown efficacy and a good safety profile.',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This approach has led to effective vaccines like Pfizer-BioNTech and Moderna. Safety',\n",
       "    'An mRNA vaccine for SARS-CoV-2 instructs cells to produce a protein that prompts an immune response, leading to protection against the virus. Approved vaccines use this technology.',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. Several mRNA vaccines are authorized or in late-stage trials. Key benefits include rapid development and scalability',\n",
       "    'mRNA vaccines for SARS-CoV-2 instruct cells to produce a protein that triggers an immune response. They have shown high efficacy and a good safety profile in clinical trials. Approved mRNA vaccines are Pfizer-BioNTech and Moderna.',\n",
       "    'mRNA vaccines teach cells how to make a protein that prompts an immune response against the virus. For SARS-CoV-2, they instruct cells to produce a spike protein. Several mRNA vaccines (e.g., Pfizer-BioNTech and Moderna',\n",
       "    'mRNA vaccines for SARS-CoV-2 teach cells how to make a piece of the virus to trigger an immune response. They have been shown to be effective and safe in clinical trials.批准',\n",
       "    'mRNA vaccines teach cells how to make a protein that helps trigger an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This induces immunity against the virus. Notably, mRNA vaccines do not alter DNA and',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. If exposed to the virus, the immune system is then prepared to fight it. mRNA vaccines',\n",
       "    'mRNA vaccines for SARS-CoV-2 teach cells how to make a protein that triggers an immune response. They have been shown to be highly effective in clinical trials and are now widely used.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'xbze5s3c': {'greedy': 'An mRNA vaccine for the SARS-CoV-2 virus, specifically mRNA-1273, began its first phase I clinical trial in March 2020 in the US. It encodes the spike protein of SARS-CoV',\n",
       "   'samples': ['The mRNA-1273 vaccine encodes the spike protein of SARS-CoV-2 and was the subject of the first phase I clinical trial in March 2020. It is part of a promising recent development in vaccine production',\n",
       "    'An mRNA-1273 vaccine developed by Moderna has entered phase I clinical trials. It encodes the S protein of SARS-CoV-2. International collaboration is crucial for rapid vaccine development and testing.',\n",
       "    'The mRNA-1273 vaccine encodes the S protein of SARS-CoV-2 and was the first mRNA-based vaccine to enter clinical trials in March 2020. It shows promise but faces challenges in rapid development and testing',\n",
       "    'The first phase I clinical trial of an mRNA-1273 vaccine began in the US in March 2020. It encodes the spike protein of SARS-CoV-2. Production of mRNA-based vaccines is a promising recent',\n",
       "    'An mRNA vaccine called mRNA-1273, encoding the S protein of SARS-CoV-2, entered phase I clinical trials in March 2020. It uses a novel lipid nanoparticle delivery system and shows promise but faces',\n",
       "    'An mRNA-1273 vaccine, which encodes the spike protein of SARS-CoV-2, began phase I clinical trials in March 2020 in the US. It is part of a promising recent development in vaccine production',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus, called mRNA-1273, began its first phase I clinical trial in March 2020 in the US. It uses a novel lipid nanoparticle (LNP)',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus, specifically mRNA-1273, began its first phase I clinical trial in March 2020 in the US. It uses a novel lipid nanoparticle (LNP)',\n",
       "    \"mRNA-1273, an mRNA-based vaccine against SARS-CoV-2, began its first phase I clinical trial in March 2020. It uses lipid nanoparticles to deliver the spike protein's mRNA, inducing an immune response\",\n",
       "    'An mRNA-1273 vaccine, developed by Moderna, uses mRNA to encode the S protein of SARS-CoV-2, inducing an immune response. It entered phase I clinical trials in March 2020. The approach'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 3, 4, 5, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'aju2nr9x': {'greedy': 'An mRNA vaccine for SARS-CoV-2 has shown promise, with recent studies identifying an optimized UTR combination called NASAR that enhances protein production and antigen expression both in vitro and in vivo. This suggests potential for developing an effective SARS-Co',\n",
       "   'samples': [\"An mRNA vaccine for SARS-CoV-2 shows promise due to recent advancements in mRNA technology. Researchers have identified a specific combination of 5' and 3' untranslated regions (NASAR) that enhances protein production efficiency. This optimized mRNA,\",\n",
       "    \"Messenger RNAs (mRNAs) have emerged as a promising platform for vaccination against SARS-CoV-2. A study identified an optimal combination of 5' and 3' UTRs, called NASAR, that enhances protein production\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise due to a newly identified UTR combination called NASAR, which enhances protein production and antigen expression both in vitro and in vivo. This discovery could lead to the development of an',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus is being developed, with promising results from studies on optimizing untranslated regions (UTRs) of mRNAs to enhance protein production and antigen expression. The optimized system, NASAR, shows significantly',\n",
       "    'An mRNA vaccine for SARS-CoV-2 has shown promise, with certain combinations of untranslated regions improving protein production efficiency. This has led to dramatic antigen expression both in vitro and in vivo when delivered via lipid nanoparticles, making it a potentially viable alternative',\n",
       "    'Messenger RNAs (mRNAs) have emerged as a promising platform for vaccination against SARS-CoV-2. A newly designed UTR combination called NASAR was found to be five to ten times more efficient than endogenous UTRs for',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus shows promise, with recent studies identifying an optimized UTR system called NASAR that enhances protein production. This system demonstrates effective antigen expression both in vitro and in vivo when delivered by lipid nanoparticles,',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus shows promise, with recent studies identifying an optimized UTR system called NASAR that enhances protein production and antigen expression both in vitro and in vivo. This system holds potential as an alternative SARS',\n",
       "    'An mRNA vaccine for SARS-CoV-2 has shown promise, with recent research indicating that certain optimized untranslated regions can dramatically enhance protein production and antigen expression both in vitro and in vivo. This suggests that such mRNA-based vaccines could be developed as potential',\n",
       "    'An mRNA vaccine for SARS-CoV-2 has shown promise due to a newly identified UTR combination called NASAR, which enhances protein production and antigen expression both in vitro and in vivo when delivered by lipid nanoparticles. This approach may lead to the'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'q77da2y3': {'greedy': 'An mRNA vaccine for SARS-CoV-2 has been designed using immunoinformatics to predict T and B lymphocyte epitopes. The vaccine includes 13 highly immunogenic epitopes, a strong adjuvant, and elements for proper',\n",
       "   'samples': [\"An mRNA vaccine for SARS-CoV-2 uses the virus's spike glycoprotein to generate a strong immune response, aiming to be antigenic, non-toxic, non-allergenic, and effective in inducing both T and B cell-mediated\",\n",
       "    \"An mRNA vaccine for SARS-CoV-2 uses the virus's spike glycoprotein to generate a robust immune response, involving both T and B cells, after filtering through various immunoinformatics tools and simulations. The vaccine design appears promising,\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus was designed using immunoinformatics to predict T and B lymphocyte epitopes. The vaccine was found to be antigenic, non-toxic, non-allergenic, and capable of',\n",
       "    'An mRNA vaccine for SARS-CoV-2 was designed using immunoinformatics to predict T and B lymphocyte epitopes. It includes 13 epitopes, a strong adjuvant, and other components for efficient cellular trafficking and secretion',\n",
       "    'An mRNA vaccine for SARS-CoV-2 was designed using immunoinformatics to predict T and B lymphocyte epitopes. The vaccine includes 13 highly immunogenic epitopes, a potent adjuvant, trafficking elements, a secretion',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus targets the spike glycoprotein, aiming to induce both T and B cell-mediated immune responses. It involves using immunoinformatics to predict and filter epitopes, ensuring the vaccine is antigen',\n",
       "    '',\n",
       "    'An mRNA vaccine for SARS-CoV-2 has been designed using immunoinformatics, incorporating T and B lymphocyte epitopes that are antigenic, non-toxic, and capable of inducing strong immune responses, making it a promising vaccine candidate',\n",
       "    \"An mRNA vaccine for SARS-CoV-2 was designed using immunoinformatics to target the virus's spike glycoprotein. The vaccine includes 13 epitopes, an adjuvant, trafficking elements, a secretion booster, and link\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been designed using immunoinformatics to predict T and B lymphocyte epitopes, which were then filtered based on antigenicity, toxicity, allergenicity, and cytokine induc'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '7ln7p715': {'greedy': \"An mRNA vaccine for the SARS-CoV-2 virus has shown promise in clinical trials, demonstrating efficacy and safety. It works by introducing a piece of the virus's genetic material (mRNA) that instructs cells to produce a harmless viral protein\",\n",
       "   'samples': [\"An mRNA vaccine for the SARS-CoV-2 virus has shown promising results, with several vaccines in development and some already authorized for use. These vaccines instruct cells to produce a piece of the virus's spike protein, which triggers an immune response without\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise, demonstrating both in vitro and clinical efficacy. It is one of the direct acting agents being developed against the virus.',\n",
       "    \"An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials. It trains the immune system to recognize and fight the virus by introducing a small piece of the virus's genetic material. Several mRNA vaccines, such as those\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials, demonstrating efficacy and safety. These vaccines instruct cells to produce a protein that triggers an immune response, providing protection against the virus. Several mRNA vaccines, including',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise in clinical trials with high efficacy rates. The vaccine trains the immune system to recognize and fight the virus without causing illness. It is being rapidly developed and deployed worldwide as part of',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials. It teaches the body to produce a protein that triggers an immune response against the virus. Several such vaccines have been authorized for emergency use worldwide. However,',\n",
       "    \"An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials. The vaccine instructs cells to produce a harmless piece of the virus's spike protein, prompting an immune response. Several mRNA vaccines, including those developed by\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials. It teaches the body to produce a protein that triggers an immune response, offering protection against the virus. Several mRNA vaccines, including Pfizer-BioNTech',\n",
       "    \"An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials, with several different versions currently being developed and tested by various companies and research institutions. These vaccines instruct cells to produce a harmless piece of the virus's spike\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise in clinical trials, demonstrating both in vitro and clinical efficacy. It is one of the direct acting agents currently being developed and tested against SARS-CoV-2.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 1],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'oiu80002': {'greedy': 'An mRNA vaccine for the SARS-CoV-2 virus has been developed and tested. It encodes the SARS-CoV-2 spike protein and is delivered via lipid nanoparticles. This vaccine induces high and dose-dependent antibody titers, robust neutral',\n",
       "   'samples': ['An mRNA vaccine for the SARS-CoV-2 virus has shown remarkable results, inducing high and dose-dependent SARS-CoV-2-specific antibody titers in mice, robust neutralization, a Th1-biased immune response, no A',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus involves encoding the spike protein within self-amplifying RNA encapsulated in lipid nanoparticles. It induces strong, dose-dependent antibody responses and robust neutralization of both pseudo-virus and wild-type virus',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been developed and shown to produce high and dose-dependent SARS-CoV-2-specific antibody titers in mice, robust neutralization of both a pseudo-virus and wild-type virus,',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been developed, which uses self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated in a lipid nanoparticle (LNP). It induces high and dose-dependent',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus encodes the viral spike protein and is delivered via lipid nanoparticles. It induces high and dose-dependent antibody titers and robust neutralization of the virus, with a Th1-biased immune',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown remarkable antibody titers and robust neutralization of the virus. It induces a Th1-biased response and no ADE, and also elicits cellular responses. The vaccine is',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown remarkable success. It induces high and dose-dependent SARS-CoV-2-specific antibody titers and robust neutralization of both pseudo-virus and wild-type virus. The vaccine el',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus encodes the viral spike protein and is delivered via lipid nanoparticles. It induces high and dose-dependent antibody titers and robust neutralization of the virus, with neutralization levels surpassing those seen',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been shown to produce high and dose-dependent antibody titers in mice, robust neutralization of both pseudo-virus and wild-type virus, a Th1-biased immune response, no',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been developed and shown to induce high and dose-dependent antibody titers in mice, robust neutralization of both pseudo-virus and wild-type virus, a Th1-biased response,'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 5, 6, 2, 2],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'bchcy4hn': {'greedy': 'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This primes the immune system to recognize and fight the virus. mRNA vaccines are stable, quick',\n",
       "   'samples': ['An mRNA vaccine for SARS-CoV-2 instructs cells to produce a viral protein, which triggers an immune response. Examples include Pfizer-BioNTech and Moderna vaccines.',\n",
       "    'An mRNA vaccine for SARS-CoV-2 instructs cells to produce a viral protein, stimulating an immune response. Examples include Pfizer-BioNTech and Moderna vaccines. They are easy to manufacture and show high efficacy. Safety and stability concerns',\n",
       "    'mRNA vaccines for SARS-CoV-2 instruct cells to produce a protein that triggers an immune response. They have shown high efficacy and good safety profiles in clinical trials. Approved mRNA vaccines include Pfizer-BioNTech and Moderna.',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This induces immunity against the virus. Approved mRNA vaccines exist for COVID-19.',\n",
       "    'An mRNA vaccine for SARS-CoV-2 instructs cells to produce a protein that triggers an immune response. Approved vaccines use this technology to provide immunity against COVID-19.',\n",
       "    'mRNA vaccines teach cells how to make a protein that prompts an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. Approved mRNA vaccines are effective and have good safety profiles. They can be rapidly produced and scaled',\n",
       "    'mRNA vaccines teach cells how to make a protein that helps trigger an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This stimulates immunity against the virus. Several mRNA vaccines (e.g., Pfizer-Bio',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. This approach has led to effective vaccines like Pfizer-BioNTech and Moderna. Safety',\n",
       "    'mRNA vaccines for SARS-CoV-2 teach cells how to make a protein that triggers an immune response. They have shown high efficacy and are relatively easy to produce and distribute. Clinical trials supported their safety and effectiveness. Approved mRNA vaccines include Pfizer-B',\n",
       "    'mRNA vaccines teach cells how to make a protein that triggers an immune response. For SARS-CoV-2, they instruct cells to produce a spike protein. Several are authorized or in late-stage trials.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 2, 3, 4, 0, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'el7d8lck': {'greedy': 'An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials, demonstrating efficacy and safety. It works by introducing a piece of genetic material (mRNA) that instructs cells to produce a harmless viral protein, triggering',\n",
       "   'samples': [\"An mRNA vaccine for the SARS-CoV-2 virus has shown promise, with several having demonstrated efficacy in clinical trials. These vaccines instruct cells to produce a harmless piece of the virus's spike protein, prompting an immune response. They have been approved\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials, demonstrating both in vitro and clinical efficacy.',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise in clinical trials. It teaches the body to produce a protein that triggers an immune response, providing protection against the virus. Several such vaccines have been approved for emergency use by regulatory',\n",
       "    \"An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials. It works by introducing a small piece of the virus's genetic material (mRNA) that instructs cells to produce a protein from the virus, which\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise in clinical trials, demonstrating high efficacy and safety.',\n",
       "    \"An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials. It trains the immune system to fight off the virus by introducing a small piece of the virus's genetic material, enabling the body to develop an immune response\",\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise in both in vitro and clinical trials. It targets the SARS-CoV-2 RNA genome. However, specific details regarding its efficacy and development timeline are not provided in the',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise, with several such vaccines being developed and tested. Some have already demonstrated promising efficacy in clinical trials.',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown promise, demonstrating both in vitro and clinical efficacy. However, more information and research are still needed to fully understand its effectiveness and long-term impact.',\n",
       "    \"An mRNA vaccine for the SARS-CoV-2 virus has shown promising results in clinical trials, demonstrating both safety and efficacy. These vaccines instruct cells to produce a harmless piece of the virus's spike protein, which triggers an immune response. Several mRNA\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  '1c15qxb8': {'greedy': 'An mRNA vaccine for the SARS-CoV-2 virus has been developed and shown to produce high and dose-dependent SARS-CoV-2-specific antibody titers in mice. It also induces robust neutralization of both pseudo-virus and wild-type',\n",
       "   'samples': ['An mRNA vaccine for the SARS-CoV-2 virus has been shown to produce high and dose-dependent SARS-CoV-2-specific antibody titers in mice. It also induces robust neutralization of both pseudo-virus and wild-type virus,',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus encodes the SARS-CoV-2 spike protein and is encapsulated in a lipid nanoparticle. It induces high and dose-dependent SARS-CoV-2-specific antibody titers and',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus involves using self-amplifying RNA encoding the SARS-CoV-2 spike protein delivered via lipid nanoparticles. It induces high and dose-dependent antibody titers, robust neutralization, a Th',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been developed using self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated in a lipid nanoparticle. It induces high, dose-dependent antibody titers and robust',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus encodes the viral spike protein and is delivered via lipid nanoparticles. It induces strong antibody and T-cell responses, including neutralizing antibodies more potent than those found in recovered patients. The vaccine also',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown remarkable results, including high and dose-dependent antibody titers, robust neutralization of both pseudo-virus and wild-type virus, Th1-biased immune response, no ADE',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown remarkable success in producing high and dose-dependent antibody titers in mice, robust neutralization of the virus, and a Th1-biased immune response. It also induces strong cellular',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been developed using self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated in a lipid nanoparticle. It induces high and dose-dependent antibody titers, robust',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has been shown to produce high and dose-dependent SARS-CoV-2 specific antibody titers in mice. It also induces robust neutralization of both pseudo-virus and wild-type virus,',\n",
       "    'An mRNA vaccine for the SARS-CoV-2 virus has shown remarkable success, inducing high and dose-dependent antibody titers, robust neutralization, a Th1-biased response, and strong cellular immunity. It also lacks antibody-dependent enhancement.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 3, 0, 7],\n",
       "   'entropy': 2.0253262207700677}},\n",
       " '17': {'no': {'greedy': 'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for the latest information.',\n",
       "   'samples': ['Clinical trials are ongoing, check websites like ClinicalTrials.gov for the latest information.',\n",
       "    'As of October 2021, numerous clinical trials are ongoing or completed. Check sites like ClinicalTrials.gov for the most current information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check reputable sources like ClinicalTrials.gov for the latest information.',\n",
       "    'Clinical trials are ongoing. Check resources like ClinicalTrials.gov for up-to-date information.',\n",
       "    'Clinical trials are ongoing, check websites like ClinicalTrials.gov for current options.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check websites like clinicaltrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials for coronavirus treatments and vaccines are ongoing. Check websites like ClinicalTrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials are ongoing or completed for coronavirus treatments and vaccines. Check reputable sources like ClinicalTrials.gov for the most current information.',\n",
       "    'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like clinicaltrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials for COVID-19 treatments and vaccines are ongoing. Check clinicaltrials.gov or local health authorities for the most current information.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 4, 3, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'h10o18ss': {'greedy': 'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for the latest information.',\n",
       "   'samples': ['Clinical trials for COVID-19 treatments and vaccines are ongoing. Check reputable sources like clinicaltrials.gov for the latest information.',\n",
       "    'Clinical trials are ongoing, check websites like ClinicalTrials.gov for updates.',\n",
       "    'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like clinicaltrials.gov for up-to-date information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check websites like ClinicalTrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials are ongoing for treatments and vaccines against the coronavirus. Check sites like ClinicalTrials.gov for up-to-date information.',\n",
       "    'Clinical trials are ongoing, check resources like ClinicalTrials.gov for up-to-date information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check resources like ClinicalTrials.gov for updates.',\n",
       "    'Clinical trials for COVID-19 vaccines and treatments are ongoing. Check current trials at sites like clinicaltrials.gov.',\n",
       "    'Clinical trials are ongoing, check websites like ClinicalTrials.gov for the latest information.',\n",
       "    'Clinical trials for COVID-19 treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for the most current information.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 0, 1, 0, 1, 0],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  'dzvfaa8z': {'greedy': 'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for the latest information.',\n",
       "   'samples': ['As of October 2021, numerous clinical trials are ongoing or have recently concluded for coronavirus vaccines and treatments. Check reliable sources like clinicaltrials.gov for the latest information.',\n",
       "    'Clinical trials for COVID-19 treatments and vaccines are ongoing. Check reputable sources like clinicaltrials.gov for the most current information.',\n",
       "    'As of September 2023, numerous clinical trials are ongoing for COVID-19 treatments and vaccines. Check reputable sources like clinicaltrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials are ongoing for coronavirus treatments and vaccines. Check reputable sources like ClinicalTrials.gov for up-to-date information.',\n",
       "    'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like clinicaltrials.gov for the latest information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check websites like clinicaltrials.gov for updates.',\n",
       "    'Clinical trials for COVID-19 vaccines and treatments are ongoing. Check resources like ClinicalTrials.gov for the most up-to-date information.',\n",
       "    'Yes, as of the latest data, clinical trials for COVID-19 vaccines and treatments are ongoing. Check reputable sources for the most current information.',\n",
       "    'Yes, as of the latest updates, clinical trials for coronavirus vaccines and treatments are ongoing. Check websites like ClinicalTrials.gov for the most current information.',\n",
       "    'Clinical trials for coronavirus treatments and vaccines are ongoing. Check reputable sources like ClinicalTrials.gov for the most up-to-date information.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 2, 1, 3, 4, 1],\n",
       "   'entropy': 1.4184836619456564},\n",
       "  'tjsa86l7': {'greedy': 'Yes, there were 360 clinical studies registered in China and 74 in the U.S. as of March 9, 2020, focusing on various interventions including Traditional Chinese Medicine, antiviral therapies, and vaccines',\n",
       "   'samples': ['Yes, there were 360 studies with a total sample size of 268, 773 participants registered on the Chinese clinical trial registration website, and 74 studies with a total sample size of 73,',\n",
       "    'Yes, there were 360 clinical studies registered in China and 74 in the U.S. as of March 9, 2020, involving a total of over 340,000 participants.',\n",
       "    'Yes, there were 360 interventional studies registered on Chinese clinical trial registration websites and 74 interventional studies registered on the U.S. NIH clinical trial registration website as of March 9, 2020. The most',\n",
       "    'Yes, as of March 9, 2020, there were 360 clinical studies registered in China and 74 in the U.S., totaling over 340,000 participants.',\n",
       "    'Yes, there were 360 clinical studies registered in China and 74 studies registered in the U.S. as of March 9, 2020, focusing on various interventions including Traditional Chinese Medicine, antiviral therapies,',\n",
       "    'Yes, there were 360 interventional studies registered in China and 54 interventional studies registered in the United States as of March 9, 2020. These studies covered various interventions including Traditional Chinese Medicine, antiv',\n",
       "    'Yes, there were 360 interventional studies with a total sample size of 268, 773 participants registered on the Chinese clinical trial registration website, and 54 interventional studies with a total sample size of',\n",
       "    'Yes, there were 360 interventional studies registered on the Chinese clinical trial registration website and 54 interventional studies registered on the U.S. NIH clinical trial registration website as of March 9, 2020. These',\n",
       "    'Yes, there are clinical trials available for coronavirus disease 2019 (COVID-19), with a total of 360 studies registered in China and 74 studies in the U.S. as of March 9,',\n",
       "    'Yes, there were 360 studies with a total sample size of 268,773 participants registered on the Chinese clinical trial registration website, and 74 studies with a total sample size of 73,72'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 3, 4, 5, 6, 0],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'jwrheaph': {'greedy': 'Yes, as of March 12, 2020, there were over 382 studies and more than 80 randomized controlled trials registered in clinical trials databases addressing COVID-19.',\n",
       "   'samples': ['Yes, as of March 12, 2020, there are over 382 studies and more than 80 randomized controlled trials registered in clinical trials databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there were over 382 studies and more than 80 randomized controlled trials registered in clinical trials databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there are over 382 studies and more than 80 randomized controlled trials registered in clinical trial databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there are over 382 studies and more than 80 randomized controlled trials registered in clinical trials databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there are over 382 studies and more than 80 randomized controlled trials registered in clinical trials databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there were over 382 studies and more than 80 randomized controlled trials registered in clinical trials databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there are over 382 studies and more than 80 randomized controlled trials registered in clinical trial databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there were over 382 studies and more than 80 randomized controlled trials registered in clinical trial databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there are over 382 studies and more than 80 randomized controlled trials registered in clinical trials databases addressing COVID-19.',\n",
       "    'Yes, as of March 12, 2020, there were over 382 studies and more than 80 randomized controlled trials registered in clinical trial databases addressing COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 1, 1, 0, 0, 0],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  'vxqdfiel': {'greedy': 'Yes, there were at least 24 clinical trials involving over 20 medicines being tested for treating coronavirus in March 2020.',\n",
       "   'samples': ['Yes, there were 24 clinical trials involving over 20 medicines identified in a search of the clinicaltrials.gov database in March 2020.',\n",
       "    'Yes, as of March 2020, there were 24 clinical trials involving over 20 medicines being tested for treating patients infected with SARS-CoV-2 (the novel coronavirus). These trials are part of efforts to find',\n",
       "    'Yes, there were at least 24 clinical trials identified in March 2020 involving more than 20 medicines for treating coronavirus.',\n",
       "    'Yes, as of March 2020, there were at least 24 clinical trials involving over 20 medicines being tested for treating coronavirus infections.',\n",
       "    'Yes, as of March 2020, there were at least 24 clinical trials involving over 20 medicines being tested for treating coronavirus.',\n",
       "    'Yes, there were at least 24 clinical trials involving more than 20 medicines as of March 2020. These trials were designed to test treatments for patients infected with SARS-CoV-2.',\n",
       "    'Yes, as of March 2020, there were at least 24 clinical trials listed in the clinicaltrials.gov database testing various medicines for treating coronavirus infections.',\n",
       "    'Yes, there were at least 24 clinical trials involving over 20 medicines being tested for the coronavirus as of March 2020.',\n",
       "    'Yes, there were 24 clinical trials involving over 20 medicines identified in March 2020 for the treatment of COVID-19.',\n",
       "    'Yes, there were at least 24 clinical trials involving more than 20 medicines being tested as of March 2020 according to the clinicaltrials.gov database.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 1, 4, 5, 3, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'ev8n2n52': {'greedy': 'Yes, there are various clinical trials ongoing for COVID-19, including treatments like Hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, Remdesivir, and vaccines',\n",
       "   'samples': ['Yes, there are various clinical trials ongoing for COVID-19, including drug-based trials of Hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, Remdesivir,',\n",
       "    'Yes, various clinical trials are ongoing for treating and preventing COVID-19, including drug-based trials, vaccine development, and other therapeutic methods.',\n",
       "    'Yes, various clinical trials are ongoing for COVID-19, including treatments like Hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, Remdesivir, and vaccines such',\n",
       "    'Yes, various clinical trials are underway for COVID-19, including drug-based trials of hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, and Remdesivir,',\n",
       "    'Yes, various clinical trials are ongoing for COVID-19, including drug-based trials with hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, and Remdesivir,',\n",
       "    'Yes, there are various clinical trials underway for COVID-19, including tests on treatments like hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, Remdesivir,',\n",
       "    'Yes, there are various clinical trials ongoing for COVID-19, including tests on Hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, ChAdOx1 nCo',\n",
       "    'Yes, there are various clinical trials ongoing for COVID-19, including treatments like hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, Remdesivir, and vaccines',\n",
       "    'Yes, there are various clinical trials ongoing for COVID-19, including treatments like Hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, Remdesivir, and vaccines',\n",
       "    'Yes, various clinical trials are ongoing for COVID-19, including hydroxychloroquine-Azithromycin, chloroquine, lopinavir/ritonavir, ChAdOx1 nCoV-1'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 2, 3, 4, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'zsgv8iec': {'greedy': 'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for the latest information.',\n",
       "   'samples': ['Clinical trials for coronavirus treatments and vaccines are ongoing. Check websites like ClinicalTrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials are ongoing for COVID-19 treatments and vaccines. Check reputable sources like clinicaltrials.gov for the latest information.',\n",
       "    'As of October 2023, many clinical trials are ongoing for coronavirus treatments and vaccines. Check clinicaltrials.gov for the most current information.',\n",
       "    'As of October 2023, numerous clinical trials for coronavirus treatments and vaccines are ongoing. Check clinicaltrials.gov or local health authorities for the most current information.',\n",
       "    'Clinical trials for coronavirus treatments and vaccines are ongoing. Check websites like ClinicalTrials.gov for updates.',\n",
       "    'Clinical trials for coronavirus treatments and vaccines are ongoing. Check reputable sources like ClinicalTrials.gov for the most current information.',\n",
       "    'Yes, as of the latest updates, clinical trials for coronavirus vaccines and treatments are ongoing. Check reputable sources like clinicaltrials.gov for the most current information.',\n",
       "    'As of September 2023, multiple clinical trials are ongoing for coronavirus treatments and vaccines. Check resources like ClinicalTrials.gov for the latest information.',\n",
       "    'Yes, as of the last update, clinical trials for coronavirus vaccines and treatments are ongoing. Check reputable sources for the most current information.',\n",
       "    'Clinical trials for COVID-19 treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for up-to-date information.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 3, 3, 2, 4, 2],\n",
       "   'entropy': 1.5571130980576455},\n",
       "  'pwd6a1vr': {'greedy': 'Clinical trials for coronavirus treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for the latest information.',\n",
       "   'samples': ['As of my last update, clinical trials for COVID-19 vaccines and treatments are ongoing. Check websites like ClinicalTrials.gov for the most current information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check reputable sources like clinicaltrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials are ongoing worldwide. Check resources like ClinicalTrials.gov for the latest studies and enrollment information.',\n",
       "    'Clinical trials for COVID-19 treatments and vaccines are ongoing. Check resources like ClinicalTrials.gov for the most current information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check websites like ClinicalTrials.gov for the latest information.',\n",
       "    'As of October 2023, numerous clinical trials are ongoing for coronavirus treatments and vaccines. Check sites like ClinicalTrials.gov for the latest information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check reputable sources like clinicaltrials.gov for up-to-date information.',\n",
       "    'Clinical trials for coronavirus vaccines and treatments are ongoing. Check resources like clinicaltrials.gov for updates.',\n",
       "    'As of October 2023, numerous clinical trials are ongoing for coronavirus treatments and vaccines. Check sites like ClinicalTrials.gov for up-to-date listings.',\n",
       "    'As of my last update, numerous clinical trials are ongoing for COVID-19 vaccines and treatments. Check websites like ClinicalTrials.gov for the most current information.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 1, 4, 4, 0],\n",
       "   'entropy': 1.5571130980576458},\n",
       "  'f5tpz8ze': {'greedy': 'Yes, over 200 clinical trials are now underway globally for the novel Coronavirus. The WHO has also organized a multinational randomized trial called SOLIDARITY to study the effectiveness of several drugs.',\n",
       "   'samples': ['Yes, over 200 clinical trials are now underway globally for the novel Coronavirus. The WHO has also organized the SOLIDARITY trial to study the effectiveness of several promising drugs.',\n",
       "    'Yes, over 200 clinical trials are now underway globally for the novel Coronavirus. The WHO has also organized a multinational randomized trial called SOLIDARITY to study the effectiveness of certain drugs.',\n",
       "    'Yes, over 200 clinical trials are now underway across the globe for effective therapies against SARS-CoV-2. The WHO has also organized the SOLIDARITY trial to study the effects of several promising drugs.',\n",
       "    'Yes, over 200 clinical trials are now underway across the globe for the novel Coronavirus. The SOLIDARITY trial, organized by the WHO, is a multinational randomized trial studying the effectiveness of several promising drugs.',\n",
       "    'Over 200 clinical trials are now underway globally for the novel Coronavirus. The WHO has also organized the SOLIDARITY trial to study the effectiveness of certain drugs.',\n",
       "    'Over 200 clinical trials are now underway globally for effective therapies against the novel Coronavirus. The WHO has also organized a multinational randomized trial called SOLIDARITY to study the effects of several promising drugs.',\n",
       "    'Over 200 clinical trials are now underway globally for effective therapies against SARS-CoV-2. The SOLIDARITY trial, organized by the WHO, is studying several promising drug combinations.',\n",
       "    'Over 200 clinical trials are now underway globally for the novel Coronavirus. The WHO has also organized a multinational randomized trial called SOLIDARITY to study the effectiveness of several promising drugs.',\n",
       "    'Yes, over 200 clinical trials are now underway globally for the novel Coronavirus. The WHO has also organized a multinational randomized trial called SOLIDARITY to study the effects of several drugs.',\n",
       "    'Yes, over 200 clinical trials are now underway globally for the novel Coronavirus. The WHO has also organized a multinational randomized trial called SOLIDARITY to study the effectiveness of several drugs.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 2, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'eitnkdi9': {'greedy': 'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents for treating COVID-19.',\n",
       "   'samples': ['Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents for treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents in treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various agents in treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents in treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents for treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents for treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents in treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents for treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents for treating COVID-19.',\n",
       "    'Yes, more clinical trials are being conducted to confirm the efficacy and safety of various potential therapeutic agents for treating COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 0, 0, 1, 0, 0, 0],\n",
       "   'entropy': 0.8979457248567797}},\n",
       " '22': {'no': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a known risk in COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a potential risk in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a known risk in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 2, 0, 3, 0, 0],\n",
       "   'entropy': 0.9404479886553263},\n",
       "  'emj1wdac': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications are a known risk in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a potential risk in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 2, 2, 2, 2, 1],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'zfs45uvp': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are a known risk in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are a recognized risk in COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 1, 0, 1, 1, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  '4mmx91s6': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications are a potential risk in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are a recognized risk in COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a recognized risk in patients with COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 1, 0, 1, 0, 1, 2],\n",
       "   'entropy': 0.9433483923290391},\n",
       "  'jot62meo': {'greedy': 'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "   'samples': ['Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in patients with COVID-19.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 1, 1, 2, 0],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  'h7x4yzet': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are a known risk.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a recognized risk in patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are a potential risk in some patients with COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 0, 1, 1, 0, 0, 1],\n",
       "   'entropy': 0.6931471805599453},\n",
       "  'shu0ai31': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are a recognized risk in COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 1, 0, 0, 0],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'j6wdshto': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications are a known risk in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 1, 1, 0, 1, 0],\n",
       "   'entropy': 0.6730116670092565},\n",
       "  '0ec1cu8q': {'greedy': 'Yes, cardiac complications are likely in patients with COVID-19, particularly those with pre-existing cardiovascular disease.',\n",
       "   'samples': ['Yes, cardiac complications are likely in patients with COVID-19, especially those with pre-existing cardiovascular disease.',\n",
       "    'Yes, cardiac complications are noted in patients with COVID-19, especially those with pre-existing cardiovascular disease. These can include acute pericarditis, left ventricular dysfunction, and acute myocardial injury.',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19, especially those with pre-existing cardiovascular disease.',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19, especially those with pre-existing cardiovascular disease.',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19, particularly those with pre-existing cardiovascular disease.',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19, particularly those with pre-existing cardiovascular disease.',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19, particularly those with pre-existing cardiovascular disease.',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19, particularly those with pre-existing cardiovascular disease.',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19. Pre-existing cardiovascular disease is associated with higher ICU admission and mortality rates. Cardiac presentations include acute pericarditis, left ventricular dysfunction, and acute myocardial injury. However',\n",
       "    'Yes, cardiac complications are likely in patients with COVID-19, especially those with pre-existing cardiovascular disease.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 2, 2, 2, 3, 0],\n",
       "   'entropy': 1.1935496040981333},\n",
       "  '1o2degbz': {'greedy': 'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "   'samples': ['Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications are a known risk in COVID-19 patients.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 1, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'oqv5zamp': {'greedy': 'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "   'samples': ['Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a known risk in patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some patients with COVID-19.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications can occur in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are possible in some COVID-19 patients.',\n",
       "    'Yes, cardiac complications are a potential risk in some patients with COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': 0.3250829733914482}},\n",
       " '32': {'no': {'greedy': 'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "   'samples': ['Yes, SARS-CoV-2 has several subtypes including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major lineages include B.1 (Alpha), B.1.1 (Beta), B.1.2 (Gamma), and B.1.351 (Eta), among',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main ones include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.6',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main lineages include B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (',\n",
       "    'Yes, SARS-CoV-2 has subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main ones are Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.6',\n",
       "    'Yes, SARS-CoV-2 has several subtypes including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 1, 6, 0],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'h0q93in1': {'greedy': 'Yes, SARS-CoV-2 has sixteen well-defined subtypes based on widely shared polymorphisms in specific genes. Six subtypes were predominant.',\n",
       "   'samples': ['Yes, SARS-CoV-2 has subtypes. Six virus subtypes were predominant among the sixteen well-defined subtypes identified in the study, based on polymorphisms in specific genes. However, all sixteen subtypes showed amino acid replacements that',\n",
       "    'Yes, SARS-CoV-2 has sixteen subtypes, distinguished by widely shared polymorphisms in specific genes. The six predominant subtypes were identified, but all sixteen show amino acid replacements with potential phenotypic implications. These subtypes likely',\n",
       "    'Yes, SARS-CoV-2 has 16 subtypes based on widely shared polymorphisms in specific genes. The six predominant subtypes are part of this classification.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. There are sixteen well-defined subtypes identified based on widely shared polymorphisms in specific genes. Six subtypes were predominant.',\n",
       "    'Yes, SARS-CoV-2 has sixteen subtypes based on widely shared polymorphisms in specific genes. Six virus subtypes were predominant.',\n",
       "    'Yes, SARS-CoV-2 has 16 subtypes, which were identified based on widely shared polymorphisms in specific genes. The six predominant subtypes were highlighted, but all 16 showed amino acid replacements with potential phenotyp',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Six predominant subtypes were identified, and there are a total of sixteen well-defined subtypes in the global population. The subtypes are defined by widely shared polymorphisms in specific genes.',\n",
       "    'Yes, SARS-CoV-2 has sixteen well-defined subtypes based on widely shared polymorphisms in certain genes. Six subtypes were predominant.',\n",
       "    'Yes, SARS-CoV-2 has sixteen well-defined subtypes based on widely shared polymorphisms in specific genes. Six virus subtypes were predominant.',\n",
       "    'Yes, SARS-CoV-2 has sixteen subtypes, which were determined based on widely shared polymorphisms in specific genes. The six predominant subtypes were identified among these. However, for more detailed information on the exact subtypes, please'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 1, 1, 3, 2, 2, 1],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  '1sbnewog': {'greedy': 'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. These are distinguished by a novel synonymous mutation of D614G.',\n",
       "   'samples': ['Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. These are differentiated by a novel synonymous mutation of D614G.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. They are distinguished by a novel synonymous mutation of D614G.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. These subtypes are distinguished by a novel synonymous mutation of D614G.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. They are differentiated by a novel synonymous mutation of D614G.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. These are distinguished by a novel synonymous mutation at D614G.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. These are distinguished by a novel synonymous mutation at D614G.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b. They are differentiated by a novel synonymous mutation of D614G.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b.',\n",
       "    'Yes, SARS-CoV-2 has subtypes SARS-CoV-2a and SARS-CoV-2b.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  '8s8gezpz': {'greedy': 'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "   'samples': ['Yes, SARS-CoV-2 has six different subtypes. However, the specific subtypes are not named in the given context.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes with over 13752 single nucleotide polymorphisms (SNPs). However, the specific subtypes are not named in the given context.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.',\n",
       "    'Yes, SARS-CoV-2 has six different subtypes.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  'di36olka': {'greedy': 'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "   'samples': ['Yes, SARS-CoV-2 has subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are named A, B, and their descendants. Lineage B is more prevalent and includes B.1, B.1.1, B.1.1.',\n",
       "    'Yes, SARS-CoV-2 has subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major ones include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 2, 2, 0, 0, 3, 0],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'wbwmmozo': {'greedy': 'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "   'samples': ['Yes, SARS-CoV-2 has subtypes. Major variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major ones include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages include B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "    'Yes, SARS-CoV-2 has subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main ones are Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.6',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are A, B, and their sub-lineages like B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are called A, B, C, etc. Lineage B is predominant and includes B.1, B.1.1, B.1.1.7'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 1, 3, 3, 4, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'vc78113o': {'greedy': 'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "   'samples': ['Yes, SARS-CoV-2 has subtypes. The main ones include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.6',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are named A, B, C, etc. Lineage B is the most common and includes sub-lineages B.1, B.1.1, etc.',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages include B.1 (Alpha), B.1.1 (Beta), B.1.2 (Gamma), and B.1.351 (Zeta',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are named A, B, and C, with B further divided into B.1, B.1.1, B.1.1.7 (Alpha),',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, and B.1.1.7 (Alpha), B.1.351 (Beta), P.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages include B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "    'Yes, SARS-CoV-2 has several sublineages, including B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 6, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'm61qihyq': {'greedy': 'The study by Tang et al. (2020) suggested the existence of two subtypes of SARS-CoV-2, but this claim has been disputed. There are multiple sublineages within SARS-CoV-2, but',\n",
       "   'samples': ['SARS-CoV-2 has subtypes, but the specific subtypes mentioned in the context are not detailed. The study by Tang et al. (2020) suggested the presence of two major types, with one being described as \"',\n",
       "    \"Based on the provided context, Tang et al. (2020) identified two types of SARS-CoV-2, but the current assessment is that the major conclusions of their study cannot be substantiated. Therefore, it's unclear if\",\n",
       "    'The study by Tang et al. (2020) suggested the existence of two subtypes of SARS-CoV-2, but this claim has not been substantiated by further research. It is important to approach such claims with caution.',\n",
       "    'Tang et al. (2020) identified two major types of SARS-CoV-2, but further examination does not support their conclusions about the nature of these types. The existence of subtypes in viruses is common, but claiming one',\n",
       "    'Tang et al. (2020) identified two subtypes of SARS-CoV-2, but their findings have been disputed. The existence and characteristics of these subtypes remain under scrutiny. Viral subtyping can be complex, and',\n",
       "    'Based on the given context, Tang et al. (2020) identified two major types of SARS-CoV-2. However, the claim about one type being \"more aggressive\" is not supported by further examination. Subtypes can',\n",
       "    'Based on the provided context, there are at least two types of SARS-CoV-2 mentioned: one described as \"more aggressive\" and another. However, the detailed examination of the study by Tang et al. suggests that the evidence for distinct',\n",
       "    \"Based on the context provided, Tang et al. (2020) identified two major types of SARS-CoV-2, but the study's main conclusions were disputed. The existence of subtypes in SARS-CoV-2 is\",\n",
       "    'The study by Tang et al. (2020) suggested there were two main subtypes of SARS-CoV-2, but this conclusion has been disputed. No definitive subtypes are currently recognized. Viral evolution is ongoing and new',\n",
       "    'The study by Tang et al. (2020) suggested the existence of two types of SARS-CoV-2, but this claim has been challenged. Therefore, it is not clear whether SARS-CoV-2 has subtypes'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 5, 7, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'sf5jd7cv': {'greedy': 'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "   'samples': ['Yes, SARS-CoV-2 has several subtypes including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.',\n",
       "    \"Yes, SARS-CoV-2 has subtypes. The main lineages are B.1 (ancestral), B.1.1 (the 'European' cluster), B.1.1.7 ('Alpha'), B.1.\",\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main ones include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.6',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.61',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages include B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 6, 6, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'il22usnh': {'greedy': 'The text does not specify any subtypes of SARS-CoV-2. It mentions that phylogenetic reconstructions suggest possible multiple introductions of the virus into Italy, but does not provide information on subtypes.',\n",
       "   'samples': ['Based on the provided context, there is no specific mention of subtypes of SARS-CoV-2. The text suggests multiple introductions of SARS-CoV-2 into Italy but does not detail any subtypes. For more information on sub',\n",
       "    'The text does not provide specific subtypes of SARS-CoV-2. It mentions that phylogenetic reconstructions suggest possible multiple introductions of the virus into Italy, implying genetic diversity but not naming specific subtypes. For precise subtypes,',\n",
       "    'The text does not specify any subtypes of SARS-CoV-2. It mentions multiple introductions but does not classify them into subtypes.',\n",
       "    'Based on the provided context, the specific subtypes of SARS-CoV-2 are not mentioned. The text suggests there may be multiple introductions of the virus to Italy, but does not classify them into distinct subtypes. For more detailed information',\n",
       "    'The text does not specify any subtypes of SARS-CoV-2. It mentions that phylogenetic reconstructions suggest possible multiple introductions of the virus into Italy, implying genetic variation but not naming specific subtypes. For more detailed information on',\n",
       "    'The text does not specify any subtypes of SARS-CoV-2; it only mentions that there were possible multiple introductions of the virus into Italy based on genomic analysis. Subtypes would need to be explicitly stated or defined in further research findings',\n",
       "    'Based on the provided context, no specific subtypes of SARS-CoV-2 are mentioned. The text discusses potential multiple introductions of the virus into Italy but does not detail subtypes. For accurate information on subtypes, further specific research or',\n",
       "    'The text does not specify any subtypes of SARS-CoV-2. It mentions that phylogenetic reconstructions suggest possible multiple introductions, but does not detail specific subtypes.',\n",
       "    'The text does not specify any subtypes of SARS-CoV-2. It suggests multiple introductions but does not categorize them into distinct subtypes.',\n",
       "    'Based on the provided context, no specific subtypes of SARS-CoV-2 are mentioned. The text suggests multiple introductions of the virus into Italy but does not describe specific subtypes. For the most up-to-date information on subtypes,'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 0, 2, 2, 0],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  'm8m5d9yo': {'greedy': 'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1, B.1.1, B.1.1.7 (Alpha), B.1.351 (Beta), P.1',\n",
       "   'samples': ['Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are B.1 (Alpha), B.1.1 (Beta), B.1.2 (Gamma), and B.1.351 (Eta),',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major lineages include B.1 (Alpha), B.1.1 (Beta), B.1.2 (Gamma), and B.1.351 (Eta), among',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. The main lineages are named A, B, and their sub-lineages like B.1.1.7 (Alpha), B.1.351 (Beta), P.',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Major variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has subtypes. Main variants include Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617',\n",
       "    'Yes, SARS-CoV-2 has several subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.',\n",
       "    'Yes, SARS-CoV-2 has subtypes, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 0, 2, 3, 0, 3, 4],\n",
       "   'entropy': 1.4708084763221112}},\n",
       " '35': {'no': {'greedy': \"As of October 2023, new datasets include Johns Hopkins University's COVID-19 case counts, WHO's global epidemiological data, and Oxford University's mobility reports. Check for updates at data sources' websites.\",\n",
       "   'samples': [\"Multiple new datasets include Johns Hopkins University's COVID-19 global case tally, WHO's daily situation reports, and Oxford University's mobility data.\",\n",
       "    'As of October 2023, several new public datasets include:',\n",
       "    \"As of October 2021, new datasets include Johns Hopkins University's COVID-19 case tracker, Oxford University's COVID-19 Government Response Stringency Index, and USAFacts' comprehensive U.S. pandemic data. Check for\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's global case count, Oxford University's mobility data, and WHO's country-wise statistics.\",\n",
       "    'Google COVID-19 Community Mobility Reports, Johns Hopkins University COVID-19 Global Cases.',\n",
       "    \"As of March 2023, new datasets include Johns Hopkins University's疫情全球统计数据, Oxford University's COVID-19政府响应评估, and WHO的每周流行病学更新。请注意，这些资源可能会随时间变化。建议\",\n",
       "    \"New public datasets related to COVID-19 include Johns Hopkins University's coronavirus pandemic data, COVID-19 Symptom Study dataset, and Oxford University's mobility dataset. Check for the latest updates from trusted sources.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's global case counts, Oxford University's mobility data, and US Census Bureau's economic indicators.\",\n",
       "    \"As of October 2023, new datasets include Johns Hopkins University's CSSE global疫情数据, mobility data from Google and Apple, and vaccine distribution data from Our World in Data. For the most current information, check dedicated COVID-1\",\n",
       "    \"As of June 2021, new public datasets include Johns Hopkins University's COVID-19 dashboard, Oxford University's COVID-19 government response tracker, and the COVID-19 Symptom Study dataset. For the most current information\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'lsvrjd4s': {'greedy': \"As of October 2023, new public datasets include Johns Hopkins University's CSSE COVID-19 Data, WHO Situation Reports, and Oxford University's COVID-19 Government Response Tracker. Always check for the latest updates from trusted sources\",\n",
       "   'samples': [\"As of my last update, new datasets include Johns Hopkins University's COVID-19 data repository, WHO's Weekly Epidemiological Update, and various country-specific datasets from health ministries. For current information, check reputable sources like these regularly.\",\n",
       "    \"Multiple new datasets, including Johns Hopkins University's global case count and US Census Bureau's economic impact data.\",\n",
       "    'As of October 2021, new public datasets include COVID-19 case and vaccination data from the European Centre for Disease Prevention and Control, and US county-level case data from the New York Times. For the most current information, check',\n",
       "    \"Multiple new datasets include Johns Hopkins University's Coronavirus Resource Center, COVID-19 Case Surveillance by the CDC, and Oxford University's mobility data.\",\n",
       "    \"Multiple datasets, including Johns Hopkins University's COVID-19 case data and Oxford University's mobility data.\",\n",
       "    \"Multiple datasets, including Johns Hopkins University's Coronavirus Resource Center and COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 case tracker and Oxford University's mobility dataset.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's Coronavirus Resource Center, OECD's Coronavirus Pandemic Data, and Google's COVID-19 Community Mobility Reports.\",\n",
       "    'As of October 2023, new public datasets include vaccine efficacy, variant prevalence, and hospitalization rates. Check sites like COVID-19 Data Tracker by CDC or WHO for updates.',\n",
       "    'As of October 2023, several new public datasets related to COVID-19 are available, including vaccine efficacy data, long-term health effects, and global vaccination rates. Check sites like COVID-19 Data Repository by the Center for'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '8lmrft9m': {'greedy': \"As of October 2023, new datasets include Johns Hopkins University's COVID-19 case counts, WHO's global pandemic data, and Oxford University's mobility reports. Check for updates at data sources' websites.\",\n",
       "   'samples': [\"As of August 2021, new public datasets include Johns Hopkins University's CSSE COVID-19 Data, COVID-19 API by Our World in Data, and CDC's COVID Data Tracker. Always check for the most recent sources\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 case tracker, Oxford University's COVID-19 Government Response Tracker, and WHO's COVID-19 Technical Briefings.\",\n",
       "    'The New York Times, Johns Hopkins CSSE, and WHO regularly update public datasets on COVID-19. Check their websites for the latest information.',\n",
       "    'The COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University is an updated dataset. Another is from the European Centre for Disease Prevention and Control. Both provide current statistics on cases, deaths, testing, and vaccinations.',\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 global case tracker and USDA's Coronavirus Food Assistance Program applications.\",\n",
       "    'The New York Times, Johns Hopkins CSSE, and ECDC regularly update COVID-19 datasets.',\n",
       "    \"Multiple datasets, including John Hopkins University's COVID-19 data repository and the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Additionally, datasets from the World Health Organization (WHO),\",\n",
       "    \"New datasets include Johns Hopkins University's COVID-19 global case tracker, Oxford University's mobility data, and US Census Bureau's American Community Survey estimates for pandemic impacts.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 case tracking, OECD's Policy Responses to Coronavirus, and WHO's COVID-19 Dashboard.\",\n",
       "    \"As of June 2023, new datasets include Johns Hopkins University's COVID-19 case tracker, WHO's weekly epidemiological update reports, and Oxford's COVID-19 government response tracker. Always check for updates from trusted sources.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'jb05x03a': {'greedy': \"As of October 2023, new datasets include Johns Hopkins University's COVID-19 case counts, WHO's global pandemic data, and Oxford University's mobility reports. Check for updates at data sources' websites.\",\n",
       "   'samples': [\"Multiple new datasets include COVID-19 case counts, hospitalizations, vaccine distribution, and genetic sequences. Check sites like COVID Open Data Initiative, EU Data Portal, and NIH's COVID-19 Data Challenge.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 global case counts, Oxford University's mobility data, and US CDC's contact tracing dataset.\",\n",
       "    'Google COVID-19 Community Mobility Reports, Johns Hopkins University Coronavirus Resource Center dataset.',\n",
       "    \"Multiple new datasets include Johns Hopkins University's Coronavirus Resource Center, Oxford University's COVID-19 Government Response Stringency Index, and WHO's Daily situation reports.\",\n",
       "    \"As of the latest update, new datasets include Johns Hopkins University's CSSE COVID-19 global case counts, WHO situation reports, and Oxford University's mobility data. Check for updates from reliable sources regularly.\",\n",
       "    \"New public datasets related to COVID-19 include Johns Hopkins University's COVID-19 Global Cases, US CDC's COVID Data Tracker, and Oxford University's COVID-19 Government Response Stringency Index.\",\n",
       "    'As of October 2023, several new public datasets related to COVID-19 include global vaccination coverage, variant prevalence, and infection rates by age group. Check sites like COVID Open Data Interface (CODI) and WHO for the',\n",
       "    \"As of the latest update, new public datasets include Johns Hopkins University's COVID-19 data repository, WHO's COVID-19 Dashboard, and Oxford University's Coronavirus Government Response Tracker. For current availability, check dedicated sites or repositories regularly.\",\n",
       "    'As of July 2023, new datasets include vaccination records, infection rates by occupation, and hospitalization data by zip code. For the most current information, check sites like COVID Open Data or the WHO.',\n",
       "    \"Multiple datasets, including Johns Hopkins University's coronavirus map and Oxford University's mobility data. Check for updates regularly as new datasets are continually being added.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'wy0y5ztd': {'greedy': \"As of October 2023, new datasets include Johns Hopkins University's COVID-19 case counts, WHO's global epidemiological data, and Oxford University's mobility reports. Check for updates at sources like Kaggle or GitHub.\",\n",
       "   'samples': [\"As of October 2023, new public datasets include Johns Hopkins University's COVID-19 case counts, WHO epidemiological data, and US CDC travel restrictions. Always check the latest sources for updates.\",\n",
       "    'As of August 2023, numerous new datasets are available, including vaccination records, hospitalization data, and variant prevalence. Check sites like COVID Open Data Repository and Eurostat for the latest.',\n",
       "    \"As of my last update, new datasets include Johns Hopkins University's疫情全球报告, WHO Situation Reports, and various government datasets like USA's COVID-19 Data Tracker. Check for updates regularly as new datasets are continuously being added.\",\n",
       "    'As of June 2023, several new public datasets include COVID-19 vaccination rates by country, daily case counts with genetic sequence data, and hospitalization statistics linked to genomic variants. For the most current information, check repositories like GitHub',\n",
       "    \"As of September 2021, new datasets include Johns Hopkins University's COVID-19 case counts, Oxford University's mobility data, and the NY Times' US vaccination records. Check for updates at sources like COVID Open Data Repo.\",\n",
       "    \"Multiple new datasets, including John Hopkins University's COVID-19 data repository and Oxford University's Government Response Stringency Index.\",\n",
       "    'Multiple new datasets include COVID-19 cases, deaths, vaccinations, and mobility trends from sources like Johns Hopkins CSSE, Oxford University, and Google.',\n",
       "    \"New public datasets related to COVID-19 include Johns Hopkins University's Coronavirus Resource Center, COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, and the European Centre for Disease Prevention and Control\",\n",
       "    \"As of August 2023, new datasets include Johns Hopkins University's疫情全球概览, Oxford University's COVID-19政府干预措施, and The New York Times' US-specific cases and deaths. For the most current information,\",\n",
       "    \"As of June 2023, new datasets include Johns Hopkins University's comprehensive COVID-19 case counts, WHO's global dashboard, and Oxford University's mobility reports. Check for updates at data.gov or similar sources.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'fvgxzbmx': {'greedy': \"As of October 2023, new public datasets include Johns Hopkins University's CSSE COVID-19 Data, WHO Coronavirus (COVID-19) Dashboard, and Oxford University's COVID-19 Government Response Stringency Index. For\",\n",
       "   'samples': [\"As of the latest update, new datasets include Johns Hopkins University's COVID-19 global case data, WHO's country-wise statistics, and USAFacts' comprehensive U.S. data. Check official sources for the most current offerings.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's global case counts, WHO epidemic data, and Oxford University mobility reports.\",\n",
       "    \"As of my last update, several new public datasets include John Hopkins University's comprehensive dataset, USAFacts' national and state-level data, and the COVID-19 Open Data Repository. Check for updates as new datasets are continually being published.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's global case tally, COVID-19 Symptom Study app data, and Oxford University's mobility reports.\",\n",
       "    \"As of my last update, several new datasets include Johns Hopkins University's Coronavirus Resource Center, WHO Situation Reports, and COVID-19 API from European Centre for Disease Prevention and Control. Check for updates regularly as new datasets are continuously being released.\",\n",
       "    \"New datasets include Johns Hopkins University's global case counts, Oxford University's mobility data, and US Census Bureau's socioeconomic information linked to virus spread.\",\n",
       "    \"As of October 2023, new public datasets include COVID-19 case counts and vaccination rates from the WHO, US CDC's surveillance data, and national government sources. For the most current information, check data.gov or similar platforms.\",\n",
       "    \"As of my last update, several new public datasets related to COVID-19 include Johns Hopkins University's Coronavirus Resource Center dataset, and the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University\",\n",
       "    \"As of June 2023, new public datasets include Johns Hopkins University's COVID-19 data repository, Oxford Coronavirus Government Response Tracker, and USAFacts' comprehensive COVID-19 impact statistics. Always check for updates at the sources\",\n",
       "    \"As of June 2021, new datasets include Johns Hopkins University's COVID-19 case data, WHO's pandemic dashboard, and Oxford University's COVID-19 government response tracker. However, availability may have changed since then. For\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'okqsvg8q': {'greedy': \"As of October 2023, new datasets include Johns Hopkins University's COVID-19 case data, WHO's global pandemic statistics, and Oxford University's mobility reports. Check for updates at sources like Kaggle or GitHub.\",\n",
       "   'samples': [\"Multiple new datasets include COVID-19 case counts, hospitalizations, vaccination rates, and mobility data. Check sites like COVID-19 Data Repository by Johns Hopkins CSSE and Google's Mobility Reports for updated information.\",\n",
       "    \"Multiple datasets, including Johns Hopkins University's case count, mobility data from Google and Apple, and hospitalization data from the New York Times.\",\n",
       "    'The New York Times, Johns Hopkins CSSE, and WHO regularly update COVID-19 datasets. Check their websites for the latest information.',\n",
       "    'FAOSTAT COVID-19 Impact on Food Systems, Oxford Coronavirus Government Response Tracker.',\n",
       "    \"New datasets include Johns Hopkins University's COVID-19 case data, Oxford University's mobility data, and USAFacts' comprehensive US statistics.\",\n",
       "    \"As of August 2021, new datasets include Johns Hopkins University's comprehensive coronavirus dataset, Oxford University's COVID-19 Government Response Stringency Index, and the COVID-19 Symptom Study dataset from King's College London. Check\",\n",
       "    \"As of my last update, new public datasets include Johns Hopkins University's Coronavirus Resource Center, Oxford University's COVID-19 Government Response Stringency Index, and the European Centre for Disease Prevention and Control's reports. For the most current information, check\",\n",
       "    'New public datasets include COVID-19 case counts, hospitalizations, vaccine distribution, and genetic sequencing data. Check sources like COVID-19 Data Repository by Johns Hopkins CSSE and WHO.',\n",
       "    'As of August 2021, the New York Times publishes a comprehensive dataset on US cases and deaths. The COVID-19 Epidemiology Data Repository offers detailed epidemiological data from multiple countries. Johns Hopkins CSSE provides updated global case counts',\n",
       "    \"As of September 2023, numerous new datasets include COVID-19 vaccinations, variants, hospitalizations, and case counts by country/region. Check sites like COVID-19 Open Data Repository and Europe's Open Data Portal for the\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'x6p8zmxs': {'greedy': \"As of October 2023, new public datasets include Johns Hopkins University's CSSE COVID-19 Global Cases, WHO Weekly Epidemiological Update, and Oxford University's COVID-19 Government Response Tracker. Always check for the latest sources\",\n",
       "   'samples': [\"New public datasets include Johns Hopkins University's Coronavirus Resource Center, COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, and Oxford University's Government Response Stringency Index. Regular updates from various national\",\n",
       "    \"As of June 2021, new datasets include Johns Hopkins University's COVID-19 data, WHO's Weekly Epidemiological Record, and Oxford University's COVID-19 government response tracker. For current information, check data.gov or similar\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 global cases, US COVID Tracking Project's test data, and Oxford University's mobility reports.\",\n",
       "    \"As of October 2021, new datasets include Johns Hopkins University's COVID-19 case counts, Oxford University's mobility data, and US CDC's vaccination records. Check for updates regularly as new datasets are continually being added.\",\n",
       "    \"As of June 2023, new datasets include Johns Hopkins University's COVID-19 case data, Oxford University's mobility reports, and WHO's pandemic dashboard. For current information, check dedicated government and research organization websites.\",\n",
       "    \"As of August 2021, new datasets include Johns Hopkins University's global COVID-19 case count, Oxford University's COVID-19 Government Response Stringency Index, and US CDC's COVIDView reports. Check for updates regularly as\",\n",
       "    'As of August 2023, new datasets include COVID-19 case counts, vaccination records, and hospitalization data from government health departments and international organizations like WHO and CDC. Check official sources for the most current information.',\n",
       "    \"As of my last update, new datasets include Johns Hopkins University's COVID-19 case tracking, WHO's疫情更新, and Oxford University's mobility data. For the most current information, check reliable sources like these directly.\",\n",
       "    'The New York Times, Johns Hopkins CSSE, and COVID-19 API by Center for Systems Science and Engineering provide updated public datasets.',\n",
       "    \"New datasets include Johns Hopkins University's global case counts, COVID-19 Symptom Study app data, and Oxford University's mobility reports.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'qp0h50t3': {'greedy': \"As of October 2023, new datasets include Johns Hopkins University's COVID-19 case counts, WHO's global pandemic data, and Oxford University's mobility reports. Check for updates at data sources' websites.\",\n",
       "   'samples': [\"As of October 2023, several new public datasets related to COVID-19 are available, including vaccination records, hospitalization data, and variant tracking. Examples include the CDC's Vaccination Data Tracker and WHO's Global COVID-1\",\n",
       "    'Google Mobility Reports, Johns Hopkins University COVID-19 Data Repository, US Census Bureau American Community Survey coronavirus supplements.',\n",
       "    \"As of my last update, new datasets include Johns Hopkins University's COVID-19 global case counts, mobility data from Google and Apple, and hospitalization data from various countries. For the most current information, check recent releases from sources like WHO,\",\n",
       "    \"As of July 2023, new datasets include Johns Hopkins University's CSSE global COVID-19 case data, WHO's COVID-19 Weekly Epidemiological Update, and Oxford COVID-19 Government Response Tracker. Check for updates\",\n",
       "    \"As of my last update, new datasets include Johns Hopkins University's COVID-19 case counts, Oxford University's mobility data, and USAFacts' comprehensive state-level metrics. Check for updates from reliable sources like these for current information.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 Global Cases, USAFacts COVID-19 tracker, and Oxford University's mobility data.\",\n",
       "    \"Multiple new datasets, including Johns Hopkins University's and Oxford University's疫情相关的新的公共数据集包括约翰霍普金斯大学和牛津大学提供的数据集。请注意，由于数据集会随时间更新，请访问相关网站获取最新信息\",\n",
       "    \"New datasets include Johns Hopkins University's COVID-19 case tracker and Oxford University's mobility data.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's COVID-19 global cases, deaths, and recoveries; Oxford University's mobility data; and the US CDC's contact tracing dataset.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's global case counts, Oxford University's mobility data, and the COVID-19 Symptom Study's health reports.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 5, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'u7ir986m': {'greedy': \"As of October 2023, new public datasets include Johns Hopkins University's CSSE COVID-19 Global Cases, WHO Weekly Epidemiological Update, and Oxford University's COVID-19 Government Response Tracker. Always check for the latest sources\",\n",
       "   'samples': [\"Multiple new datasets include Johns Hopkins University's COVID-19 case tracker and WHO's COVID-19 situation reports.\",\n",
       "    'As of October 2023, new public datasets include vaccine rollout data, long-term economic impact assessments, and infection rate projections. Check sites like COVID Open Data or data.gov for the latest.',\n",
       "    \"As of June 2023, several new public datasets include Johns Hopkins University's COVID-19 Global Cases Data, WHO's Coronavirus Disease (COVID-19) Dashboard, and Oxford's COVID-19 Government Response Stringency Index\",\n",
       "    \"New public datasets related to COVID-19 include Johns Hopkins University's COVID-19 Global Cases, US COVID Tracking Project's state-level data, and Oxford University's COVID-19 Government Response Stringency Index.\",\n",
       "    \"Multiple new datasets, including Johns Hopkins University's global case count and US Census Bureau's economic impact data.\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's global case count, WHO's country-level statistics, and Oxford University's mobility data.\",\n",
       "    'As of my last update, several new public datasets include the COVID-19 Open Access Dataset (COHAB) by Google and the COVID-19 Epidemiology Data API by AWS. Always check the latest sources for updates.',\n",
       "    \"As of June 2023, several new public datasets include: Johns Hopkins University's comprehensive COVID-19 case data, WHO's global dashboard, and Oxford's government response measures tracker. For the most current datasets, check data repositories like\",\n",
       "    \"As of September 2021, new datasets include Johns Hopkins University's COVID-19 case data, Oxford University's mobility data, and the European Centre for Disease Prevention and Control's vaccination data. Always check for updates at official sources.\",\n",
       "    \"New datasets include Johns Hopkins University's global case count, Oxford University's mobility data, and USAFacts' state-level statistics.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'mwoe4h2h': {'greedy': \"As of October 2023, new public datasets include Johns Hopkins University's CSSE COVID-19 Data, WHO Situation Reports, and Oxford University's COVID-19 Government Response Tracker. Always check for the latest sources.\",\n",
       "   'samples': [\"Multiple new datasets include Johns Hopkins University's COVID-19 data, Oxford University's mobility data, and US CDC's contact tracing dataset.\",\n",
       "    \"As of my last update, new public datasets include Johns Hopkins University's COVID-19 case tracker, Our World in Data's compilation of global vaccination rates, and the COVID-19 Symptom Study dataset from ZOE. Check for updates at\",\n",
       "    \"New public datasets include Johns Hopkins University's Coronavirus Resource Center, COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, and Oxford University's Government Response Stringency Indices. Regular updates are available from\",\n",
       "    'Google Mobility Reports, Johns Hopkins University COVID-19 Data Repository.',\n",
       "    \"As of my last update, new datasets include Johns Hopkins University's COVID-19 data, WHO reports, and various government datasets. Check for the most current sources.\",\n",
       "    \"As of my last update, several new datasets include Johns Hopkins University's COVID-19 data, mobility data from Google and Apple, and healthcare utilization data from the CDC. Check for updates at official sources.\",\n",
       "    \"As of my last update, several new datasets include Johns Hopkins University's COVID-19 data repository, WHO's Coronavirus Disease (COVID-19) Dashboard, and US CDC's COVID Data Tracker. For the most current information, check reputable sources\",\n",
       "    \"Multiple new datasets include Johns Hopkins University's global case count, WHO's country-wise data, and Oxford University's mobility data.\",\n",
       "    'The New York Times, Johns Hopkins CSSE, and COVID-19 API by Our World in Data provide updated public datasets. Other sources include data.gov and ECDC.',\n",
       "    \"New datasets include Johns Hopkins University's COVID-19 global case tracker and Oxford University's COVID-19 Government Response Stringency Index.\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 4, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057}},\n",
       " '2': {'no': {'greedy': 'The coronavirus is not alive and does not respond to changes in weather. However, transmission rates can change with weather conditions.',\n",
       "   'samples': ['The coronavirus is not alive and does not respond to changes in weather. However, its transmission tends to decrease with warmer temperatures and increased humidity.',\n",
       "    'Coronaviruses do not respond to changes in weather. They are primarily transmitted through close contact and respiratory droplets.',\n",
       "    'The coronavirus does not respond to changes in weather. It is a virus and its survival is more influenced by factors like temperature, humidity, and surface conditions rather than living organisms or environmental changes. However, it generally fares better in colder temperatures and drier',\n",
       "    'The coronavirus is not responsive to weather changes. It primarily spreads through human contact and aerosols.',\n",
       "    'The coronavirus is not alive and cannot respond to changes in weather. However, transmission rates can change with temperature and humidity.',\n",
       "    'Coronaviruses do not respond to weather changes. They primarily spread through person-to-person contact, respiratory droplets, and surfaces.',\n",
       "    'The coronavirus is not responsive to changes in weather; it primarily spreads through respiratory droplets.',\n",
       "    'The coronavirus is not alive and cannot respond. It spreads more efficiently indoors, where air circulation is poor.',\n",
       "    'The coronavirus is not responsive to changes in weather. It primarily spreads through respiratory droplets and close contact, not environmental factors like temperature or humidity.',\n",
       "    'The coronavirus is not alive and does not respond to changes in weather. However, transmission rates can decrease with warmer temperatures and increased humidity.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 1, 4, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '4hbwg18z': {'greedy': 'The coronavirus inactivation is influenced by temperature and relative humidity, with lower temperatures and higher relative humidity generally leading to faster inactivation. However, specific responses may vary depending on the coronavirus strain. For accurate predictions, refer to the developed models and spreadsheet mentioned',\n",
       "   'samples': ['Coronaviruses generally become less infectious at higher temperatures and humidity levels. The response can be predicted using models that consider temperature and relative humidity, though specific conditions may vary based on the strain.',\n",
       "    'Coronaviruses generally become less infectious as temperature and relative humidity increase, based on the data reviewed in the article. However, specific responses may vary among different coronavirus strains.',\n",
       "    \"Coronaviruses tend to be more stable at lower temperatures and higher relative humidity. Changes in temperature and relative humidity can affect the virus's ability to survive on surfaces and in liquids, though specific responses vary among different coronaviruses. Higher temperatures\",\n",
       "    'Coronaviruses generally decrease in infectivity with increasing temperature and relative humidity, as evidenced by a log10 reduction in virus infectivity over time. A model developed using global data suggests that the inactivation of coronaviruses can be predicted',\n",
       "    'The coronavirus inactivation is influenced by temperature and relative humidity, with higher temperatures and lower relative humidity generally leading to faster inactivation.',\n",
       "    'The coronavirus inactivation is influenced by temperature and relative humidity, with specific models predicting inactivation based on these factors. Higher temperatures and lower relative humidity generally lead to faster inactivation.',\n",
       "    'The coronavirus inactivation is influenced by temperature and relative humidity, with specific models predicting inactivation based on these factors. Higher temperatures and lower relative humidity generally lead to faster inactivation.',\n",
       "    'The coronavirus responds to changes in temperature and relative humidity, with a model predicting inactivation considering these factors. Warmer temperatures and lower humidity generally lead to faster inactivation.',\n",
       "    'The coronavirus inactivation is influenced by temperature and relative humidity, with lower temperatures and higher relative humidity generally leading to faster inactivation. However, specific responses may vary depending on the particular coronavirus strain.',\n",
       "    'The coronavirus inactivation is influenced by temperature and relative humidity, with higher temperatures and lower relative humidity generally leading to faster inactivation. However, exact responses vary and can be predicted using models developed from existing data.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 4, 4, 5, 6],\n",
       "   'entropy': 1.7480673485460891},\n",
       "  'tjplc5j6': {'greedy': 'The coronavirus, specifically studied through TGEV and MHV surrogates, persists longer at lower temperatures (4°C) and lower humidity (20%), while higher temperatures (40°C) lead to faster inactivation. The relationship between in',\n",
       "   'samples': ['The coronavirus, specifically studied through TGEV and MHV surrogates, persists longer at lower temperatures (4°C) and lower humidity (20%), while higher temperatures (40°C) lead to faster inactivation. The relationship between in',\n",
       "    'The coronavirus survives longer at lower temperatures and lower humidity levels. At higher temperatures, survival is shorter. The relationship between inactivation and humidity is not straightforward, showing greater survival at both low (20%) and high (80%) humidity compared to',\n",
       "    'The coronavirus persists longer at lower temperatures (4°C) and lower humidity (20%), while higher temperatures (40°C) lead to faster inactivation. The survival rate is not consistent with humidity levels, showing greater survival at both low (2',\n",
       "    'The coronavirus, specifically TGEV and MHV used as surrogates, persists longer at lower temperatures (4°C) and lower humidity (20%), while higher temperatures (40°C) lead to faster inactivation. The relationship between in',\n",
       "    'The coronavirus, specifically tested through TGEV and MHV surrogates, persists longer at lower temperatures (4°C) and at very low or very high relative humidity levels (20%, 80%), while degrading faster at intermediate humidity',\n",
       "    'The coronavirus, specifically using TGEV and MHV as surrogates, shows persistence on surfaces ranging from 5 to 28 days at temperatures between 4°C and 40°C. Lower relative humidity (20%) and higher',\n",
       "    'The coronavirus survives longer at lower temperatures (4°C) and lower humidity (20%), with survival times decreasing at higher temperatures (20°C and 40°C) and moderate humidity (50%). Survival is not consistently monotonic with respect',\n",
       "    \"The coronavirus persists longer at lower temperatures (4°C) and higher humidity (80%), while inactivation is faster at higher temperatures (40°C) and lower humidity (20%). There's also an interaction between temperature and humidity affecting virus survival\",\n",
       "    'The coronavirus studied (TGEV and MHV) persists longer at lower temperatures (4°C) and shorter persistence at higher temperatures (40°C). Lower relative humidity (20%) provides a protective effect, while moderate (50%) and',\n",
       "    'The coronavirus persists longer at lower temperatures (4°C) and lower humidity (20%), while higher temperatures (40°C) lead to faster inactivation. The relationship between inactivation and humidity is not monotonic, with better survival at low ('],\n",
       "   'cluster_ids': [0, 1, 1, 0, 2, 3, 1, 1, 4, 1],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  '03s9spbi': {'greedy': \"The coronavirus, particularly SARS-CoV-2, shows decreased virulence in humid and hot weather during the early stages of an epidemic. However, the long-term effects of temperature on the virus's behavior are less clear.\",\n",
       "   'samples': ['The coronavirus, particularly SARS-CoV-2, may experience decreased virulence and initial contagion rates in higher temperatures and humidity, though its effectiveness at later stages remains uncertain.',\n",
       "    'The coronavirus, particularly SARS-CoV-2, may have reduced infectivity in humid and hot weather, though the effect is more pronounced in the early stages of the epidemic. Seasonal impacts on later stages of the epidemic are uncertain.',\n",
       "    'The coronavirus, particularly SARS-CoV-2, may decrease in virulence in humid and hot weather based on some studies. However, the impact of temperature on contagion rates is more notable during the early stages of an epidemic. Seasonal effects',\n",
       "    'The new coronavirus (SARS-CoV-2) shows decreased initial contagion rates in higher temperatures, based on data from 21 countries and French administrative regions. Seasonal temperature effects on later epidemic stages are uncertain.',\n",
       "    'The coronavirus, particularly in its early stages, may become less virulent in humid and hot weather. However, the effect of temperature on later stages of the epidemic remains uncertain.',\n",
       "    'The coronavirus responds to changes in weather, with higher temperatures potentially decreasing the velocity of contagion during the initial stages of the epidemic. However, the effect of temperature on contagion rates may vary at later stages of the epidemic and across different geographic locations.',\n",
       "    'The coronavirus may become less virulent in humid and hot weather, but the effects on initial contagion rates are more pronounced in early stages of the epidemic. Seasonal temperature impacts on later stages of the epidemic remain uncertain.',\n",
       "    'The coronavirus, particularly SARS-CoV-2, may experience decreased virulence in humid and hot weather during the early stages of an epidemic. However, the effectiveness of this trend at later stages remains uncertain.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, shows decreased virulence in humid and hot weather during the early stages of the epidemic. However, its response at later stages remains unclear.',\n",
       "    'The coronavirus, particularly SARS-CoV-2, shows decreased virulence in humid and hot weather conditions. However, the effects of seasonal temperatures on contagion rates are more pronounced during the early stages of the epidemic.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 0, 3, 4, 0, 0, 1],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'az7f7zgr': {'greedy': 'The coronavirus, specifically SARS-CoV-2, is less stable in summer due to stronger sunlight, while it can remain infectious for longer periods in winter.',\n",
       "   'samples': ['The coronavirus, specifically SARS-CoV-2, is more stable outdoors during winter in temperate-zone cities but becomes less stable during summer. Sunlight, particularly ultraviolet radiation, plays a significant role in inactivating the virus.',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer in winter due to lower UV exposure, but is inactivated faster during summer.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is more stable outdoors during winter in temperate-zone cities but becomes less stable during summer. Sunlight plays a significant role in inactivating the virus faster during warmer months.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable and inactivates faster in summer due to increased UV radiation compared to winter. Weather conditions can affect its viability outdoors, posing higher risks in winter when it can remain infectious longer.',\n",
       "    'SARS-CoV-2 remains infectious longer in winter due to lower UV exposure, but is inactivated faster in summer due to higher UV radiation.',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer during winter in temperate-zone cities but is inactivated faster during summer in many populous cities due to sunlight.',\n",
       "    'The coronavirus (SARS-CoV-2) is more stable and remains infectious for longer periods outdoors during winter in many temperate-zone cities but is inactivated faster during summer, similar to influenza A virus. Sunlight plays a significant role in in',\n",
       "    'The coronavirus (SARS-CoV-2) is more stable and can remain infectious outdoors for longer periods during winter in many temperate-zone cities. It is rapidly inactivated during summer due to sunlight exposure, similar to influenza A virus.',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer during winter in temperate-zone cities but is inactivated faster during summer in many populous cities.',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer in winter due to reduced UV exposure, but is inactivated faster in summer due to increased UV radiation.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 4, 5, 5, 6, 3],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'tpfndwvq': {'greedy': 'The given context does not discuss how the coronavirus responds to changes in weather. It focuses on the relationship between the number of spike proteins and the light scattering properties of the virus. Weather conditions are not mentioned.',\n",
       "   'samples': ['The given context does not provide information on how the coronavirus responds to changes in weather. The context discusses the shape, spike proteins, and light scattering properties of coronavirus virions but does not mention any relationship between the virus and weather conditions.',\n",
       "    \"The given context does not discuss how the coronavirus responds to changes in weather. The information provided focuses on the spike proteins' influence on the virus's shape and its impact on light scattering properties. No data about the virus's reaction to weather conditions is presented\",\n",
       "    \"The given context does not discuss how the coronavirus responds to changes in weather. The information provided focuses on the viral spike proteins, their role in infection, and the relationship between the number of spike proteins and the virus's infectivity. There is no mention\",\n",
       "    \"The given context does not discuss how the coronavirus responds to changes in the weather. It focuses on the structure of the virus and its interaction with light. Weather conditions could indirectly affect the virus's spike protein number and infectivity, but this information is not\",\n",
       "    'The provided context does not discuss how the coronavirus responds to changes in the weather. The information focuses on the shape and characteristics of the viral particles, specifically regarding the number of spike proteins and their impact on light scattering. Weather conditions are not mentioned in the',\n",
       "    \"The given context does not discuss how the coronavirus responds to changes in weather. It focuses on the viral spike proteins' role in infection and a mathematical model of light scattering from the virus. Weather conditions are not mentioned.\",\n",
       "    'The given context does not discuss how the coronavirus responds to changes in weather. It focuses on the viral spike proteins and their effect on light scattering. Weather conditions are not mentioned.',\n",
       "    'The given context does not provide information on how the coronavirus responds to changes in weather. The text focuses on the structure of the virus and its light scattering properties.',\n",
       "    'The given context does not provide information on how the coronavirus responds to changes in weather. The context discusses the structure and light scattering properties of the virus, not its response to environmental conditions.',\n",
       "    'The given context does not mention any response of the coronavirus to changes in weather. The information focuses on the spike proteins, the shape of the virus, and light scattering properties. Weather conditions are not discussed.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 1, 1, 1],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  '0pujch9v': {'greedy': 'The passage does not provide information on how the coronavirus specifically responds to changes in the weather. Michael Le Page suggests that changing seasons may not effectively control the outbreak.',\n",
       "   'samples': ['The text does not provide information on how the coronavirus specifically responds to changes in the weather. Michael Le Page suggests that changing seasons may not effectively stop the outbreak.',\n",
       "    \"The text provided does not give specific information on how the coronavirus responds to changes in the weather. Michael Le Page suggests that changing seasons may not effectively stop the outbreak. More research is needed to understand the virus's weather-related behaviors.\",\n",
       "    \"The passage does not provide information on how the coronavirus specifically responds to changes in the weather. Michael Le Page's statement suggests uncertainty regarding the effectiveness of seasonal changes in controlling the outbreak.\",\n",
       "    \"The passage does not provide information on how the coronavirus specifically responds to changes in weather. It only indicates uncertainty regarding whether changing seasons will help control the outbreak. For specific information on weather's impact, additional research would be needed.\",\n",
       "    'There is no definitive evidence that changes in weather affect the behavior or spread of the coronavirus.',\n",
       "    'The given context does not provide specific information on how the coronavirus responds to changes in the weather. Michael Le Page suggests that changing seasons may not effectively help control the outbreak. For accurate information, refer to current scientific research and health advisories.',\n",
       "    'The given context does not provide specific information about how the coronavirus responds to changes in the weather. To summarize: we do not know if changing seasons will affect the outbreak. For accurate information, consult recent scientific studies or health authorities.',\n",
       "    'The passage does not provide information on how the coronavirus specifically responds to changes in weather. It only states that Michael Le Page is uncertain whether changing seasons will help control the outbreak. More research would be needed to understand any potential weather-related effects on the virus',\n",
       "    'There is no clear evidence that changes in weather directly affect the spread or behavior of the coronavirus. Seasonal changes may indirectly impact transmission through factors like indoor gatherings and viral survival on surfaces, but their overall effect remains uncertain. Experts continue to monitor these factors',\n",
       "    \"There is no definitive evidence that coronavirus responds to changes in weather; seasonality's impact on outbreaks is unclear.\"],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 0, 3, 1, 4, 5],\n",
       "   'entropy': 1.6094379124341},\n",
       "  '0j5eebym': {'greedy': 'The given context does not discuss how the coronavirus responds to changes in weather. It focuses on the relationship between the number of spike proteins and the light scattering properties of the virus. Weather conditions are not mentioned.',\n",
       "   'samples': ['The given context does not discuss how the coronavirus responds to changes in weather. The text focuses on the shape, spike proteins, and light scattering properties of the virus. Weather conditions are not mentioned.',\n",
       "    'The given context does not mention any information about how the coronavirus responds to changes in the weather. The context focuses on the mathematical model of the coronavirus virions and their light scattering properties.',\n",
       "    'The given context does not discuss how the coronavirus responds to changes in the weather. The information provided focuses on the viral spike proteins, the shape of the virus, and the characteristics of light scattered by the virus. There is no mention of weather conditions or',\n",
       "    \"The given context does not discuss how the coronavirus responds to changes in weather. It focuses on the viral spike proteins and their relation to light scattering and the virus's shape. Weather conditions are not mentioned.\",\n",
       "    'The given context does not mention any response of the coronavirus to changes in weather. The context discusses the structure and light scattering properties of the coronavirus, but does not address its behavior or response to environmental conditions like weather.',\n",
       "    'The given context does not discuss how the coronavirus responds to changes in the weather. It focuses on the relationship between the number of spike proteins and the characteristics of light scattered by the virus. Weather conditions are not mentioned.',\n",
       "    \"The given context does not discuss how the coronavirus responds to changes in weather. The text focuses on the spike proteins and their role in viral infectivity, as well as a mathematical model of the coronavirus's shape and light scattering properties. Weather conditions are not\",\n",
       "    \"The context provided does not discuss how the coronavirus responds to changes in weather. It focuses on the mathematical modeling of the virus's spike proteins and their impact on light scattering properties. Weather conditions are not mentioned.\",\n",
       "    'The context provided does not mention how the coronavirus responds to changes in weather. It focuses on the structure and light scattering properties of the virus related to the number of spike proteins. Weather changes are not discussed.',\n",
       "    'The context provided does not discuss how the coronavirus responds to changes in weather. It focuses on the number of spike proteins and their impact on light scattering properties, not environmental factors.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.9433483923290393},\n",
       "  '7emv2bao': {'greedy': 'The coronavirus, specifically SARS-CoV-2, is less stable in summer due to higher temperatures and UV radiation, while it can remain infectious for longer periods in winter under cooler conditions.',\n",
       "   'samples': ['The coronavirus, specifically SARS-CoV-2, is less stable under sunlight during warmer months, leading to faster inactivation. In contrast, it can remain infectious for longer periods in cooler temperatures, posing a greater risk of transmission outdoors during winter in',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is more stable outdoors during winter in temperate-zone cities and can remain infectious for longer periods. However, it becomes less stable during summer, suggesting that sunlight may play a role in inactivating',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable in summer due to increased ultraviolet radiation, while it can remain infectious for longer periods in winter in many temperate-zone cities.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable and inactivates faster under intense sunlight and higher temperatures, as observed during summer in many cities. In contrast, it can remain infectious for longer periods in cooler, winter conditions,',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer in winter and shorter in summer due to UV radiation.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is more stable outdoors during winter in temperate-zone cities but becomes less stable during summer due to increased ultraviolet radiation. Sunlight helps inactivate the virus faster during summer.',\n",
       "    'SARS-CoV-2 is less stable under summer sunlight, leading to faster inactivation, while it can remain infectious longer in winter conditions.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable in summer due to increased ultraviolet radiation, while it can remain infectious for longer periods in winter under certain conditions.',\n",
       "    'The SARS-CoV-2 virus is more stable outdoors during winter in temperate-zone cities but becomes less stable during summer. Sunlight appears to inactivate the virus faster than influenza A during warmer months.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable in warmer weather and can remain viable for longer periods in colder weather. It is more rapidly inactivated by sunlight during summer months in many cities.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 4, 3, 5, 3],\n",
       "   'entropy': 1.6434177197931799},\n",
       "  '4xijeti6': {'greedy': 'The coronavirus, specifically SARS-CoV-2, is less stable in summer due to higher temperatures and UV radiation, while it can remain infectious for longer periods in winter under certain conditions.',\n",
       "   'samples': ['The coronavirus, specifically SARS-CoV-2, is less stable and inactivates faster under summer conditions due to higher UV radiation compared to winter conditions where it can remain infectious for a longer time outdoors.',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer during winter in temperate-zone cities but is inactivated faster during summer in many populous cities due to sunlight.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable under sunlight and warmer temperatures, leading to faster inactivation during summer in many cities. In contrast, it can remain infectious for longer periods in colder, darker weather conditions, particularly in',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer during winter in temperate-zone cities but is inactivated faster during summer in many populous cities due to sunlight.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable in summer due to increased ultraviolet radiation, while it can remain infectious for longer periods in winter. Sunlight plays a role in inactivating the virus faster during warmer months.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is less stable in sunlight and warm temperatures, leading to faster inactivation during summer in many cities. In contrast, it can remain infectious outdoors for longer periods during winter in temperate zones.',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer in winter due to lower UV radiation, posing a continued re-aerosolization risk; it degrades faster in summer due to higher UV radiation, similar to influenza A.',\n",
       "    'The SARS-CoV-2 virus is more stable outdoors during winter months in temperate-zone cities but becomes less stable during summer. Sunlight, particularly UV radiation, can inactivate the virus faster than influenza A.',\n",
       "    'SARS-CoV-2 remains infectious outdoors longer in winter due to lower UV radiation, posing a continued re-aerosolization risk. In summer, it is inactivated faster than influenza A due to higher UV radiation.',\n",
       "    'The coronavirus, specifically SARS-CoV-2, is more stable and can remain infectious outdoors for longer periods during winter in temperate-zone cities. It becomes less stable and inactivates faster during summer, suggesting that sunlight plays a role in reducing'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 1, 1, 3, 4, 5, 6],\n",
       "   'entropy': 1.7480673485460891},\n",
       "  'jg387csa': {'greedy': 'The provided context does not discuss how the coronavirus responds to changes in weather. Weather conditions can influence the transmission of the virus through air-borne aerosols and droplets, but the given information does not address this aspect. For a comprehensive understanding, one',\n",
       "   'samples': ['The provided context does not discuss how coronaviruses respond to changes in weather. Weather conditions can affect the stability and spread of airborne particles containing viruses but this information is not given in the context.',\n",
       "    'The given context does not provide information on how coronaviruses respond to changes in weather. The focus is on their transmission, interaction with biological and environmental surfaces, and the importance of soft matter science in understanding and combating the pandemic. Weather conditions could',\n",
       "    \"The given context does not discuss how coronaviruses respond to changes in weather. The text focuses on the virus's behavior in soft matter contexts such as body fluids, cell membranes, and interactions with surfaces, but it does not address weather-related factors\",\n",
       "    'The provided context does not discuss how the coronavirus responds to changes in the weather. Weather conditions such as temperature and humidity can affect the stability and transmission of coronaviruses, but this information is not included in the given text. For more detailed information',\n",
       "    \"The provided context does not discuss how the coronavirus responds to changes in the weather. It focuses on the virus's structure and its interactions with bodily fluids, cell membranes, and surfaces, as well as transmission via aerosols and droplets. Weather conditions might\",\n",
       "    'The provided context does not discuss how the coronavirus responds to changes in weather. Weather conditions can influence the stability and transmission of airborne particles containing the virus but do not directly affect the virus itself in terms of adaptation or mutation due to environmental factors. Further research',\n",
       "    'The given context does not provide information on how the coronavirus responds to changes in the weather. Weather conditions can affect virus survival and transmission, but specific details are not discussed in the provided text. For accurate information, consult current scientific research on environmental factors impacting',\n",
       "    'The provided context does not discuss how the coronavirus responds to changes in the weather. Weather conditions like temperature and humidity can affect virus stability and transmission, but this information is not included in the given text.',\n",
       "    \"The context provided does not discuss how the coronavirus responds to changes in weather. The information focuses on the virus's behavior in soft matter contexts like bodily fluids, cell membranes, and interactions with surfaces. Weather impacts on viral spread are generally related to factors like\",\n",
       "    \"The provided context does not discuss how the coronavirus responds to changes in weather. It focuses on the role of soft matter in understanding the virus's behavior in bodily fluids, surfaces, and aerosols/droplets, but it does not address environmental factors like\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 0, 5, 6, 2],\n",
       "   'entropy': 1.8343719702816235}},\n",
       " '14': {'no': {'greedy': 'Super spreaders of COVID-19 have been documented, with estimates suggesting around 10-20% of cases leading to 80% of transmissions. Evidence shows these events often occur in specific settings like indoor gatherings or poorly ventilated',\n",
       "   'samples': ['Super spreader events account for a significant portion of COVID-19 cases, often linked to large indoor gatherings, close contact settings like choir rehearsals, and crowded restaurants. Evidence suggests these events can result in multiple secondary infections from a single infected individual',\n",
       "    'Studies indicate that a small proportion of COVID-19 cases are responsible for a large number of transmissions, suggesting the existence of \"super spreader\" events.',\n",
       "    'Super spreaders have been observed, where a small proportion of infections are responsible for a large majority of transmissions. Evidence suggests that superspreading events can occur in various settings, including households and social gatherings. Specific factors like viral load, transmission settings,',\n",
       "    'Super spreaders account for a disproportionate number of infections. Evidence suggests they can infect many people (often 10x more) than average. Factors include occupation, vocalization, and masks.',\n",
       "    'Super spreaders of COVID-19 have been observed, with estimates suggesting about 10-20% of cases leading to 80% of transmissions. Specific events like choir practices and family gatherings have shown high transmission rates. However,',\n",
       "    'Studies suggest that a small proportion of COVID-19 cases are responsible for a large majority of transmissions, indicating the existence of super spreader events.',\n",
       "    'Super spreaders account for a disproportionate number of infections, with some events linked to as many as 75% of cases from a single exposure. Evidence suggests certain factors like large gatherings, indoor settings, and asymptomatic or pre-symptomatic',\n",
       "    'Super spreaders account for a disproportionate number of cases in outbreaks, though exact evidence and rates vary. Factors like occupation, age, and compliance with guidelines influence transmission.',\n",
       "    'Super spreaders have been observed in various settings, including households and larger events. Transmission can occur from a single infected individual to multiple contacts. Studies suggest that superspreading events are relatively rare but can significantly impact overall transmission.',\n",
       "    'Super spreaders account for a disproportionate share of infections. Evidence suggests that a small number of individuals are responsible for a large portion of transmissions. For example, in China, it was reported that 61% of infections could be traced back to just'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '0dlv1ukh': {'greedy': 'Super spreaders of COVID-19 have been observed, with some individuals infecting dozens or even hundreds of others. Evidence suggests these events can occur in various settings like restaurants, choir practices, and funerals. Transmission often results from close contact and',\n",
       "   'samples': ['Super spreaders of COVID-19 have been documented, with some events involving a single infected person infecting over 50 others. Evidence includes large outbreaks in settings like meat processing plants, religious gatherings, and funerals.',\n",
       "    'Super spreader events have been documented, where a small number of infected individuals transmit the virus to a large number of people. Evidence shows such events can significantly drive viral transmission.',\n",
       "    'Studies show that a small proportion of COVID-19 cases are responsible for a large majority of transmissions, indicating the existence of super spreaders. Evidence comes from outbreak investigations and data analysis.',\n",
       "    'Super spreader events have been documented where a single infected person infects many others, though the frequency of such events is relatively low. Evidence suggests these events can significantly contribute to community transmission.',\n",
       "    'Super spreaders account for a disproportionate number of infections. Evidence shows they can transmit the virus to many people, often in a short period. Examples include large indoor gatherings and choir practices.',\n",
       "    'Studies indicate that a small fraction of COVID-19 cases are responsible for a large number of infections, suggesting the existence of super spreaders. Evidence comes from various outbreaks linked to events like funerals and religious gatherings.',\n",
       "    'Super spreaders have been observed in various outbreaks, often associated with large gatherings or settings with close proximity. Evidence suggests that a small proportion of cases can lead to significant transmission events. Factors include asymptomatic or presymptomatic传播者在COVID-',\n",
       "    'Super spreaders account for a disproportionate number of infections. Evidence shows that a small percentage of COVID-19 cases are linked to superspreading events or individuals. Exact data varies, but studies suggest around 10-20% of cases',\n",
       "    'Super spreader events have been documented where a single infected person infects multiple others, though the exact number varies. Evidence suggests such events can significantly contribute to virus transmission.',\n",
       "    'Super spreaders have been documented, with some events involving a single infected person infecting over 50 others. Evidence includes multiple large-scale outbreaks linked to specific individuals.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 5, 6, 1, 1],\n",
       "   'entropy': 1.7480673485460891},\n",
       "  '8ngri1x0': {'greedy': 'A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases, all else equal.',\n",
       "   'samples': ['A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases.',\n",
       "    'A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases. This indicates that higher densities of super-spreader businesses are linked to higher rates of COVID-19 cases.',\n",
       "    'A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases.',\n",
       "    'The study found a positive association between the density of super-spreader businesses and COVID-19 cases. A 1 percentage point increase in the density of super-spreader businesses is associated with a 5% higher rate of COVID-19 cases',\n",
       "    \"A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases, according to the study's negative binomial regression analysis.\",\n",
       "    'A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases.',\n",
       "    'A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases. This was found through analyzing the relationship between the density of super-spreader businesses in a county and the rate of COVID',\n",
       "    'A positive association was found between the density of super-spreader businesses and COVID-19 cases. Specifically, a 1 percentage point increase in the density of super-spreader businesses is associated with a 5% higher rate of COVID-19',\n",
       "    'A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases. This was determined through a negative binomial regression analysis.',\n",
       "    'A 1 percentage point increase in the density of super-spreader businesses is associated with 5% higher COVID-19 cases.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 0, 1, 2, 2, 0],\n",
       "   'entropy': 1.0296530140645734},\n",
       "  'oocco483': {'greedy': 'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which can expose new cases to high viral loads, potentially explaining the role of super spreaders in the propagation of COVID-19.',\n",
       "   'samples': ['Experimental veterinary research supports the notion that exposure to high viral loads from superspreaders can lead to high-intensity infections, which in turn expose new cases to high viral loads, potentially explaining the heterogeneity in the spread of COVID-19.',\n",
       "    'Evidence suggests that exposure to high viral loads from superspreaders can lead to high-intensity infections, exposing new cases to high viral loads. This notion is supported by experimental veterinary research.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which can expose new cases to high viral loads, potentially explaining the phenomenon of super spreaders in COVID-19.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which can expose new cases to high viral loads, potentially explaining the role of superspreading events in COVID-19.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which can expose new cases to high viral loads, potentially explaining super spreaders in COVID-19.',\n",
       "    'Evidence suggests that superspreading events may be linked to exposure to high viral loads, which can lead to high-intensity infections and further expose new cases to high viral loads. This notion is supported by experimental veterinary research. However, specific human data is',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which exposes new cases to high viral loads, potentially explaining the phenomenon of super spreaders in COVID-19.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which exposes new cases to high viral loads, potentially explaining the role of superspreading events in the propagation of COVID-19.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which exposes new cases to high viral loads. This mechanism is proposed to explain the heterogeneity in the propagation of COVID-19.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in high-intensity infection, which exposes new cases to high viral loads.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 1, 1, 0, 0],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  'g83oxgig': {'greedy': 'Super spreaders have been observed in outbreaks, often in settings like nursing homes or large events. Transmission can occur through close contact with infected individuals.',\n",
       "   'samples': ['Super spreader events have been documented, where a small number of infected individuals transmit the virus to a large number of people. Evidence shows such events can significantly contribute to viral transmission in communities. Examples include indoor gatherings and poorly ventilated spaces.',\n",
       "    'Super spreaders have been documented, with some events leading to multiple infections. Evidence suggests that a small proportion of cases are responsible for a large majority of transmissions.',\n",
       "    'Super spreaders account for a disproportionate number of infections in outbreaks, though specific individuals remain challenging to identify due to varying transmission dynamics. Evidence suggests certain factors like age, underlying health conditions, and viral load may contribute to super spreading. However, more research',\n",
       "    'Super spreaders of COVID-19 have been observed, where a small proportion of infected individuals transmit the virus to a disproportionately high number of others. Evidence suggests this occurs through close contact and high viral loads. Specific cases and studies highlight these events but',\n",
       "    'Super spreaders of COVID-19 have been observed, with some individuals infecting many more people than average. Evidence suggests these events can significantly contribute to virus transmission. Factors including viral load, mask usage, and social behaviors influence super spreading events.',\n",
       "    'Studies show that a small proportion of COVID-19 cases account for a large number of infections, indicating super spreader events are common. Evidence suggests these events can occur in various settings like households and restaurants.',\n",
       "    'Super spreaders account for a disproportionate number of cases. Evidence suggests that a small fraction of infections lead to many secondary infections. No single characteristic definitively identifies super spreader events.',\n",
       "    'Super spreaders account for a disproportionate share of transmissions, with some events leading to over 75% of cases. Evidence shows certain individuals can infect many more people than average.',\n",
       "    'Super spreaders can significantly increase virus transmission. Evidence shows that a small proportion of infected individuals account for a large majority of transmissions, highlighting the importance of isolating and monitoring such cases. Specific examples include large outbreaks linked to single events or individuals.',\n",
       "    'Super spreaders have been observed in various settings, contributing to significant outbreaks. Evidence shows they can transmit the virus to multiple individuals, though the exact number varies. Factors like viral load and transmission opportunities are believed to play a role.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 1, 1, 6, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'koq7upoq': {'greedy': 'Super spreaders of COVID-19 have been observed, with some individuals infecting dozens or even hundreds of others. Evidence suggests these events are more common in indoor settings with poor ventilation and among older adults or those with underlying health conditions. However,',\n",
       "   'samples': ['Studies indicate that a small number of COVID-19 cases are responsible for a large portion of transmissions, suggesting the existence of super spreaders. Evidence includes outbreaks linked to specific events or individuals.',\n",
       "    'Super spreader events have been documented, where a small number of COVID-19 cases lead to many secondary infections. Evidence suggests these often occur in settings like choir practices, restaurants, and weddings, emphasizing the importance of social distancing and mask-wearing',\n",
       "    'Super spreaders have been observed in outbreaks, often associated with indoor gatherings, close contact settings, and specific events like funerals or religious services. Evidence suggests that a small number of cases can cause a large proportion of transmissions.',\n",
       "    'Super spreaders of COVID-19 have been documented, with some individuals infecting dozens or even hundreds of others. Evidence suggests these events often occur in settings like choir practices, restaurants, and religious gatherings. Transmission can be attributed to a combination of',\n",
       "    'Super spreaders can significantly contribute to COVID-19 transmission, though not all infected individuals become super spreaders. Evidence suggests that a small proportion of cases are responsible for a large majority of transmissions. Factors like viral load and environment play a role.',\n",
       "    'Super spreaders account for a disproportionately large number of infections. Evidence suggests certain individuals can infect many more people than average, but specific characteristics are not always clear.',\n",
       "    'Super spreaders can significantly contribute to the transmission of COVID-19. Evidence suggests that a small proportion of cases are associated with superspreading events, where one infected person infects multiple others. Studies indicate such events often occur in crowded indoor settings',\n",
       "    'Studies indicate that a small fraction of COVID-19 cases are responsible for a majority of transmissions, highlighting the role of super spreaders. Evidence suggests these events can occur in various settings like households, restaurants, and religious gatherings.',\n",
       "    'Super spreader events have been documented where a single infected person infects multiple others, though the prevalence of super spreaders for COVID-19 is not significantly higher than for other diseases. Evidence suggests such events can occur in various settings like restaurants,',\n",
       "    'Super spreaders can significantly increase case numbers. Evidence shows some individuals infect many more people than average, though reasons vary.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 5],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '5906wju4': {'greedy': 'Experimental veterinary research supports the notion that exposure to high viral loads may result in infections of high intensity, leading to more superspreading events in humans.',\n",
       "   'samples': ['Experimental veterinary research supports the notion that exposure to high viral loads may result in infections of high intensity, potentially explaining the phenomenon of super spreaders in the context of COVID-19.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in infections of high intensity, leading to more superspreading events in humans.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may lead to infections of high intensity, potentially explaining the role of superspreading events in the propagation of COVID-19.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in infections of high intensity, which can lead to more superspreading events in humans.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in infections of high intensity, leading to further high viral load exposures and potential superspreading events in humans.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in infections of high intensity, leading to more superspreading events in humans.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads from super spreaders can result in high-intensity infections, which further increases the risk of transmitting high viral loads to others.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads may result in infections of high intensity, which can lead to more highly infectious new cases in a cascading manner.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads from super spreaders can result in high-intensity infections, which may lead to further super spreading events.',\n",
       "    'Experimental veterinary research supports the notion that exposure to high viral loads from super spreaders can result in high-intensity infections, which further increase the likelihood of superspreading events.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 1, 4, 5, 3, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'p48bw6s4': {'greedy': 'Super spreaders have been reported in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. Evidence suggests their role in the rapid growth of the epidemic. However, detailed scientific literature on this topic is limited. Early identification and',\n",
       "   'samples': ['Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to the growth of the epidemic. Early identification of these individuals is crucial for effective containment strategies. However, stigmatization can lead to underreporting and hidden cases',\n",
       "    'Evidence shows that super spreaders significantly contributed to the rapid spread of COVID-19, as observed in various outbreaks where a small number of individuals were responsible for a disproportionate number of infections. These events underscore the need for early identification and containment strategies targeting',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. Evidence suggests their role in accelerating epidemic growth. However, limited scientific literature exists specifically on this topic. Early identification and containment strategies targeting',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. This phenomenon has been noted and studied in relation to the rapid growth of the epidemic. However, specific details are not provided in the',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. This phenomenon has been noted beyond COVID-19, with reports dating back over a century. Evidence suggests these individuals significantly accelerate the',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to the number of cases. However, specific details about them are limited in the scientific literature. Evidence suggests their role in accelerating epidemic growth necessitates early identification for effective',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to a much larger number of cases. However, detailed scientific literature on this topic is limited. Early identification and containment of super spreaders are crucial for effective epidemic control',\n",
       "    'Evidence suggests that super spreaders contributed disproportionately to a much larger number of cases during the ongoing COVID-19 pandemic. These individuals tend to have a high number of secondary cases originating from each primary case. However, specific details about super spreaders in',\n",
       "    \"Super spreaders have been reported in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. Evidence suggests their role in accelerating the epidemic's growth. Early identification and containment strategies targeting these individuals are crucial for effective epidemic management.\",\n",
       "    'Evidence indicates that super spreaders contributed disproportionately to a larger number of cases during the ongoing COVID-19 pandemic. However, detailed scientific literature on this topic is limited.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 2],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'w4l2vpiy': {'greedy': 'The study estimated the basic reproductive number (R(0)) and the dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes indicative of super',\n",
       "   'samples': ['Evidence suggests that large cluster sizes, compatible with super-spreading, were unlikely based on relatively large values of the dispersion factor (k). This was estimated from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan,',\n",
       "    'The study estimated the basic reproductive number (R(0)) and the dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore. The relatively large values of k suggested that',\n",
       "    'Empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore was used to estimate the basic reproductive number (R(0)) and the dispersion factor (k), indicating that large cluster sizes compatible with super',\n",
       "    'The study estimated the basic reproductive number (R(0)) and the dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes indicative of super',\n",
       "    'The study estimated the basic reproductive number (R(0)) and dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes compatible with super-sp',\n",
       "    'The study estimated the basic reproductive number (R(0)) and dispersion factor (k) from clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes indicative of super-spreading events were',\n",
       "    'The study estimated R₀ and k from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes indicative of super-spreading were unlikely due to relatively large k values.',\n",
       "    'The study estimated the basic reproductive number (R(0)) and the dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore. The relatively large values of k indicated that',\n",
       "    'The study estimated the basic reproductive number (R(0)) and the dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes indicative of super',\n",
       "    'Empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore was used to estimate the basic reproductive number (R₀) and the dispersion factor (k), indicating that large cluster sizes compatible with super-sp'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 2, 1, 1, 2, 3],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'na3vrf5q': {'greedy': 'Super spreaders have been reported in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. Evidence suggests their role in the rapid growth of the epidemic. However, detailed scientific literature on this topic is limited. Early identification and',\n",
       "   'samples': ['Super spreaders have been reported in the context of the ongoing COVID-19 pandemic, contributing disproportionately to the growth of the epidemic. Early identification and containment strategies are crucial for managing the spread. Evidence suggests these individuals play a significant role in transmission dynamics',\n",
       "    'Super spreaders have been reported in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. Evidence suggests their role is significant in the rapid growth of the epidemic. However, specific details and studies on this topic are limited.',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to the spread of the virus. This phenomenon has been noted beyond COVID-19, with reports dating back over a century. However, detailed scientific literature on this',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to the spread of the virus. Evidence includes reports of specific events or individuals where a small number of people caused a significant increase in cases. However, detailed scientific literature',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. This phenomenon has been documented, although detailed information remains limited in scientific literature. These individuals significantly impact the rate of disease spread, making',\n",
       "    \"Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to the spread of the virus. This phenomenon has been noted and studied during the pandemic's course.\",\n",
       "    \"Super spreaders have been reported in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. Evidence suggests their role in accelerating the epidemic's growth.\",\n",
       "    'Super spreaders have been reported during the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. Evidence suggests their presence can lead to an explosive growth in the epidemic. Early identification and containment strategies are crucial to mitigate their impact.',\n",
       "    'Super spreaders have been observed in the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. This phenomenon has been documented but remains underreported in scientific literature. Early identification and containment strategies targeting super spreaders are crucial for effective',\n",
       "    'Super spreaders have been reported during the ongoing COVID-19 pandemic, contributing disproportionately to a larger number of cases. They play a significant role in the explosive growth of the epidemic. However, their identification and early reporting are hindered due to stigma'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 1, 0, 5, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  '2t4fsfy9': {'greedy': 'The study estimated the basic reproductive number (R0) and the dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes indicative of super-sp',\n",
       "   'samples': ['Evidence suggests that large cluster sizes, indicative of super-spreading events, were unlikely during the early phases of outbreaks in Hong Kong, Japan, and Singapore based on estimated dispersion factors (k) with relatively large values.',\n",
       "    'The study estimated R0 and k from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, indicating that large cluster sizes compatible with super-spreading were unlikely due to relatively large k values.',\n",
       "    'Evidence suggests that super-spreading events are not common during the early phase of COVID-19 outbreaks in Hong Kong, Japan, and Singapore, as indicated by relatively large dispersion factors (k). This implies that large cluster sizes resulting from super-spreading',\n",
       "    'Evidence suggests that while super-spreading events can occur, they are not likely to result in very large cluster sizes based on the relatively large dispersion factor (k) observed in some outbreaks. This was inferred from empirical data on clusters of epidemiologically-linked COVID',\n",
       "    'The evidence shows that relatively large values of the dispersion factor (k) imply unlikely large cluster sizes indicative of super-spreading events during the early phase of outbreaks in Hong Kong, Japan, and Singapore.',\n",
       "    'The evidence suggests that large cluster sizes indicative of super-spreading are unlikely based on relatively large values of the dispersion factor (k). This was inferred by estimating the basic reproductive number (R0) and dispersion factor (k) from empirical data on clusters',\n",
       "    'The study estimated the basic reproductive number (R0) and dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore, suggesting that large cluster sizes indicative of super-spreading',\n",
       "    'Evidence shows that large values of the dispersion factor \\\\( k \\\\) suggest the absence of significant super-spreading events in the early phases of COVID-19 outbreaks in Hong Kong, Japan, and Singapore.',\n",
       "    'Empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore was used to estimate R0 and k, indicating that large cluster sizes compatible with super-spreading were unlikely due to relatively large values of k',\n",
       "    'The study estimated the basic reproductive number (R0) and the dispersion factor (k) from empirical data on clusters of epidemiologically-linked COVID-19 cases in Hong Kong, Japan, and Singapore. Large values of k suggested that super-spreading'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 0, 3, 4, 0, 1, 5],\n",
       "   'entropy': 1.6094379124341}},\n",
       " '19': {'no': {'greedy': 'At least 60% alcohol.',\n",
       "   'samples': ['At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol is effective against Covid-19.',\n",
       "    'At least 60% alcohol.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 1, 0],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  'o6pupkuj': {'greedy': 'At least 60% alcohol.',\n",
       "   'samples': ['At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol is effective against COVID-19.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol is effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 0, 0, 0, 1, 2],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  '0a8sp3iz': {'greedy': 'At least 60% alcohol.',\n",
       "   'samples': ['At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 0, 1, 0, 0, 0],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'rq8sjc8q': {'greedy': 'At least 60% alcohol.',\n",
       "   'samples': ['At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol is effective against COVID-19.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol is effective against Covid-19.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol is effective against COVID-19.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 0, 0, 1, 0, 0],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  'hma2kvn2': {'greedy': 'No specific type of hand sanitizer is mentioned as effective against COVID-19 in the given context. The context suggests using alcohol-based hand sanitizers as recommended by WHO, but does not claim they can destroy COVID-19 specifically.',\n",
       "   'samples': ['Alcohol-based hand sanitizers containing ethanol or isopropyl alcohols are recommended for hand hygiene to help prevent the spread of viruses like COVID-19. They need to contain at least 60% alcohol to be effective.',\n",
       "    'Alcohol-based hand sanitizers containing ethanol or isopropyl alcohols are recommended by WHO for hand hygiene. However, there is currently no hand sanitizer that can specifically destroy the COVID-19 virus. Prevention focuses on hygiene and immune support rather',\n",
       "    'Alcohol-based hand sanitizers containing ethanol or isopropyl alcohols are recommended by WHO for frequent hand hygiene. However, the provided context does not specify a particular formulation to destroy COVID-19; it highlights the importance of proper use and',\n",
       "    'Based on the given context, no specific type of hand sanitizer is mentioned as effective against COVID-19. Alcohol-based hand sanitizers containing ethanol, isopropyl alcohol, or hydrogen peroxide are recommended for hand hygiene, but their effectiveness against',\n",
       "    'No specific type of hand sanitizer is mentioned as capable of destroying COVID-19 in the given context. The text suggests using alcohol-based hand sanitizers as recommended by WHO, but does not claim they can destroy the virus.',\n",
       "    'Based on the given context, no specific type of hand sanitizer is mentioned as capable of destroying COVID-19. The context suggests alcohol-based hand sanitizers containing ethanol, isopropyl alcohols, or hydrogen peroxides are recommended for',\n",
       "    'The provided context does not specify the exact type of hand sanitizer needed to destroy COVID-19. Alcohol-based hand sanitizers containing ethanol or isopropyl alcohol are recommended by WHO for frequent hand hygiene. However, their effectiveness against viruses like S',\n",
       "    'The context provided does not specify a particular type of hand sanitizer needed to destroy COVID-19. It suggests using alcohol-based hand sanitizers containing ethanol, isopropyl alcohols, or hydrogen peroxides, but emphasizes their proper use',\n",
       "    'The provided context does not specify a particular type of hand sanitizer needed to destroy COVID-19. According to WHO, alcohol-based hand sanitizers containing ethanol, isopropyl alcohols, or hydrogen peroxides are recommended. However,',\n",
       "    'No specific type of hand sanitizer is mentioned in the context that can destroy COVID-19. Alcohol-based hand sanitizers containing ethanol or isopropyl alcohols are recommended for hand hygiene, but they do not \"destroy\" the virus;'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 5, 3, 6, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'uhhk4t7f': {'greedy': 'Alcohol-based hand sanitizers with at least 60% alcohol concentration are effective against COVID-19.',\n",
       "   'samples': ['Hand sanitizers with at least 60% alcohol concentration are recommended to effectively destroy COVID-19. Avoid those with added methanol or below 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol concentration are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19. Avoid those containing methanol or with insufficient alcohol concentration.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol concentration are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol concentration are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol concentration are effective against destroying COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 1, 1, 2, 2, 2, 2],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'eevs62xf': {'greedy': 'No specific type of hand sanitizer is mentioned as effective against COVID-19 in the given context. The context suggests using alcohol-based hand sanitizers containing ethanol, isopropyl alcohols, or hydrogen peroxides, but does not claim',\n",
       "   'samples': ['There is currently no specific type of hand sanitizer that can destroy the COVID-19 virus; alcohol-based hand sanitizers containing at least 60% alcohol are recommended by the WHO for hand hygiene. However, they should be used judiciously',\n",
       "    'There is currently no specific type of hand sanitizer that can destroy COVID-19; frequent hand washing with soap and water or using alcohol-based hand sanitizers with at least 60% alcohol content are recommended by health authorities.',\n",
       "    'There is currently no specific type of hand sanitizer that can destroy the COVID-19 virus. WHO recommends alcohol-based hand sanitizers containing at least 60% alcohol, but emphasizes proper use and limitations. No vaccine or medication is available yet.',\n",
       "    'Alcohol-based hand sanitizers containing ethanol or isopropyl alcohols are recommended by WHO for hand hygiene to help destroy COVID-19. However, they should be used correctly and with caution due to potential health and environmental risks.',\n",
       "    'Alcohol-based hand sanitizers containing ethanol or isopropyl alcohols are recommended for hand hygiene to help prevent the spread of COVID-19. However, they should be used properly and not excessively.',\n",
       "    'Based on the given context, there is no specific type of hand sanitizer mentioned as effective against COVID-19. The context suggests alcohol-based hand sanitizers containing ethanol, isopropyl alcohols, or hydrogen peroxides, but notes',\n",
       "    'Based on the given context, there is no specific type of hand sanitizer mentioned as capable of destroying COVID-19. Hand sanitizers containing ethanol, isopropyl alcohols, or hydrogen peroxides are recommended for frequent hand hygiene,',\n",
       "    'The given context does not specify the exact type of hand sanitizer needed to destroy COVID-19. Alcohol-based hand sanitizers containing ethanol, isopropyl alcohols, or their combinations are recommended by WHO for frequent hand hygiene. However,',\n",
       "    'Based on the given context, there is no specific type of hand sanitizer mentioned as capable of destroying COVID-19. Hand sanitizers containing alcohol (ethanol or isopropyl alcohols) are recommended by WHO for hand hygiene, but',\n",
       "    'The current review does not specify a particular type of hand sanitizer; it suggests that alcohol-based hand sanitizers containing ethanol, isopropyl alcohols, or hydrogen peroxides are recommended by WHO for frequent hand hygiene. However, it also'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '20ipkh78': {'greedy': 'Alcohol-based hand sanitizers with at least 60% alcohol concentration are effective against destroying COVID-19.',\n",
       "   'samples': ['Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol concentration are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol concentration are needed to effectively destroy COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying Covid-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying COVID-19.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 0, 0, 2, 3, 0],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  '09w2yec8': {'greedy': 'At least 60% alcohol.',\n",
       "   'samples': ['At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 0, 0, 0, 0, 0],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  'z6cda4o2': {'greedy': 'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "   'samples': ['Hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against destroying SARS-CoV-2, the virus that causes COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.',\n",
       "    'Alcohol-based hand sanitizers with at least 60% alcohol content are effective against COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 0, 1, 1, 1, 1, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'jb05x03a': {'greedy': 'At least 60% alcohol.',\n",
       "   'samples': ['At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'At least 60% alcohol.',\n",
       "    'Alcohol-based hand sanitizer with at least 60% alcohol.',\n",
       "    'At least 60% alcohol.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 0, 0, 0, 1, 0],\n",
       "   'entropy': 0.5004024235381879}},\n",
       " '42': {'no': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Possibly, but more research is needed. Vitamin D may support immune function, but evidence for its direct impact on COVID-19 is limited.',\n",
       "    'Preliminary evidence suggests Vitamin D may help prevent and treat COVID-19, but more research is needed.',\n",
       "    'Possibly, but more research is needed. Early studies suggest a link, but results are not conclusive.',\n",
       "    'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune function, but more research is needed to determine its specific impact on COVID-19.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for its specific impact on COVID-19 prevention and treatment is limited. More research is needed.',\n",
       "    'Possibly, vitamin D may support immune function, but evidence for preventing or treating COVID-19 is limited.',\n",
       "    'Possibly, some studies suggest Vitamin D may help reduce risk or severity, but more research is needed.',\n",
       "    \"Some studies suggest Vitamin D may support immune health and reduce COVID-19 risk, but evidence is limited. It's not a direct treatment. Consult healthcare provider for advice.\",\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'vjgrq22k': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Vitamin D may help, but evidence is limited. Supplementation may reduce risk or severity. Further research needed.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune health, but more research is needed to determine its specific impact on COVID-19 prevention and treatment.',\n",
       "    'Possibly, but more research is needed. Vitamin D may influence immune response, but evidence for its effect on COVID-19 is limited and inconclusive.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for preventing or treating COVID-19 is limited. Further research is needed.',\n",
       "    'Possibly, vitamin D may help prevent or treat COVID-19 by supporting immune function, but evidence is limited. Further research is needed.',\n",
       "    'Possibly, but more research is needed. Early studies suggest a link, but results are inconsistent.',\n",
       "    'Possibly, but evidence is limited. Vitamin D may modulate immune response, but more research is needed.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for its impact on COVID-19 is limited. More research is needed.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune function and reduce COVID-19 risk, but more research is needed.',\n",
       "    'Vitamin D may support overall immune function, but its direct impact on COVID-19 prevention and treatment is not definitively established. Further research is needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 2, 3, 5, 2],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'b18l7je9': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Evidence suggests Vitamin D may support immune health, potentially reducing COVID-19 risk and severity, but more research is needed.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune health, but more research is needed to determine its specific impact on COVID-19 prevention and treatment.',\n",
       "    'Possibly, but more research is needed. Vitamin D may support immune function, but its effects on COVID-19 are unclear.',\n",
       "    'Vitamin D may support overall immune function, potentially aiding in COVID-19 prevention and treatment, but more research is needed.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune health, but more research is needed on its specific effects for COVID-19 prevention and treatment.',\n",
       "    'Possibly, vitamin D may help reduce risk and severity, but more research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent and treat COVID-19, but more research is needed.',\n",
       "    'Possibly, vitamin D may help reduce risk and severity, but evidence is limited.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 1, 3, 1, 4, 1, 0],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  'gj42zytf': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Possibly, but more research is needed. Early studies suggest a link, but results are inconclusive. Vitamin D may help maintain immune health.',\n",
       "    'Possibly, vitamin D may support immune function, but evidence for preventing or treating COVID-19 is limited.',\n",
       "    'Possibly, vitamin D may help reduce risk and severity. More research needed.',\n",
       "    'Possibly, vitamin D may support immune function, but evidence for its specific impact on COVID-19 is limited.',\n",
       "    'Possibly, some studies suggest Vitamin D may support immune function and reduce risk of respiratory infections but evidence is limited. Vitamin D does not treat COVID-19. Consult healthcare provider for advice.',\n",
       "    'Possibly, vitamin D may help prevent or treat COVID-19 by supporting immune function, but evidence is limited.',\n",
       "    'Vitamin D may help prevent and treat COVID-19 by supporting immune function, but more research is needed.',\n",
       "    'Vitamin D may influence immune response, potentially aiding in COVID-19 management, but more research is needed.',\n",
       "    'Some studies suggest Vitamin D may help, but more research is needed.',\n",
       "    'Possibly, vitamin D may help reduce risk and severity. Evidence mixed. More research needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'zx767txr': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Some studies suggest Vitamin D may support immune health, potentially aiding in COVID-19 prevention and treatment, but more research is needed.',\n",
       "    'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "    'Possibly, vitamin D may help reduce risk and severity, but more research is needed.',\n",
       "    'Possibly, Vitamin D may support immune function and reduce risk, but evidence is limited. Further research needed.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for its specific impact on COVID-19 prevention and treatment is limited. More research is needed.',\n",
       "    'Vitamin D may support immune function, potentially aiding in COVID-19 prevention and treatment, but evidence is limited. Consult healthcare provider for guidance.',\n",
       "    'Possibly, studies suggest Vitamin D may support immune function, but more research is needed.',\n",
       "    'Some studies suggest Vitamin D may support immune health, potentially impacting COVID-19 outcomes, but more research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Evidence suggests Vitamin D may support immune health and reduce risk of respiratory infections but more research is needed on its direct impact on COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 4, 0, 5, 0, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '0ngg5pef': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Vitamin D may support overall immune health, which could aid in preventing and treating COVID-19, but evidence is limited. Further research is needed.',\n",
       "    'Some studies suggest Vitamin D may help, but more research is needed. Vitamin D supports immune function, which could be beneficial against COVID-19.',\n",
       "    'Vitamin D may support overall immune function, potentially aiding in COVID-19 prevention and treatment, but evidence is limited.',\n",
       "    'Vitamin D may help prevent or treat COVID-19 by enhancing immune function, but evidence is limited.',\n",
       "    'Evidence suggests Vitamin D may support immune health and reduce COVID-19 risk, but more research is needed.',\n",
       "    'Vitamin D may help prevent or treat COVID-19 by enhancing immune function, but more research is needed. Early studies show promise.',\n",
       "    'Possibly, studies suggest Vitamin D may support immune function, but more research is needed.',\n",
       "    'Possibly, Vitamin D may help reduce severity and risk of infections, but more research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent or mitigate COVID-19, but more research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 1, 1, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'ke5hxd8o': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune health, but more research is needed on its direct impact on COVID-19 prevention and treatment.',\n",
       "    'Possibly, some studies suggest Vitamin D may help reduce risk and severity. More research is needed.',\n",
       "    \"Some studies suggest Vitamin D may support immune function and reduce COVID-19 risk, but evidence is limited. It's not a substitute for other preventive measures. Consult a healthcare provider.\",\n",
       "    'Possibly, Vitamin D may help reduce severity and risk of infections, but evidence is limited.',\n",
       "    \"Possibly, but more research is needed. Some studies suggest Vitamin D may help reduce risk or severity, but results are inconsistent. It's not a substitute for other防控措施。请注意，维他命D补充剂不能替代其他防护措施，如有\",\n",
       "    'Vitamin D may help, but evidence is limited. Supplementation may reduce severity and mortality. Consult healthcare provider for guidance.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Possibly, Vitamin D may help reduce severity and risk of COVID-19 infections, but more research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 2, 5, 0, 6, 0],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'b4w5k7lh': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Possibly, some studies suggest Vitamin D may help, but more research is needed.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for its direct impact on COVID-19 prevention and treatment is limited. More research is needed.',\n",
       "    'Possibly, but evidence is limited. Vitamin D may support immune function, but its direct impact on COVID-19 is unclear. Further research needed.',\n",
       "    'Some studies suggest Vitamin D may help, but more research is needed.',\n",
       "    'Possibly, some studies suggest Vitamin D may help, but more research is needed.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for its impact on COVID-19 prevention and treatment is limited and inconclusive.',\n",
       "    'Vitamin D may support overall immune health, potentially impacting COVID-19 outcomes, but evidence is limited. Further research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent or mitigate COVID-19, but more research is needed.',\n",
       "    \"Some studies suggest Vitamin D may help, but evidence is limited. It's important to follow official health guidelines.\"],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 1, 4, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'gwf79fj6': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Evidence suggests Vitamin D may support immune health, potentially aiding in COVID-19 prevention and treatment, but more research is needed.',\n",
       "    'Vitamin D may help, but evidence is limited. Supplementing with Vitamin D may reduce risk or severity, but results vary. Further research needed.',\n",
       "    'Possibly, some studies suggest Vitamin D may help reduce risk and severity. More research needed.',\n",
       "    'Possibly, but evidence is limited. Vitamin D may support immune function, but more research is needed on its specific effects for COVID-19.',\n",
       "    'Vitamin D may help prevent or treat COVID-19 by supporting immune function, but evidence is limited.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune health, but more research is needed on its specific effects for COVID-19.',\n",
       "    'Vitamin D may influence COVID-19 outcomes, but evidence is limited. Some studies suggest it could help, especially in those with deficiencies. More research is needed.',\n",
       "    'Some studies suggest Vitamin D may support immune function and reduce risk of respiratory infections, but evidence for its direct impact on COVID-19 prevention and treatment is limited and inconclusive. More research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent and treat COVID-19, but more research is needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 4, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'hj9zco81': {'greedy': 'Possibly, Vitamin D may help reduce severity and risk of infection, but more research is needed.',\n",
       "   'samples': ['Possibly, Vitamin D may support immune function, but evidence for its specific impact on COVID-19 prevention and treatment is limited and inconclusive. Further research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Evidence suggests Vitamin D may support immune function and reduce risk of respiratory infections, but more research is needed on its impact specifically for COVID-19 prevention and treatment.',\n",
       "    'Some studies suggest Vitamin D may help, but evidence is limited.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for its direct impact on COVID-19 prevention and treatment is limited. More research is needed.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Possibly, Vitamin D may help reduce severity and risk of infections, but evidence is limited.',\n",
       "    'Preliminary evidence suggests Vitamin D may support immune function, but more research is needed to determine its specific impact on COVID-19 prevention and treatment.',\n",
       "    'Some studies suggest Vitamin D may help prevent or treat COVID-19, but more research is needed.',\n",
       "    'Possibly, Vitamin D may support immune function, but evidence for preventing or treating COVID-19 is limited. Further research is needed.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 1, 5, 6, 1, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'yjx6ejrh': {'greedy': 'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage.',\n",
       "   'samples': ['Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage.',\n",
       "    'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage.',\n",
       "    'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage.',\n",
       "    'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage associated with the disease.',\n",
       "    'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage associated with the cytokine storm syndrome.',\n",
       "    'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage associated with the cytokine storm syndrome.',\n",
       "    'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage associated with the cytokine storm syndrome.',\n",
       "    'Yes, according to the context, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing infection-induced multiple organ damage.',\n",
       "    'Yes, Vitamin D may have protective and therapeutic effects against COVID-19, potentially preventing multiple organ damage associated with the disease.',\n",
       "    'Yes, according to the context, Vitamin D may have protective and therapeutic effects against COVID-19 and prevent multiple organ damage associated with the cytokine storm syndrome.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 2, 2, 3, 1, 4],\n",
       "   'entropy': 1.5047882836811906}},\n",
       " '33': {'no': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA vaccines, viral vector vaccines, inactivated virus vaccines, and protein-based vaccines. Some leading candidates include Pfizer-BioNTech, Moderna, AstraZeneca, and Sinovac.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 1, 1, 3, 0, 3],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'bzz9foxx': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA vaccines (e.g., Pfizer-BioNTech, Moderna), viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson), inactivated virus vaccines, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, inactivated virus, and protein subunit types, are being tested globally. Examples include Pfizer/BioNTech, Moderna, AstraZeneca, and Sinovac.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, inactivated virus, and protein subunit types, are being tested. Some leading examples include Pfizer-BioNTech, AstraZeneca-Oxford, Sinovac, and Moderna.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 3, 1, 3, 4, 5, 0],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  '6mewd1gl': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['Multiple vaccine candidates are being tested, including mRNA vaccines (e.g., Pfizer-BioNTech, Moderna), viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson), and inactivated virus vaccines. Other types like protein sub',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, inactivated virus, and protein-based vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, and inactivated virus types, are being tested globally. Examples include Pfizer/BioNTech, AstraZeneca/Oxford, and Sinovac.',\n",
       "    'Multiple vaccine candidates, including mRNA (e.g., Pfizer-BioNTech, Moderna), viral vector (e.g., AstraZeneca, Johnson & Johnson), inactivated virus (e.g., Sinopharm, Sinovac), and',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, and inactivated virus types.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 3, 4, 5, 5, 6, 0],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'oud565zt': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['Multiple vaccine candidates are being tested, including mRNA vaccines (e.g., Pfizer-BioNTech, Moderna), viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson), inactivated virus vaccines, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA, viral vector, inactivated virus, and protein subunit types. Examples include Pfizer-BioNTech, AstraZeneca-Oxford, Sinovac, and Moderna.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 1, 1, 6, 5],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'gf44xeb6': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['Multiple vaccine candidates are being tested, including mRNA, viral vector, inactivated virus, and protein-based vaccines.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'Multiple vaccine candidates, including mRNA (Moderna, Pfizer/BioNTech), viral vector (AstraZeneca, Johnson & Johnson), and inactivated virus (Sinovac) vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 2, 2, 4, 5, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'aoxsl823': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, inactivated virus, and protein subunit types, are being tested globally. Notable ones include Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA, viral vector, inactivated virus, and protein subunit types. Examples include Pfizer-BioNTech, AstraZeneca, Sinopharm, and Moderna.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA vaccines, viral vector vaccines, inactivated virus vaccines, and protein-based vaccines. Examples include Pfizer-BioNTech, Moderna, AstraZeneca, and Sinopharm.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 1, 3, 0, 2, 0],\n",
       "   'entropy': 1.2206072645530173},\n",
       "  'n6tdfpro': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA vaccines (e.g., Pfizer-BioNTech, Moderna), viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson), inactivated virus vaccines, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, and inactivated virus types. Some examples are Pfizer-BioNTech, AstraZeneca, and Sinovac.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA vaccines (e.g., Pfizer-BioNTech, Moderna), viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson), inactivated virus vaccines, and protein subunit vaccines.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 1, 0, 4, 1, 2],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  '4yuhtvim': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 2, 0, 2, 2, 0],\n",
       "   'entropy': 0.8979457248567797},\n",
       "  'esqq01qy': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'mRNA, viral vector, and protein-subunit vaccines.',\n",
       "    'mRNA, viral vector, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 5, 4, 5, 0],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'rgi28k3d': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein-based vaccines.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, and inactivated virus types, are being tested. Notable candidates include Pfizer-BioNTech, Moderna, AstraZeneca, and Sinovac.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'mRNA, viral vector, and inactivated virus vaccines are being tested.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 2, 1, 4, 1, 2],\n",
       "   'entropy': 1.4184836619456564},\n",
       "  '91e70966': {'greedy': 'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "   'samples': ['mRNA, viral vector, and inactivated virus vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, inactivated virus, and protein subunit types, are being tested. Examples include Pfizer-BioNTech, AstraZeneca, Sinovac, and Moderna.',\n",
       "    'Multiple vaccine candidates, including mRNA, viral vector, inactivated virus, and protein-based vaccines.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates, including mRNA (e.g., Pfizer-BioNTech, Moderna), viral vector (e.g., AstraZeneca, Johnson & Johnson), inactivated virus (e.g., Sinovac), and protein subunit (',\n",
       "    'mRNA, viral vector, and protein subunit vaccines.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA, viral vector, inactivated virus, and protein-based vaccines. Some leading candidates include Pfizer-BioNTech, Moderna, AstraZeneca, and Sinovac.',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.',\n",
       "    'Multiple vaccine candidates are being tested, including mRNA vaccines (e.g., Pfizer-BioNTech, Moderna), viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson), and inactivated virus vaccines. Clinical trials are ongoing to',\n",
       "    'mRNA, viral vector, inactivated virus, and protein subunit vaccines are being tested.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 1, 1, 0, 1, 3, 1],\n",
       "   'entropy': 1.0888999753452235}},\n",
       " '36': {'no': {'greedy': 'The SARS-CoV-2 spike protein has a trimeric structure with an ectodomain containing receptor-binding domain and several glycosylation sites.',\n",
       "   'samples': ['The SARS-CoV-2 spike protein has a trimeric structure with a receptor-binding domain.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric, glycosylated structure with an ectodomain containing receptor-binding and fusion domains.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with an ectodomain containing receptor-binding domain and angiotensin-converting enzyme 2 binding site.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with an amino-terminal domain, a receptor-binding domain, and a carboxy-terminal domain.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric, glycosylated structure with an S1 and S2 subunit. The receptor-binding domain (RBD) is in the S1 subunit.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric, glycoprotein structure.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with a receptor-binding domain.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with a receptor-binding domain. Briefly.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with a receptor-binding domain.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric, glycoprotein structure.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 0, 0, 0, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  '908d8bax': {'greedy': 'The SARS-CoV-2 spike protein has a trimeric structure with each monomer consisting of two subunits, S1 and S2. The S1 subunit contains the receptor-binding domain (RBD) that binds to the ACE',\n",
       "   'samples': ['The SARS-CoV-2 spike protein has a trimeric structure with each monomer consisting of a complex of several different proteins. The exact structure can vary slightly between individual spikes, but it typically includes the S1 subunit which binds to',\n",
       "    'The SARS-CoV-2 spike protein has a protein structure that allows it to interact with host cells. (Note: The actual detailed structure is complex and typically requires visual aids like images or diagrams for full comprehension, which are not provided here.)',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with each monomer consisting of a complex arrangement of amino acids that enable it to bind to and enter host cells. (This answer assumes that the image being referred to contains information',\n",
       "    'The SARS-CoV-2 spike protein has a protein structure that features interactions with other proteins, as recent crystal structure data has shown. However, the exact structure is not specified in the given context.',\n",
       "    'The SARS-CoV-2 spike protein has a protein structure that is crucial for viral entry into host cells. Recent crystal structure data have been released, enabling deeper research into its interactions. (Note: The actual 3D structure image is not',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with each monomer consisting of three domains: N-terminal domain (NTD), receptor-binding domain (RBD), and C-terminal domain (CTD). RBD binds to',\n",
       "    'The SARS-CoV-2 spike protein structure has been crystallized and its crystal structure analyzed.',\n",
       "    'The SARS-CoV-2 spike protein has a trimeric structure with each monomer consisting of three functional domains: the receptor-binding domain (RBD), the n-terminal domain (NTD), and the S2 subunit. The R',\n",
       "    'The context mentions the SARS-CoV-2 spike protein but does not provide its specific structure. To answer, we would need the exact crystal structure details, which are not given in the prompt. Answer: Not specified in the context.',\n",
       "    'The context mentions crystal structure data for the SARS-CoV-2 spike protein, but does not provide specific details about its structure.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 6, 3],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '34ljq0qt': {'greedy': 'The full-length structural model of the SARS-CoV-2 spike protein was used in the study. However, specific details about its exact 3D structure are not provided in the context. To get the exact structure, one would need to refer',\n",
       "   'samples': ['The SARS-CoV-2 spike protein contains two potential cleavage sites, Arg685/Ser686 and Arg815/Ser816.',\n",
       "    'The full-length structural model of the SARS-CoV-2 spike protein was used in the study. However, the specific details of its structure are not provided in the context. Answer: Full-length structural model of SARS-CoV-2 spike',\n",
       "    'The full-length structural model of the SARS-CoV-2 spike protein was used in the study. It contains two different loops with cleavage sites that interact with TMPRSS2.',\n",
       "    'The full length structural model of TMPRSS2 was developed and docked against the resolved structure of SARS-CoV-2 spike protein. No specific structure of the SARS-CoV-2 spike is mentioned in the text.',\n",
       "    'The full-length structural model of TMPRSS2 was developed and docked against the resolved structure of SARS-CoV-2 spike protein. The docking simulations showed that TMPRSS2 interacts with two different loops of SARS-CoV-2 spike protein',\n",
       "    'The SARS-CoV-2 spike protein has a structure that includes two different loops containing potential cleavage sites for the serine protease TMPRSS2.',\n",
       "    'The SARS-CoV-2 spike protein contains two different loops, each containing different cleavage sites. The loops are interacted with by TMPRSS2. The N-terminal cleavage site is Arg685/Ser686, while',\n",
       "    'The full length structural model of TMPRSS2 was developed and docked against the resolved structure of SARS-CoV-2 spike protein. No specific structure of SARS-CoV-2 spike protein itself is mentioned.',\n",
       "    'The full length structural model of the SARS-CoV-2 spike protein was used in the study. However, no specific structural details beyond this are provided in the given context.',\n",
       "    'The SARS-CoV-2 spike protein contains two cleavage sites, Arg685/Ser686 and Arg815/Ser816, which are targeted by the serine protease TMPRSS2 for priming'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 3, 1, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  't4bqmgcl': {'greedy': 'The SARS-CoV-2 spike protein is slightly more positively charged than that of SARS-CoV and has a 30% higher binding energy to the host ACE2 receptor.',\n",
       "   'samples': ['The SARS-CoV-2 spike protein is highly similar to that of SARS-CoV, sharing 77% sequence identity, and is slightly more positively charged, potentially increasing its affinity to bind to the host ACE2 receptor. This leads',\n",
       "    'The SARS-CoV-2 spike protein is slightly more positively charged than that of SARS-CoV and has a 30% higher binding energy to the host ACE2 receptor.',\n",
       "    'The SARS-CoV-2 spike protein is highly similar to that of SARS-CoV, sharing 77% sequence identity, and is slightly more positively charged, which may enhance its binding to the ACE2 receptor. It has a higher',\n",
       "    'The S protein of SARS-CoV-2 is slightly more positively charged than that of SARS-CoV, with four more positively charged residues and five less negatively charged residues. This results in a 30% higher binding energy to the host',\n",
       "    'The S protein of SARS-CoV-2 is slightly more positively charged than that of SARS-CoV and has a 30% higher binding energy to the host ACE2 receptor. It shares a sequence identity of 77% with',\n",
       "    'The SARS-CoV-2 spike protein is highly similar to that of SARS-CoV, sharing a sequence identity of 77%, and is slightly more positively charged, leading to a 30% higher binding energy to the host ACE',\n",
       "    'The SARS-CoV-2 Spike protein is slightly more positively charged and has a 30% higher binding energy to the ACE2 receptor compared to SARS-CoV. It shares 77% sequence identity with the SARS-CoV',\n",
       "    'The S protein of SARS-CoV-2 is slightly more positively charged than that of SARS-CoV, with four more positively charged residues and five less negatively charged residues. This leads to a 30% higher binding energy to the host',\n",
       "    'The S protein of SARS-CoV-2 is slightly more positively charged than that of SARS-CoV, with four more positively charged residues and five less negatively charged residues. This results in a 30% higher binding energy to the host',\n",
       "    'The S protein of SARS-CoV-2 is slightly more positively charged than that of SARS-CoV and has a 30% higher binding energy to the host ACE2 receptor. It shares a sequence identity of 77% with'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 1, 3, 4, 5, 2, 4],\n",
       "   'entropy': 1.7480673485460894},\n",
       "  '2bz78yl1': {'greedy': 'The SARS-CoV-2 spike protein is slightly more positively charged than that of SARS-CoV and has a 30% higher binding energy to the host ACE2 receptor.',\n",
       "   'samples': ['The SARS-CoV-2 Spike protein is slightly more positively charged and has a 30% higher binding energy to the host ACE2 receptor compared to SARS-CoV. It shares 77% sequence identity with the SARS-Co',\n",
       "    'The SARS-CoV-2 Spike (S) protein is slightly more positively charged than that of SARS-CoV, with four more positively charged residues and five less negatively charged residues. This leads to a higher binding energy to the host ACE2',\n",
       "    'The SARS-CoV-2 spike protein is highly similar to that of SARS-CoV, sharing 77% sequence identity, and is slightly more positively charged due to differences in the number of positively and negatively charged residues. This results in',\n",
       "    'The SARS-CoV-2 spike protein is slightly more positively charged than that of SARS-CoV and has a 30% higher binding energy to the host ACE2 receptor.',\n",
       "    \"The S protein of SARS-CoV-2 is slightly more positively charged than SARS-CoV's S protein and has a 30% higher binding energy to the host ACE2 receptor. It shares 77% sequence identity with the\",\n",
       "    'The S protein of SARS-CoV-2 is slightly more positively charged than that of SARS-CoV, with four more positively charged residues and five less negatively charged residues. This leads to a 30% higher binding energy to the host',\n",
       "    'The S protein of SARS-CoV-2 is slightly more positively charged than that of SARS-CoV, with four more positively charged residues and five less negatively charged residues. This may increase its affinity to bind to negatively charged regions of other molecules',\n",
       "    \"The S protein of SARS-CoV-2 is slightly more positively charged than SARS-CoV's, with four more positively charged residues and five fewer negatively charged residues. This leads to a higher binding energy to the host ACE2 receptor by\",\n",
       "    \"The SARS-CoV-2 spike protein is slightly more positively charged than SARS-CoV's and has a 30% higher binding energy to the ACE2 receptor.\",\n",
       "    'The SARS-CoV-2 Spike protein is slightly more positively charged than that of SARS-CoV, with four more positively charged residues and five less negatively charged residues. This results in a 30% higher binding energy for SARS-Co'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 0, 3, 4, 1, 0, 3],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  '5ftpxlfe': {'greedy': 'The SARS-CoV-2 spike protein has an α helical conformation.',\n",
       "   'samples': ['The SARS-CoV-2 spike protein has an α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has an α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has a stable α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has a stable α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has a stable α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has an α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has a stable α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has a stable α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has an α helical conformation.',\n",
       "    'The SARS-CoV-2 spike protein has an α helical conformation.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 1, 0, 1, 1, 0, 0],\n",
       "   'entropy': 0.6931471805599453},\n",
       "  '4nfxdppt': {'greedy': 'The protein structure of the SARS-CoV-2 spike is not explicitly detailed in the given context. The text focuses on the interaction between different human ACE2 variants and the SARS-CoV-2 spike protein but does not provide specific details about',\n",
       "   'samples': ['The study focuses on the binding of different human ACE2 allelic variants with the SARS-CoV-2 spike protein, but does not provide specific details about the protein structure of the SARS-CoV-2 spike itself. To answer this question',\n",
       "    'The protein structure of the SARS-CoV-2 spike includes key interacting residues that bind to human ACE2. Variations in the spatial orientation of these residues among different ACE2 allelic variants can influence binding affinity and potentially resistance to SARS-Co',\n",
       "    'The protein structure of the SARS-CoV-2 spike is not specified in the given context. The text discusses the interaction between the SARS-CoV-2 spike protein and various human ACE2 variants but does not provide details about the specific structure',\n",
       "    'The protein structure of the SARS-CoV-2 spike is not detailed in the provided context. To answer this question accurately, one would need specific structural information about the spike protein, which is typically obtained from cryo-electron microscopy or X-ray',\n",
       "    'The protein structure of the SARS-CoV-2 spike includes key interacting residues that are involved in binding with human ACE2. Despite overall structural similarities, the spatial orientation of these key residues varies among different human ACE2 allelic variants. Some variants',\n",
       "    'The protein structure of the SARS-CoV-2 spike includes key interacting residues that form intermolecular interactions with human ACE2. Different human ACE2 allelic variants show varying spatial orientations of these key residues, which can affect binding affinity. Some',\n",
       "    'The protein structure of the SARS-CoV-2 spike is not explicitly described in the text provided. The study focuses on the interaction between the spike protein of SARS-CoV-2 and different human ACE2 allelic variants but does not detail',\n",
       "    'The study did not provide specific details about the protein structure of the SARS-CoV-2 spike. It focused on how different human ACE2 variants interact with the SARS-CoV-2 spike protein. For more detailed information about the spike protein',\n",
       "    'The protein structure of the SARS-CoV-2 spike is not explicitly detailed in the provided context. The passage focuses on the interaction between various human ACE2 variants and the SARS-CoV-2 spike protein but does not provide specific details about',\n",
       "    'The protein structure of the SARS-CoV-2 spike includes key interacting residues that bind to human ACE2. Variations in these residues can affect binding affinity and potentially resistance to infection.'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 3, 4, 0, 0, 0, 1],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'klb8oe9q': {'greedy': \"The S protein of SARS-CoV-2 is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures when not stabilized by another protomer's beta sheet.\",\n",
       "   'samples': ['The S protein of SARS-CoV-2 is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures when not stabilized by a beta sheet from another protomer',\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, with the protomer state being flexible. Two regions in the S2 domain and the hinge connecting the S1 and S2 subunits lose their secondary structures without the stabilizing',\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures when not stabilized by a beta sheet from another protomer',\n",
       "    \"The SARS-CoV-2 spike protein is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures when not stabilized by another protomer chain's beta sheet.\",\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures when not stabilized by a beta sheet from another protomer',\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, with the protomer state being flexible. Without a stabilizing beta sheet from another protomer chain, two regions in the S2 domain and the hinge connecting the S1 and',\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, particularly in the S2 domain and the hinge connecting the S1 and S2 subunits, which can lose their secondary structures without a stabilizing beta sheet from another protomer',\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures without the stabilizing beta sheet from another protomer chain',\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures without a stabilizing beta sheet from another protomer chain',\n",
       "    'The S protein of SARS-CoV-2 is structurally flexible, with two regions in the S2 domain and the hinge connecting the S1 and S2 subunits losing their secondary structures without the presence of a stabilizing beta sheet from another'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 2, 3, 4, 4, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'd3rrnjz2': {'greedy': 'The SARS-CoV-2 spike protein has a receptor-binding domain (RBD) that binds to human ACE2. 3,860 amino acid mutations in the RBD (T333-C525) were simulated',\n",
       "   'samples': ['The SARS-CoV-2 spike protein has a receptor-binding domain (RBD) that binds to human ACE2 (hACE2). 3,860 amino acid mutations in the RBD (T333-C52',\n",
       "    'The spike protein of SARS-CoV-2 has a receptor-binding domain (RBD) that interacts with human ACE2 (hACE2). 3,860 amino acid mutations in the spike protein RBD (T333',\n",
       "    'The SARS-CoV-2 spike protein has a receptor-binding domain (RBD) that binds to human ACE2 (hACE2). 3,860 amino acid mutations in the RBD (T333-C52',\n",
       "    'The SARS-CoV-2 spike protein includes a receptor-binding domain (RBD) that binds to human ACE2. There are 3,860 amino acid mutations in the RBD (T333-C525).',\n",
       "    'The SARS-CoV-2 spike protein has a receptor-binding domain (RBD) that interacts with human ACE2 (hACE2). 3,860 amino acid mutations in the RBD (T333-C52',\n",
       "    'The spike protein of SARS-CoV-2 includes receptor-binding domain (RBD) T333-C525. This domain has 3,860 amino acid mutations which were simulated and analyzed for stability and affinity to h',\n",
       "    'The SARS-CoV-2 spike protein has a receptor-binding domain (RBD) that interacts with human ACE2. The protein structure includes 3,860 amino acid mutations in the RBD (T333-C52',\n",
       "    'The spike protein of SARS-CoV-2 includes receptor-binding domain (RBD) which binds to human ACE2. There are 3,860 amino acid mutations in the RBD (T333-C525).',\n",
       "    'The SARS-CoV-2 spike protein has a receptor-binding domain (RBD) that interacts with human ACE2. 3,860 amino acid mutations in the RBD (T333-C525) were simulated',\n",
       "    'The SARS-CoV-2 spike protein includes a receptor-binding domain (RBD) that interacts with human ACE2. There are 3,860 amino acid mutations in the RBD (T333-C525).'],\n",
       "   'cluster_ids': [0, 1, 0, 1, 2, 3, 2, 2, 4, 4],\n",
       "   'entropy': 1.5571130980576455},\n",
       "  'g81ylcxq': {'greedy': 'The SARS-CoV-2 spike protein has a prefusion conformation. To answer your question directly:',\n",
       "   'samples': ['The SARS-CoV-2 spike protein has a prefusion conformation. According to a 3.2 Å-resolution cryo-EM structure, the HexaPro variant retains this prefusion spike conformation.',\n",
       "    'The SARS-CoV-2 spike protein is a metastable trimeric class I fusion protein that exists in a prefusion conformation. Answer briefly. The SARS-CoV-2 spike protein is a metastable trimeric class I',\n",
       "    'The SARS-CoV-2 spike protein is a metastable trimeric class I fusion protein and, in its native state, adopts a prefusion conformation. [Source] Given the reference text. The prefusion conformation is maintained by',\n",
       "    'The SARS-CoV-2 spike is a metastable prefusion trimeric class I fusion protein. A 3.2 Å-resolution cryo-EM structure of the prefusion spike was used as a basis for designing variants.',\n",
       "    'The prefusion spike conformation.',\n",
       "    'The SARS-CoV-2 spike protein has a prefusion structure.',\n",
       "    'The SARS-CoV-2 spike is a metastable trimeric class I fusion protein that retains a prefusion conformation. The HexaPro variant of the spike protein, with six beneficial proline substitutions, maintains this prefusion structure.',\n",
       "    'The prefusion spike conformation.',\n",
       "    'The SARS-CoV-2 spike protein has a prefusion conformation. To confirm this, a 3.2 Å-resolution cryo-EM structure of the HexaPro variant was determined, which retains the prefusion spike conformation.',\n",
       "    'The prefusion spike conformation.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 2, 4, 2, 0, 2],\n",
       "   'entropy': 1.3592367006650063},\n",
       "  'sygnmiun': {'greedy': 'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2, and is then processed by TMPRSS2.',\n",
       "   'samples': ['The SARS-CoV-2 spike protein (S-protein) binds to the host cell receptor ACE2 and is processed by TMPRSS2. The S-protein is crucial for viral entry into host cells.',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to the host cell receptor ACE2 and is processed by TMPRSS2 to infect host cells.',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2.',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2. To enter host cells, it binds to ACE2 and is then processed by TMPRSS2.',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2, and is then processed by TMPRSS2.',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to the ACE2 receptor and is processed by TMPRSS2. The structure involves binding to ACE2 and subsequent processing for infection.',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2. The S-protein must be processed by TMPRSS2 to enter host cells. Mutations in the S-protein affect its interaction with ACE',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2. To enter host cells, it first binds to ACE2 and is then processed by TMPRSS2. Mutations in the S-protein can',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2. It undergoes processing by TMPRSS2 to enter host cells. The protein structure is involved in receptor binding and contributes to the viral host range',\n",
       "    'The SARS-CoV-2 spike protein (S-protein) binds to its receptor, ACE2, and is then processed by TMPRSS2. To predict infection risks, researchers modelled S-protein:ACE2 complexes from 21'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 1, 2, 2, 2, 3],\n",
       "   'entropy': 1.1682824501765625}},\n",
       " '16': {'no': {'greedy': 'Up to 3 days on plastic and stainless steel.',\n",
       "   'samples': ['Coronavirus can remain viable on surfaces from a few hours to several days, depending on the material and environmental conditions.',\n",
       "    'Coronavirus can remain viable on surfaces from a few hours to several days, depending on the surface and environmental conditions.',\n",
       "    'Up to several days. Exact duration depends on surface and environmental conditions.',\n",
       "    'Up to 3 days on plastic and steel, several hours to days on other surfaces.',\n",
       "    'Up to 3 days. Factors include surface material and environmental conditions.',\n",
       "    'Up to 3 days on plastic and stainless steel, several hours on other surfaces.',\n",
       "    'Up to 3 days. Variability depends on the surface and other factors.',\n",
       "    'Up to 3 days. Factors include surface material and environmental conditions.',\n",
       "    'Coronavirus can remain viable on surfaces from a few hours to several days, depending on the surface and environmental conditions.',\n",
       "    'Up to 3 days on plastic and steel, several hours on copper, and 24 hours on cardboard.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 2, 1, 1, 2, 1, 1],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  'ou7w3zkv': {'greedy': 'Coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed, unventilated spaces for at least 30 minutes.',\n",
       "   'samples': ['Coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed, unventilated spaces for at least 30 minutes.',\n",
       "    'Coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed unventilated spaces for at least 30 minutes.',\n",
       "    'Different coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in the air in closed, unventilated spaces for at least 30 minutes.',\n",
       "    'Coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed, unventilated spaces for at least 30 minutes.',\n",
       "    'Coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in the air in closed, unventilated spaces for at least 30 minutes.',\n",
       "    'Coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed, unventilated spaces for at least 30 minutes.',\n",
       "    'Coronaviruses can persist on surfaces for a few days, with persistence time varying from minutes to up to one month depending on environmental conditions. SARS-CoV-2 can remain infectious in the air in closed unventilated spaces for at least',\n",
       "    'Coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed unventilated spaces for at least 30 minutes.',\n",
       "    'Coronaviruses can persist on surfaces for a few days, with persistence time varying from minutes to up to one month depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed, unventilated spaces for at least',\n",
       "    'Different coronaviruses can persist on surfaces for a few days, with persistence time varying from minutes to up to one month depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed unventilated spaces for at least'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 1, 0, 3, 1, 3, 2],\n",
       "   'entropy': 1.3661588475692017},\n",
       "  'k9xhphpl': {'greedy': 'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "   'samples': ['Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is likely similar in this regard.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is expected to have a similar stability based on its genetic similarity to other coronaviruses.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 0, 0, 0, 1, 0, 0],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  'ssq0dwmn': {'greedy': 'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "   'samples': ['Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for 2-9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is likely to follow similar stability patterns based on previous coronaviruses. However,',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 2, 0, 0, 0, 0],\n",
       "   'entropy': 0.639031859650177},\n",
       "  '80dfqjql': {'greedy': 'Coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "   'samples': ['Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.'],\n",
       "   'cluster_ids': [0, 1, 0, 1, 1, 1, 1, 0, 0, 1],\n",
       "   'entropy': 0.6730116670092565},\n",
       "  'khpc9f98': {'greedy': 'Some human coronavirus 229E remained viable on surfaces for up to 7 days under simulated classroom conditions.',\n",
       "   'samples': ['Some strains of coronavirus, like CoV-229E, can remain viable on surfaces for up to 7 days under certain conditions.',\n",
       "    'Some strains of coronavirus, like CoV-229E, can remain viable on surfaces for up to 7 days under certain conditions. However, stability varies by strain and conditions.',\n",
       "    'Some strains of coronavirus, like CoV-229E, can remain viable on surfaces for up to 7 days under certain conditions. However, this can vary depending on the specific strain and environmental factors.',\n",
       "    'Some strains of coronavirus, like CoV-229E, can remain viable on surfaces for up to 7 days under certain conditions. However, this may vary depending on the specific strain and environmental conditions.',\n",
       "    'Some human coronavirus 229E (CoV-229E) remained viable on surfaces for up to 7 days under simulated classroom conditions.',\n",
       "    'Up to 7 days, according to the tests conducted under classroom-like conditions.',\n",
       "    'Some human coronavirus 229E (CoV-229E) remained viable on surfaces for up to 7 days under classroom conditions.',\n",
       "    'Some human coronavirus 229E remained viable on surfaces for up to 7 days under simulated classroom conditions.',\n",
       "    'Some human coronavirus 229E remained viable for up to 7 days on surfaces under simulated classroom conditions.',\n",
       "    \"Some human coronavirus 229E remained viable for up to 7 days on surfaces under simulated classroom conditions. However, it's important to note that stability can vary for different coronaviruses.\"],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 0, 0, 0, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  '04awj06g': {'greedy': 'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to studies specifically addressing',\n",
       "   'samples': ['The provided context does not specify the stability of the virus on surfaces. To answer your question about surface stability, I would need additional information or research on that topic. Based on current knowledge, SARS-CoV-2 can remain viable on surfaces for',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to additional studies or',\n",
       "    'The provided context does not specify the stability of the virus on surfaces, only in nasal mucus and sputum.',\n",
       "    'The provided context does not specify the stability of the virus on surfaces, only its stability in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to additional studies or guidelines on coronavirus survival on',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to studies specifically addressing',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to additional sources or',\n",
       "    \"The provided context does not specify the stability of the virus on surfaces. To answer that, further information would be needed. The given information pertains to the virus's stability in nasal mucus and sputum under different environmental conditions. For surface stability\",\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to specific studies addressing',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to specific studies on',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to studies specifically addressing'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 5, 4, 4, 4],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  '4819g00y': {'greedy': 'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to studies specifically addressing',\n",
       "   'samples': ['The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, further research or guidelines from health authorities would be',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. To answer your question, scientific research suggests that SARS-CoV-2 can remain viable on surfaces for several hours to days, but this duration varies depending on the type of surface',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, further research or data would be needed.',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. To answer your question, more specific studies on surface stability would be needed.',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, additional sources would be needed.',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, refer to specific studies or guidelines on coronavirus survival',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on its stability in nasal mucus and sputum under different environmental conditions. For information on surface stability, additional research or data would be needed.',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on the stability of the virus in nasal mucus and sputum under different environmental conditions. For information on surface stability, further research or data specific to this topic would',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on its stability in nasal mucus and sputum under different environmental conditions. To answer your question about surface stability, you would need information specifically related to that scenario.',\n",
       "    'The provided context does not specify the stability of the virus on surfaces. It focuses on its stability in nasal mucus and sputum under different environmental conditions. For information on surface stability, you would need to refer to specific studies focusing on this aspect'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 6, 6, 4],\n",
       "   'entropy': 1.8343719702816237},\n",
       "  '0y8lfjkx': {'greedy': 'The provided context does not specify the stability of coronaviruses on surfaces, only in water and wastewater. To answer your question directly based on the given information, it is not addressed. For accurate surface stability information, refer to specific studies on this',\n",
       "   'samples': ['The provided context does not specify the stability of coronaviruses on surfaces. The information given focuses on their survival in water and wastewater at different temperatures. For surface stability, further research would be needed.',\n",
       "    'The given context does not provide information on the stability of coronavirus on surfaces. The text focuses on the survival of coronaviruses in water and wastewater under specific temperature conditions. To answer your question about surface stability, you would need to look for data',\n",
       "    'The given context does not provide information on the stability of coronavirus on surfaces. It focuses on the survival of coronaviruses in water and wastewater under specific conditions. To answer your question about surface stability, further research would be needed. Generally, coron',\n",
       "    'The provided context does not specify the stability of coronavirus on surfaces. It focuses on the survival of coronaviruses in water and wastewater. For information on surface stability, additional research would be needed. Typically, coronaviruses can remain viable on',\n",
       "    'The given context does not provide information on the stability of coronavirus on surfaces. It focuses on the survival of coronaviruses in water and wastewater at different temperatures and with varying levels of organic matter and bacteria. For information on surface stability, you would',\n",
       "    'The provided context does not specify the stability of coronaviruses on surfaces. It focuses on their survival in water and wastewater at different temperatures. For surface stability, refer to specific studies on coronavirus persistence on various materials.',\n",
       "    'The provided context does not specify the stability of coronaviruses on surfaces. The information given is about their survival in water and wastewater. To answer the question about surface stability would require additional data.',\n",
       "    'The given context does not provide information about the stability of coronaviruses on surfaces. The text focuses on their survival in water and wastewater at different temperatures. For information on surface stability, additional research or data would be needed.',\n",
       "    'The provided context does not specify the stability of coronaviruses on surfaces, only their survival in water and wastewater. To answer your question about surface stability would require additional information.',\n",
       "    'The provided context does not specify the stability of coronaviruses on surfaces, only their survival in water and wastewater. Surface stability can vary. To determine surface stability, refer to specific studies on this topic.'],\n",
       "   'cluster_ids': [0, 0, 1, 1, 0, 2, 1, 3, 3, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  'tjplc5j6': {'greedy': 'Coronalvirus can persist for days on surfaces under certain conditions, with survival ranging from 5 to 28 days depending on temperature and humidity. At 4°C, it can persist for up to 28 days, while at',\n",
       "   'samples': ['Coronavirus can persist for up to 28 days on surfaces under certain conditions, particularly at lower temperatures and lower humidity levels.',\n",
       "    'Up to 28 days at 4°C, depending on humidity levels. Survival is more rapid at higher temperatures. Low and high humidity provide greater protection against inactivation.',\n",
       "    'Coronalviruses can persist for 5 to 28 days on surfaces under certain conditions, with survival being greatest at low relative humidity (20%) and high relative humidity (80%). At 4 degrees Celsius, infectious virus can persist',\n",
       "    'Up to 28 days, depending on temperature and humidity conditions.',\n",
       "    'Coronalviruses can persist for days on surfaces under certain conditions, specifically at 4°C for up to 28 days and at 20°C for 5 to 28 days, depending on relative humidity.',\n",
       "    'Up to 28 days under favorable conditions (e.g., 4°C, 20% RH). Stability decreases at higher temperatures and relative humidities.',\n",
       "    'Up to 28 days under certain conditions, specifically at 4°C and 20% RH. Survival varies with temperature and humidity.',\n",
       "    'Under optimal conditions, infectious SARS-CoV-1 can persist for up to 28 days on stainless steel surfaces. However, survival times can vary depending on temperature and humidity. Generally, lower temperatures and higher or lower humidity levels can prolong viral',\n",
       "    'Up to 28 days under certain conditions, particularly at lower temperatures and lower humidity levels.',\n",
       "    'Coronavirus, specifically using TGEV and MHV as surrogates, can persist for 5 to 28 days on stainless steel surfaces under certain conditions, particularly at low humidity (20%) and temperatures ranging from 4°C to'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 0, 2, 4, 2, 0],\n",
       "   'entropy': 1.5047882836811906},\n",
       "  '7ftq02ev': {'greedy': 'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the type of surface and environmental conditions.',\n",
       "   'samples': ['Coronavirus can remain stable on surfaces from a few hours to several days, depending on the type of surface and environmental conditions.',\n",
       "    'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the surface material and environmental conditions.',\n",
       "    'The stability of the coronavirus on surfaces varies, but it can survive for several hours to a few days depending on the material.',\n",
       "    'The stability of the coronavirus on surfaces can vary, but it typically remains viable for several hours to a few days. On hard surfaces like plastic and stainless steel, it can survive for up to three days. Regular cleaning and disinfection are crucial to reduce',\n",
       "    'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the surface material and environmental conditions.',\n",
       "    'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the type of surface and environmental conditions.',\n",
       "    'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the type of surface and environmental conditions.',\n",
       "    'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the type of surface and environmental conditions.',\n",
       "    'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the surface material and environmental conditions.',\n",
       "    'Coronavirus can remain stable on surfaces from a few hours to several days, depending on the type of surface and environmental conditions.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 1, 0, 0, 0, 1, 0],\n",
       "   'entropy': 0.9433483923290391}},\n",
       " '45': {'no': {'greedy': 'Increased anxiety, depression, and stress.',\n",
       "   'samples': ['Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  'ub0tl046': {'greedy': 'Increased anxiety, depression, and stress.',\n",
       "   'samples': ['Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  'v1yodbnz': {'greedy': 'Increased anxiety, depression, and stress.',\n",
       "   'samples': ['Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '1m5juaqg': {'greedy': 'Increased anxiety, depression, and stress.',\n",
       "   'samples': ['Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '68pl1t5i': {'greedy': 'Increased anxiety, depression, and stress.',\n",
       "   'samples': ['Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '4q1j6g44': {'greedy': 'The COVID-19 pandemic has significant short- and long-term mental health impacts, including stress, anxiety, depression, and other psychological distress due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 20',\n",
       "   'samples': ['The COVID-19 pandemic has had significant short- and long-term mental health impacts, including stress, anxiety, depression, and other psychological issues due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2',\n",
       "    'The COVID-19 pandemic has led to significant short- and long-term mental health impacts due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The COVID-19 pandemic has had significant short- and long-term mental health impacts, including stress, anxiety, depression, and trauma.',\n",
       "    'The COVID-19 pandemic has led to significant short- and long-term mental health effects due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The COVID-19 pandemic has led to significant short- and long-term mental health effects due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The COVID-19 pandemic has significant short- and long-term mental health impacts, including stress, anxiety, depression, and other psychological issues due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 20',\n",
       "    'The pandemic has had significant short- and long-term mental health effects, including societal, economic, and environmental impacts. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The pandemic has led to significant short- and long-term mental health effects due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The COVID-19 pandemic has had significant short- and long-term mental health impacts, including stress, anxiety, depression, and trauma.',\n",
       "    'The pandemic has led to significant short- and long-term mental health impacts, including stress, anxiety, depression, and trauma.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 1, 3, 1, 4, 2, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'hze88sr4': {'greedy': 'The full extent of the mental health impact of the COVID-19 pandemic is unknown but expected to be severe and enduring. It affects almost every aspect of society. Rapid innovation and service development are underway to improve population mental health.',\n",
       "   'samples': ['The COVID-19 pandemic is anticipated to have a severe and enduring impact on mental health, affecting services globally. Mental health effects extend across society, with innovation and service development underway to positively impact population mental health.',\n",
       "    'The full extent of the mental health impact of COVID-19 is unknown but expected to be severe and enduring. Mental health effects extend across society and have driven rapid innovation and service development.',\n",
       "    'The COVID-19 pandemic is anticipated to have a severe and enduring impact on mental health, affecting services globally. Mental health effects stretch across society and require rapid innovation and collaborative efforts for positive impacts.',\n",
       "    \"The COVID-19 pandemic has led to significant mental health challenges globally, with potential severe and lasting impacts. Mental health services are experiencing strain, and there's a need for rapid innovation and collaborative efforts to address these issues.\",\n",
       "    'The full extent of the mental health impact of the COVID-19 pandemic is unknown but expected to be severe and enduring. It affects almost every aspect of society. Rapid innovation and service development are underway.',\n",
       "    'The full extent is unknown but expected to be severe and enduring, affecting almost every aspect of society. Rapid innovation and service development are underway to address these impacts.',\n",
       "    \"The full extent of the mental health impact of the COVID-19 pandemic is unknown but expected to be severe and enduring, affecting nearly every aspect of society. Mental health services are experiencing significant challenges, and there's a drive for rapid innovation and service\",\n",
       "    'The full extent is unknown but expected to be severe and enduring, affecting almost every societal element. It has driven rapid innovation in mental health services.',\n",
       "    'The full extent of the mental health impact of the COVID-19 pandemic is not yet known, but it is expected to be severe and enduring, affecting almost every aspect of society. Mental health services are facing significant challenges, but there is also evidence',\n",
       "    'The COVID-19 pandemic has led to significant mental health impacts, stretching across society and prompting rapid innovation and service development. The full extent remains uncertain but is expected to be severe and enduring. Mental health services are being affected globally.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 1, 1, 1, 1, 3, 2],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  '6ngsyo8o': {'greedy': 'The COVID-19 pandemic has led to significant short- and long-term mental health impacts, including stress, anxiety, depression, and other psychological distress due to societal, economic, and environmental changes. (PsycInfo Database Record (c)',\n",
       "   'samples': ['The COVID-19 pandemic has significant short- and long-term mental health impacts due to its extensive societal, economic, and environmental effects. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The COVID-19 pandemic has led to significant short- and long-term mental health effects, including stress, anxiety, depression, and PTSD.',\n",
       "    'The COVID-19 pandemic has significant short- and long-term mental health impacts, including increased stress, anxiety, depression, and trauma due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 202',\n",
       "    'The COVID-19 pandemic has led to significant short- and long-term mental health impacts due to its societal, economic, and environmental effects. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The pandemic has led to significant short- and long-term mental health impacts, including stress, anxiety, depression, and trauma.',\n",
       "    'The COVID-19 pandemic has had significant short- and long-term mental health impacts, including stress, anxiety, depression, and other psychological effects due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2',\n",
       "    'The pandemic has led to significant short- and long-term mental health effects, including increased stress, anxiety, depression, and other psychological issues due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 202',\n",
       "    'The pandemic has led to significant short- and long-term mental health effects due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2020 APA, all rights reserved).',\n",
       "    'The COVID-19 pandemic has significant short- and long-term mental health impacts, including increased stress, anxiety, depression, and other psychological distress due to societal, economic, and environmental changes. (PsycInfo Database Record (c) 2',\n",
       "    'The COVID-19 pandemic has led to significant short- and long-term mental health effects due to its widespread societal, economic, and environmental impacts. (PsycInfo Database Record (c) 2020 APA, all rights reserved).'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 2, 4, 5, 4, 3],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'wbwd7m5w': {'greedy': 'The full extent of the mental health impact of the COVID-19 pandemic is unknown but expected to be severe and enduring. It affects almost every aspect of society. Rapid innovation and service development are underway to address these challenges.',\n",
       "   'samples': ['The COVID-19 pandemic is anticipated to have a severe and enduring impact on mental health services globally, affecting almost every element of society. Mental health effects stretch across multiple disciplines and healthcare settings. Rapid innovation and service development are underway in response.',\n",
       "    'The full extent of the mental health impact of the COVID-19 pandemic is unknown but expected to be severe and enduring, affecting almost every element of society. Rapid innovation and service development are occurring to address these impacts.',\n",
       "    'The COVID-19 pandemic has led to significant mental health impacts, stretching across nearly all societal elements, with potential severe and enduring effects. Mental health services are facing challenges worldwide. Rapid innovation and service development are underway in response.',\n",
       "    'The full extent of the mental health impact of the COVID-19 pandemic is unknown but expected to be severe and enduring. It affects various elements of society and requires rapid innovation and service development.',\n",
       "    'The COVID-19 pandemic is anticipated to have a severe and enduring impact on mental health, affecting services globally. Mental health effects extend across society and require rapid innovation and collaborative efforts for positive impacts.',\n",
       "    'The COVID-19 pandemic is expected to have a severe and enduring impact on mental health, affecting almost every aspect of society. Mental health services are facing significant challenges globally. Rapid innovation and service development are occurring in response.',\n",
       "    'The COVID-19 pandemic is expected to have a severe and enduring impact on mental health, affecting services globally. Mental health effects extend across society and innovative service developments are underway.',\n",
       "    'The full extent of the mental health impact of the COVID-19 pandemic is not yet known, but it is anticipated to be severe and enduring, affecting almost every aspect of society. Mental health services are facing challenges globally. However, there is evidence',\n",
       "    'The COVID-19 pandemic is expected to have a severe and enduring impact on mental health, affecting almost every aspect of society. Mental health services are facing challenges and driving rapid innovation and service development. The full extent of the impact is still unknown.',\n",
       "    'The full extent of the mental health impact of the COVID-19 pandemic is unknown but expected to be severe and enduring, affecting nearly every aspect of society. Mental health services have faced challenges, prompting rapid innovation and service development.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 3, 2, 4, 2, 1],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  'o4zoxrod': {'greedy': 'Increased anxiety, depression, and stress.',\n",
       "   'samples': ['Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0},\n",
       "  '43rpqe53': {'greedy': 'Increased anxiety, depression, and stress.',\n",
       "   'samples': ['Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.',\n",
       "    'Increased anxiety, depression, and stress.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': -0.0}},\n",
       " '15': {'no': {'greedy': 'Up to 3 days, depending on surface and conditions.',\n",
       "   'samples': ['Up to 3 days on some surfaces.',\n",
       "    'Up to 3 days, depending on surface and conditions.',\n",
       "    'Up to a few days on surfaces, depending on the material.',\n",
       "    'Up to 3 days, depending on surface and conditions.',\n",
       "    'Up to a few days on some surfaces.',\n",
       "    'Up to 3 days, depending on surface and conditions.',\n",
       "    'Up to a few days on some surfaces. Exact duration varies.',\n",
       "    'Up to 3 days on some surfaces.',\n",
       "    'Up to 3 days, depending on surface and conditions.',\n",
       "    'Up to 3 days on some surfaces.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 1, 1, 0, 1, 0],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  '0y8lfjkx': {'greedy': 'In tap water at 23°C, coronaviruses can be inactivated within 10 days, while in tap water at 4°C, it takes over 100 days. In wastewater at 23°C, coron',\n",
       "   'samples': ['Coronaviruses can survive from 2 to 100+ days outside the body, depending on factors like temperature and presence of organic matter. Generally, they survive longer at lower temperatures.',\n",
       "    'In tap water at 23°C, coronaviruses can be inactivated within 10 days, while in tap water at 4°C, it takes more than 100 days. In wastewater at 23°C,',\n",
       "    'Coronavirus survival outside the body depends on temperature and other factors, but it generally ranges from a few days at room temperature to over 100 days at very cold temperatures.',\n",
       "    'Coronaviruses can survive from 2 to 100+ days outside the body, depending on factors like temperature and presence of organic matter. Generally, they survive longer at lower temperatures.',\n",
       "    'In tap water at 23°C, coronaviruses are inactivated in about 10 days, while at 4°C it takes over 100 days. In wastewater, they die off within 2 to 4 days',\n",
       "    'Coronavirus can survive for up to 100 days at 4°C in tap water and around 10 days at 23°C in tap water. In wastewater, it can survive for 2-4 days. Survival times vary depending',\n",
       "    'Coronaviruses can survive for 2-4 days in wastewater and up to >100 days in tap water at 4°C, but they die off more quickly at higher temperatures.',\n",
       "    'In tap water at 23°C, coronaviruses can be inactivated in about 10 days, while at 4°C it takes more than 100 days. In wastewater, coronaviruses die off within',\n",
       "    'Coronavirus survival time outside the body varies depending on factors like temperature and presence of organic matter. In general, it can live from a few hours to a few days. Specifically, at 23°C in tap water, it can survive up to',\n",
       "    'Coronaviruses can survive from 2 to 4 days in wastewater and up to over 100 days in tap water at 4°C, but typically survive for about 10 days at 23°C in tap water.'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 3, 4, 5, 3, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '959w9sln': {'greedy': 'The coronavirus can survive on surfaces for several hours to days. Factors affecting survival include temperature, humidity, and surface material. Generally, it lasts longer on hard surfaces than on soft ones.',\n",
       "   'samples': ['The coronavirus can survive on surfaces for a few hours to several days. Factors like temperature, humidity, and surface type affect its survival. Generally, it lasts longer on hard surfaces than on soft ones. For example, it can survive up to 3',\n",
       "    'The coronavirus can survive outside the body for several hours to days on surfaces, depending on the material. Factors include temperature, humidity, and type of surface.',\n",
       "    'The coronavirus can survive outside the body for several hours to days, depending on conditions. Factors include temperature, humidity, and surface type. Generally, it lasts longer on hard surfaces than on fabrics or tissues. Exact durations can vary. (Approx 1',\n",
       "    'The coronavirus can survive on surfaces for several hours to a few days. Factors affecting survival include temperature, humidity, and surface material. Higher temperatures and humidity generally reduce survival time.',\n",
       "    'The coronavirus can survive outside the body for several hours to a few days, depending on conditions. Factors include surface type, temperature, and humidity. Generally, it lasts longer on hard surfaces than on soft ones.',\n",
       "    'The coronavirus can survive on surfaces for several hours to a few days. Factors affecting survival include temperature, humidity, surface material, and exposure to disinfectants. Briefly, it lasts from hours to days outside the body.',\n",
       "    'The coronavirus can survive on surfaces for several hours to a few days. Factors affecting survival include temperature, humidity, surface type, and presence of contaminants. Cooler temperatures and drier conditions generally prolong survival.',\n",
       "    'The coronavirus can survive on surfaces for a few hours to several days. Factors affecting survival include temperature, humidity, surface material, and exposure to disinfectants. Generally, it lasts longer on hard surfaces than on soft ones.',\n",
       "    'The coronavirus can survive on surfaces for a few hours to several days. Factors like temperature, humidity, and surface type influence its longevity. Generally, it lasts longer on hard surfaces than on fabrics. Proper cleaning and disinfection can help reduce the risk of',\n",
       "    'The coronavirus can survive on surfaces for several hours to days. Factors affecting survival include temperature, humidity, surface type, and virus load.'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 2, 1, 3, 4, 4, 5],\n",
       "   'entropy': 1.7480673485460894},\n",
       "  'hgau3922': {'greedy': 'The coronavirus can survive on surfaces for several hours to days. Factors affecting survival include temperature, humidity, and surface material. Generally, it lasts longer on hard surfaces than on soft ones. Cleaning and disinfecting surfaces regularly helps reduce risk.',\n",
       "   'samples': ['The coronavirus can survive on surfaces for a few hours to several days. Survival time depends on factors such as the material surface, temperature, humidity, and exposure to sunlight. Viruses generally survive longer under cooler, drier conditions. Wet environments or high',\n",
       "    'The coronavirus can survive on surfaces for several hours to days. Survival time depends on factors such as surface type, temperature, humidity, and exposure to sunlight. Generally, it lasts longer on hard surfaces than on soft ones. Avoid touching surfaces unnecessarily and practice',\n",
       "    'The coronavirus can survive on surfaces for several hours to days. Factors affecting survival include temperature, humidity, and surface material. Higher temperatures and humidity generally reduce survival time. Specific durations vary among different coronaviruses.',\n",
       "    'The coronavirus can survive on surfaces for several hours to days. Factors affecting survival include temperature, humidity, surface material, and exposure to disinfectants. Generally, it lasts longer on hard surfaces than on fabrics. Cleaning and disinfecting surfaces regularly is',\n",
       "    'The coronavirus can survive on surfaces for a few hours to several days, depending on conditions like temperature, humidity, and type of surface. Factors affecting survival include environmental conditions and surface materials.',\n",
       "    \"The coronavirus can survive on surfaces for a few hours to several days, depending on factors like type of surface, temperature, humidity, and exposure to UV light. Generally, it's shorter on porous materials compared to hard surfaces. Regular cleaning and disinfection\",\n",
       "    'The coronavirus can survive on surfaces for several hours to days. Factors like temperature, humidity, and surface type influence its survival. Generally, it lasts longer on hard surfaces than soft ones. Cleaning and disinfecting surfaces regularly can help reduce the risk of',\n",
       "    'The coronavirus can survive on surfaces for a few hours to several days. Factors affecting survival include temperature, humidity, surface material, and viral load.',\n",
       "    'Coronavirus can survive on surfaces for several hours to days. Factors affecting survival include temperature, humidity, and the type of surface. Drying conditions generally reduce viral viability.',\n",
       "    'The coronavirus can survive on surfaces for several hours to days. Factors include surface type, humidity, temperature, and presence of contaminants. Drying out reduces its viability. Cleaning and disinfecting surfaces can help reduce risk.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 3, 4, 5, 6, 5],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'ou7w3zkv': {'greedy': 'Different coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed, unventilated spaces for at least 30 minutes.',\n",
       "   'samples': ['Different coronaviruses can persist on inanimate surfaces for a few days, varying from minutes to up to one month depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed unventilated spaces for at least',\n",
       "    'The most common coronaviruses can persist on surfaces for up to one month under certain conditions. SARS-CoV-2 can remain infectious in the air in unventilated spaces for at least 30 minutes. Conditions such as environmental factors',\n",
       "    'Different coronaviruses can persist on inanimate surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in the air in closed, unventilated spaces for at least 30 minutes',\n",
       "    'Different coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in the air in closed, unventilated spaces for at least 30 minutes.',\n",
       "    'Different coronaviruses can persist on surfaces for a few days, varying from minutes to up to one month depending on environmental conditions. SARS-CoV-2 can remain infectious in the air in closed, unventilated spaces for at least',\n",
       "    'Different coronaviruses can persist on surfaces from minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed unventilated spaces for at least 30 minutes.',\n",
       "    'Different coronaviruses can persist on inanimate surfaces for minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in the air in closed, unventilated spaces for at least 30 minutes',\n",
       "    'The most common coronaviruses can persist on surfaces for up to one month, while SARS-CoV-2 can remain infectious in the air in closed, unventilated spaces for at least 30 minutes. Conditions such as environmental factors',\n",
       "    'Different coronaviruses can persist on inanimate surfaces for minutes to up to one month, depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed unventilated spaces for at least 30 minutes.',\n",
       "    'Coronaviruses can persist on surfaces for a few days, varying from minutes to up to one month depending on environmental conditions. SARS-CoV-2 can remain infectious in air in closed unventilated spaces for at least 30 minutes'],\n",
       "   'cluster_ids': [0, 1, 0, 2, 2, 3, 3, 4, 4, 3],\n",
       "   'entropy': 1.5571130980576458},\n",
       "  '7ftq02ev': {'greedy': 'The coronavirus can survive outside the body for several hours to days on surfaces, depending on the material. Viral viability decreases over time.',\n",
       "   'samples': ['The coronavirus can survive on surfaces from a few hours to several days, depending on the material.',\n",
       "    \"Up to 3 days on some surfaces. (This answer is based on general information about the virus's lifespan outside the body and may vary.)\",\n",
       "    'The coronavirus can survive outside the body from a few hours to several days, depending on the surface and environmental conditions.',\n",
       "    'The coronavirus can survive on surfaces from a few hours to a few days.',\n",
       "    'The coronavirus can survive outside the body for several hours to several days, depending on the surface and environmental conditions.',\n",
       "    'The coronavirus can live outside the body for several hours to days, depending on the surface and environmental conditions.',\n",
       "    'The coronavirus can survive outside the body for several hours to a few days, depending on the surface and environmental conditions.',\n",
       "    'Up to 3 days. (Note: The exact duration can vary depending on conditions like surface type and environmental factors.)',\n",
       "    'The coronavirus can survive outside the body for several hours to days, depending on factors like surface type and environmental conditions.',\n",
       "    'The coronavirus can survive on surfaces from a few hours to a few days. Exact duration varies by surface material and environmental conditions.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 2, 3, 4, 4, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  'k9xhphpl': {'greedy': 'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is expected to have a similar persistence based on its genetic similarity to other coronaviruses.',\n",
       "   'samples': ['Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is expected to have a similar lifespan based on previous coronaviruses.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    \"Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2's persistence likely follows a similar pattern.\",\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is expected to have a similar persistence, though specific data may vary.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 likely has a similar lifespan, though more research is needed.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 likely has a similar lifespan based on previous human coronaviruses.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is likely to have a similar lifespan based on its genetic similarity to other coronaviruses.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 1, 0, 0, 1, 0, 0],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  '80dfqjql': {'greedy': 'Up to 9 days on inanimate surfaces like metal, glass, or plastic.',\n",
       "   'samples': ['The novel coronavirus SARS-CoV-2 can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'The coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Up to 9 days on inanimate surfaces like metal, glass, or plastic.',\n",
       "    'Up to 9 days on inanimate surfaces like metal, glass, or plastic.',\n",
       "    'Up to 9 days on inanimate surfaces like metal, glass, or plastic.',\n",
       "    'Up to 9 days on inanimate surfaces like metal, glass, or plastic.',\n",
       "    'The coronavirus can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Up to 9 days on inanimate surfaces like metal, glass, or plastic.',\n",
       "    'Up to 9 days on inanimate surfaces like metal, glass, or plastic.',\n",
       "    'Up to 9 days on inanimate surfaces like metal, glass, or plastic.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 2, 1, 2, 2, 2],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  'ssq0dwmn': {'greedy': 'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "   'samples': ['Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is expected to have a similar lifespan based on related coronaviruses.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 likely has a similar persistence time based on the characteristics of other coronaviruses.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is likely to have a similar lifespan based on these findings.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 is likely to have a similar lifespan based on the available information.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human and veterinary coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2, specifically, can also persist on these surfaces for an undetermined period but can be',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days.',\n",
       "    'Human coronaviruses can persist on inanimate surfaces like metal, glass, or plastic for up to 9 days. SARS-CoV-2 likely has a similar persistence time, though more research is needed.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 1, 0, 2, 0, 3],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'u5nxm9tu': {'greedy': 'The provided context does not address how long the coronavirus can live outside the body. It focuses on the duration of protective immunity after infection with seasonal human coronaviruses. For information on the survival of SARS-CoV-2 outside the body,',\n",
       "   'samples': ['The provided context does not discuss how long the coronavirus can live outside the body. It focuses on the duration of immunity following coronavirus infections.',\n",
       "    'The provided context does not address how long the coronavirus can live outside the body. The context focuses on the duration of protective immunity after infection with seasonal human coronaviruses, not the survival time of the virus outside a host.',\n",
       "    'The provided context does not address how long the coronavirus can live outside the body. The text focuses on the duration of immunity following infection with seasonal human coronaviruses. For information on the survival of SARS-CoV-2 outside the body,',\n",
       "    'The provided context does not discuss how long the coronavirus can live outside the body. It focuses on the duration of protective immunity after infection with seasonal human coronaviruses.',\n",
       "    'The given context does not provide information on how long the coronavirus can live outside the body. It focuses on the duration of immunity following infection with seasonal human coronaviruses. For information on the survival of SARS-CoV-2 outside the body',\n",
       "    'The provided context does not discuss how long the coronavirus can live outside the body. It focuses on the duration of protective immunity after infection with seasonal human coronaviruses. To answer your question directly: The survival time of the SARS-CoV-',\n",
       "    'The given context does not provide information on how long the coronavirus can live outside the body. The text focuses on the duration of protective immunity following coronavirus infections.',\n",
       "    'The provided context does not discuss how long the coronavirus can live outside the body. It focuses on the duration of protective immunity following infection with seasonal human coronaviruses.',\n",
       "    'The provided context does not address how long the coronavirus can live outside the body. The text focuses on the duration of protective immunity after infection with seasonal human coronaviruses.',\n",
       "    'The provided context does not discuss how long the coronavirus can live outside the body. It focuses on the duration of protective immunity following infection with seasonal human coronaviruses. For information on the longevity of the SARS-CoV-2 virus outside the'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 1, 0, 0, 1, 1, 1],\n",
       "   'entropy': 0.6931471805599453},\n",
       "  'aqqvww7f': {'greedy': 'The provided context does not contain information about how long the coronavirus can live outside the body. The study describes the infection of primate CNS tissue following different inoculation routes but does not address the stability of the virus outside a host.',\n",
       "   'samples': ['The provided context does not contain information about how long the coronavirus can live outside the body. The study describes the infection of primate CNS tissue following peripheral inoculation but does not address the stability of the virus outside a host. Answering the specific question',\n",
       "    'The given context does not provide information about how long the coronavirus can live outside the body. To answer this question, one would need to refer to studies specifically addressing the survival of coronaviruses outside a host organism.',\n",
       "    \"The given context does not provide information about how long the coronavirus can live outside the body. The study describes the infection of primate CNS tissue following peripheral inoculation with coronavirus. To determine the virus's survival outside the body, specific studies on coronavirus stability\",\n",
       "    \"The given context does not provide information on how long the coronavirus can live outside the body. The text describes an experiment with primates and does not discuss the virus's survival outside a host. Answer: Not provided.\",\n",
       "    \"The context provided does not contain information about how long the coronavirus can live outside the body. The study describes the infection of primate CNS tissue following peripheral inoculation with coronavirus JHM OMp1 but does not discuss the virus's stability outside a host\",\n",
       "    'The given context does not provide information on how long the coronavirus can live outside the body. The study focuses on the infection of primate CNS tissue following peripheral inoculation. The duration of virus survival outside the body is not addressed in this research.',\n",
       "    'The given context does not provide information on how long the coronavirus can live outside the body. The study focuses on the infection of primate CNS tissue following different inoculation routes. To answer the question about the survival of the virus outside the body, you',\n",
       "    'The provided context does not contain information about how long the coronavirus can live outside the body. The text discusses the infection of primate CNS tissue by intranasal and intravenous inoculation with coronavirus JHM OMp1 and does not address extracellular',\n",
       "    'The provided context does not contain information about how long the coronavirus can live outside the body. The study focuses on the infection of primate CNS tissue following different routes of inoculation. To answer your question, you would need to refer to studies specifically investigating',\n",
       "    'The provided context does not contain information about how long the coronavirus can live outside the body. The study focuses on the infection of primate CNS tissue after peripheral inoculation. To answer your question, you would need to refer to specific studies on the stability'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 2, 2, 3, 4, 3, 5],\n",
       "   'entropy': 1.7480673485460894}},\n",
       " '31': {'no': {'greedy': 'Coronavirus causes COVID-19, is highly contagious, and has higher mortality. Flu is seasonal, caused by different viruses, and generally less severe.',\n",
       "   'samples': ['Coronavirus (COVID-19) is novel, more infectious, and causes more severe illness than seasonal flu. It also lacks a seasonal pattern.',\n",
       "    'Coronavirus (COVID-19) is caused by a novel virus, whereas seasonal flu is caused by influenza viruses. They have different symptoms and transmission rates.',\n",
       "    'Coronavirus can cause more severe illness and has no vaccine or specific treatment yet. Flu has seasonal patterns and effective vaccines.',\n",
       "    'Coronavirus can cause more severe illness and has no vaccine or specific treatment yet. Seasonal flu has annual vaccines and treatments available.',\n",
       "    'The coronavirus (COVID-19) and seasonal flu are both respiratory illnesses but caused by different viruses. COVID-19 is caused by SARS-CoV-2, while seasonal flu is caused by influenza viruses. Symptoms can overlap but tend to',\n",
       "    'Coronavirus can cause more severe illness and has global impact, while seasonal flu is more predictable and causes milder illness in most people.',\n",
       "    'Coronavirus causes more severe illness, has no vaccine or antiviral treatment, and spreads more efficiently.',\n",
       "    'Coronavirus causes COVID-19, is highly contagious, and some infected individuals show no symptoms. Seasonal flu causes Influenza, typically peaks in winter, and symptoms are usually more severe.',\n",
       "    'Coronavirus (COVID-19) is caused by a different virus than the flu, has longer incubation periods, and can be more deadly. Symptoms overlap but severity differs. Vaccines exist for seasonal flu, not yet for coronavirus.',\n",
       "    'Coronavirus (COVID-19) is caused by a novel virus, while seasonal flu is caused by Influenza viruses. Symptoms can overlap but coronavirus can cause more severe illness. Vaccines exist for flu but not yet for coronavirus. Transmission patterns'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 8],\n",
       "   'entropy': 2.1639556568820564},\n",
       "  'thb2pox2': {'greedy': 'Coronavirus causes longer-lasting symptoms and has higher mortality rate. It spreads more efficiently and causes more severe illness in some people.',\n",
       "   'samples': ['Coronavirus can cause more severe illness and has global impact, while seasonal flu is more predictable and usually less severe.',\n",
       "    'Coronavirus causes COVID-19, is highly contagious, and has higher mortality. Flu is seasonal, caused by different viruses, and generally less severe.',\n",
       "    'The coronavirus (COVID-19) is a novel virus, while seasonal flu has been around for centuries. Symptoms and severity vary. Some people have noted that COVID-19 can be more severe and has a higher mortality rate than the seasonal flu',\n",
       "    'Coronavirus (COVID-19) is caused by a novel virus, while seasonal flu is caused by Influenza viruses. Symptoms and severity can vary, with coronavirus often causing more severe illness in some cases. Vaccines exist for seasonal flu but',\n",
       "    'The coronavirus (COVID-19) is a novel virus, while seasonal flu has been around for centuries. Symptoms can be similar but severity varies. COVID-19 often causes more severe illness and has higher mortality rates. Transmission patterns and available vaccines',\n",
       "    'Coronavirus causes more severe illness and has no vaccine, while seasonal flu is generally milder and has an annual vaccine.',\n",
       "    'The coronavirus causes COVID-19, is highly contagious, and has unique symptoms like loss of taste or smell. It also has higher mortality rates in some cases.',\n",
       "    'The coronavirus (COVID-19) spreads more easily, causes more severe illness in some people, and had no previous immunity in the population.',\n",
       "    'Coronavirus (COVID-19) is caused by a novel virus, spreads more easily, has a longer incubation period, and often causes more severe symptoms, especially in certain age groups. Flu is caused by different viruses with distinct characteristics.',\n",
       "    'Coronavirus causes longer-lasting symptoms and has higher mortality. It spreads more efficiently and causes more severe illness in some individuals.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 5, 6, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  '431ksdno': {'greedy': 'The coronavirus tends to infect different hosts with smaller variations compared to a subclass of the influenza virus, and some human-coronaviruses show annual changes. If SARS-CoV-2 behaves similarly to Influenza H types, it could',\n",
       "   'samples': ['The coronavirus tends to show smaller genetic variations compared to a subclass of the influenza virus, and has less variation among different host species, which may facilitate its infection of various hosts. However, some coronaviruses, particularly those frequently found in humans,',\n",
       "    'The coronavirus has smaller variations compared to a subclass of the influenza virus, and its variations among different hosts are small. Additionally, while many coronaviruses are more conservative, those found among humans show annual changes, unlike the Influenza H',\n",
       "    'The coronavirus tends to show smaller variations within the same virus and among different hosts, compared to a subclass of the influenza virus. Additionally, while many coronaviruses are more conservative, those found in humans can show annual changes, indicating a potential for',\n",
       "    'The coronavirus has smaller variations within its genome compared to a subclass of the influenza virus, and differences among coronaviruses in various hosts are small, which may facilitate host infection. Additionally, while many coronaviruses are more conservative, some show',\n",
       "    'The coronavirus tends to show smaller genetic variations among different hosts compared to a subclass of the influenza virus, and some human-coronaviruses exhibit annual changes, unlike the stable Influenza H-type viruses. Additionally, there are multiple other coron',\n",
       "    'The coronavirus tends to infect different hosts with smaller variations compared to a subclass of the influenza virus, and some human coronaviruses show annual changes while many others are more conservative. If SARS-CoV-2 behaves like Influenza H',\n",
       "    'The coronavirus has smaller variations compared to a subclass of the influenza virus, and differences among coronaviruses in various hosts are small, potentially facilitating infection across different species. Additionally, while many coronaviruses are more conservative, those in humans show',\n",
       "    'The coronavirus tends to infect various hosts with smaller genetic variations compared to a subclass of the influenza virus, and some human-coronaviruses show annual changes while others remain more conservative. If the SARS-CoV-2 behaves like Influen',\n",
       "    'The coronavirus tends to infect various hosts with smaller genetic variations compared to a subclass of the influenza virus, and some human-coronaviruses show annual changes. Additionally, there are many other coronaviruses that could potentially cause future pandemics.',\n",
       "    'The coronavirus typically shows smaller variations among different hosts compared to a subclass of the influenza virus, and some human-coronaviruses exhibit annual changes, unlike the more stable Influenza H types. Additionally, there are multiple coronaviruses'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 4, 5, 4, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'kz0mas3w': {'greedy': 'Coronavirus causes longer-lasting symptoms and higher death rates. It spreads more easily and causes pneumonia.',\n",
       "   'samples': ['Coronavirus (COVID-19) is a novel virus, while seasonal flu has been around for decades. Symptoms and severity vary; some people with coronavirus experience no symptoms. Recovery times and treatments differ between the two. Vaccines exist for seasonal flu but',\n",
       "    'Coronavirus can cause more severe illness and has global impact. Flu viruses mutate more frequently. Both can cause respiratory symptoms.',\n",
       "    'Coronavirus (COVID-19) is caused by a novel virus, whereas seasonal flu is caused by influenza viruses. They have different symptoms and require different treatments. The coronavirus can lead to more severe illness in some cases.',\n",
       "    'Coronavirus (COVID-19) is caused by a different virus than the seasonal flu. Symptoms and transmission methods share some similarities, but the viruses are distinct. COVID-19 is generally more severe.',\n",
       "    'The coronavirus (COVID-19) is caused by a different virus than the flu, has unique symptoms like loss of taste and smell, and can spread more easily in communities. Severity and transmission methods also differ.',\n",
       "    'Coronavirus causes longer-lasting symptoms and can be asymptomatic. It has a higher mortality rate and spreads more easily.',\n",
       "    'Coronavirus causes a novel illness (COVID-19), while seasonal flu has been around for centuries. Symptoms and severity vary, with coronavirus often causing more severe illness. Transmission rates and global impact also differ significantly.',\n",
       "    'Coronavirus (COVID-19) is caused by a novel virus, spreads more easily, has a longer incubation period, and can be more severe. Seasonal flu is caused by different viruses with varying symptoms and transmission rates.',\n",
       "    'Coronavirus causes COVID-19, spreads more easily, has higher mortality rate, and has no vaccine yet. Seasonal flu has annual variants, better treatments, and existing vaccines.',\n",
       "    'Coronavirus causes a novel illness with higher mortality, while seasonal flu is more common and usually less severe.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 3, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'kvh60zd5': {'greedy': \"The manuscript examines factors like viral viability, transmission, ecology, and observed patterns to explore seasonality, but it doesn't directly compare coronavirus to flu. Seasonal differences may vary.\",\n",
       "   'samples': ['The manuscript examines differences through viral viability, transmission, ecological patterns, and observed epidemiology, focusing on seasonality. (Note: A more detailed answer would require specific data not provided in the context.)',\n",
       "    'The manuscript does not provide a direct comparison between coronavirus and seasonal flu. To answer briefly: The manuscript focuses on the seasonality of SARS-CoV-2, not contrasting it with seasonal flu.',\n",
       "    \"The manuscript examines the seasonality of SARS-CoV-2 by analyzing its viability, transmission, ecological patterns, and observed epidemiology in the Southern Hemisphere's summer and early fall. It does not directly compare SARS-CoV-2 to seasonal\",\n",
       "    'The manuscript focuses on the seasonality of SARS-CoV-2, contrasting it with data on influenza. Differences include viral viability, transmission patterns, and observed epidemic trends across seasons. No specific contrasts are detailed here.',\n",
       "    \"The manuscript examines evidence on viral viability, transmission, ecology, and observed epidemiology to explore seasonality, but it doesn't directly compare to seasonal flu. Differences are not specified.\",\n",
       "    'The manuscript examines different aspects such as viral viability, transmission patterns, ecology, and observed seasonal trends to compare the coronavirus to the flu. No direct comparison is made in the given context.',\n",
       "    'The manuscript examines the seasonality of SARS-CoV-2 through viral viability, transmission, ecology, and observed epidemiology, unlike seasonal flu.',\n",
       "    'The manuscript examines evidence on viral viability, transmission, ecology, and seasonal patterns, but does not directly compare the coronavirus to seasonal flu. Differences are not explicitly stated.',\n",
       "    'The manuscript examines differences in the seasonality of SARS-CoV-2 compared to influenza, using multiple lines of evidence. It does not directly compare the two viruses but looks at how SARS-CoV-2 behaves differently across seasons. Flu tends',\n",
       "    \"The manuscript focuses on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its seasonality, unlike seasonal flu. It reviews evidence on viral viability, transmission, ecological patterns, and observed epidemiology in the Southern Hemisphere's summer\"],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 3, 4, 3, 1, 5],\n",
       "   'entropy': 1.6434177197931796},\n",
       "  '4d979wj4': {'greedy': 'The coronavirus (NCP) and seasonal flu are both respiratory illnesses but caused by different viruses. Symptoms can overlap, but the coronavirus is generally more severe.',\n",
       "   'samples': ['',\n",
       "    '',\n",
       "    'The coronavirus (NCP) and seasonal flu are both respiratory viruses but the coronavirus is a novel strain not previously seen in humans, causing more severe symptoms and requiring different approaches for diagnosis and control.',\n",
       "    '',\n",
       "    'The coronavirus (NCP) and seasonal flu are both respiratory illnesses but the coronavirus is caused by a novel strain of the SARS-CoV-2 virus, while seasonal flu is caused by different strains of the influenza virus. Symptoms and transmission methods can',\n",
       "    'The coronavirus (NCP) and seasonal flu are caused by different viruses and have distinct symptoms and transmission methods.',\n",
       "    'The coronavirus (NCP) and seasonal flu are both respiratory illnesses but the coronavirus is caused by a novel strain of the virus, while seasonal flu is caused by known influenza viruses. Symptoms and severity can vary.',\n",
       "    'The coronavirus is a novel virus, while seasonal flu is caused by influenza viruses that change每年更新。新冠病毒是一种新型病毒，而季节性流感是由不断变化的流感病毒引起的。 (Note: The translation uses \"每年更新\" to convey that',\n",
       "    'The coronavirus (NCP) and seasonal flu are caused by different viruses and have distinct symptoms and transmission methods.',\n",
       "    'The coronavirus (NCP) and seasonal flu are caused by different viruses and can have distinct symptoms and transmission patterns.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 2, 3, 4, 2, 4],\n",
       "   'entropy': 1.5047882836811908},\n",
       "  '3xw4qjoy': {'greedy': 'The coronavirus is a lipid-bound, enveloped virus with similar size characteristics to endemic human coronaviruses, while the seasonal flu is not specified in the context provided. However, both are affected by humidity levels.',\n",
       "   'samples': ['The coronavirus is a lipid-bound, enveloped virus with similar size characteristics to endemic human coronaviruses, while the seasonal flu is not specified in the context provided. Both are subject to reduced viability and transmission with increased humidity. However, the context',\n",
       "    'The coronavirus is a lipid-bound, enveloped virus with similar size characteristics to endemic human coronaviruses, while the seasonal flu is not specified in the context provided. However, the key difference highlighted is the potential impact of humidity on their transmission,',\n",
       "    'The coronavirus is a lipid-bound, enveloped virus similar in size to endemic human coronaviruses, while the context does not provide specific differences between the coronavirus and seasonal flu. However, it notes that both may be affected similarly by changes in humidity',\n",
       "    'Coronavirus is a lipid-bound, enveloped virus with similar size characteristics to endemic human coronaviruses, unlike the seasonal flu. This characteristic makes it more sensitive to changes in humidity.',\n",
       "    'The coronavirus is a lipid-bound, enveloped virus with similar size characteristics to endemic human coronaviruses, while the seasonal flu is not specified to have these exact characteristics. Answer: The coronavirus is a lipid-bound, enveloped virus.',\n",
       "    'The coronavirus is a lipid-bound, enveloped virus similar in size to endemic human coronaviruses, while influenza is not described in those specific terms in the given context. Both are affected by humidity levels.',\n",
       "    'The coronavirus is a lipid-bound, enveloped virus similar in size to endemic human coronaviruses, unlike the seasonal flu virus. This similarity suggests it may be subject to the same dynamics of reduced viability and transmission with increased humidity.',\n",
       "    '',\n",
       "    'The coronavirus is a lipid-bound, enveloped virus with similar size characteristics to endemic human coronaviruses, unlike the seasonal flu. Answer briefly. The coronavirus is a lipid-bound, enveloped virus. Answer briefly.',\n",
       "    'The coronavirus is a lipid-bound, enveloped virus similar in size to endemic human coronaviruses, whereas the seasonal flu is an influenza virus.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 1, 3, 4, 3, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'euecd8bd': {'greedy': 'The coronavirus (NCP) and seasonal flu are both respiratory illnesses but caused by different viruses. Symptoms can overlap, but the coronavirus is generally more severe.',\n",
       "   'samples': ['The coronavirus is a novel strain, while seasonal flu refers to regular influenza that recurs annually. They can sometimes co-circulate, complicating diagnosis and treatment.',\n",
       "    '',\n",
       "    'The coronavirus (NCP) and seasonal flu are both respiratory viruses but the coronavirus is a novel strain not previously seen in humans, causing more severe illness in some cases. Seasonal flu viruses, on the other hand, are well-known and cause m',\n",
       "    'The coronavirus is a novel virus, while seasonal flu is caused by influenza viruses that change每年更新。新型冠状病毒与季节性流感的主要区别在于，新型冠状病毒是新型病毒，而季节性流感是由每年都会变异的流感病毒引起的。 (',\n",
       "    'The coronavirus is a novel strain, while seasonal flu refers to regular influenza that recurs annually. They can sometimes co-circulate during certain seasons.',\n",
       "    'The coronavirus is a novel strain not previously identified in humans, while seasonal flu viruses are familiar strains that circulate annually.',\n",
       "    'The coronavirus is a novel strain, while seasonal flu refers to influenza that recurs annually. They can both cause respiratory illness, but their symptoms and impacts may vary.',\n",
       "    'The coronavirus causing NCP is a novel strain, while seasonal flu refers to influenza that occurs annually. They have different symptoms and require different approaches for prevention and control.',\n",
       "    'The coronavirus is a novel strain not seasonal like influenza.',\n",
       "    'The coronavirus is a novel strain not seasonal like flu.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 4, 5, 6, 6, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'g5shtcs5': {'greedy': 'Coronaviruses display marked winter seasonality between December and April, similar to influenza viruses, but HCoV-229E is an exception, being detected only in 2008 winter and sporadically afterward. Both viruses',\n",
       "   'samples': ['Coronaviruses display marked winter seasonality between December and April, similar to influenza viruses, but HCoV-229E is an exception, being detected only in 2008 winter and sporadically afterwards. Additionally,',\n",
       "    'Coronaviruses display marked winter seasonality similar to influenza viruses but differ in that HCoV-229E is only detected in winter 2008 and sporadically thereafter. Other coronaviruses have different dominant seasons',\n",
       "    'Coronaviruses display marked winter seasonality between December and April, similar to influenza viruses, but HCoV-229E is an exception, being detected only in 2008 winter and sporadically afterward. Both viruses',\n",
       "    'Coronaviruses display marked winter seasonality similar to influenza viruses but are not detected in summer months. HCoV-229E is an exception, being confined to the winter of 2008 and sporadic afterward.',\n",
       "    'Coronaviruses display marked winter seasonality similar to influenza viruses but differ in that HCoV-229E is only detected in winter 2008 and is sporadic in subsequent winters.',\n",
       "    'Coronaviruses display marked winter seasonality between December and April, similar to influenza viruses, but HCoV-229E is an exception, being detected only in the winter of 2008. Additionally, coronavir',\n",
       "    'Coronaviruses display marked winter seasonality like influenza viruses but HCoV-229E is an exception, being confined to the winter of 2008 and sporadic in the following year. Both viruses are less prevalent in',\n",
       "    'Coronaviruses display marked winter seasonality similar to influenza viruses but differ in that HCoV-229E is only detected in winter 2008 and sporadically afterwards. Other coronaviruses have different dominant seasons',\n",
       "    'Coronaviruses display marked winter seasonality between December and April, similar to influenza viruses, but HCoV-229E is an exception, being confined to the winter of 2008 and sporadic in the following year',\n",
       "    'Coronaviruses display marked winter seasonality similar to influenza viruses but differ in that HCoV-229E is only detected in the winter of 2008 and is sporadic in the following year. Additionally, the other'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 3, 0, 4, 1, 2, 4],\n",
       "   'entropy': 1.6094379124341005},\n",
       "  'clxza5zy': {'greedy': 'The provided context focuses on the seasonality of specific coronaviruses (229E, HKU1, NL63, and OC43) but does not directly compare coronaviruses to the seasonal flu. To answer your',\n",
       "   'samples': ['The provided context focuses on seasonal patterns in coronaviruses 229E, HKU1, NL63, and OC43 but does not compare them directly to the seasonal flu. To answer your question, coronaviruses',\n",
       "    'The provided context focuses on the seasonality of specific coronaviruses and does not directly compare coronaviruses to the seasonal flu. For a direct comparison, note that coronaviruses (including those mentioned) typically cause mild respiratory illness and',\n",
       "    'The provided context does not differentiate between coronaviruses and the seasonal flu. It focuses on the seasonality of specific coronaviruses and does not compare them to the flu. For comparison, coronaviruses generally cause milder illnesses than',\n",
       "    'The given context does not provide information on how coronaviruses differ from the seasonal flu. To answer your question, more details about the characteristics and behaviors of both viruses would be needed.',\n",
       "    'The provided context focuses on the seasonality of specific coronaviruses (229E, HKU1, NL63, OC43) and does not compare them directly to the seasonal flu. For a comparison, note that while',\n",
       "    'The provided context focuses on the seasonal patterns of four coronaviruses (229E, HKU1, NL63, OC43) but does not compare coronaviruses with the seasonal flu. Therefore, based on the',\n",
       "    'The provided context focuses on seasonal patterns of specific coronaviruses but does not compare coronaviruses to the seasonal flu. For a direct comparison, note that coronaviruses causing common colds can be more prevalent in winter, similar to',\n",
       "    'The provided context does not differentiate between coronaviruses and the seasonal flu. They are separate types of viruses.',\n",
       "    'The given context focuses on the seasonal behavior of specific coronaviruses but does not directly compare them to the seasonal flu. To answer your question directly: Coronaviruses, including those studied (229E, HKU1, NL',\n",
       "    'The provided context does not differentiate between coronavirus and seasonal flu. It only discusses the seasonality of specific coronaviruses (229E, HKU1, NL63, OC43) without comparing them to the seasonal flu.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 0, 0, 3, 4, 5, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '080lwu4p': {'greedy': 'The passage does not provide information on how coronavirus differs from seasonal flu; it only states that human coronaviruses are associated with influenza-like illness in Peru.',\n",
       "   'samples': ['The coronavirus can cause influenza-like illness, but it is distinct from seasonal flu as it is not associated with influenza viruses.',\n",
       "    'The coronavirus can cause influenza-like illness and is more prevalent in the fall-winter season compared to seasonal flu.',\n",
       "    'Coronavirus can cause influenza-like illness, but it is not the same as seasonal flu. They may co-circulate during the same season.',\n",
       "    'The passage does not provide a direct comparison between coronavirus and seasonal flu. It only states that human coronaviruses are relatively frequently associated with influenza-like illness in Peru. For accurate differentiation, refer to medical sources.',\n",
       "    'The passage does not provide a direct comparison between coronavirus and seasonal flu. It only mentions that human coronaviruses are associated with influenza-like illness and are prevalent in Peru, especially during the fall-winter season.',\n",
       "    \"The passage doesn't directly compare coronaviruses to seasonal flu, but it indicates that human coronaviruses are frequently associated with influenza-like illness in Peru. It also notes that most infections occur in the fall-winter season. However, without\",\n",
       "    'The passage does not provide a direct comparison between coronavirus and seasonal flu. It only mentions that human coronaviruses are associated with influenza-like illness and are prevalent in certain seasons. For a comparison, one would need to look at differences in symptoms,',\n",
       "    'The coronavirus can cause influenza-like illness, but it is distinct from seasonal flu, which it often co-occurs with. It is more prevalent in the fall-winter season.',\n",
       "    'The given context does not provide specific differences between coronavirus and seasonal flu, only that human coronaviruses were found to be relatively frequently associated with influenza-like illness in Peru. To accurately answer the question, information on the characteristics or symptoms distinguishing the two',\n",
       "    'The given context does not provide specific differences between coronaviruses and seasonal flu. To answer your question accurately, coronaviruses can cause respiratory illnesses similar to the flu but are typically less severe. They are often associated with milder symptoms and'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 5, 2, 6, 7],\n",
       "   'entropy': 2.0253262207700677}},\n",
       " '30': {'no': {'greedy': 'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "   'samples': ['Remdesivir may be moderately effective in reducing recovery time, but evidence of its overall effectiveness against COVID-19 is limited.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time, but its overall benefit for COVID-19 is debated.',\n",
       "    'Yes, remdesivir has been shown to be somewhat effective in treating COVID-19, particularly in reducing hospital stay duration. However, its overall impact is modest.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Yes, remdesivir has been shown to be effective in treating COVID-19, but its efficacy is limited.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is debated. It shortens recovery time in some patients.',\n",
       "    'Yes, remdesivir has been shown to be somewhat effective in treating COVID-19, but its efficacy is modest.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in treating COVID-19.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, but its benefits are modest.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time, but its overall effectiveness for COVID-19 is debated.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 5, 6, 5, 1],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'wcdq0fqj': {'greedy': 'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "   'samples': ['Remdesivir may help, but its effectiveness is limited. It shortens recovery time slightly and reduces mortality in severe cases.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19, though its benefits are modest.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, though its efficacy varies.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time, but its overall impact on mortality is less clear.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, but its efficacy varies. Consult medical professionals for guidance.',\n",
       "    'Yes, remdesivir is considered moderately effective for treating COVID-19.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, but its benefits are modest.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, shortening recovery time, but its overall impact is limited.',\n",
       "    'Yes, remdesivir may help reduce the recovery time for COVID-19 patients.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 3, 2, 0, 1, 1],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'zlmv67ia': {'greedy': 'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "   'samples': ['Yes, remdesivir has shown some effectiveness in treating COVID-19, shortening recovery time. However, its benefits are modest.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Yes, remdesivir is considered moderately effective for treating COVID-19.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, but its benefits are modest.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, but its benefits are modest.',\n",
       "    \"Remdesivir may be moderately effective, but evidence is limited. It's not a definitive cure.\",\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is modest.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19, but its benefits are modest.',\n",
       "    'Yes, remdesivir may help shorten recovery time for some COVID-19 patients.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, shortening recovery time.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 2, 3, 4, 5, 1, 1],\n",
       "   'entropy': 1.6094379124341},\n",
       "  '40vtvseh': {'greedy': 'Yes, remdesivir has been shown to be moderately effective in treating COVID-19.',\n",
       "   'samples': ['Yes, remdesivir is considered effective for COVID-19, but its benefits are modest.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, though its efficacy varies.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time for some COVID-19 patients, but its overall impact on mortality or severe outcomes remains debated.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, but its benefits are modest.',\n",
       "    'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Yes, remdesivir is considered effective for treating COVID-19, but its benefits are modest.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is modest.',\n",
       "    'Yes, remdesivir is considered moderately effective in reducing mortality and hospital stay duration for COVID-19 patients. However, its use has limitations and it should be used in combination with other treatments. Consult healthcare professionals for guidance.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is modest. It shortens recovery time in some patients.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in reducing recovery time for COVID-19 patients.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 3, 0, 0, 4, 0, 3],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  '928lhz2l': {'greedy': 'Remdesivir may be moderately effective in reducing recovery time, but its overall impact on mortality is less clear. Effectiveness varies.',\n",
       "   'samples': ['Yes, remdesivir may be effective in treating COVID-19, but its efficacy varies.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19, but its impact is modest.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its benefits are debated. Clinical trials have reported mixed results. Consult healthcare providers for the latest recommendations.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its benefits are limited. Clinical trials have demonstrated a potential reduction in recovery time. However, it should be used under medical supervision.',\n",
       "    'Remdesivir may help, but its effectiveness for COVID-19 is debated. Some studies show modest benefits, while others find little to no effect. Use should be decided on a case-by-case basis.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on reducing mortality is modest. More research is needed.',\n",
       "    'Yes, remdesivir is considered effective in treating COVID-19, though its efficacy has some limitations.',\n",
       "    'Yes, remdesivir has been shown to be somewhat effective in treating COVID-19.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 0, 4, 4, 3, 3, 5],\n",
       "   'entropy': 1.6957425341696346},\n",
       "  'm2k6usaz': {'greedy': 'Yes, remdesivir has been shown to be moderately effective in treating COVID-19.',\n",
       "   'samples': ['Remdesivir may be moderately effective in reducing recovery time for COVID-19 patients, but its overall impact on mortality is debated. More research is needed.',\n",
       "    \"Remdesivir may be somewhat effective, but its benefits are limited. It's approved for emergency use, but more research is needed.\",\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, but its impact on mortality is debated.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time but evidence of its overall effectiveness against COVID-19 is limited.',\n",
       "    'Remdesivir may be somewhat effective, but its benefits are modest.',\n",
       "    'Yes, remdesivir is considered moderately effective for treating COVID-19.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on reducing mortality is modest.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its benefits are debated.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, shortening recovery time, but its overall impact is limited.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time but its overall effectiveness for COVID-19 is debated.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 4, 5, 4, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'twn38v3a': {'greedy': 'Yes, remdesivir has been shown to be moderately effective in treating COVID-19.',\n",
       "   'samples': ['Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time for some COVID-19 patients. Effectiveness can vary.',\n",
       "    'Yes, remdesivir is considered moderately effective in reducing mortality and hospital stay duration for COVID-19 patients. However, its overall impact is limited.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its benefits are limited. It shortens recovery time and reduces mortality in severe cases.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in treating COVID-19. However, its benefits are limited. Consult medical professionals for the most accurate advice.',\n",
       "    'Yes, remdesivir is considered effective in treating COVID-19, though its efficacy is moderate.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time but its overall effectiveness for COVID-19 treatment remains debated.',\n",
       "    'Remdesivir may be somewhat effective in treating COVID-19, but its benefits are modest. Clinical trials show it can reduce recovery time. However, its overall impact on mortality and severe outcomes remains debated. Always follow medical advice for treatment.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19, though its impact is modest.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19. However, its impact on mortality is modest.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 4, 5, 6, 4, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'op4t2mu4': {'greedy': 'Remdesivir may be moderately effective in reducing recovery time, but its overall impact on mortality is less clear. Effectiveness varies.',\n",
       "   'samples': ['Yes, remdesivir is considered moderately effective for treating COVID-19.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, though its efficacy varies.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is modest.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is modest.',\n",
       "    'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, shortening recovery time.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, shortening recovery time. However, its overall benefit remains debated.',\n",
       "    'Yes, remdesivir is considered moderately effective for treating COVID-19.',\n",
       "    'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is debated. Clinical trials indicate it may shorten recovery time.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 3, 3, 1, 0, 3, 4],\n",
       "   'entropy': 1.5571130980576455},\n",
       "  '11wfbtbc': {'greedy': 'Remdesivir may be moderately effective in reducing recovery time, but its overall impact on mortality is less clear. Effectiveness varies.',\n",
       "   'samples': ['Yes, remdesivir is considered effective for COVID-19 treatment.',\n",
       "    'Yes, remdesivir is considered effective for treating COVID-19, though its benefits are modest.',\n",
       "    'Yes, remdesivir is considered moderately effective for treating COVID-19.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, shortening recovery time, but its overall benefit remains debated.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, though its benefits are modest.',\n",
       "    'Remdesivir may help shorten recovery time but its overall effectiveness for COVID-19 is debated. More research is needed.',\n",
       "    'Yes, remdesivir has been shown to be somewhat effective in treating COVID-19.',\n",
       "    'Remdesivir may help shorten recovery time but its overall effectiveness for COVID-19 is debated.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 3, 3, 2, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  '0b8thzom': {'greedy': 'Remdesivir may be moderately effective in reducing recovery time, but its overall impact on mortality is less clear. Effectiveness varies.',\n",
       "   'samples': ['Yes, remdesivir is considered effective in treating COVID-19, though its benefits are modest.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, shortening recovery time, but its overall impact is limited.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19. However, its benefits are modest. Consult healthcare providers for the latest recommendations.',\n",
       "    'Yes, remdesivir is considered moderately effective in treating COVID-19.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time for COVID-19 patients, but its overall impact on mortality and severe outcomes is less clear. Effectiveness varies.',\n",
       "    'Yes, remdesivir is considered moderately effective for treating COVID-19.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on mortality is modest.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its benefits are modest.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19.',\n",
       "    'Remdesivir may be moderately effective in reducing recovery time for some COVID-19 patients, but its overall impact is debated. Effectiveness varies.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 1, 2, 0, 0, 3, 3],\n",
       "   'entropy': 1.2206072645530175},\n",
       "  'hgpgeel6': {'greedy': 'Yes, remdesivir is considered moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "   'samples': ['Yes, remdesivir has shown some effectiveness in treating COVID-19. However, its benefits are limited. Consult healthcare professionals for guidance.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in treating COVID-19.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, shortening recovery time. However, its overall benefit remains debated.',\n",
       "    'Remdesivir has shown some effectiveness in treating COVID-19, but its impact on reducing mortality is modest. It shortens recovery time in some patients.',\n",
       "    'Yes, remdesivir is considered moderately effective in treating COVID-19, particularly in reducing recovery time.',\n",
       "    'Yes, remdesivir has been shown to be moderately effective in reducing recovery time for COVID-19 patients.',\n",
       "    'Remdesivir shows some effectiveness in treating COVID-19, but its benefits are modest.',\n",
       "    'Yes, remdesivir may be effective in treating COVID-19, but its efficacy varies.',\n",
       "    'Yes, remdesivir is considered effective in treating COVID-19, though its benefit is modest.',\n",
       "    'Yes, remdesivir has shown some effectiveness in treating COVID-19, though its benefits are modest.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 1, 3, 1, 4, 3, 3],\n",
       "   'entropy': 1.4184836619456562}},\n",
       " '13': {'no': {'greedy': 'Respiratory droplets, close contact, surfaces.',\n",
       "   'samples': ['Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Coronavirus spreads through respiratory droplets, close contact, and surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 0, 0, 0, 0],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  '9hq8xdhi': {'greedy': 'Respiratory droplets, close contact, surfaces.',\n",
       "   'samples': ['Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Coronavirus spreads through respiratory droplets, close contact, and surfaces.',\n",
       "    'Coronavirus spreads through respiratory droplets, close contact, and surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 1, 1, 0, 0, 0],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'iwy2nn17': {'greedy': 'Coronavirus can be transmitted through droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "   'samples': ['Coronavirus can be transmitted through droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Coronavirus can be transmitted through droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Droplets, contact, and aerosols. Transmission through the digestive tract, urine, eyes, and other routes is also possible.',\n",
       "    'Coronavirus can be transmitted through droplets, contact, and aerosols or possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Coronavirus can be transmitted through droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "    'The transmission routes of highly pathogenic coronaviruses include droplets, contact, and aerosols. They may also be transmitted through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Coronavirus can be transmitted through droplets, contact, and aerosols, as well as possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Droplets, contact, and aerosols. They may also be transmitted through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Droplets, contact, and aerosols, possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 1, 0, 2, 2],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  '85vnyr36': {'greedy': 'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, tear (conjunctival), and mother-to-fetus transmission have not been confirmed yet.',\n",
       "   'samples': ['The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, tear, and mother-to-fetus transmission have not yet been confirmed. Answer briefly. Main transmission routes: respiratory droplets',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is also possible, but aerosol, tear (conjunctival), and mother-to-fetus transmissions have not yet been confirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible but not confirmed. Aerosol, tear (conjunctival), and mother-to-fetus transmissions are still unconfirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission might be possible, but aerosol, conjunctival, and mother-to-fetus transmissions have not yet been confirmed. Answer briefly. Main transmission routes:',\n",
       "    'The main transmission routes of 2019-nCoV are respiratory droplets and indirect contact. Fecal-oral transmission is possible, while aerosol, conjunctival, and mother-to-fetus transmission remain unconfirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is also possible. Aerosol, conjunctival, and mother-to-fetus transmission have not been confirmed yet.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, tear (conjunctival), and mother-to-fetus transmission have not yet been confirmed. Answer: The main transmission routes',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, conjunctival, and mother-to-fetus transmissions remain unconfirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, tear (conjunctival), and mother-to-fetus transmissions have not yet been confirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible but not confirmed. Aerosol, tear (conjunctival), and mother-to-fetus transmission routes have not been confirmed yet.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 2, 1, 1, 1, 1],\n",
       "   'entropy': 1.0296530140645734},\n",
       "  '2yblpbwm': {'greedy': 'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, tear (conjunctival), and mother-to-fetus transmission have not been confirmed yet.',\n",
       "   'samples': ['The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is also possible. Aerosol, conjunctival, and mother-to-fetus transmissions have not yet been confirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible but not confirmed. Aerosol, tear (conjunctival), and mother-to-fetus transmissions have yet to be confirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible but not confirmed. Aerosol, tear (conjunctival), and mother-to-fetus transmission are not yet confirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, conjunctival, and mother-to-fetus transmissions have not been confirmed. Answering the above question, the transmission routes',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible but not confirmed. Aerosol, tear (conjunctival), and mother-to-fetus transmissions have not been confirmed yet.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is also possible. Aerosol, tear (conjunctival), and mother-to-fetus transmission routes have not yet been confirmed.',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, conjunctival, and mother-to-fetus transmissions have not yet been confirmed.',\n",
       "    'The main transmission routes of 2019-nCoV are respiratory droplets and indirect contact. Fecal-oral transmission is possible but not confirmed. Aerosol, tear (conjunctival), and mother-to-fetus transmission routes are still',\n",
       "    'The main transmission routes of coronavirus are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, tear, and mother-to-fetus transmissions remain unconfirmed.',\n",
       "    'The main transmission routes of 2019-nCoV are respiratory droplets and indirect contact. Fecal-oral transmission is possible, but aerosol, tear (conjunctival), and mother-to-fetus transmission have not been confirmed.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 1, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  'ms4xzxyv': {'greedy': 'The transmission routes of human highly pathogenic coronaviruses include droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "   'samples': ['The transmission routes of coronaviruses include droplets, contact, and aerosols, as well as possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Droplets, contact, and aerosols, as well as possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'The transmission routes of coronavirus include droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Coronavirus is transmitted through droplets, contact, and aerosols, as well as possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'The transmission routes of human highly pathogenic coronaviruses include droplets, contact, and aerosols, as well as possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'The transmission routes of coronaviruses include droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "    'Coronavirus can be transmitted through droplets, contact, and aerosols, as well as potentially through the digestive tract, urine, eyes, and other routes.',\n",
       "    'The transmission routes of human highly pathogenic coronaviruses include droplets, contact, and aerosols, as well as possibly through the digestive tract, urine, eyes, and other routes.',\n",
       "    'The transmission routes of human highly pathogenic coronaviruses include droplets, contact, and aerosols. They may also be transmitted through the digestive tract, urine, eyes, and other routes. Answer.',\n",
       "    'Coronavirus can be transmitted through droplets, contact, and aerosols, as well as possibly through the digestive tract, urine, eyes, and other routes.'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 3, 4, 4, 3, 4, 4],\n",
       "   'entropy': 1.4708084763221114},\n",
       "  'gqfltyso': {'greedy': 'Respiratory droplets, close contact, surfaces.',\n",
       "   'samples': ['Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Coronavirus spreads through respiratory droplets, close contact, surfaces, and airborne particles.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Coronavirus spreads through respiratory droplets, close contact, and surfaces.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 1, 0, 0, 0, 0, 1],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  '89fwi0q2': {'greedy': 'Respiratory droplets, close contact, surfaces.',\n",
       "   'samples': ['Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Coronavirus transmits through respiratory droplets, close contact, and surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Coronavirus primarily transmits through respiratory droplets, close contact, and surfaces.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 0, 0, 1],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  'ush6iqk5': {'greedy': 'Respiratory droplets, close contact, surfaces.',\n",
       "   'samples': ['Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Coronavirus spreads through respiratory droplets, close contact, surfaces, and airborne particles.',\n",
       "    'Respiratory droplets, close contact, surfaces.',\n",
       "    'Respiratory droplets, close contact, surfaces.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 1, 0, 0],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  'dkxi8mgw': {'greedy': 'The text does not provide information on transmission routes of coronavirus. The passage focuses on the entry mechanisms and structural aspects of the S protein in coronaviruses. Transmission routes are typically through respiratory droplets, close contact, and contaminated surfaces, but these',\n",
       "   'samples': ['The provided context does not specifically mention the transmission routes of coronaviruses. However, based on general knowledge, coronaviruses are primarily transmitted through respiratory droplets when an infected person coughs or sneezes, close contact with infected individuals',\n",
       "    'Coronaviruses primarily transmit through respiratory droplets when an infected person coughs or sneezes, and through close contact with infected individuals. They can also spread via contaminated surfaces.',\n",
       "    'The provided context does not explicitly mention the transmission routes of coronaviruses. However, based on general knowledge, coronaviruses are primarily transmitted through respiratory droplets when an infected person coughs or sneezes, close personal contact, and',\n",
       "    'Coronaviruses can transmit through receptor binding, low pH exposure, and proteolytic activation. These factors trigger conformational changes in the spike glycoprotein, allowing the virus to enter host cells.',\n",
       "    'The text does not explicitly mention the transmission routes of coronavirus. However, based on general knowledge, coronaviruses are primarily transmitted through respiratory droplets when an infected person coughs, sneezes, or talks, and through contact with contaminated surfaces',\n",
       "    'The transmission routes of coronavirus include receptor binding, low pH exposure, and proteolytic activation. These processes trigger conformational changes in the spike glycoprotein, facilitating viral entry into host cells. Additionally, coronaviruses can transmit between species',\n",
       "    '',\n",
       "    \"Coronaviruses primarily transmit through the air via respiratory droplets when an infected person coughs, sneezes, or talks. They can also spread through close personal contact, contact with contaminated surfaces, and touching one's face. Hand hygiene and\",\n",
       "    'The transmission routes of coronavirus include receptor binding, low pH exposure, and proteolytic activation.',\n",
       "    \"Coronaviruses typically transmit through respiratory droplets when an infected person coughs, sneezes, or talks. They can also spread via contact with contaminated surfaces and objects, followed by touching one's mouth, nose, or eyes. Inhalation\"],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 3, 5, 6, 3, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'yp7bniwt': {'greedy': 'Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.',\n",
       "   'samples': ['Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread by asymptomatic individuals.',\n",
       "    'Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.',\n",
       "    'Indirect transmission through contaminated objects, aerosolization in enclosed spaces, and spread by asymptomatic individuals.',\n",
       "    'Indirect transmission, virus contamination, aerosolization, asymptomatic spread.',\n",
       "    'Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.',\n",
       "    'Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.',\n",
       "    'Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.',\n",
       "    'Indirect transmission through contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.',\n",
       "    'Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.',\n",
       "    'Indirect transmission via contaminated objects, aerosolization in enclosed spaces, and spread from asymptomatic individuals.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 1, 1, 1, 3, 1, 1],\n",
       "   'entropy': 1.0888999753452235}},\n",
       " '26': {'no': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.'],\n",
       "   'cluster_ids': [0, 1, 1, 1, 1, 1, 1, 1, 1, 0],\n",
       "   'entropy': 0.5004024235381879},\n",
       "  '1jprldcz': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms often include fever, cough, and fatigue. Some people may also experience a loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Other common symptoms are sore throat and headache. Less common ones are a runny nose, nasal congestion, and diarrhea. Some people may experience loss of taste or smell.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 1, 2, 0, 0, 0],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  'e1fhje3z': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Initial symptoms often include fever, cough, and fatigue. Some people may also experience a sore throat, runny nose, muscle or body aches, headache, new loss of taste or smell, congestion, nausea or vomiting, and diarrhea.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Other symptoms may include sore throat, headache, and congestion. Some may experience loss of taste or smell.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Some may also experience a sore throat, runny nose, or muscle pain. In some cases, loss of taste or smell can occur.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 2, 2, 1, 1, 1],\n",
       "   'entropy': 0.9433483923290393},\n",
       "  '6m70ltbw': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Other symptoms may include sore throat, headache, muscle or body aches, new loss of taste or smell, congestion, runny nose, nausea, vomiting, or diarrhea.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  'okqsvg8q': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Fever, cough, fatigue.',\n",
       "    'Initial symptoms often include fever, cough, and fatigue. Some people may also experience a loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 0, 0, 0, 0, 0, 0],\n",
       "   'entropy': 0.3250829733914482},\n",
       "  'jb05x03a': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Initial symptoms often include fever, cough, and fatigue. Some may experience a loss of taste or smell.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Some people may also experience a loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Some may experience a loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 1, 1, 2, 1, 1],\n",
       "   'entropy': 0.9502705392332347},\n",
       "  'wy0y5ztd': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms often include fever, cough, and fatigue. Some may experience a loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 2, 0, 0, 1, 0],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  'u7ir986m': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Initial symptoms include fever, cough, and fatigue. Some may also experience a loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Other symptoms may include headache, sore throat, and congestion.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Some people may also experience a loss of taste or smell.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Some may also experience a loss of taste or smell.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Some people may also experience a loss of taste or smell.'],\n",
       "   'cluster_ids': [0, 1, 0, 1, 1, 2, 3, 3, 0, 3],\n",
       "   'entropy': 1.313834033192747},\n",
       "  'uz9a0izu': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Initial symptoms often include fever, cough, and fatigue. Some may experience a loss of taste or smell.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Other symptoms may include sore throat, headache, and loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms often include fever, cough, and fatigue. Some may experience a loss of taste or smell.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 2, 0, 0, 2, 0, 1],\n",
       "   'entropy': 1.0296530140645734},\n",
       "  'qp0h50t3': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue. Some people may also experience a sore throat, runny nose, muscle or body aches, headache, new loss of taste or smell, congestion, nausea or vomiting, and diarrhea.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 0, 0, 2, 0, 0],\n",
       "   'entropy': 0.639031859650177},\n",
       "  '7kjwe7vf': {'greedy': 'Fever, cough, fatigue.',\n",
       "   'samples': ['Initial symptoms often include fever, cough, and fatigue. Some may experience a loss of taste or smell.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Initial symptoms include fever, cough, and fatigue.',\n",
       "    'Fever, cough, fatigue.',\n",
       "    'Fever, cough, fatigue.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 2, 1, 1, 1, 2, 2],\n",
       "   'entropy': 0.9433483923290393}},\n",
       " '4': {'no': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from pneumonia and respiratory failure due to inflammation in the lungs. Other factors include multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs. Other factors include multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 1, 0, 0, 1, 0],\n",
       "   'entropy': 0.6108643020548934},\n",
       "  '97pdrvvt': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from pneumonia and respiratory failure due to inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.'],\n",
       "   'cluster_ids': [0, 1, 0, 0, 2, 0, 3, 1, 0, 0],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'okqsvg8q': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from pneumonia and respiratory failure due to extensive lung damage. Other factors include multi-organ failure.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 0, 2, 0, 2, 0, 0],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  '91kbs20i': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from inflammation and damage to the lungs, leading to acute respiratory distress syndrome (ARDS).',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and inflammation in the lungs. Other factors include multi-organ dysfunction.'],\n",
       "   'cluster_ids': [0, 1, 2, 0, 0, 0, 0, 0, 3, 2],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'jb05x03a': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs. Other factors include multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from pneumonia and respiratory failure.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs. Other factors include multi-organ dysfunction.'],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 1, 2, 1, 0, 1],\n",
       "   'entropy': 1.0296530140645734},\n",
       "  'wy0y5ztd': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is primarily caused by severe respiratory failure due to widespread inflammation and clotting in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 1, 1, 1, 3, 1, 4],\n",
       "   'entropy': 1.2275294114572126},\n",
       "  'zxjlzyxq': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is typically caused by severe complications from pneumonia, multi-organ failure, and respiratory failure.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from inflammation and damage to the lungs, leading to respiratory failure. Other factors include multi-organ system failure.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from pneumonia and respiratory failure.'],\n",
       "   'cluster_ids': [0, 0, 1, 0, 2, 3, 0, 0, 3, 3],\n",
       "   'entropy': 1.1682824501765625},\n",
       "  'qp0h50t3': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 2, 1, 1, 2, 0],\n",
       "   'entropy': 1.0296530140645734},\n",
       "  'u7ir986m': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is typically caused by severe complications from pneumonia, multi-organ failure, and respiratory distress.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from inflammation and damage to the lungs, leading to acute respiratory failure.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from pneumonia, multi-organ failure, and respiratory failure.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from inflammation and damage to the lungs, leading to acute respiratory distress.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from inflammation in the lungs, making it difficult to breathe.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.'],\n",
       "   'cluster_ids': [0, 1, 2, 2, 0, 1, 0, 3, 4, 0],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  '5mp96lc5': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs. Other factors include multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs. Other factors include multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.'],\n",
       "   'cluster_ids': [0, 1, 1, 0, 1, 1, 2, 0, 1, 2],\n",
       "   'entropy': 1.0296530140645734},\n",
       "  '3bepui8m': {'greedy': 'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "   'samples': ['Death from COVID-19 is primarily caused by severe respiratory failure due to pneumonia and inflammation in the lungs. Other factors include multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe complications from pneumonia and respiratory failure due to inflammation in the lungs. Other factors include multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and acute respiratory distress syndrome.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and inflammation in the lungs.',\n",
       "    'Death from COVID-19 is typically caused by severe respiratory failure due to pneumonia and multi-organ dysfunction.'],\n",
       "   'cluster_ids': [0, 1, 0, 1, 0, 1, 0, 0, 0, 0],\n",
       "   'entropy': 0.6108643020548934}},\n",
       " '9': {'no': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced some restrictions.',\n",
       "   'samples': ['Lockdowns, economic downturn, vaccine rollout.',\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic downturn, healthcare strain, and vaccine rollout.',\n",
       "    'Canada implemented travel restrictions, lockdowns, and vaccination campaigns. Economic impacts included job losses and business closures. Healthcare systems faced increased strain. Socially, there was a rise in virtual interactions.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted by COVID-19, leading to lockdowns, business closures, and vaccination programs.\",\n",
       "    'COVID-19 significantly impacted Canada, causing lockdowns, economic downturn, vaccination campaigns, and healthcare strain.',\n",
       "    'Canada imposed strict travel restrictions and lockdowns, causing economic downturn, increased unemployment, and a surge in cases. Vaccination efforts mitigated some impacts.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted by COVID-19. Measures like lockdowns, travel restrictions, and vaccination campaigns have affected daily life. Economic downturn led to job losses and business closures. Healthcare systems faced strain due\",\n",
       "    'COVID-19 significantly impacted Canada, causing lockdowns, business closures, and a rise in unemployment. Vaccination campaigns have progressed but variants continue to pose challenges. Economic stimulus measures were implemented to support citizens. Healthcare systems faced strain, especially in Ontario',\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic downturn, vaccine rollout, and variants. Healthcare systems faced strain, leading to delays in non-COVID care. Economic sectors like tourism and hospitality were severely affected.',\n",
       "    'Lockdowns, economic downturn, increased healthcare demand.'],\n",
       "   'cluster_ids': [0, 0, 0, 0, 0, 0, 0, 1, 2, 1],\n",
       "   'entropy': 0.8018185525433372},\n",
       "  'woylyufz': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced some restrictions.',\n",
       "   'samples': [\"Canada's economy, healthcare system, and social life have been significantly impacted by COVID-19. Lockdowns, travel restrictions, and vaccination efforts have shaped responses. Economic support measures were implemented for citizens and businesses. Healthcare resources were strained, particularly\",\n",
       "    'Lockdowns, economic downturn, healthcare strain, vaccine rollout.',\n",
       "    'Canada implemented strict public health measures, border closures, and economic support programs in response to COVID-19.',\n",
       "    'COVID-19 significantly impacted Canada, leading to lockdowns, business closures, vaccination campaigns, and economic challenges.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted by COVID-19. Lockdowns, travel restrictions, and vaccination efforts have also influenced daily life.\",\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and introduced economic support measures. Schools and universities shifted to remote learning. Vaccination campaigns began in early 2021.',\n",
       "    \"Canada's economy, healthcare system, and social life were significantly impacted. Lockdowns, border closures, and vaccination programs were implemented. Economic support was provided to citizens and businesses. Case numbers varied by province.\",\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic downturn, vaccination campaigns, and ongoing public health measures.',\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination programs. Economy suffered; many businesses closed. Healthcare system strained. Social gatherings significantly reduced.',\n",
       "    'Canada implemented strict border controls, lockdowns, and vaccination programs. Economic impact significant; many businesses closed or struggled. Healthcare system strained. Vaccination rollout ongoing.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 2, 3, 2, 4, 2, 2],\n",
       "   'entropy': 1.4184836619456564},\n",
       "  '9zjtwp19': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced some restrictions.',\n",
       "   'samples': [\"Canada's economy, health system, and social life have been significantly impacted by COVID-19. Measures like lockdowns and travel restrictions were implemented to control the spread.\",\n",
       "    \"Canada's economy, health system, and society were significantly impacted. Lockdowns reduced economic activity. Healthcare resources strained. Social gatherings restricted. Vaccine rollout ongoing. Economic recovery gradual.\",\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic downturn, vaccine rollout, and public health challenges.',\n",
       "    \"Canada's economy, healthcare system, and society were significantly impacted. Lockdowns, travel restrictions, and business closures led to high unemployment and economic downturn. Healthcare resources were strained, and social gatherings were limited. Vaccination efforts gradually improved the situation.\",\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination programs. Economy suffered with closed businesses. Healthcare system faced increased strain. Social life significantly restricted.',\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination programs. Economy suffered; many businesses closed or downsized. Healthcare system strained.',\n",
       "    'COVID-19 significantly impacted Canada, causing widespread lockdowns, economic downturn, healthcare system strain, and vaccine rollout.',\n",
       "    'Canada implemented strict border controls, closed non-essential businesses, and enforced lockdowns. Economic impacts included high unemployment and business closures. Vaccination efforts began in early 2021.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts include job losses and business closures. Vaccination efforts have progressed but the pandemic continues to impact public health and the economy.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted by COVID-19. Lockdowns, travel restrictions, and vaccination programs have been implemented to control the spread. Economic aid and support measures were introduced for citizens and businesses.\"],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 3, 3, 4, 5, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'vgtc0k3a': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced the impact.',\n",
       "   'samples': ['COVID-19 significantly impacted Canada, leading to widespread lockdowns, economic downturn, vaccination campaigns, and public health measures.',\n",
       "    'Canada implemented strict public health measures, including lockdowns and travel restrictions. Economic impacts led to job losses and business closures. Vaccination efforts have been rolled out, but the pandemic continues to impact daily life.',\n",
       "    'Lockdowns, economic downturn, increased healthcare burden, vaccine rollout.',\n",
       "    'Canada implemented travel restrictions, lockdowns, and vaccination campaigns. Economy suffered, with widespread business closures. Healthcare system faced strain. Social gatherings were limited.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination programs have since reduced many restrictions.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have progressed but variants remain a concern.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted by COVID-19. Measures like lockdowns, travel restrictions, and vaccine rollouts have altered daily life.\",\n",
       "    'Canada implemented strict travel restrictions, lockdowns, and vaccination programs. Economic impacts included job losses and business closures. Healthcare system strain was significant. Public health measures altered daily life.',\n",
       "    'Canada implemented strict border controls, lockdowns, and vaccination programs. Economy suffered with job losses. Healthcare system faced challenges. Social gatherings were limited. Vaccination rollout began in 2021.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted. Lockdowns, border closures, and travel restrictions were implemented. Unemployment rates increased. Vaccine rollout occurred but varied provincially.\"],\n",
       "   'cluster_ids': [0, 0, 1, 1, 2, 3, 1, 1, 1, 1],\n",
       "   'entropy': 1.0888999753452235},\n",
       "  'bo6ngxot': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced some restrictions.',\n",
       "   'samples': ['COVID-19 significantly impacted Canada, leading to widespread lockdowns, economic downturn, vaccination campaigns, and public health challenges.',\n",
       "    'Canada implemented strict travel restrictions, closed non-essential businesses, and enforced lockdowns, leading to economic downturn and increased healthcare burden. Vaccination efforts have slowed virus spread.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted. Lockdowns, travel restrictions, and social distancing measures have disrupted daily life and business operations. Unemployment rates rose, and the government implemented stimulus measures. Healthcare resources strained, but\",\n",
       "    'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. The economy suffered, with high unemployment rates. Vaccination efforts began in early 2021.',\n",
       "    'COVID-19 significantly impacted Canada, leading to lockdowns, economic downturn, vaccine rollout, and changes in public health policies.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted. Lockdowns and social distancing measures led to job losses and business closures. Healthcare resources were strained, and there were changes in education and social activities.\",\n",
       "    'Lockdowns, economic downturn, healthcare strain, vaccine rollout.',\n",
       "    'Canada implemented strict border controls, lockdowns, and vaccination campaigns. Economic impacts include job losses and business closures. Healthcare systems faced increased strain.',\n",
       "    \"Canada's economy, health system, and society have been significantly impacted by COVID-19. Measures like lockdowns, travel restrictions, and vaccination campaigns have been implemented. Economic downturn, job losses, and shifts in consumer behavior are notable effects. Healthcare\",\n",
       "    \"Canada's economy, healthcare system, and social life have been significantly impacted. Lockdowns, travel restrictions, and business closures led to high unemployment rates. Healthcare strained due to virus cases. Socially, gatherings and international borders were restricted.\"],\n",
       "   'cluster_ids': [0, 0, 1, 2, 0, 3, 0, 4, 4, 5],\n",
       "   'entropy': 1.6094379124341003},\n",
       "  'swtryfq9': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced the impact.',\n",
       "   'samples': [\"Canada's economy, healthcare system, and social life were significantly impacted. Lockdowns, travel restrictions, and public health measures led to job losses and business closures. Vaccination efforts have helped reduce the impact but ongoing challenges persist.\",\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and implemented a national vaccine strategy. Economic impacts include high unemployment and business closures. Healthcare system strain was significant. Socially, it led to widespread mask-wearing and altered daily routines.',\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination campaigns. Economically, it faced challenges like closed businesses and unemployment. Healthcare systems saw increased strain. Socially, there was widespread disruption and changed behaviors.',\n",
       "    'Lockdowns, economic downturn, vaccine rollout.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and implemented a national immunization program. Economically, it faced recession. Healthcare systems saw increased strain.',\n",
       "    'Canada implemented strict public health measures, closed borders, and provided economic support. Healthcare system strain and economic downturn occurred. Vaccination rollout progressed slowly initially but accelerated.',\n",
       "    'Canada implemented strict border controls, lockdowns, and vaccination programs. Economic impacts included job losses and business closures. Healthcare systems faced strain.',\n",
       "    'COVID-19 significantly impacted Canada with widespread lockdowns, economic downturn, healthcare strain, and vaccination programs.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and implemented a national immunization program. Economic impacts included job losses and business closures. Healthcare systems faced increased strain.',\n",
       "    \"Canada's economy, healthcare system, and society have been significantly impacted. Lockdowns, travel restrictions, and social distancing measures were implemented. The country faced supply chain disruptions, job losses, and an increased burden on healthcare resources. Vaccination efforts are\"],\n",
       "   'cluster_ids': [0, 1, 1, 2, 2, 2, 2, 2, 2, 2],\n",
       "   'entropy': 0.8018185525433373},\n",
       "  'okqsvg8q': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced some restrictions.',\n",
       "   'samples': ['Canada imposed travel restrictions, closed non-essential businesses, and introduced economic support measures. Schools and universities shifted to remote learning. Lockdowns varied by province. Vaccination rollout began in early 2021.',\n",
       "    'Canada imposed strict travel restrictions, lockdowns, and public health measures. The economy suffered with job losses and business closures. Vaccination efforts gradually resumed activities.',\n",
       "    \"Canada's economy, health system, and social activities were significantly impacted. Lockdowns, travel restrictions, and a surge in cases led to job losses and business closures. Vaccination efforts gradually resumed normalcy.\",\n",
       "    'Canada implemented strict travel bans, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination campaigns began in Q1 2021.',\n",
       "    'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts began in early 2021.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and encouraged remote work. Schools and universities also shifted to online learning. Economic impact led to stimulus packages and job losses. Healthcare systems faced increased strain. Vaccination campaigns began in 202',\n",
       "    \"Canada's economy, health system, and social life have been significantly impacted by COVID-19. Lockdowns, travel restrictions, and public health measures have led to job losses and business closures. Vaccination efforts are underway but the pandemic continues to\",\n",
       "    'Lockdowns, economic downturn, vaccine rollout.',\n",
       "    \"Canada's economy, health system, and social life were significantly impacted. Lockdowns, travel restrictions, and business closures reduced economic activity. Healthcare systems faced strain, especially in hospitals. Socially, there was increased isolation and changed daily routines.\",\n",
       "    'COVID-19 significantly impacted Canada, causing lockdowns, economic downturn, vaccination campaigns, and changes in public health policies.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 5, 7, 6],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  '1k48jx7v': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced some restrictions.',\n",
       "   'samples': ['Canada implemented travel restrictions, lockdowns, and vaccination programs. Economic impact included job losses and business closures. Healthcare system faced increased strain.',\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination programs. Economic impacts include job losses and business closures. Healthcare system strained. Vaccination rollout reduced cases but variants remain concern.',\n",
       "    'COVID-19 significantly impacted Canada, causing widespread lockdowns, economic downturn, vaccination campaigns, and public health challenges.',\n",
       "    \"Canada's economy, healthcare system, and society were significantly impacted by COVID-19, including lockdowns, vaccine rollout, and increased caseloads.\",\n",
       "    \"Canada's economy, healthcare system, and social activities were significantly impacted. Lockdowns, travel restrictions, and business closures occurred. Vaccination campaigns and public health measures were implemented.\",\n",
       "    'Canada implemented strict border controls, lockdowns, and vaccination campaigns. Economic impacts included job losses and business closures. Healthcare systems faced increased strain.',\n",
       "    'COVID-19 significantly impacted Canada with widespread lockdowns, economic downturn, vaccination campaigns, and variant outbreaks affecting public health measures.',\n",
       "    'Canada implemented strict public health measures, closed borders, and provided economic support.',\n",
       "    'COVID-19 significantly impacted Canada, causing widespread lockdowns, economic downturn, vaccination campaigns, and public health challenges.',\n",
       "    'COVID-19 significantly impacted Canada, leading to widespread lockdowns, economic downturn, vaccine distribution efforts, and public health challenges.'],\n",
       "   'cluster_ids': [0, 0, 0, 1, 0, 1, 2, 3, 2, 1],\n",
       "   'entropy': 1.2798542258336674},\n",
       "  'wy0y5ztd': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. The economy suffered with high unemployment rates, while healthcare systems faced increased strain. Vaccination efforts have since reduced the impact.',\n",
       "   'samples': ['Canada implemented strict travel bans, lockdowns, and public health measures. Economic impacts included job losses and business closures. Vaccination efforts have been ongoing.',\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic downturn, vaccine rollout, and ongoing public health measures.',\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination programs. Economy suffered; unemployment rose. Healthcare system strained. Social gatherings and businesses closed.',\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination programs. Economic impact included job losses and business closures. Healthcare system strained, but overall response considered moderate compared to some other countries.',\n",
       "    \"Canada's economy, healthcare system, and social life have been significantly impacted by COVID-19. Lockdowns, travel restrictions, and vaccination efforts have been implemented.\",\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic downturn, healthcare strain, and vaccination campaigns.',\n",
       "    'Canada implemented travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination programs were rolled out to combat the virus.',\n",
       "    \"Canada's economy, healthcare system, and social life have been significantly impacted. Lockdowns, travel restrictions, and business closures led to high unemployment and economic challenges. Healthcare resources strained, and public gatherings restricted. Vaccination efforts are ongoing.\",\n",
       "    'Canada implemented travel restrictions, lockdowns, and vaccination campaigns. Economic impact included job losses and business closures. Healthcare system faced increased strain.',\n",
       "    \"Canada implemented lockdowns, travel restrictions, and vaccination programs. Economic impacts include job losses and business closures. Healthcare system strained. Socially, there's increased isolation and mental health concerns.\"],\n",
       "   'cluster_ids': [0, 0, 1, 2, 1, 2, 3, 1, 1, 4],\n",
       "   'entropy': 1.4708084763221112},\n",
       "  'jb05x03a': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced some restrictions.',\n",
       "   'samples': ['Canada implemented strict border controls, lockdowns, and vaccination programs. Economic impact significant; many businesses struggled or closed. Healthcare system strained but generally managed cases effectively. Vaccination campaign largely successful, though variants pose ongoing challenges.',\n",
       "    'Canada implemented strict border controls, lockdowns, and vaccination programs. Economy suffered with job losses. Healthcare system faced challenges. Social gatherings were restricted.',\n",
       "    \"Canada's economy, healthcare system, and social life have been significantly impacted. Lockdowns, border closures, and public health measures were implemented. Economic support was provided to citizens and businesses. Vaccination campaigns are ongoing. (28 words)\",\n",
       "    'Canada imposed strict travel restrictions, closed non-essential businesses, and encouraged remote work. Healthcare system strained, economy significantly impacted with widespread closures and job losses. Vaccination program initiated but uneven across regions. Mask mandates and social distancing measures enforced.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and introduced economic support measures. Lockdowns varied by province. Vaccination campaigns began in early 2021.',\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic downturn, vaccine rollout, and variants influencing public health measures.',\n",
       "    'Canada implemented strict travel bans, business closures, and vaccination programs. Economic impacts included high unemployment and business closures. Healthcare systems faced strain. Socially, there was increased remote working and learning.',\n",
       "    'Canada imposed travel restrictions, lockdowns, and vaccination campaigns. Economic impact led to closures and job losses. Healthcare system faced strain. Public health measures altered daily life significantly.',\n",
       "    'Canada implemented strict public health measures, border closures, and economic support. Lockdowns varied by province. Healthcare systems faced significant strain. Vaccination campaigns have since been rolled out.',\n",
       "    'COVID-19 significantly impacted Canada, leading to widespread lockdowns, economic downturn, vaccine rollout, and public health challenges.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 5, 7, 1],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'zlpz435d': {'greedy': 'Canada implemented strict travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts included job losses and business closures. Vaccination efforts have since reduced the impact.',\n",
       "   'samples': ['Canada implemented strict travel bans, lockdowns, and vaccination programs. Economic impact included job losses and business closures. Healthcare system strained but generally well-equipped to handle surge. Public health measures and international aid have been key responses.',\n",
       "    'Canada implemented travel restrictions, closed non-essential businesses, and enforced physical distancing to control spread. The economy suffered with high unemployment. Healthcare system strained. Vaccine rollout began in 2021.',\n",
       "    \"Canada's economy, health system, and social life were significantly impacted. Lockdowns reduced economic activity. Healthcare strained with infections. Social gatherings were restricted. Vaccination campaigns have since eased some measures.\",\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and encouraged remote work. Schools and universities shifted to online learning. Economic impacts led to job losses and business closures. Vaccination programs were rolled out.',\n",
       "    'Canada imposed travel restrictions, closed non-essential businesses, and encouraged remote work. Economic impacts include job losses and business closures. Healthcare systems faced increased strain. Vaccine rollout began in 2021.',\n",
       "    'Canada implemented strict border controls, lockdowns, and vaccination programs. Economic impact included job losses and business closures. Healthcare system strained. Vaccination campaign progressed slowly initially but accelerated later.',\n",
       "    'COVID-19 significantly impacted Canada with lockdowns, economic challenges, and healthcare strain. Vaccination campaigns have helped control the spread.',\n",
       "    'Canada imposed travel restrictions, lockdowns, and vaccination campaigns. Economic impacts included job losses and business closures. Healthcare systems faced increased strain.',\n",
       "    \"Canada's economy, healthcare system, and social life were significantly impacted. Lockdowns, travel restrictions, and public health measures led to job losses, business closures, and a rise in cases. Vaccination efforts helped control the spread but ongoing variants pose\",\n",
       "    'Canada implemented lockdowns, travel restrictions, and vaccination campaigns. Economic impacts included job losses and business closures. Healthcare system strained. Public health measures and support programs were introduced.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 2, 5, 6, 0],\n",
       "   'entropy': 1.8866967846580784}},\n",
       " '1': {'no': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife coronavirus that evolved in bats and possibly transmitted to humans via intermediate animals. The first cases were identified in Wuhan, China in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The virus is thought to have emerged from the Huanan Seafood Market in Wuhan in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that was transmitted to humans, likely through an intermediate animal host. The Wuhan wet market in China has been linked to the outbreak.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife infection that spread to humans, likely through an intermediate animal host. The first cases were identified in Wuhan, China in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a live animal market.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 2, 4, 2, 5, 6, 6],\n",
       "   'entropy': 1.8343719702816235},\n",
       "  'jb05x03a': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be Wuhan, China, from a wildlife market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a wildlife market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife coronavirus that likely originated in bats and possibly passed to humans via intermediate animals.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that infected humans, likely through an intermediate animal host. The first cases were identified in Wuhan, China in December 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife infection, likely involving bats and possibly intermediate hosts before spreading to humans.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely emerged from bats and possibly passed through another animal before infecting humans.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 0, 4, 5, 6, 6],\n",
       "   'entropy': 1.8866967846580784},\n",
       "  'wy0y5ztd': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be a wildlife virus that likely originated in bats and possibly passed to humans via an intermediate animal. The first cases were identified in Wuhan, China in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely originated in bats and possibly passed to humans via an intermediate animal. The first cases were identified in Wuhan, China in December 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via intermediate animal hosts. The first cases were identified in Wuhan, China in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The virus is thought to have emerged from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals. The exact animal source is still under investigation.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that infected humans, likely through an intermediate host. The Wuhan Wet Market in China was initially linked, but the exact source remains uncertain.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a live animal market. The exact animal source remains uncertain, but it is thought to be bats.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans through an intermediate animal host, with bats considered a probable reservoir.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 2, 4, 5, 6, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'okqsvg8q': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China, where a bat coronavirus was likely transmitted to another animal before jumping to humans.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that jumped species to infect humans, likely through an intermediate host. The first cases were identified in Wuhan, China in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The first cases were identified in December 2019. The virus is thought to have emerged from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The first cases were identified in December 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold wildlife.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 0, 5, 5, 5, 0],\n",
       "   'entropy': 1.6434177197931796},\n",
       "  'qp0h50t3': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be Wuhan, China. The exact source remains uncertain, but it is thought to have emerged from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a wildlife market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China, where bats were sold.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The first cases were reported in December 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife coronavirus that likely jumped to humans via an intermediate host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The exact source remains uncertain, but it is thought to have emerged from a wet market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The exact source remains unclear, but it is thought to have emerged from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 1, 7, 8],\n",
       "   'entropy': 2.163955656882057},\n",
       "  'rzpbpxw2': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be Wuhan, China, from a wildlife market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wildlife and live animals in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The exact source is unknown, but it is thought to have originated in bats and possibly passed to humans through another animal.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The exact source is unclear but it is thought to have emerged from a wet market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The first cases were identified in December 2019. The virus is thought to have emerged from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.'],\n",
       "   'cluster_ids': [0, 1, 1, 2, 1, 3, 4, 5, 6, 7],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'u7u75sl0': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be a wildlife infection, specifically involving bats and possibly intermediate hosts.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that jumped species to humans, likely through an intermediate animal host at a wet market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans through an intermediate animal host.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wildlife and live animals in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a wildlife market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely originated in bats and possibly passed to humans via intermediate animals.',\n",
       "    \"The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wildlife and live animals in late 2019. However, the virus's exact source remains unclear.\",\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The exact source is still under investigation, but it is thought to have emerged from a live animal market.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 3, 5, 7],\n",
       "   'entropy': 2.0253262207700677},\n",
       "  'u7ir986m': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be a wildlife virus that jumped species to humans, likely through an intermediate animal at a wet market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The virus is thought to have emerged from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The first cases were reported in December 2019.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that jumped species to humans, likely through pangolins and bats. The first cases were identified in Wuhan, China in December 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that jumped to humans, likely through an intermediate host, with bats considered a possible reservoir.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that spilled over into humans, likely through an intermediate host. The first cases were identified in Wuhan, China in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 5],\n",
       "   'entropy': 2.163955656882057},\n",
       "  't5ycl437': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife coronavirus that emerged in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to the outbreak.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a wildlife market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The first cases were reported in December 2019. The virus is thought to have emerged from the Huanan Seafood Market in Wuhan.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The first cases were linked to a wet market in Wuhan, though some suggest it may have originated elsewhere or through laboratory泄漏事件发生后，武汉的疫情状况如何',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a live animal market. However, the exact source remains unclear.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that jumped to humans, likely through an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact animal source remains uncertain.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wildlife and live animals in late 2019.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China, where bats were sold.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 7, 8, 9],\n",
       "   'entropy': 2.3025850929940455},\n",
       "  'ofx56c28': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife infection that jumped to humans, likely through the Huanan Seafood Market in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.',\n",
       "    \"The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wildlife and live animals in late 2019. However, the virus's original source remains uncertain.\",\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that infected humans, likely through an intermediate animal host. The Wuhan wet market in China has been linked to early cases.',\n",
       "    \"The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wildlife and live animals in late 2019. However, the virus's exact source remains uncertain.\",\n",
       "    'The origin of COVID-19 is believed to be a wildlife coronavirus that jumped species to infect humans, likely through an intermediate animal host. The Wuhan wet market in China has been linked to the outbreak.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife market in Wuhan, China.'],\n",
       "   'cluster_ids': [0, 1, 2, 1, 3, 4, 5, 6, 7, 1],\n",
       "   'entropy': 1.9730014063936128},\n",
       "  'gdfxiosc': {'greedy': 'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to early cases, but the exact source remains unclear.',\n",
       "   'samples': ['The origin of COVID-19 is believed to be Wuhan, China, from a market that sold both wild and farmed animals.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that emerged in Wuhan, China.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that jumped to humans, likely through an intermediate animal host.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely originated in bats and possibly passed to humans via an intermediate animal. The exact source remains uncertain.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that was transmitted to humans, likely through intermediate animals. The Wuhan wet market in China has been linked to the outbreak.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China, from a live animal market.',\n",
       "    'The origin of COVID-19 is believed to be Wuhan, China. The exact source remains uncertain, but it is thought to have originated in animals before spreading to humans.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife coronavirus that jumped species to infect humans, likely through an intermediate animal host. The Wuhan wet market in China has been linked to the outbreak.',\n",
       "    'The origin of COVID-19 is believed to be a wildlife virus that likely jumped to humans via an intermediate animal host. The Wuhan wet market in China has been linked to the outbreak, but the exact animal source remains uncertain.'],\n",
       "   'cluster_ids': [0, 1, 2, 3, 4, 5, 6, 1, 3, 7],\n",
       "   'entropy': 2.0253262207700677}}}"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data = load_pickle_file('output/sample/trec-covid/sample.pkl')\n",
    "data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "frag",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
